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Abstract 
Rheumatoid arthritis (RA) is the most prevalent inflammatory joint disease. B cells have a 
role in both the pathogenesis of RA and the regulation of bone cell activity. Depletion of B 
cells by the anti-CD20 antibody rituximab (RTX) is a highly effective treatment of RA, which 
is now well established. However, the role of B-cells in bone turnover is controversial. The 
aim of this thesis was to investigate the effects of B cell depletion on bone turnover in RA. It 
is postulated that prolonged B cell depletion in patients with RA may have a beneficial effect 
on the bone loss that would otherwise be expected in active disease. Furthermore, this affect 
may be direct through modulation of osteoclastogenesis or indirect through attenuation of 
systemic inflammation and increased physical activity. Preliminary results in forty-six RA 
patients six months after RTX indicated that there was a significant suppression in bone 
resorption accompanied to a lesser degree by an increase in bone formation. However, in a 
second prospective cohort of forty-five RA patients treated with RTX over twelve months, 
bone mineral density (BMD) fell at the femur sites, but was maintained at the lumbar spine 
and forearm. There was a significant increase in bone formation, but no significant change in 
bone resorption or osteocyte markers. Additionally, the effects of RTX on bone turnover were 
influenced by vitamin D status, gender and menopausal state. Results of in vitro 
osteoclastogenesis with peripheral blood mononuclear cells (PBMCs) isolated from the blood 
of twelve self-reported healthy volunteers; indicated that in vitro B cell depletion via 
magnetic-activated cell sorting (MACS), significantly increased osteoclast formation. In 
contrast, PBMCs isolated from the blood of five RA patients, up to twelve months post B cell 
depletion with RTX, resulted in decreased osteoclast formation using the same standardised 
culture system. In summary, the results of the pilot study showed that B cell depletion 
significantly decreased bone resorption and increased bone formation in RA, possibly via a 
direct effect on osteoclasts and osteoblasts, respectively, or at least partially explained by the 
decreased inflammation and disease activity. However, this was not confirmed in the 
prospective study as the results were confounded by a high prevalence of vitamin D 
deficiency and these patients had significant falls in femur BMD and evidence of higher bone 
turnover. Furthermore, as there were no control groups it was difficult to establish whether 
depletion of B cells had in fact slowed down the expected bone loss in these patients. The 
results of the in vitro experiments indicated that under basal conditions i.e. in healthy 
subjects, the production of osteoprotegerin by B cells outweighed the production of receptor 
activator of nuclear factor - κb ligand (RANKL). However, in pro-inflammatory states, where 
B cells are activated e.g. RA, B cells produce cytokines like RANKL that stimulate 
osteoclastogenesis resulting in an increased production of osteoclasts. Hence B cell depletion 
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in this latter situation caused a reduction in osteoclast generation. Further work is now 
required to investigate if subsets of pathogenic B cells i.e. not found in healthy individuals are 
specific to inflammatory bone erosion. 
 
  
 iii 
 
Dedication  
 
I would like to dedicate this thesis to “MY PARENTS” who have always loved me 
unconditionally and have been a source of great encouragement and inspiration. Your good 
example taught me to work hard for the things that I want to achieve. A very special thank 
you for all your help and for the immeasurable ways, in which you have supported me in my 
determination to pursue my ambition throughout my life, 
 
I also dedicate this thesis to “MY HUSBAND” for his encouragement and patience and to 
“MY DAUGHTERS” for their belief that I would get there in the end. 
 
  
 iv 
 
  
 v 
 
Declaration 
 
I hereby declare that I am the sole author of this thesis. This is a true copy of my thesis, 
including any required final revisions, as accepted by my examiners. It has not already been 
accepted or in the process of being submitted for any other degree.  
 vi 
 
  
 vii 
 
Acknowledgements 
First and foremost I would like to express my sincere gratitude and thanks to my supervisor 
Professor Jaap van Laar for his patience, motivation and valuable guidance and support, you 
have been a tremendous mentor for me. I would also like to express my profound appreciation 
to my other supervisors; Dr Harish K Datta, Dr Stephen P Tuck and Professor Roger M 
Francis, for all their assistance and support throughout the project. I would like to thank you 
all for encouraging my research and for allowing me to grow as a research scientist, your 
expertise and advice have been priceless. 
I would like to express my deep gratitude to Dr John Drury and Tina Porter for believing I 
could do it and for giving me a chance to start this project, especially to you Tina for your 
eternal support, for giving me a gentle push when necessary and for always believing that I’d 
get there in the end. 
Thanks are also due to my colleagues in Pathology, especially Andrea Boyce and Anthony 
Donnelly for their help with the clinical trial samples, to Cheryl Goodrum and Andrew 
Teggert for help with the bone marker analysis and to Tony Holden and Graeme Singh for 
their help with the FACS analysis. Also to the Phlebotomy team and members of staff who 
were always willing to donate samples. 
I must extend a very special thank you to Lee Simpson for his assistance with the in vitro 
experiments, for the endless hours counting cells and for always being willing to help and 
give his best suggestions; it would have been a lonely lab without him. Likewise to Dr 
Vanessa Hogan for listening and for her helpful guidance at the start of this epic journey. 
I acknowledge Julie Rowbotham and the R&D department for their guidance and advice 
managing the clinical trials. I must also acknowledge the patients, investigators and study 
personnel in The Netherlands who made the pilot study possible and also those in the 10 UK 
centres who facilitated the prospective ‘HORUS’ study. My thanks also to Dr Kamran 
Naraghi and Dr Mohsen Elshahaly for their help with this study. 
I recognize that this research would not have been possible without research grants from 
South Tees R&D and Roche Products Limited (Welwyn Garden City, UK) providing funding 
for the prospective trial; I express my gratitude to both.  
A special thanks to my family. Words cannot express how grateful I am to everyone, for all 
your support and the sacrifices you’ve made on my behalf. Finally I would like to express 
appreciation to my husband and best friend Paul who was always my support in the many 
moments of absolute panic. 
 
 
 viii 
 
 
 ix 
 
Abbreviations 
 
1, 25(OH)2D3: 1, 25-dihydroxy vitamin D3 
25OHD:  25- hydroxy cholecalciferol 
Ab:   Antibody 
ACPA:  Anti-cyclic Citrullinated Peptide Antibody 
ACR:   American College of Rheumatology 
ALP:   Alkaline Phosphatase (Total) 
AP-1:   Activator Protein-1 
APRIL:  A PRoliferation-Inducing Ligand 
ATF-4:  Activating Transcription Factor-4 
Bach2:  Basic leucine zipper transcription factor 2 
BAFF:  B cell Activating Factor 
BALP:  Bone specific Alkaline Phosphatase 
Bcl6:   B cell lymphoma 6  
BCR:   B Cell Receptor 
βCTX:  Beta-isomerised Carboxy terminal Telopeptide of type I collagen 
Be:   B effector cell 
BiP:   Immunoglobulin Binding Protein 
Blimp1:  B lymphocyte-induced maturation protein 1 
BMD:   Bone Mineral Density 
BMI:   Body Mass Index 
BMP:    Bone Morphogenetic Protein 
BSA:   Bovine Serum Albumin 
BSAP:   B cell lineage-Specific Activation factor 
BTM:   Bone Turnover Marker 
Ca:   Calcium 
CCa:   Corrected Calcium 
CD:   Cluster of Differentiation or Classification Determinant 
CE:   Conformité Européenne 
c-fms:   colony-stimulating factor 1 receptor 
CLL:   Chronic Lymphocytic Leukaemia 
CRP:   C-Reactive Protein 
CTX:   Carboxy-terminal cross-linked Telopeptides of type I collagen 
CTX-MMP:  Carboxy-terminal cross-linked Telopeptide - MMP 
 x 
 
CV:   Coefficient of Variation 
CXCL12:  C-X-C motif chemokine 12 
DAP12:  Dnax-Activating Protein 12 
DAS28:  Disease Activity Score using 28 tender or swollen joints 
DKK:   DicKKopf- related protein  
DMARD:  Disease Modifying Anti Rheumatic Drug 
DMP-1:  Dentin Matrix Protein-1 
DMSO:  Dimethyl SulfOxide 
DPBS:   Dulbecco’s Phosphate Buffered Saline 
DPD:    DeoxyPyriDinoline 
DXA:   Dual-energy X-ray Absorptiometry 
ECLIA:  ElectroChemiLuminescent ImmunoAssay 
EDTA:  Ethylene Diamine Tetraacetic Acid 
eGFR:   estimated Glomerular Filtration Rate 
ELISA:  Enzyme Linked ImmunoSorbent Assay 
ESR:   Erythrocyte Sedimentation Rate 
FACS:  Fluorescence Activated Cell Sorting 
FcRγ:   Fc Receptor gamma chain  
FcRL4:  Fc Receptor-Like protein 4 
FCS:   Fetal Calf Serum 
FSH:   Follicle Stimulating Hormone 
Fz:   Frizzled protein 
GC:   Germinal centre 
G-CSF:  Granulocyte -Colony Stimulating Factor 
GSα:   G protein α subunit  
HAQ:   Health Assessment Questionnaire 
HELP:  type I collagen alpha 1 HELicoidal Peptide 
HSC:   Hematopoietic Stem Cell 
HBSS:   Hank's Balanced Salt Solution 
hsCRP:  high sensitivity C-Reactive Protein 
IDS:   Immuno Diagnostic Systems 
IFN-γ:   InterFeroN-gamma 
Ig:   Immunoglobulin 
IL:   InterLeukin 
IRF:   Interferon Regulatory Factor 
 xi 
 
ISCD:   International Society for Clinical Densitometry 
ITAM:  Immuno receptor Tyrosine-based Activation Motif 
JCUH:  The James Cook University Hospital 
KL
-/-
:   Klotho mutant mice 
kDa:   kilo Dalton 
LH:   Luteinising Hormone 
LRP:   Low-density lipoprotein Receptor-related Protein  
LS:   Lumbar Spine 
LSC:   Least significant change 
LT-α:   LymphoToxin-alpha 
µg/L:   micrograms per Litre 
µl:   microlitre 
µm:   micron 
ml:   millilitre 
MACS:  Magnetic-Activated Cell Sorting 
M-CSF:  Macrophage -Colony Stimulating Factor 
αMEM:  Minimum Essential Medium 
MEPE:  Matrix Extracellular Phosphoglycoprotein 
MHC:   Major Histocompatibility Complex 
MHRA:  Medicines and Healthcare Products Regulatory Agency 
MN:   Mean Neck of Femur 
MoM:   Multiple of the Median 
MSC:   Mesenchymal Stem Cell 
MT:   Mean Total Femur 
MT1-MMP:  Membrane-Type Matrix MetalloProteinase 1 
MTX:   Methotrexate 
MZ:   Marginal Zone 
n:   number in the sample 
ng/L:   nanograms per Litre 
NEQAS:  National External Quality Assessment Service 
NFATc1:  Nuclear Factor of Activated T cells, cytoplasmic 1 
NK-κb:  Nuclear factor kappa-light-chain-enhancer of activated b cells 
NICE:   National Institute for Health and Care Excellence     
NTX:   amiNo terminal Telopeptide of type I collagen 
OB:   Osteoblast 
 xii 
 
OC:   Osteoclast 
OPG:   Osteoprotegerin 
OSCAR:  OSteoClast-Associated immunoglobulin-like Receptor 
OSTEOC:  Osteocalcin 
OSX:   Osterix 
Pax5:   Paired box protein 5 
pmol/L:  picomoles per Litre 
PBMC:  Peripheral Blood Mononuclear Cell 
PBS:   Phosphate Buffered Saline 
PICP:    Procollagen type 1 Carboxy-terminal Propeptide 
PINP:   Procollagen type 1 amiNo-terminal Propeptide 
pNPP:   p-NitroPhenyl Phosphate  
PO4:   Phosphate 
PPR:   PTH/ PTHrP Receptor 
PSA:   Prostate Specific Antigen 
PTH:   ParaThyroid Hormone 
PTHrP:  ParaThyroid Hormone related Protein 
PYD:    Pyridinoline 
QC:   Quality Control 
QCT:   Quantitative Computed Tomography 
QUS:   Quantitative UltraSound 
Rs   Spearman correlation coefficient 
RA:   Rheumatoid Arthritis 
RANK:  Receptor Activator of Nuclear factor - κb  
RANKL:  Receptor Activator of Nuclear factor - κb Ligand 
RF:   Rheumatoid Factor  
RPM:   Revolutions Per Minute 
RPMI:  Roswell Park Memorial Institute 
RTX:   Rituximab 
RUNX2:  Runt-related transcription factor X2 
sRANKL:  soluble Receptor Activator of Nuclear factor - kB Ligand 
SCL:   Sclerostin 
SD:   Standard Deviation 
SDF-1:  Stromal cell-Derived Factor 1 
SHBG:  Sex Hormone Binding Globulin 
 xiii 
 
SJC:   Swollen Joint Count 
TFH:   Follicular T helper cell 
TGF-β:  Transforming Growth Factor-beta 
TJC:   Tender Joint Count 
TMB:   3, 3', 5, 5' TetraMethyl Benzidine 
TNF-α:  Tumour Necrosis Factor-alpha 
TRAF-6:  TNF Receptor-Associated Factor-6 
TRAP:  Tartrate Resistant Acid Phosphatase  
TRAP5b:  Tartrate Resistant Acid Phosphatase isoform 5b 
TREM-2:  Triggering Receptor Expressed on Myeloid cells-2 
TSH:   Thyroid Stimulating Hormone 
UD Radius:  Ultra-Distal Radius 
UK:   United Kingdom 
VAS:   Visual Analogue Scale 
VCAM 1:  Vascular Cell Adhesion Molecule 1 
WHO:   World Health Organisation  
Wnt:   Wingless-int 
wrCRP:  Wide Range C-Reactive Protein 
XBP1:   X-box Binding Protein 1 
  
 xiv 
 
 
 
 
 
 
  
 xv 
 
Table of Contents 
Abstract .............................................................................................................................. i 
Dedication ........................................................................................................................ iii 
Declaration........................................................................................................................ v 
Acknowledgements ........................................................................................................ vii 
Abbreviations .................................................................................................................. ix 
List of Figures ................................................................................................................ xix 
List of Tables ................................................................................................................. xxi 
Chapter 1. General Introduction ....................................................................................... 1 
1.1 B cells .......................................................................................................................... 1 
1.1.1 B cell development ..................................................................................................... 1 
1.1.2 B cell regulation ......................................................................................................... 5 
1.1.3 Autoantibody production ............................................................................................ 5 
1.1.4 Cytokine production ................................................................................................... 6 
1.2 Bone ............................................................................................................................. 7 
1.2.1 Bone structure ............................................................................................................ 7 
1.2.2 Bone mineral density .................................................................................................. 9 
1.2.3 Bone metabolism ...................................................................................................... 10 
1.2.4 Bone cell differentiation and regulation .................................................................. 13 
1.2.5 Biochemical markers of bone turnover .................................................................... 19 
1.3 Interactions between the immune and skeletal systems ............................................. 25 
1.3.1 Osteoblasts and B cells ............................................................................................ 25 
1.3.2 Osteoclasts and B cells ............................................................................................. 26 
1.3.3 B cells and the RANK-RANKL-OPG system ............................................................ 26 
1.4 Rheumatoid arthritis .................................................................................................. 28 
1.4.1 Epidemiology ............................................................................................................ 28 
1.4.2 Pathogenesis of bone loss in rheumatoid arthritis ................................................... 28 
1.4.3 Pathway of care ........................................................................................................ 32 
1.4.4 The role of B cells in rheumatoid arthritis ............................................................... 33 
1.5 The effect of B cell depletion on bone turnover in rheumatoid arthritis ................... 34 
1.5.1 Current evidence from clinical trials ....................................................................... 34 
1.6 Project aims ..................................................................................................................... 35 
Chapter 2. Materials and methods .................................................................................. 37 
2.1 Materials ......................................................................................................................... 37 
2.1.1 Biomarker reagents .................................................................................................. 38 
 xvi 
 
2.1.2 In vitro reagents ....................................................................................................... 39 
2.2 Methods .......................................................................................................................... 40 
2.2.1 Biomarker assays ..................................................................................................... 40 
2.2.2 In vitro experiments ................................................................................................. 53 
2.3 Subjects .......................................................................................................................... 62 
The main characteristics and time-lines of the sub studies are summarised in table 6. ... 62 
2.3.1 Pilot study ................................................................................................................ 64 
2.3.2 Prospective study ..................................................................................................... 64 
2.3.3 Osteoclast work ....................................................................................................... 65 
2.4 Statistical analysis .......................................................................................................... 66 
2.4.1 Pilot study ................................................................................................................ 66 
2.4.2 Prospective study ..................................................................................................... 67 
2.4.3 Osteoclast work ....................................................................................................... 67 
Chapter 3. The effects of B cell depletion on bone turnover in patients with rheumatoid 
arthritis - the pilot study .................................................................................................. 69 
3.1 Introduction .................................................................................................................... 69 
3.2 Materials and methods.................................................................................................... 69 
3.2.1 Patient cohort .......................................................................................................... 70 
3.2.1 Biomarker measurements ........................................................................................ 70 
3.2.2 Statistical analysis ................................................................................................... 70 
3.3 Results ............................................................................................................................ 70 
3.3.1 Demographic and clinical characteristics ............................................................... 70 
3.3.2 Changes in biomarker levels ................................................................................... 74 
3.3.3 Time course of change in bone turnover ................................................................. 74 
3.3.4 The effect of gender and menopausal status ............................................................ 78 
3.3.5 The effect of concomitant medication ...................................................................... 78 
3.3.6 Correlations between inflammatory activity and bone turnover ............................. 78 
3.4 Discussion ...................................................................................................................... 83 
3.5 Conclusion ...................................................................................................................... 84 
Chapter 4. The effects of B cell depletion on bone turnover in patients with rheumatoid 
arthritis - the prospective study ....................................................................................... 87 
4.1 Introduction .................................................................................................................... 87 
4.2 Materials and methods.................................................................................................... 87 
4.2.1 Patient cohort .......................................................................................................... 88 
 xvii 
 
4.2.2 Clinical and laboratory assessments........................................................................ 88 
4.2.3 Bone mineral density measurements ........................................................................ 90 
4.2.4 Biomarker measurements ......................................................................................... 90 
4.2.5 Statistical analysis .................................................................................................... 90 
4.3 Results ............................................................................................................................. 91 
4.3.1 Demographic and clinical characteristics ............................................................... 91 
4.3.2 Changes in bone mineral density ............................................................................. 95 
4.3.3 Changes in biomarker levels .................................................................................... 98 
4.3.4 Correlations between inflammatory activity and bone density or bone turnover .... 99 
4.3.5 The effects of vitamin D .......................................................................................... 104 
4.4 Discussion ..................................................................................................................... 108 
4.5 Conclusion .................................................................................................................... 110 
Chapter 5. In vitro osteoclastogenesis .......................................................................... 111 
5.1 Introduction ................................................................................................................... 111 
5.2 Osteoclastogenesis protocol .......................................................................................... 115 
5.2.1 Methods .................................................................................................................. 115 
5.2.2 Results .................................................................................................................... 116 
5.2.3 Discussion .............................................................................................................. 123 
5.3 The effect of in vitro B cell depletion ........................................................................... 125 
5.3.1 Methods .................................................................................................................. 125 
5.3.2 Results .................................................................................................................... 127 
5.3.3 Discussion .............................................................................................................. 137 
5.4 The effects of ex vivo B cell depletion .......................................................................... 139 
5.4.1 Methods .................................................................................................................. 139 
5.4.2 Results .................................................................................................................... 140 
5.4.3 Multiple regression analysis to explore factors affecting osteoclastogenesis ....... 150 
5.4.4 Discussion .............................................................................................................. 151 
5.5 Conclusion .................................................................................................................... 152 
Chapter 6. Discussion ................................................................................................... 153 
6.1 Discussion ................................................................................................................ 153 
6.2 Conclusion ............................................................................................................... 156 
6.3 Future perspective ......................................................................................................... 156 
References .................................................................................................................... 161 
Appendix A. Generic Materials .................................................................................... 177 
 xviii 
 
General reagents ................................................................................................................. 177 
General consumables .......................................................................................................... 177 
General equipment ............................................................................................................. 178 
Appendix B. Tests for normality of data....................................................................... 181 
Pilot Study .......................................................................................................................... 181 
Prospective Study ............................................................................................................... 209 
In vitro unfractionated and CD20 depleted PBMC comparisons ....................................... 353 
Ex vivo number of TRAP
+
 cells generated per visit ........................................................... 385 
Appendix C. Multiple regression analysis .................................................................... 393 
Stepwise regression model 1 – unfractionated mononuclear cells ..................................... 393 
Stepwise regression model 2 – CD20 depleted mononuclear cells .................................... 396 
Appendix D. Publications arising from this thesis ........................................................ 399 
Original publication in peer reviewed journals .................................................................. 399 
Submitted for publication ................................................................................................... 399 
Abstracts ............................................................................................................................. 400 
 
 
  
 xix 
 
List of Figures 
 
Figure 1 Graphical representations of the pathways leading particularly to B cell and 
osteoclast differentiation from hematopoietic stem cells ........................................................... 2 
Figure 2 Expression of B cell specific markers during the differentiation of early progenitor B 
cells into mature memory B cells and/or plasma cells ............................................................... 4 
Figure 3 Illustration of cortical and trabecular bone .................................................................. 8 
Figure 4 The bone remodelling cycle ....................................................................................... 12 
Figure 5 Graphical representations of the pathways leading particularly to osteoblast and 
osteocyte differentiation from mesenchymal stem cells........................................................... 15 
Figure 6 Osteoclast cells stained with tartrate resistant acid phosphatase ............................... 17 
Figure 7 Osteoclast differentiation ........................................................................................... 18 
Figure 8 The effect of age on individual biomarkers for the pilot study .................................. 46 
Figure 9 Ratio of the multiples of the median for a marker of bone formation and bone 
resorption to signify bone turnover in patients with rheumatoid arthritis ................................ 47 
Figure 10 The effect of age on individual biomarkers for the prospective study ..................... 52 
Figure 11 Diagrammatic representation of the microscope slide showing orientation and 
counting areas, labelled 1-9 respectively .................................................................................. 58 
Figure 12 Infinity analyse software showing the cell area and circumference measurement for 
3 TRAP
+
 osteoclast-like cells ................................................................................................... 59 
Figure 13 Flowchart showing the pilot study numbers at each time point ............................... 72 
Figure 14 Ratio of bone marker multiples of the median depicting bone turnover in forty-six 
rheumatoid arthritis patients’ pre and 6 months post rituximab ............................................... 76 
Figure 15 Change in individual bone markers over the course of the study ............................ 77 
Figure 16 The effects of gender and menopausal status on median biomarker levels ............. 80 
Figure 17 Location of the ten UK centres recruiting into the prospective study...................... 89 
Figure 18 Consort flow diagram for the prospective study ...................................................... 92 
Figure 19 Change in individual bone markers over the course of the study .......................... 101 
Figure 20 Change in individual inflammatory markers over the course of the study ............ 102 
Figure 21 Ratio of bone marker multiples of the median depicting bone turnover in thirty 
rheumatoid arthritis patients pre and 3, 6, 9 and 12 months post rituximab .......................... 103 
Figure 22 Comparison with and without the addition of cytokines (×200) ........................... 118 
Figure 23 Evaluation of PBMC plating density (×200) showing typical patterns of TRAP+ 
cell formation at each concentration ....................................................................................... 119 
Figure 24 Evaluation of the time of culture period (×200) showing typical patterns of TRAP+ 
cell formation at each day ....................................................................................................... 120 
Figure 25 Representative TRAP
+
 multinucleated cells on a glass coverslip .......................... 121 
Figure 26 Representative actin ring formation on a glass coverslip....................................... 121 
Figure 27 Representative resorption pits on a bone slice, visualised by toluidine blue staining
 ................................................................................................................................................ 122 
Figure 28 The effect of the initial number of monocytes on TRAP
+
 cells generated from 
twelve healthy volunteer peripheral blood mononuclear cells ............................................... 130 
Figure 29 The effect of the initial number of B cells on TRAP
+
 cells generated from twelve 
healthy volunteer peripheral blood mononuclear cells ........................................................... 131 
Figure 30 The effect of the initial number of T cells on TRAP
+
 cells generated from twelve 
healthy volunteer peripheral blood mononuclear cells ........................................................... 132 
Figure 31 An example of a patient culture at baseline, 3, 6 and 12 months ........................... 144 
Figure 32 The effect of the initial number of monocytes on TRAP
+ 
cells generated from four 
rheumatoid arthritis patient cultures ....................................................................................... 146 
Figure 33 TRAP
+
 cells generated from five rheumatoid arthritis patient cultures before and 3, 
6, 12 months post rituximab ................................................................................................... 147 
 xx 
 
Figure 34 The effect of the initial number of B cells on TRAP
+
 cells generated from four 
rheumatoid arthritis patient cultures ...................................................................................... 148 
Figure 35 The effect of the initial numbers of T cells on TRAP
+
 cells generated from four 
rheumatoid arthritis patient cultures ...................................................................................... 149 
 
  
 xxi 
 
List of Tables 
 
Table 1 Major advantages and disadvantages of commonly used bone turnover markers ...... 21 
Table 2 Types of bone loss in rheumatoid arthritis .................................................................. 31 
Table 3 Biomarker precision data for the pilot study ............................................................... 44 
Table 4 Manufacturer defined biomarker reference ranges ...................................................... 45 
Table 5 Biomarker precision data for the prospective study .................................................... 50 
Table 6 Main characteristics of all the sub studies ................................................................... 63 
Table 7 Baseline characteristics of the forty-six rheumatoid arthritis patients ........................ 73 
Table 8 Change in biomarker concentration for the forty-six rheumatoid arthritis patients .... 75 
Table 9 Effect of bisphosphonate treatment on change in biomarker concentration for forty-
six rheumatoid arthritis patients from baseline to six months .................................................. 81 
Table 10 Correlations between the percentage change from baseline of biomarker values for 
patients not on bisphosphonates or prednisolone (n=18) ......................................................... 82 
Table 11 Baseline characteristics of the prospective study patients ......................................... 93 
Table 12 Change in bone mineral density from baseline to 12 months ................................... 96 
Table 13 Change in biomarkers from baseline to twelve months .......................................... 100 
Table 14 Change in bone mineral density and biomarkers by vitamin D category from 
baseline to 12 months ............................................................................................................. 106 
Table 15 Osteoclast culture techniques described in recent literature .................................... 114 
Table 16 Unfractionated and CD20 depleted cultures in twelve healthy volunteers ............. 128 
Table 17 Comparison of CD20 depleted mononuclear cells using either magnetic-activated 
cell sorting or in vitro rituximab ............................................................................................. 134 
Table 18 Effect of in vitro rituximab on unfractionated and CD14
+
 purified peripheral blood 
mononuclear cells ................................................................................................................... 136 
Table 19 Baseline trial data for five rheumatoid arthritis patients ......................................... 141 
Table 20 Bone marker and bone mineral density results at each visit for five rheumatoid 
arthritis patients ...................................................................................................................... 142 
Table 21 Median cell counts at baseline and at 3, 6 and 12 month post-rituximab from four 
rheumatoid arthritis patient cultures ....................................................................................... 145 
 
  
 xxii 
 
  
  
 
 
 
 
 
 
 
Chapter 1 
General Introduction
  
  
 
Chapter 1                                                                                                      General Introduction                       
1 
 
Chapter 1. General Introduction 
 
Chapter one, the general introduction is divided into six main parts. To begin section one is a 
brief summary of B cell development, regulation and function. The second section describes 
bone structure, individual bone cells and the regulation of bone re-modelling, the stages of 
which can be identified using biochemical markers of bone turnover. Section three describes 
the interactions between the immune and skeletal system, currently referred to as 
‘Osteoimmunology’. Section four is a general overview of rheumatoid arthritis (RA), 
epidemiology, mechanisms of bone loss and RA management and finally current 
understanding of the effects of B cell depletion on bone turnover in RA. Taken together the 
sections form the theoretical basis to this study and the general aims are specified in the final 
section. 
 
1.1 B cells 
The immune system is a highly evolved process designed to protect the body from invading 
pathogens present in the environment, it is typically divided into two main categories; innate 
and adaptive. B cells are an important component of the adaptive immune system, which 
allows an individual to develop a specific response to an antigen and remember that antigen, 
allowing for a faster more robust response to that infection in the future. The adaptive 
immune response comprises of cell-mediated components; facilitated by T cells that recognise 
and directly attack foreign antigens that have entered into body cells; and humoral 
components, mediated by specific antibodies produced by B cells. A simple definition of B 
lymphocytes is a population of cells that express clonally diverse cell surface immunoglobulin 
(Ig) receptors recognizing specific antigenic epitopes (LeBien and Tedder 2008).  
 
1.1.1 B cell development 
B cells develop directly from lymphoid stem cells in the hematopoietic tissue (Figure 1) of the 
foetal liver from 8-9 weeks gestation in humans, production then transfers into the bone 
marrow where it continues into adulthood (Asma et al. 1984). B cells initially mature, 
independently of an antigen, into pro-B cells; then progress through pre-B cells to immature B 
cells (Figure 2). Thereafter they enter an antigen-dependent phase in the peripheral lymphoid 
tissues. The B cell receptor (BCR) is activated after encountering exogenous antigen in the 
extra-follicular region and they progress from ‘naive’ mature to ‘naive activated’ B cells and 
migrate to the follicular region (Dalakas 2008).   
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Figure 1 Graphical representations of the pathways leading particularly to B cell and 
osteoclast differentiation from hematopoietic stem cells 
Hematopoietic stem cells give rise to both myeloid and lymphoid lineages of blood cells. Myeloid cells include; 
neutrophils, basophils, eosinophils and monocytes, dendritic cells, macrophages and osteoclasts. Lymphoid cells 
include; natural killer cells, T cells and B cells. 
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During the first step of the follicular response, the activated B cells migrate to the inter-
follicular foci to receive help for further proliferation and differentiation from activated 
cluster of differentiation (CD)4
+
 T helper cells, which start to differentiate into follicular T 
helper (TFH) cells. The activated B cells present processed antigen through direct cell-to-cell 
contact with the T cell receptor on the surface of TFH cells via major histocompatibility 
complex (MHC) class II. The B cells in turn receive co-stimulation via binding of CD40 
ligand on T cells to CD40 on B cells leading to full activation, enabling an immediate extra-
follicular humoral response as a subset of activated B cells differentiate into short-lived 
plasmablasts, producing low-affinity antibodies to the antigen (Nera et al. 2015). 
Communication between these cells also primes a subset of activated T cells and B cells that 
then migrate to the B cell follicle and form germinal centres (GC). GCs are made up of dark 
and light zones; they are checkpoints where both positive and negative selection of B cells for 
the production of plasmablasts and memory B cells takes place. Additionally, a subset of 
plasmablasts migrates to the bone marrow where they become long-lived plasma cells (Nera 
et al. 2015). Specific B cell surface molecules are expressed during differentiation; CD19, 
CD20, CD27, CD38 and CD138, they identify each of the transitional phases of B cell 
maturation (Figure 2) and ensure and regulate communication with the extracellular 
environment and initiate intracellular pathway signalling. Notably the CD19 molecule is 
expressed on all B lineage cells (Johnsen et al. 2014). In addition naive B cells are generally 
divided into three subsets; follicular or B-2 cells, classed as the standard type of B cell 
discussed in this section, plus two minor subsets; B-1 cells, primarily developed from the 
foetal liver and mainly found in peritoneal and pleural cavities and marginal zone (MZ) B 
cells particularly located within the spleen (Allman and Pillai 2008). 
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Figure 2 Expression of B cell specific markers during the differentiation of early 
progenitor B cells into mature memory B cells and/or plasma cells 
B cells develop from hematopoietic stem cells that originate from bone marrow. When B cells mature they 
migrate through the blood and become activated when they bind to an antigen. There are many B cell specific 
membrane-bound proteins expressed during B cell development from early lymphoid progenitor cells to mature 
memory B cells and/or plasma cells. 
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1.1.2 B cell regulation 
B cell activation and terminal differentiation is a complex mechanism under the influence of 
two main categories of transcription factors. Those factors promoting B cell phenotype but 
preventing premature differentiation to plasma cells; paired box protein 5 (Pax5), B cell 
lymphoma 6 protein (Bcl6), basic leucine zipper transcription factor 2 (Bach2), PU.1 and 
interferon regulatory factor 8 (IRF8); and those factors driving terminal differentiation into 
antibody secreting cells; X-box binding protein 1 (XBP1), B lymphocyte-induced maturation 
protein 1 (Blimp-1) and IRF4 (Nera et al. 2015). 
Additionally, BCR signalling typically induces proliferation and differentiation of mature B 
cells into antibody-secreting cells or memory B cells, but potentially can dictate the functional 
response and act as a developmental checkpoint for B-cell maturation. Clonal selection 
mechanisms have evolved to prevent the maturation of B cells that would otherwise produce 
autoreactive antibodies i.e. blocking the BCR can lead to receptor editing, cellular anergy 
and/or death by apoptosis of immature B cells (Harnett et al. 2005). Moreover, in the germinal 
centres, B cells, which have undergone somatic mutation resulting in potentially autoreactive 
antibodies, are programmed to die (peripheral tolerance) unless rescued by antigen and 
cognate follicular dendritic cell or T cell-derived signals (Harnett et al. 2005). 
 
1.1.3 Autoantibody production 
B cells are unique cells capable of forming terminally differentiated plasma cells producing 
antibodies (Ab). Antibodies are normally produced in response to a foreign protein or 
substance, such as an infectious organism within the body; they provide effective protection 
particularly after re-exposure to a previously encountered pathogen. An autoantibody is an 
antibody that is directed against one or more of the body’s own proteins. In a healthy immune 
system, B cells only bind to non-self-antigens; immature B cells that recognise self-antigens 
undergo negative selection by apoptosis or change their antigen specificity. Additionally, B 
cells that recognise self-antigens lose their ability to respond and are prevented from 
migrating to the follicular region. Autoimmune diseases develop when these mechanisms fail, 
and pathogenic, self-reactive B cells are produced (Lipsky 2001). It is clear that the presence 
of autoantibodies is a feature of rheumatoid arthritis (RA) and a number of autoantibodies 
have been described including rheumatoid factor (RF), anti–cyclic citrullinated protein 
antibody (ACPA) and antibodies to immunoglobulin binding protein (BiP). The 
autoantibodies often appear before overt clinical symptoms and are associated with a more 
severe disease outcome (Agrawal et al. 2007). Only RA and ACPA are used clinically, but 
neither factor has one hundred percent specificity e.g. RF is present in fifty to eighty percent 
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of RA patients, but also around ten percent of the general population and although ACPA is 
more specific to RA, a limited proportion of ‘healthy’ individuals also test positive (Mewar 
and Wilson 2006).  
1.1.4 Cytokine production 
The role of B cells in autoimmunity is not restricted to the production of autoantibodies; it is 
mediated in part by their ability to produce various cytokines that play important roles during 
infection, autoimmune disease, allergy and cancer (Fillatreau 2012). Moreover, B cell 
cytokine production is regulated by extrinsic signalling provided by other immune cell types 
and depends on their differentiation state and activation conditions. Naive B cells do not 
secrete many cytokines upon activation. In contrast, naive T cells initiate cytokine production 
almost immediately after activation. Once B cells acquire the capacity to produce cytokines, 
they become capable of cross-regulating responses via polarization/inhibition and can even 
negatively regulate the entire immune system (Vazquez et al. 2015). Cytokines produced by B 
cells (reviewed in Youinou et al. 2009) can be classified as: 
 Pro-inflammatory cytokines; such as interleukin (IL)-1, IL-6, tumour necrosis 
factor-alpha (TNF-α), interferon-gamma (IFN- γ), lymphotoxin-alpha (LT-α) 
 Immunosuppressive cytokines, such as IL-10 and transforming growth factor-beta 
(TGF- β1)  
 Hematopoietic growth factors; such as granulocyte colony-stimulating factor (G-
CSF), macrophage colony stimulating factor (M-CSF) and IL-7 
 
Two main B effector (Be) subgroups have been described; Be1 and Be2 that produce distinct 
patterns of cytokines depending on the cytokine environment in which the cells were 
stimulated during their primary encounter with antigen and T cells ( Harris et al. 2000). Lund 
further subdivides the pro-inflammatory cytokines into Be subgroups; Be1 primed by Th1 
cells and antigen, produce IFN-γ, IL-12 associated with type 1 immune responses; and Be2 
primed by Th2 cells and antigen, produce IL-2, IL-4, TNF-α and IL-6 often associated with 
allergic responses (Lund 2008). Furthermore, B cells may also play a regulatory role by 
modulating the production of IL-10, an anti-inflammatory cytokine that can suppress harmful 
immune responses (Mauri et al. 2003, Fillatreau 2015) or TGF-β1 (Lund 2008). 
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1.2 Bone  
 
1.2.1 Bone structure 
Bone is a specialised connective tissue hardened by mineralisation with calcium phosphate. 
The ground substance of bone consists primarily of glycoproteins and proteoglycans, the 
fibres of bone are composed of type-I collagen impregnated with mineral in the form of 
hydroxyapatite ([Ca3 (PO4)2] Ca (OH) 2). The main function of bone is to provide structural 
support to the human body and locomotion through muscle attachment; however it also serves 
as a mineral reservoir, shields vital organs and facilitates the production of red and white 
blood cells. The rate of bone turnover, collagen matrix, size, structure, geometry and density 
all combine to determine the bone’s overall mechanical properties (Datta et al. 2008).   
There are two main histological types of bone tissue; cortical and trabecular bone (Figure 3). 
In general each bone has an outer cortical layer surrounding the trabecular bone in the centre. 
The cortical bone has an outer membrane called the periosteum consisting of two fibrous 
layers, the inner layer having osteogenic potential enabling new bone formation. In addition, 
the inner surface of cortical bone is lined by the endosteum that also contains osteoblasts and 
osteoclasts. The endosteum is the boundary between the cortical and trabecular bone. Cortical 
compact bone is dense without any cavities; the fundamental unit is the osteon or Haversian 
system, a central vascular canal surrounded by concentric lamellae of mineralised fibres, 
osteocytes are interspersed between lamellae in tiny spaces called lacunae. Volkmann’s canals 
at right angles connect the osteons together. In contrast, the inner trabecular or cancellous 
bone is spongy with numerous cavities and is made up of a three-dimensional scaffold of 
pillars which are constantly modified to accommodate load, it is ideally suited to withstand 
compressive stress. Trabecular bone contains an irregular network of spaces allowing room 
for blood vessels, bone marrow and hematopoietic stem cells. The rate of bone turnover varies 
according to the type of bone, being highest in sites such as vertebrae where trabecular bone 
predominates, and lowest in sites such as the hip composed of cortical bone (Datta et al. 
2008).   
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Figure 3 Illustration of cortical and trabecular bone 
This image was obtained from; SEER - U.S. National Cancer Institute's Surveillance, 
Epidemiology and End Results (https://commons.wikimedia.org/w/index.php?curid=378948) 
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1.2.2 Bone mineral density 
Bone mineral density (BMD) can be described as the amount of bone mass per unit volume 
(volumetric density, g/cm
3
) or per unit area (areal density g/cm
2
), measured in vivo by 
densitometry and reflects the strength of bones characterised by their calcium content (Kanis 
2008). BMD measurements have an important clinical role in the diagnosis of osteoporosis, 
assessment of future fracture risk and monitoring response to treatment (Blake and Fogelman 
2010). Many techniques are available to assess BMD, such as quantitative ultrasound (QUS) 
and quantitative computed tomography (QCT), but the most widely validated technique is 
dual-energy X-ray absorptiometry (DXA), since the absorption of X-rays are very sensitive to 
the calcium content of tissue, of which bone is the most important source (Kanis et al. 2008). 
Nevertheless, the BMD from DXA estimates areal density, the scan is a two-dimensional 
projection image for any given skeletal site and does not entirely control for bone size among 
patients e.g. men tend to have higher BMD than women, based on larger bone size (Blake and 
Fogelman 2010). Additionally, DXA BMD measurement tends to integrate cortical and 
trabecular changes and explains little about the actual structural properties of bone (Nelson et 
al. 2005). BMD can be measured at multiple sites e.g. lumbar spine, hip, forearm, each site 
having unique performance characteristics. The hip being the optimal site for predicting hip 
fracture risk and the spine, because of the metabolically active trabecular bone in the vertebral 
bodies, for monitoring response to treatment (Blake and Fogelman 2009). Although severe 
degenerative changes of the lumbar spine and the presence of compression fractures can result 
in false elevations in BMD measured by DXA (Nelson et al. 2005). The forearm, mainly 
cortical bone in the shaft, is considered less responsive to changes in bone and mineral 
metabolism but should be measured when the other sites are unavailable, when 
hyperparathyroidism is suspected, or in very obese patients (Nelson et al. 2005). 
Technical developments in the measurement of BMD have led to its adoption as the standard 
for diagnosis of osteoporosis, however the relatively poor sensitivity contrasting with high 
specificity means that many potential fractures will be missed if BMD assessment is used 
alone (Rabinda et al. 2011). The World Health Organisation (WHO) has defined osteoporosis 
in postmenopausal women and men above 50 years of age as a femoral neck BMD, measured 
by DXA, of 2.5 standard deviations (SD) or more below the young female adult mean (T-
score), likewise osteopenia is defined as a T-score between –1.0 SD and –2.5 SD below the 
young female, adult mean (Kanis 2004). However, several studies have reported that the 
majority of fragility fractures occur in postmenopausal women that don’t fit these criteria 
(Schuit et al. 2004). Other clinical risk factors such as; body mass index (BMI); previous 
fragility fracture; glucocorticoid therapy; current smoking; alcohol intake exceeding 
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3units/day; RA and other secondary causes of osteoporosis, independently contribute to 
fracture risk (Compston 2015). The inclusion of femoral neck BMD and all these risk factors 
into the fracture risk assessment algorithm (FRAX) 10 year probability of fracture tool, 
significantly improves prediction of hip and major osteoporotic fracture (Kanis 2004).  
The effectiveness of osteoporotic therapy can be assessed by serial BMD measurements 
usually by DXA, but quantifiable changes in bone mass are small and are only apparent after 
twelve to twenty-four months, furthermore they only measure net balance in a very small 
portion of the skeleton (Blank et al. 2006). BMD measurement by DXA is affected by; 
accuracy, largely due to inhomogeneous distributions of adipose tissue in the human body and 
precision errors as discussed below. The magnitude of these errors is especially important for 
the interpretation of follow-up measurements. DXA scanners generally have stable calibration 
and effective instrument quality control procedures to detect any long-term drifts (Blake and 
Fogelman 2010). However, DXA reproducibility is affected by machine and operator error 
plus patient variability i.e. weight or degenerative changes (Blank et al. 2006). Therefore 
BMD changes observed on follow-up scans are interpreted in terms of least significant change 
(LSC) and only changes greater than the LSC are regarded as clinically significant. 
Technologists must properly and consistently position patients on initial and subsequent scans 
and identify and correct errors in analysis. The International Society for Clinical Densitometry 
(ISCD) states that the minimum acceptable precision for an individual technician should be; 
1.9% (LSC 5.3%) at the lumbar spine; 1.8% (LSC 5.0%) at the total hip; and 2.5% (LSC 
6.9%) at the femoral neck (ISCD 2007). Intervals between measurements depend on the 
patient’s clinical status, but given the need to exceed the LSC and the relatively modest 
changes in BMD observed with most treatments it is generally going to be a minimum of 
twelve months before a significant change can be observed. 
 
1.2.3 Bone metabolism 
Bone is a dynamic tissue and is constantly being remodelled throughout an individual’s 
lifetime; beginning before birth and continuing until death. Mature bone tissue is removed 
from the skeleton i.e. bone resorption and new bone tissue is formed i.e. bone formation. 
Generally a state of equilibrium is maintained between these processes and they are tightly 
coupled through a variety of regulatory signals. Approximately twenty percent of bone tissue 
is replaced annually varying by site and type; however a number of factors such as hormones, 
cytokines, disease, medication and nutritional status can influence the rate of bone turnover 
(Carey et al. 2006). In childhood and during the teenage years the balance shifts towards 
formation as the skeleton develops, peak bone mass is reached during the third decade and 
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from then onwards resorption predominates. There are sex-specific differences and women 
normally lose about one to two percent of their bone mass per year as oestrogen levels decline 
after the menopause however, it has been reported that thirty percent of women lose bone at a 
much faster rate (Garnero et al. 2000). Bone remodelling is a highly synchronised process, 
accomplished within basic multicellular units at numerous skeletal sites (Figure 4). 
Resorption is a complex procedure requiring dissolution of the bone mineral and degradation 
of the organic matrix. Initially activated osteoclasts form a sealing zone whereby integrin 
receptors bind to specific amino acids in the organic matrix. Osteoclasts break down bone by 
pumping hydrogen ions across their metabolically active ruffled borders to decalcify the 
inorganic matrix; additionally they release lysomal enzymes; tartrate resistant acid 
phosphatase (TRAP) and cathepsin K, plus matrix metalloproteases (MMPs), which 
effectively digest the exposed type-1 collagen releasing specific degradation products (Schett 
2007). Osteoblasts are attracted to this eroded surface and begin to form new osteoid; 
comprising of type I collagen and non-collagen proteins such as bone sialoprotein, 
osteocalcin, osteonectin, osteopontin and vitamin D3 receptor. Type 1 procollagen is 
synthesised by fibroblasts and osteoblasts; it contains both N (amino) and C (carboxy) 
terminal extensions i.e. propeptides, which are removed by specific proteases during its 
conversion to collagen and its subsequent incorporation into the bone matrix. Osteoblasts also 
secrete bone alkaline phosphatase (BALP) to create sites for calcium and phosphate 
deposition ready for osteoid mineralization (Franz-Odenaal et al. 2006). Initially 
hydroxyapatite crystals are deposited in the osteoid then a slower mineralisation process 
continues over several months, followed by a period of quiescence (Wheater et al. 2013).  
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Figure 4 The bone remodelling cycle 
The skeleton is continuously remodelled throughout life. Bone remodelling involves the removal of bone by 
osteoclasts followed by formation of new bone matrix by osteoblasts. RANKL binds to its cellular receptor 
RANK on pre-osteoclasts and promotes their differentiation and activation. OPG a decoy receptor for RANKL 
can reduce bone resorption by binding to RANKL and preventing further osteoclastic activity. Activated 
osteoclasts create resorption pits with low pH to dissolve the inorganic matrix and lysomal enzymes, such as 
TRAP and cathepsin K, effectively digest the exposed type-1 collagen releasing specific degradation products. 
Osteoblasts are attracted to this eroded surface and begin to form new osteoid. Type-1 pro-collagen is cleaved at 
the amino- and carboxy-terminals releasing propeptides into the blood. Initially hydroxyapatite crystals are 
deposited in the osteoid then a slower mineralisation process continues over several months, followed by a 
period of quiescence (Wheater et al. 2013). 
BALP: bone alkaline phosphatase; CTX: carboxy-terminal cross-linked telopeptides of type I collagen; DPD: 
deoxypyridinoline; NTX: amino-terminal cross-linked telopeptide of type I collagen; OPG: osteoprotegerin; 
PICP: procollagen type 1 carboxy-terminal propeptide; PINP: procollagen type 1 amino-terminal propeptide; 
PYD: pyridinoline; RANK: receptor activator of nuclear factor kappa B; RANKL: receptor activator of nuclear 
factor kappa B ligand; TRAP: tartrate resistant acid phosphatase
. 
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1.2.4 Bone cell differentiation and regulation 
There are three basic types of bone cell; osteocytes, osteoblasts and osteoclasts. This brief 
summary describes their respective differentiation from progenitor cells and local regulation. 
 
Osteocytes 
Osteocytes are the most abundant cells in bone, it is estimated that there are over forty-two 
billion osteocytes in the adult human skeleton (Buenzli and Sims 2015). Osteocytes originate 
from mesenchymal stem cells through osteoblast differentiation (Figure 5), whereby 
osteoblasts can; become encased in mineralised osteoid as osteocytes, remain inactive 
osteoblasts, bone-lining cells or undergo programmed cell death (Franz-Odenaal et al. 2006). 
Osteocytes occupy small pores in the bone called lacunae, they connect with each other, to 
cells on the mineralised surface or to blood vessels via elongated dendritic processes 
contained within fluid filled micro-canals or canaliculi. This osteocytic lacunar-canalicular 
system allows the transport of proteins produced and secreted by osteocytes to act on other 
cells or tissues. Historically it was believed that osteocytogenesis was a passive process, 
however recent evidence particularly in a mouse model, suggests that the osteocyte network is 
a highly complex communication system and osteocytogenesis is an active invasive process, 
dependent on membrane-type matrix metalloproteinase 1 (MT1-MMP) and continuous 
cleavage of type-I collagen for maintenance of the osteocyte phenotype (Holmbeck et al. 
2005). Recent reviews exploring osteocyte function have also recognised that osteocytes are; 
mechanosensory cells responsible for the maintenance of bone structure and mass, important 
regulators of both osteoclastic and osteoblastic activity and key endocrine cells with a role in 
phosphate and calcium metabolism (Dallas and Bonewald 2010, Bonewald 2011, Buenzli and 
Sims 2015). In vivo studies have shown that osteocyte depletion results in profound loss of 
trabecular bone mass (Noble et al. 2003, Gross et al. 2005, You et al. 2008), and suggest a 
close interaction between osteocytes and other bone cells, highlighting their role in the 
regulation of both bone formation and resorption. Recent research has focused on treatments 
targeting the Wnt signalling pathway in the management of osteoporosis and related bone 
diseases. 
Osteocytes can regulate osteogenesis through direct contact with osteoblasts via their 
dendritic processes. The critical signalling pathways described for osteoblast differentiation 
and maturation are either; canonical wingless-int (Wnt)/ β-catenin or non-canonical. Frizzled 
(Fz), low-density lipoprotein receptor-related protein (LRP)5 and LRP6 are co-receptors for 
transduction of canonical Wnt signalling that leads eventually to β-catenin stabilization and 
regulation of gene transcription (Datta et al. 2008). Dickkopf (DKK) proteins and sclerostin 
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(SCL), a product of the Sost gene, are both  secreted by osteocytes and bind to LRP5 and 
LRP6 preventing activation of Wnt signalling in the canonical pathway and also oppose bone 
morphogenetic protein (BMP) action (Li et al. 2005). Similarly, osteocytes can influence 
osteoclastogenesis as they are a major source of receptor activator of nuclear factor - κb 
ligand (RANKL) (Nakashima et al. 2011) and osteoprotegerin (OPG) (Kramer et al. 2010). 
Additionally research has targeted the complex regulation of osteocyte action by expression 
of the parathyroid hormone (PTH)/ PTH related protein (PTHrP) receptor’s (PPR’s). 
Osteocyte activation of PPR leads to down-regulation of Sost and increased Wnt signalling 
stimulating bone formation, accompanied by up-regulation of RANKL expression and 
osteoclast number increasing resorption. In contrast the main effect of PPR deletion on 
osteocytes is reduced osteoclast and osteoblast numbers and decreased bone remodelling 
(Bellido et al. 2013). 
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Figure 5 Graphical representations of the pathways leading particularly to osteoblast 
and osteocyte differentiation from mesenchymal stem cells 
Mesenchymal stem cells have the capacity to differentiate into a number of cell types including both osteoblasts 
and osteocytes, in addition to dermal cells, chondrocytes, myoblasts, stromal cells, fibroblasts and adipocytes 
depending on the local environmental factors to which they are exposed. 
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Osteoblasts 
Osteoblasts are mononuclear cells of mesenchymal origin (Figure 5) they are committed bone 
precursor cells responsible for osteogenesis. Osteoblast numbers are therefore dependent on 
the rate of mesenchymal cell proliferation and differentiation into osteoblasts, which depends 
on multiple transcription factors and regulatory signals, and also on osteoblast apoptosis. 
RUNX2, osterix (OSX), homeobox proteins; MSX2, DLX3, DLX5, DLX6 and members of 
the activator protein-1 (AP-1) family such as Fos and activating transcription factor-4 (ATF4) 
have all been reviewed and established as critical transcription factors for osteoblast 
formation (Gonciulea and Jan de Beur 2015). Additionally, Wnt/ β-catenin, BMP a 
transforming growth factor-beta (TGF-β) super-family member and insulin-like growth 
factor-1 (IGF-1) provide the regulatory signals for osteoblast formation (Gonciulea and Jan de 
Beur 2015). Osteoblasts are found in the growing portions of bone, including the periosteum 
and endosteum and they are responsible for making osteoid. Following matrix formation the 
majority of osteoblasts die by apoptosis or either become incorporated in the matrix as 
osteocytes or remain on the surface as bone lining cells (Franz-Odenaal et al. 2006). 
 
Osteoclasts 
Osteoclasts are end-differentiated cells formed from circulating precursors of the monocyte/ 
macrophage lineage (Figure 1) from hematopoietic stem cells (HSC). The precursor cells 
migrate to the bone microenvironment and fuse together depending on local regulatory factors 
(Schett 2007). Osteoclasts are large, highly specialized, multinucleated cells (Figure 6) and 
are specialized in bone resorption. Osteoclastogenesis is critically dependent on two factors; 
macrophage-colony stimulating factor (M-CSF), a polypeptide growth factor and RANKL, a 
TNF related cytokine. M-CSF binds to colony-stimulating factor 1 receptor (c-fms), on 
osteoclast precursors and triggers their survival and proliferation (Figure 7). RANKL, 
expressed on the surface of osteoblasts, binds to its cellular receptor; receptor activator of 
nuclear factor - κb (RANK) on pre-osteoclasts and promotes their differentiation and 
activation (Blair and Zaidi 2006). Conversely, OPG a decoy receptor secreted by osteoblasts 
and other stromal cells can reduce bone resorption by binding and neutralising RANKL, thus 
inhibiting osteoclastogenesis and inducing osteoclast apoptosis (Lacey et al 1998).  
 
 
 
 
Chapter 1                                                                                                      General Introduction 
17 
 
 
 
Figure 6 Osteoclast cells stained with tartrate resistant acid phosphatase 
Osteoclasts are the cells responsible for bone resorption. This image shows giant multinucleated osteoclasts with 
ruffled borders that have stained positive for tartrate resistant acid phosphatase. 
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Figure 7 Osteoclast differentiation 
Osteoclasts are derived from the hematopoietic cell lineage. M-CSF and RANKL are both required and provide 
the necessary signals enabling promyeloid precursor cells to differentiate into mature osteoclasts. M-CSF acts 
through its receptor c-Fms and stimulates the proliferation and prevents the apoptosis of early osteoclast 
precursors. RANKL, a tumour necrosis family member, targets specialized osteoclast differentiation specifically 
in the bone marrow milieu. RANKL binds and activates its cellular receptor RANK thereby inducing a signalling 
cascade leading to the differentiation and fusion of osteoclast precursor cells. The effects of RANKL can be 
counterbalanced by OPG, a soluble decoy receptor which binds and neutralises RANKL, thus inhibiting 
osteoclastogenesis and inducing osteoclast apoptosis.  
M-CSF: macrophage colony- stimulating factor; OPG: osteoprotegerin; RANK: receptor activator of nuclear 
factor - κb; RANKL: receptor activator of nuclear factor - κb ligand; TRAP: tartrate resistant acid phosphatase. 
  
Chapter 1                                                                                                      General Introduction 
19 
 
The production of RANKL and OPG by osteoblasts is influenced by hormones (PTH, 
oestrogen, glucocorticoids); growth factors (BMP, IGF1, TGF-β) and cytokines (TNF-α, IL-1, 
IL-6, IL-17) and the balance between RANKL and OPG can therefore determine the degree of 
osteoclastic bone resorption (Geusens 2012, Gonciulea and de Beur 2015).  RANKL-RANK 
interactions also involve downstream signalling molecules; TNF receptor-associated factor-6 
(TRAF-6) activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κb); a 
family of dimeric transcription factors that recognise a common DNA sequence called the κb 
site, and finally nuclear factor of activated T cells cytoplasmic-1 (NFATc1) leading to an 
increase in intracellular calcium and tyrosine phosphorylation (Asagiri and Takayanagi 2006). 
Current evidence suggests that osteoclast-associated receptor (OSCAR) and a triggering 
receptor expressed on myeloid cells-2 (TREM-2) are also involved (Datta et al 2008). 
OSCAR is expressed by pre-osteoclasts and signals via an adapter molecule Fc receptor 
gamma chain (FcRγ) (Barrow et al. 2011), which has an immuno-receptor tyrosine-based 
activation motif (ITAM) that is critical for the activation of calcium signalling. DNAX 
activation protein-12 (DAP12), another ITAM –harbouring adaptor is also involved. The 
precise mechanism is not yet understood however, cooperation between RANK, OSCAR and 
TREM-2 signalling leads to an increased phosphorylation of ITAM.  
 
1.2.5 Biochemical markers of bone turnover 
The rate of bone turnover can be assessed by the measurement of specific proteins/ enzymes 
generated during the bone remodelling process (Figure 4) and released into the blood. Bone 
turnover markers (BTMs) have been used in research for a long time but they have only 
recently found a niche in the clinical management of bone diseases. However, BTMs are not 
known to control skeletal metabolism and are not disease specific; they reflect the entire 
skeleton regardless of the underlying cause. Furthermore, several BTMs are present in tissues 
other than bone and can therefore be influenced by non-skeletal processes (Seibel 2005). 
BTMs can be measured in blood or urine and are used in selective combinations of formation 
and resorption markers that express the metabolic activity of osteoblasts or osteoclasts 
respectively. Over the last few years new markers have been identified and new sensitive 
assays have been developed that are more specific to the bone matrix, currently there is an 
extensive list of BTMs available and this makes it very difficult to compare research 
evidence. Many of these assays have now been automated, improving their reliability, speed 
and cost effectiveness for clinical practice. Nevertheless, analytical aspects such as within and 
between batch precision, accuracy and standardisation, remain problematic (Seibel et al. 
2001). An American study in 2010 compared six commercial laboratories over an eight month 
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period and concluded that reproducibility varied substantially for urine NTX and serum 
BALP (Schafer et al. 2010). The International Osteoporosis Foundation, the International 
Federation of Clinical Chemistry and Laboratory Medicine (Vasikaran et al. 2011) and the 
National Bone Health Alliance (Bauer et al. 2012), have recommended that a marker of bone 
formation; procollagen type 1 amino-terminal propeptide (PINP) and bone resorption: 
carboxy-terminal cross-linked telopeptides of type I collagen (CTX), are used as reference 
analytes in all future clinical studies. Furthermore they stipulate that these markers should be 
measured by standardised assays to minimise immunochemical heterogeneity and recommend 
that manufacturers adopt international reference standards and minimise batch to batch 
variability (Vasikaran et al. 2011). Moreover, the regulation of pre-analytical sample 
collection has also been recognised to minimise the effects of biological variation. Bone 
turnover shows a circadian rhythm, this is more obvious in markers of bone resorption; βCTX 
is highest between 01:30 and 04:30 hours and may be more than twice that at the nadir 
between 11:00 and 15:00 hours (Wichers et al. 1999), but this disparity is diminished with 
fasting (Bjarnason 2002). Bone formation markers osteocalcin and PICP follow the same 
diurnal pattern but show only twenty percent difference and BALP has two peaks at 14:00 and 
23:30 hours with a nadir thirty percent reduced at 06:30 (Hannon and Eastell 2000). Blood 
samples should therefore be collected early morning and following an overnight fast to 
diminish these effects. The advantages and disadvantages of using individual markers of bone 
formation and resorption have recently been reviewed; a summary is included in Table 1 
(Wheater et al. 2013).  
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Table 1 Major advantages and disadvantages of commonly used bone turnover markers 
BONE MARKER ADVANTAGES DISADVANTAGES SAMPLE   
Bone alkaline phosphatase (BALP) Low intra-individual  variability  <10% , not affected by renal 
function (Brown et al. 2009) 
Food has little effect (Clowes et al. 2002) 
Long circulatory half-life  1-2 days (Swaminathan 2001) 
Sample stability (Quist et al. 2004) 
Up to 20% cross reactivity with liver isoforms; 2 peaks at 14:00 and 
23:30hrs, nadir 30% ↓at 06:30 (Seibel 2005) 
Changes with therapy minimal i.e. less than LSC of 25% (Brown et al. 
2009) 
Multiple methodologies, can measure mass or activity (Vasikaran et al. 
2011) 
Automated and manual 
immunoassays 
Serum, EDTA plasma 
Osteocalcin  
 
EDTA sample more stable (Stokes et al. 2011) 
Late marker of osteoblast activity (Brown et al. 2009) 
Intact molecule unstable, Influenced by Vit K status, renal function and 
circadian variability (Brown et al. 2009) 
Large inter-lab variation (Vasikaran et al. 2011) 
Released during formation and resorption (Swaminathan 2001) 
Short half-life of a few minutes (Blumsohn et al 1995) 
Osteocalcin gene regulated at transcriptional level by 1,25(OH)2 D3 
(Seibel 2005) 
Automated and manual 
immunoassays 
Multiplex microarray 
Serum, EDTA plasma 
Procollagen type 1 amino-terminal 
propeptide (PINP) 
Low intra-individual variability and good assay precision 
(Vasikaran et al. 2011) 
Small circadian rhythm (Brown et al. 2009) 
Stable at room temp (Stokes et al. 2011) 
Change from baseline ↓up to 80% with anti-resorptive and ↓up to 
200% with PTH medication within 3months (Brown et al. 2009) 
Total assay affected by delayed clearance of monomeric fraction  e.g. in 
renal failure or metastatic bone disease (Marin et al. 2011) 
 
Automated and manual 
immunoassays 
Multiplex microarray 
Total or Intact fractions 
Serum, EDTA plasma 
Carboxy-terminal cross-linked 
telopeptides of type 1 collagen  
(CTX) 
Variability↓  fasting (Bjarnson et al. 2002) 
Sample stability, especially EDTA (Stokes et al. 2011) 
Substantial ↓ post anti-resorptive treatment (Bergmann et al. 2009) 
Blood sample now preferential 
Large circadian variation – highest values between 01:30 – 04:30  of 
approx. 2x nadir  at 11:00-15:00 (Wichers et al 1999) 
Automated and manual 
immunoassays 
Multiplex microarray 
Urine , serum, EDTA 
plasma 
Tartrate resistant acid phosphatase 
–isoform 5b (TRAP5b) 
Characteristic of osteoclastic activity (Seibel 2005) 
 
Unstable at room temperature (Halleen et al. 2000) 
Circadian variability ↑ immediately after exercise (Rogers et al. 2011) 
Manual immunoassays. 
Serum 
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Bone formation markers 
Bone formation markers are osteoblastic enzymes or by-products of osteoblast formation 
measured in plasma or serum. The most commonly measured bone formation markers include 
PINP, osteocalcin and BALP. More than ninety percent of organic bone matrix consists of 
type I collagen, which is derived from type I procollagen synthesised by fibroblasts and 
osteoblasts. Type I procollagen contains both N (amino) and C (carboxy) terminal extensions 
(propeptides), which are removed by specific proteases during the conversion of procollagen 
to collagen (Figure 7) and its subsequent incorporation into the bone matrix. PINP is widely 
used and is the marker of choice (Vasikaran et al. 2011), procollagen type I carboxy-terminal 
propeptide (PICP) has a short half-life of six to eight minutes and is cleared by liver 
endothelial cells via the mannose receptor so is sensitive to certain hormones, PINP on the 
other hand is cleared via the scavenger receptor (Hannon and Eastell 2006). Osteocalcin is the 
most abundant non-collagen protein in the bone matrix and is bound to hydroxyapatite via 
three vitamin K dependent, gamma-carboxyglutamic acid residues, enabling binding to 
calcium. During bone synthesis it is produced by osteoblasts and is stimulated by vitamin D3 
(Rosenquist et al. 1995). Although osteocalcin is also released during bone resorption and is 
therefore regarded as a marker of bone turnover (Seibel 2005). BALP is present in osteoblast 
plasma membranes and is released into the circulation after enzymatic cleavage by 
phospholipase during mineralisation of osteoid. BALP activity or mass concentration can be 
measured in serum with comparable results (Avbersek-Luznik et al. 2007). 
 
Bone resorption markers 
The majority of bone resorption markers are degradation products of bone collagen, the 
exception being tartrate-resistant acid phosphatase (TRAP) and cathepsin K. Historically 
urinary markers were used and relied on complete twenty-four hour collections or creatinine 
ratios. Type I collagen has a triple helix structure, the strands are stabilised by intra-molecular 
covalent cross-links between lysine or hydroxylysine residues that join the non-helical end of 
one collagen molecule to the helical portion of the adjacent molecule. There are two major 
cross-link molecules, pyridinoline (PYD) and deoxypyridinoline (DPD), formed 
extracellularly after the collagen is deposited in the bone matrix. These cross-linked 
molecules are released into the circulation from bone during the breakdown of mature 
collagen only and are excreted in the urine as free molecules. DPD is the more bone specific 
marker as PYD is also found in type II collagen (Hannon and Eastell 2006). Type I collagen 
alpha 1 helicoidal peptide (HELP)  can also be measured, preferably in a twenty-four hour 
urine sample, it is cleaved from the helical region of type I collagen by cathepsin K during 
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bone resorption (Seibel 2005). Approximately sixty percent of the cross-links are released in 
the form of peptide bound molecules, namely carboxy-terminal and amino-terminal cross-
linked telopeptides of type I collagen (CTX and NTX respectively). CTX is generated by 
cathepsin K activity, the CTX epitope contains an aspartyl-glycine motif that is susceptible to 
spontaneous isomerisation and racemisation generating four isoforms (Swaminathan 2001); 
the α-aspartic acid converts to the β-form as the bone ages. Specialized serum immunoassays 
are now available that target βCTX indicative of the breakdown of mature type I collagen, this 
is currently the preferred marker of bone resorption (Vasikaran et al. 2011). NTX is also 
cleaved by cathepsin K and can be measured by specific immunoassays but is less often used. 
Carboxy-terminal cross-linked telopeptide -MMP (CTX-MMP) cleaved from type I collagen 
by MMP can also be measured in serum by a manual immunoassay but is less responsive to 
the usual osteoporotic treatments (Vasikaran et al. 2011). There are at least five different 
isoforms of acid phosphatase expressed by different tissues and cells in the body and all are 
inhibited by L(+) tartrate except band 5. The polypeptide chain of TRAP is cleaved by 
proteases into two distinct sub-forms 5a and 5b, which activate phosphatase activity; TRAP-
5a is thought to be expressed by macrophages and TRAP-5b is present in large quantities in 
the ruffled border of osteoclasts and reportedly reflects osteoclast numbers (Alatalo et al. 
2004). Activated osteoclasts secrete TRAP5b which then cleaves type I collagen into 
fragments. Finally cathepsin K, a cysteine protease present in the ruffled border of actively 
resorbing osteoclasts that cleaves telopeptide and helical regions of type I collagen can be 
measured in serum by manual immunoassay. However, it is unstable at room temperature and 
the clinical validity of the assay needs further investigation (Seibel 2005).  
 
Osteocyte markers 
Osteocytes produce various factors that can be measured in serum such as SCL, DKK-1, 
dentin matrix protein-1 (DMP-1) and matrix extracellular phosphoglycoprotein (MEPE). 
Currently these assays are only used in research; their diagnostic importance has yet to be 
validated due to their large analytical and biological variability (Wheater et al. 2013). SCL 
levels correlate positively with age, body mass index (BMI) and BMD and negatively with 
osteocalcin and calcium (Amrein et al. 2012). Serum SCL levels are regulated by both 
oestrogens and PTH in postmenopausal women (Mirza et al. 2010); levels are decreased in 
women with postmenopausal osteoporosis compared with non-osteoporotic early 
postmenopausal women and positively correlated to lumbar spine BMD. Furthermore, levels 
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are increased after 6 months treatment with risedronate, but remain essentially unchanged 
after 6 months teriparatide treatment (Polyzos et al. 2012). 
  
Osteoclastogenesis markers 
Osteoclast regulatory proteins are measured in research only. A limited number of 
commercial assays are available to measure these proteins but with limited success (Bowsher 
and Sailstad 2008). RANKL is expressed in vivo in either a membrane-bound or soluble form. 
Additionally, in serum it can be either a free molecule or OPG-bound, as a consequence there 
have been methodological differences between immunoassays making it difficult to compare 
results. Furthermore, circulating RANKL levels may not reflect the bone microenvironment 
(Kearns et al. 2008). 
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1.3 Interactions between the immune and skeletal systems 
Osteoimmunology is a research field focused on the molecular understanding of the interplay 
between the skeletal and immune systems. The close interaction between immune progenitors 
and the skeleton is facilitated by their proximity in the bone marrow and a number of cell 
surface receptors, cytokines and signalling pathways serve a critical role in both systems 
(Datta et al. 2008). Crosstalk between bone cells and B cells is bidirectional, in that bone cells 
can regulate the development and maturation of B cells and B cells can regulate both 
osteoblastic and osteoclastic activity under different physiological and pathological 
conditions. The mechanisms that underlie these interactions are only partially understood as is 
the precise role of B cells in bone turnover. The following section contains a brief overview of 
the interactions between B cells and bone cells and the factors that influence them. 
 
1.3.1 Osteoblasts and B cells  
The differentiation of hematopoietic progenitors in the bone marrow requires specific 
microenvironments or ‘niches’ provided by various subsets of  stromal cells; osteoblast 
lineage cells play a supportive role here particularly in the maintenance of B lymphopoiesis. 
Osteoblasts are mononuclear cells of mesenchymal origin, the transcription factor RUNX2 is 
required for osteoblastogenesis reinforced by OSX and evidence of osteoblast maturation 
comes from the expression of BALP, type I collagen and non-collagen proteins; osteocalcin 
and osteopontin. Panaroni and Wu (Panaroni and Wu 2013) suggest that it is the earlier 
developmental stages of the osteoblast lineage that are crucial to B lymphopoiesis and these 
osteoblastic cells are an important source of both C-X-C motif chemokine 12 (CXCL12); 
necessary for the development of early B cell precursors and their retention in the bone 
marrow and IL-7; important for progression to pre-B cells. Most of this evidence for the 
osteoblastic support of B cell development comes from murine studies. One such study has 
shown that cells of the osteoblastic lineage are both necessary and sufficient for murine B cell 
commitment and maturation from HSCs via lymphoid progenitors. HSCs cultured on purified 
osteoblasts in vitro stimulated B cell differentiation by; vascular cell adhesion molecule 1 
(VCAM-1), stromal cell-derived factor 1 (SDF-1 also known as CXCL12) and IL-7 signalling 
pathways induced by PTH. To confirm osteoblastic involvement cytokines produced by non-
osteoblastic cells i.e. c-Kit ligand, IL-6 and IL-3, were added and the authors found that HSC 
differentiation shifted towards myelopoiesis. Furthermore, selective elimination of osteoblasts 
in vivo resulted in severely depleted early B cell lineages (Zhu et al. 2007). Expression of both 
CXCL12 and IL-7 is increased by PTH, in a further study blockade of PTH signalling by 
ablation of the heterotrimeric G protein α subunit (GSα); a major downstream mediator of 
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PPR signalling, led to a 59% decrease in the number of B cells in the bone marrow but not in 
the other hematopoietic lineages and IL-7 expression was diminished in GSα-deficient 
osteoblasts (Wu et al. 2008). 
 
1.3.2 Osteoclasts and B cells  
The role of osteoclasts in B cell development is uncertain. A murine study of zoledronate-
induced osteopetrosis in normal mice found a decrease in B cell numbers in the bone marrow 
which was not directly related to zoledronate. The zoledronate did not directly affect the B 
cell differentiation, proliferation or apoptosis but induced a decrease in CXCL12 and IL-7 
expression by stromal cells associated with osteoblastic activity, the authors further confirmed 
that the results were due to reduced osteoclastic activity; zolendronate did not directly affect 
the osteoblasts (Mansour et al. 2011). The authors concluded that osteoclasts can modulate B-
cell development in the bone marrow by controlling the bone microenvironment and the 
osteoblastic activity but they could not rule out the hypothesis that osteoclasts may directly 
affect B lymphopoiesis. A study by Manabe et al proposed a further link between osteoclast 
and B cell differentiation; klotho mutant mice (KL
-/-
); the mouse model for human ageing that 
has reduced bone turnover during bone metabolism rather than a decrease in the 
differentiation potential of osteoclast progenitors, exhibited a decrease in osteoclasts 
associated with a decrease in B cells (Manabe et al. 2001). Additionally, they reported that 
early developmental stage B cells have the potential, when stimulated by M-CSF and 
RANKL, to differentiate into osteoclasts in vitro (Manabe et al. 2001). But these findings 
were later challenged in another study using fluorescence-activated cell sorting (FACS) to 
identify subsets of bone marrow cells that had osteoclastogenic potential, the authors reported 
that highly purified CD45
+
 bone marrow cells were not capable of osteoclastogenesis in vitro 
(Jacquin et al. 2006). The Pax5 gene codes for the transcription factor B cell lineage-specific 
activation factor (BSAP); Horowitz et al. show that Pax5
-/-
 mice have a development arrest of 
B cell lineage at the pro-B cell stage they are also osteopenic with a 100% increase in 
osteoclast numbers and 60% reduction in their bone mass, the authors suggest that Pax5 is a 
possible transcription factor for normal regulation of osteoclastogenesis (Horowitz et al. 
2004). 
 
1.3.3 B cells and the RANK-RANKL-OPG system 
Bone homeostasis is delicately balanced between bone resorption by osteoclasts and bone 
formation by osteoblasts in healthy individuals and osteoclastogenesis is controlled by the 
ratio of RANKL to its decoy receptor OPG. B cells can produce the pro-osteoclastogenic 
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cytokine RANKL (Choi et al. 2001) and under pathologic conditions such as RA this process 
is markedly enhanced by pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-17 
(Schett 2006). Furthermore, in a recent study Yeo et al. assessed the cytokine messenger RNA 
expression profiles in CD4 and CD8 T cells, B cells, macrophages and neutrophil populations 
in synovial fluid and in the peripheral blood of twelve RA patients and found that B cells had 
the highest expression of RANKL (Yeo et al. 2011). However, B cells can also produce OPG; 
the cytokine that inhibits osteoclast differentiation from the progenitor cells (Weitzmann et al. 
2000). In vivo animal studies on the role of mature B cells in bone remodelling have been 
equally inconsistent. In a murine study, five weeks after ovariectomy, bone turnover remained 
imbalanced with increased osteoclastogenesis and decreased bone formation but there was an 
increase in B cells expressing RANKL with normal or decreased T cells (Garcia-Perez et al. 
2006). In contrast, Li et al report that cells of the B lineage are responsible for 64% of the 
total bone marrow OPG production, with 45% from mature B cells. Furthermore T cells 
through CD40 ligand to CD40 co-stimulation promote OPG production by B cells. B-cell 
knockout mice were consistently osteoporotic and deficient in OPG; the RANKL/OPG ratio 
had increased in favour of RANKL activated osteoclastogenesis in these mice, generating 
more TRAP
+
 osteoclast-like cells (Li et al. 2007). The authors suggest that the production of 
OPG by B cells outweighs the production of RANKL under basal conditions (Li et al. 2007). 
It appears that mature B cells have the capacity to both inhibit and stimulate 
osteoclastogenesis. It is not therefore surprising that while some studies have shown B cells to 
stimulate osteoclastogenesis, others have shown that B cells are inhibitory. It is now known 
that B cells contribute to RANKL production in the inflamed rheumatoid joint (Yeo et al. 
2011) and in particular switched memory B cells have the greatest propensity to produce 
RANKL (Meednu et al. 2015). Meednu et al. hypothesise that the role of B cells in bone 
erosion is developmental and stage-dependent; they confirmed that stimulated B cells promote 
in vitro osteoclastogenesis from monocytes in a RANKL dependent manner (Meednu et al. 
2015). Recently a subset of B cells, expressing FcRL4, has been identified in the rheumatoid 
synovium that are capable of producing RANKL and TNF-α and these pathogenic B cells are 
reportedly not found in healthy individuals (Yeo et al. 2015). FcRL4
+
 B cells also express 
high levels of CD20 and are therefore significantly reduced with rituximab (RTX) (Yeo et al. 
2015).  
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1.4 Rheumatoid arthritis 
 
1.4.1 Epidemiology 
RA is a progressive, systemic, autoimmune disease, characterised by widespread and 
persistent inflammation of the synovial lining of the joints and tendon sheaths. The typical 
age of onset is 20 to 45yrs and over 75% of patients are female (Silman and Pearson 2002). 
The prevalence of RA in the United Kingdom (UK) is approximately 1.2% in women and 
0.44% in men (Symmons et al. 2002). The skeletal complications of RA consist of focal 
erosion of marginal and subchondral bone, juxta-articular osteoporosis and generalised bone 
loss with reduced bone mass. The prevalence of osteoporosis in RA patients ranges from 25 to 
50%, depending on the history of prednisone therapy (Kelly et al. 2002).  The consequences 
of this profound bone loss are painful joints, loss of physical function, fatigue and together 
with the other symptoms of RA have a major impact on social life. The disease is costly to 
individuals and their families and to society as a whole in both economic and social terms. 
RA causes significant functional disability by the first decade of onset in about 50% of 
patients, with an approximate life expectancy reduction of up to 18yrs in 80% of the patients 
after the second decade of progression (Kosinski et al. 2002). Although the aetiology of RA is 
largely unknown and no cure exists, treatments have been developed to target pain reduction, 
improvement in physical function and reduction in disease progression (Scott et al. 1987). 
 
1.4.2 Pathogenesis of bone loss in rheumatoid arthritis 
Under physiological conditions bone remodelling is a tightly controlled process in which the 
equilibrium is maintained between bone formation and bone resorption. In pathological states 
such as RA, there is a shift towards increased resorption. RA is associated with a generalized 
skeletal bone loss, in addition to periarticular osteopenia and local bone erosions, summarised 
in Table 2. RA patients have an increased risk of vertebral and non-vertebral fractures 
compared with age and gender-matched controls; this risk is increased in patients with 
longstanding disease, low BMI and in those taking oral glucocorticoids (van Staa et al. 2006).  
Early RA patients have an annual decrease of -2.4% and -4.3% of BMD at the lumbar spine 
(LS) and femur respectively (Gough et al. 1994). Additionally some studies have reported that 
the greatest reduction in bone density occurs at the foreram sites and that forearm BMD 
correlates with clinical features of disease activity and markers of bone turnover (Franck and 
Gottwalt 2009). Several factors such as disease activity, female gender, older age, 
glucocorticoid use and decreased mobility are known to promote generalised bone loss with 
reduced bone mass in RA patients. However disease activity is the major predictor and is 
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independent of the other factors (Schett 2006). Furthermore, RA patients are reported to have 
lower levels of total 25-hydroxyvitamin D (25OHD) and this is associated with increased 
disease activity and musculoskeletal pain (Kostoglou-Athanassiou et al. 2012). Serum 
25OHD is also negatively associated with the disease activity score (DAS)28, erythrocyte 
sedimentation rate (ESR), platelets, IL-17 and IL-23 and patients with osteoporosis and 
osteopenia have significantly lower levels of 25OHD than those with normal BMD (Hong et 
al. 2014).  
In contrast, the main cause of periarticular bone loss and marginal joint erosions is chronic 
inflammation of the synovial membranes. Osteoclasts have been highlighted as mediators of 
this erosive process, additionally inhibition of the Wnt signalling pathway results in 
impairment of bone formation resulting in a lack of repair of the erosions (Deal 2012). The 
synovial membrane is transformed into hypertrophic inflammatory tissue, based on the influx 
of inflammatory cells including B cells and osteoclast differentiation appears to be enhanced 
leading to increased bone resorption (Jimenez-Boj et al. 2005).  These are areas of high bone 
breakdown, activated osteoclasts secrete TRAP-5b which then cleaves type I collagen into 
fragments, CTX is released into the circulation and is indicative of this increased breakdown 
of mature type I collagen. The bone compartment in closest proximity to the inflammed joints 
suffer the most severe damage (Schett 2006). RANKL is expressed by osteoblasts and 
activated T and B cells, upregulation of RANKL by pro-inflammatory cytokines such as 
TNF-α, together with decreased levels of OPG are thought to be responsible for the increased 
osteoclastogenesis and therefore bone resorption in RA patients (Haynes et al. 2001, Xu et al. 
2012). Furthermore, bone formation is also suppressed; DKK-1 is upregulated in the inflamed 
synovium and in cartilage adjacent to inflammatory tissue, possibly mediated by TNF-α 
(Diarra et al. 2007). DKK-1 suppresses Wnt signalling leading to decreased bone formation 
and suppression of OPG contributing to the overall bone loss and decreased levels of bone 
formation markers such as PINP and BALP in blood. However, these biomarkers represent 
total bone cell activity and cannot distinguish local from generalised bone loss in RA. BTMs 
are used in research in selective combinations of formation and resorption markers that 
express the metabolic activity of osteoblasts or osteoclasts respectively, they are not known to 
control skeletal metabolism and are not disease specific; they reflect the entire skeleton 
regardless of the underlying cause (Seibel 2005). Nevertheless, bone resorption and formation 
markers can be correlated with inflammatory markers (CRP, ESR) and disease activity 
(DAS28) and with lumbar spine, hip and forearm BMD to help clarify the cause of the bone 
loss. Additionally, Bieglmayer and Kudlacek (Bieglmayer and Kudlacek 2009) have 
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suggested combining a marker of formation and resorption to gain a direct insight into the 
changes in the balance of bone turnover in relation to a reference value.
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Table 2 Types of bone loss in rheumatoid arthritis 
 
 Focal bone erosions 
 
Periarticular osteopenia Generalized skeletal bone loss 
Clinical features 
(Deal 2012) 
Joint erosions Loss of trabeculae Reduced bone mass 
 
Contributing factors 
(Deal 2012 unless otherwise 
stated) 
 
 
 
 
 
 
 
Chronic inflammation of synovial 
membranes  
Increased osteoclast precursors (monocytes) 
Inflammatory B and T cells (Jimenez-Boj et al. 
2005) 
Pro-inflammatory cytokines (TNF-α) (Schett 
2006) 
Pro-osteoclastogenesis factors (RANKL) 
Up-regulated DKK-1  
 
Inflammatory cytokines from 
synovium triggering osteoclast-
mediated bone loss  
 
Disease activity (Schett 2006) 
Female gender  
Older age 
Glucocorticoid use  
Decreased mobility 
Decreased vitamin D (Kostoglou-
Athanassiou et al. 2012) 
 
Bone biomarkers 
(Deal 2012 unless otherwise 
stated) 
↑ bone resorption  
↑ DKK-1 (Diarra 2007) 
↓ bone formation  
 
Inhibition of bone formation Bone resorption ˃ bone formation 
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1.4.3 Pathway of care 
The presentation of RA and its prognosis are highly variable both within and between 
individuals, involving genetic and environmental factors and possibly chance (McInnes and 
Schett 2011). Because of this variety in disease expression the pathway of care for RA is 
diverse and dependent on individual patient responses to therapies. The current strategy is to 
start therapy as soon as possible after diagnosis and to escalate the treatment to achieve 
clinical remission; as assessed by disease activity (McInnes and Schett 2011). Bakker et al. 
evaluated the results of four clinical trials; FIN-RACo, TICORA, BeSt and the CAMERA 
study and found that the current concept of ‘tight control’ resulted in greater improvement and 
a higher percentage of patients achieving remission compared to placebo (Bakker et al. 2007). 
Treatment traditionally started with disease modifying anti-rheumatic drugs (DMARD's) 
including methotrexate (MTX), sulfasalazine, leflunomide and glucocorticoids, however the 
current strategy is to use a combination of conventional DMARDs and biologics (Bakker et 
al. 2007). The development of biologic therapies targeting TNF (adalimumab, etanercept and 
infliximab) resulted in further improvements in outcomes related to the capacity of these 
treatments to retard radiographic progression of the disease and improve physical function, as 
reported in the ARMADA trial (Weinblatt et al. 2003). However, their use has been limited 
by their high costs and the uncertainty about the long term side effects. There is now evidence 
that B cells contribute significantly to the pathogenesis of RA and the focus of new biological 
therapies therefore target B cell depletion. RTX was the first B cell depleting agent used in 
combination with MTX, it is licensed for the treatment of adults with severe active RA who 
have had an inadequate response to, or intolerance of other DMARD’s, including one or more 
TNF-α inhibitors (NICE technology appraisal guidance - TA195 August 2010). RTX is a 
genetically engineered, chimeric mouse-human, monoclonal antibody that depletes the B-cell 
population by targeting cells bearing the CD20 surface marker. This results in significant 
depletion of peripheral B cells from early pre B cells to mature B cells, sparing other cell 
lineages (Figure 1) and stem cells, therefore immunoglobulin secretion by plasma cells is 
maintained. Several control trials have reported that RTX is an effective treatment in RA e.g. 
DANCER trial (Emery et al. 2006), REFLEX trial (Cohen et al. 2006) and a short course of 
treatment with RTX has been shown to result in long term improvement of disease activity in 
patients with previously refractory RA (Teng et al. 2007). However, biologic and clinical 
responses to RTX vary greatly; RTX induces clinical responses that last for years in some 
patients whereas in others the benefits last only a few months (Silverman 2006). Silverman 
proposes that other mechanisms in addition to simple pharmacokinetic clearance of RTX are 
involved e.g. tissue depots of RTX in the bone marrow resulting in prolonged B cell depletion 
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(Silverman 2006). Additionally, combination therapy with MTX may diminish the capacity to 
produce pro-inflammatory cells including B cell survival factors such as B cell activating 
factor (BAFF) and a proliferation-inducing ligand (APRIL) (Silverman 2006).  
 
1.4.4 The role of B cells in rheumatoid arthritis 
The role of T cells in the pathogenesis of RA is well established but the contribution of B 
cells is less well defined. Recent research indicates that B cells may play several critical roles 
(reviewed in Silverman and Carson 2003, Panayi 2005, Mauri and Ehrenstein 2007): 
 B cells are the source of autoantibodies, namely RF and ACPA, which contribute to 
immune complex formation and complement activation in the joints. RF is present in fifty 
to eighty percent of RA patients, it is reactive against antigenic determinants on the Fc 
fragment of the IgG molecule, the severity of RA has been correlated with RF levels, 
‘seropositive’ RA being associated with more aggressive articular disease (Panayi 2005). 
Additionally, it is thought that B cells with RF specificity migrate to the synovium to 
present a variety of complex antigens to T cells, thus extending the inflammatory response 
and amplifying RF production in the synovium (Panayi 2005). Although the biologic 
significance of ACPA is unclear citrullination may be a by-product of abnormal protein 
metabolism. B cells from RA patients appear to have greater resistant to certain apoptotic 
stimuli, ACPA titres are increased and could possibly be linked to impaired lymphocyte 
clonal regulation in these patients (Silverman and Carson 2003). 
 B cells are very efficient antigen-presenting cells and can contribute to T cell activation, 
proliferation and pro-inflammatory activities, through expression of co-stimulatory 
molecules. A study by Takemura et al. in the rheumatoid synovium of a mouse model 
proposed that B cells provided a critical function in T cell activation this was later 
confirmed following B cell depletion (Takemura et al. 2001). 
 B cells both respond to and produce the chemokines and cytokines (TNF-α, IL6) that 
promote leukocyte infiltration into the joints, formation of ectopic lymphoid structures, 
angiogenesis, and synovial hyperplasia (Mauri and Ehrenstein 2007).  
 In contrast to the detrimental effects of B cells in RA described above B cells may also 
have a protective role. Synovial inflammatory tissue can completely disrupt the cortical 
bone barrier, exposing and replacing the underlying fat-rich bone marrow with B cell-rich 
mononuclear cell aggregates. However, new bone formation has been described here and 
it has been hypothesised that these aggregates have a protective effect providing a 
physical barrier to shield bone marrow at these sites of pannus penetration (Jimenez-Boj et 
al. 2005, Hayer et al. 2008). 
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1.5 The effect of B cell depletion on bone turnover in rheumatoid arthritis 
The effectiveness of B cell depletion therapies in RA has demonstrated that B cells play a key 
role in the perpetuation of RA. RA is associated with chronic inflammation and bone loss and 
cytokines are recognised as important factors; the joint is infiltrated by multiple inflammatory 
cell populations including T cells, B cells, macrophages and neutrophils, all of which 
contribute to the local cytokine network. However, RANKL, the key cytokine driving bone 
destruction by osteoclast activation, is produced by synovial B cells in RA (Yeo et al. 2011, 
Meednu et al. 2015). Crosstalk between B cells and bone cells is bidirectional; bone cells can 
regulate the development and maturation of B cells and B cells can regulate osteoblastic and 
osteoclastic activity. The mechanisms that underlie these interactions are only partially 
understood as is the precise role of B cells in bone turnover. Defects in the RANKL-RANK-
OPG signalling axis result in altered bone phenotypes. While the role of B cells during normal 
bone remodelling appears minimal, activated B cells play an important role in RA related 
skeletal damage (Horowitz 2010).  
 
1.5.1 Current evidence from clinical trials 
Keystone et al. provided the first evidence that RTX causes a significant reduction in joint 
damage progression in patients with severe refractory RA previously enrolled into the 
REFLEX trial; 287 patients received RTX plus MTX and 192 received placebo plus MTX. 
After 56 weeks there was a significant improvement in the Genant-modified Sharp score 
(Keystone et al. 2009). Similar results were reported in patients enrolled into the IMAGE 
trial; 249 patients received MTX alone, 249 received RTX (2× 500mg) plus MTX and 250 
received RTX (2× 1000mg) plus MTX. After 52 weeks there was a significant improvement 
in the Genant-modified Sharp score in patients treated with RTX (2× 1000mg) in 
combination with MTX (Tak et al. 2011). A small study of 13 patients with active RA was the 
first to investigate the effects of RTX on systemic bone remodelling. However, there was no 
significant difference in serum markers of osteoclastogenesis (OPG, sRANKL), bone 
formation (PICP, BAP) or bone resorption (TRAP5b), but DPD a urinary marker of bone 
resorption was significantly reduced after 15 months (Hein et al. 2011). Finally a further 
group reported that RTX significantly affects the RANK/RANKL/OPG system in the 
synovium and peripheral blood of 28 patients with active RA. After 16 weeks the number of 
RANK positive osteoclast precursors in synovial tissue had significantly decreased by 99% 
and RANKL expression had decreased by 37%, serum RANKL and OPG had both decreased 
but the OPG/RANKL ratio had increased. These alterations in the RANK/RANKL/OPG 
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system were not related to radiological progression, as assessed by the Sharp-van der Hijde 
score of their hands and feet. However, joint destruction was stabilised in a large majority of 
patients, indicating that RTX’s interference with the mediators of osteoclastogenesis resulted 
in the inhibition of further bone loss. (Boumans et al.2012). 
These studies have shown that RTX not only significantly reduces clinical symptoms and 
inflammation in RA but also inhibits the progression of structural joint damage, highlighting 
the connection between B cells and bone homeostasis in RA and advocating that B cells may 
play a key pathogenic role in bone erosion. Some of these effects may be indirect through 
attenuation of systemic inflammation, while others may be direct as a result of the absence of 
B cells during osteoclast formation. 
 
1.6 Project aims 
This project aims to address the role of human B cells in bone turnover. Given the impact of 
B-cells in the pathogenesis of RA and apparent importance in regulating bone cell activity it is 
postulated that prolonged B cell depletion in patients with RA may have a beneficial effect on 
the bone loss that would otherwise be expected in active disease. Furthermore, this affect may 
be direct through modulation of osteoclastogenesis or indirect through attenuation of systemic 
inflammation and increased physical activity. Therefore, the main study aims were:  
1) To initially explore the effects of B cell depletion on serum biomarkers of bone 
turnover before and after RTX treatment in a cohort of patients with severe RA. 
2) To confirm and extend these findings in a second cohort of RA patients to additionally 
measure the change in bone density and to explore factors that may influence the 
outcome such as change in disease activity and vitamin D status. 
3) To evaluate and create a robust, reproducible protocol for osteoclast formation and 
characterisation from peripheral blood in vitro, representative of in vivo conditions 
without the addition of endogenous substances.  
4) Finally to use this culture system to investigate the potential role of B cells on 
osteoclastogenesis; using healthy volunteer blood depleted of B cells in vitro, plus 
blood from RA patients following B cell depletion ex vivo. 
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Chapter 2. Materials and methods 
 
This Chapter contains a general description of all the materials, methods and subjects that 
were used throughout this study to investigate the aims of this work outlined in Chapter 1. 
Initially a range of automated and manual bone turnover assays were evaluated for use in the 
following clinical studies: 
1. Pilot study to investigate the effect of in vivo B cell depletion on markers of bone 
turnover pre and 6 months post RTX in RA patients. 
2. Prospective study to investigate the effect of in vivo B cell depletion on bone mineral 
density and bone turnover markers pre and 3, 6 and 12 months post RTX in RA 
patients. 
Finally, to investigate in vitro osteoclastogenesis, a protocol for osteoclast formation and 
characterisation from peripheral blood was optimised for use in the following experiments: 
1. Potential role of B cells on in vitro osteoclastogenesis in healthy volunteer 
unfractionated and CD20 depleted peripheral blood mononuclear cells (PBMCs). 
2. Potential role of B cells on osteoclastogenesis in RA patient PBMCs pre and 3, 6 and 
12 months post RTX ex vivo. 
Throughout this thesis in vitro (Latin translation: in glass) experiments are defined as; 
osteoclast culture, using unfractionated and artificially depleted CD20
-
 PBMCs in the 
laboratory. In contrast, ex vivo (Latin translation: out of the living) experiments refer to; 
osteoclast culture, using PMBCs isolated from RA patient blood pre and post CD20 depletion 
using RTX administered as a 1000mg intravenous infusion in the Rheumatology clinic i.e. 
with minimal alteration of natural conditions.  
Specific details of any modifications to these general methods are explained in more detail in 
the relevant sections of the respective Chapters. All the experiments for this research project 
were carried out in the Research laboratories or Pathology department at The James Cook 
University Hospital (JCUH), Middlesbrough.  
 
2.1 Materials 
All the materials used in this research, unless otherwise stated, were obtained from companies 
or their distributers based in the United Kingdom.  All generic reagents, consumables and 
equipment are listed in appendix A. 
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2.1.1 Biomarker reagents 
 The manual ELISA kits for DKK1; product code BI-20413 and Sclerostin; product code 
BI-20492 were purchased from Oxford Biosystems Cadama (Wheatley, Oxford, OX33 
1NB, UK), a UK distributor for Biomedica Medizinprodukte (1210 Vienna, Austria). 
 The manual ELISA kits for ampli sRANKL; product code FS-04PL; OPG; product code 
FS-01PL were purchased from IDS Ltd. (Boldon, Tyne and Wear, NE35 9PD, UK), a UK 
distributer for Biomedica Medizinprodukte (1210 Vienna, Austria). 
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 The manual ELISA kit for TRAP isoform 5b; product code SB-TR201APL and the 
automated chemiluminescence assays for 25OHD; product code IS-2700PL; 25OHD tri-
level control set; product code IS-2730; BALP; product code IS-2800; IDS-iSYS BALP 
tri-level control set; product code IS-2830; βCTX; product code IS-3000PLV3 2011-11; 
CTX-I tri-level control set; product code IS-3030 and intact PINP; product code IS-
4000PL; PINP tri-level control set; product code IS-4030, were obtained from IDS Ltd. 
(Boldon, Tyne and Wear, NE35 9PD, UK). 
 The automated electrochemiluminescent assays for βCTX; product code  11972308 122; 
N-MID Osteocalcin; product code 12149133 122; PTH; product code 11972103; total  
PINP; product code 03141071 190, PreciControl Bone 3 levels; product code 11972227 
122 and PreciControl Varia 2 levels; product code 05618860 190 were purchased from 
Roche Diagnostics Ltd. Burgess Hill, West Sussex, RH15 9RY, UK) . 
 The latex-enhanced immunoturbidimetric assay for wide range CRP (wrCRP); product 
code 10494060 was purchased from Siemens Healthcare Diagnostics (Camberley, Surrey, 
GU16 8QD, UK). 
 Multichem S Plus - level 1; product code CH101CRP, level 2; product code CH102CRP 
and level 3: product code CH103CRP were purchased from Technopath Ltd. 
(Leatherhead, Surrey KT22 9AD). 
 
2.1.2 In vitro reagents 
 Peripheral blood mononuclear cell isolation: Lymphoprep; product code 1114544 (250ml) 
was purchased from Axis-Shield Diagnostics (Dundee, DD2 1XA, UK).  
 Osteoclast culture: Roswell Park Memorial Institute (RPMI) 1640 medium; product code 
R0883 (500ml), Corning 6 and 24 well plastic microplate with lid; product codes 353046, 
3524 and coverslips (round glass 13mm diameter); product code LABS6310149, were 
purchased from LabShop
®
 (Hartlepool, Cleveland, TS25 2DL, UK). Minimum Essential 
Medium (αMEM); product code 225171-020 (500ml) and Glutamax-I supplement; 
product code 35050-038 (100ml), were purchased from Invitrogen Life Technologies 
(Paisley PA4 9RF, UK). 13 mm circular bone slices were kindly donated by Dr HK Datta 
(ICM, Newcastle University). 
 Osteoclastogenesis experiments: Human recombinant - Macrophage Colony Stimulating 
Factor (MCSF); product code 216-MC-025 (25µg@10µg/ml) and human recombinant 
RANKL; product code 6449-TEC (10µg@500ng/ml), were purchased from R&D 
Systems (Abingdon, OX14 3NB, UK). 
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 Osteoclast characterisation: Tartrate Resistant Acid Phosphatase (TRAP) staining kit; 
product code 386 and Trypan Blue; product code T8154 (20ml), were purchased from 
LabShop
®
 (Hartlepool, Cleveland, TS25 2DL, UK), a UK distributor for Sigma-Aldrich 
Company Ltd. (Gillingham, SP8 4XT, UK). Toluidine Blue O Basic Blue 17 CI: 52040; 
product code S3382 (25g), was purchased from RALamb dry dyes at Fischer Scientific 
UK Ltd. (Loughborough, Leicestershire, LE11 5RG, UK). UK).  Alexa Fluor 488 
Phallodin; product code A12379 (300 units) was purchased from Invitrogen Life 
Technologies (Paisley PA4 9RF, UK).  
 Fluorescence Activated Cell Sorting (FACS) reagents: ONCOMARK CD14/CD64  CE 
reagent; product code 333179, CD3 PERCP-CY5.5 CE reagent; product code 332771, 
CD19 PERCP-CY5.5 CE reagent; product code 332780,  CD45 APC (2D1) CE reagent; 
product code 340910 and TruCOUNT tubes; product code 340334, were purchased from 
BD Biosciences (Oxford, OX4 4DQ, UK). 
 B cell depletion: Magnetic-Activated Cell Sorting (MACS) BSA Stock solution; product 
code 130-091-376 (75ml), autoMACS
™
 Rinsing Solution; product code 130-091-222 
(1.45L), LD columns; product code 130-042-901 (25 pack), MS columns; product code 
130-042-201 (25 pack), CD20 MicroBeads human; product code 130-091-104 (2ml) and 
CD14 MicroBeads human; product code 130-050-201 (2ml), were purchased from 
Miltenyi Biotec (Bisley, Surrey GU24 9DR, UK). 
  RTX (1ml containing10mg/ml); gratefully donated by ICM, Newcastle University. 
 
2.2 Methods 
The methods used in this thesis comprised of manual and automated assays of bone turnover 
markers and osteotropic factors, in vitro osteoclastogenesis from PBMCs and following B cell 
depletion. These studies involved modification of osteoclastogenesis and these experiments 
are described in detail in subsequent relevant Chapters.  
 
2.2.1 Biomarker assays 
The following automated and manual biomarkers were considered and evaluated for use in the 
pilot and prospective studies. The major advantages and disadvantages of individual markers 
was outlined in Chapter 1 section 1.2.4 and summarised in Table 1, where possible automated 
assays were used to improve technical variability. The manual enzyme linked immunosorbent 
assays (ELISA's) were carried out in duplicate and the final absorbance’s were read on the 
Labtech 4000 microplate reader (Labtech International Ltd. Uckfield, East Sussex, TN22 
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1QQ, UK) in conjunction with automated MANTRA software to calculate the sample 
concentration from a standard curve using pre-defined linear algorithms. Low and high levels 
of quality control (QC) material were included in each batch.  
Automated electro-chemiluminescent immunoassays (ECLIA) were done in singleton on the 
Roche Elecsys 2010 (Roche Diagnostics Ltd. Burgess Hill, West Sussex, RH15 9RY, UK) 
unless otherwise stated. All biomarker experiments were carried out in serum or ethylene 
diamine tetraacetic acid (EDTA) plasma and following the manufacturer's guidelines, unless 
stated otherwise. The majority of commercial bone biomarker assays are CE (Conformité 
Européenne) marked for clinical diagnostic use. The CE marking is the manufacturer's 
declaration that the product meets the requirements of the applicable European Commission 
directives. It also shows that the manufacturer has checked that these products meet European 
Union health, safety or environmental requirements and are 'fit for purpose' i.e. they should 
only be used within the scope of the manufacturer's instructions. Although technological 
advances have greatly enhanced the accuracy and reliability of BTM measurement, the assays 
still vary significantly (Seibel et al. 2001, Schafer et al. 2010). Studies from well-
characterised populations have reported BTM reference ranges in large cohorts (Glover et al. 
2008, Eastell et al. 2012). However, only reference ranges established using the same assay 
method with standardised pre-analytical conditions are comparable.     
Recommendations by the Bone Marker Standards Working Group have proposed that a 
marker of bone resorption i.e. βCTX and a marker of bone formation i.e. PINP are used as 
reference analytes in all research studies (Vasikaran et al. 2011, Bauer et al. 2012) and so 
these markers were used in both clinical studies described in this Chapter. The majority of 
bone resorption markers are degradation products of type I collagen and βCTX is the marker 
of choice (Vasikaran et al. 2011). βCTX was measured  in 50µl serum (Kit insert - Roche; 
βCTX; 11972308 122 V8 2007-07), an automated ECLIA already used diagnostically within 
Pathology and therefore subject to external validation using samples from the United 
Kingdom National External Quality Assessment Service (UK-NEQAS). The measurable 
range of this βCTX assay was 10-6000ng/L.  
PINP, a commonly used marker of bone formation measured in 20µl serum (Kit insert - 
Roche; TPINP; 03141071 190 V6 2008-05), has low inter-individual variability (Vasikaran et 
al. 2011) and is relatively stable in serum at room temperature (Stokes et al. 2011). The 
measurable range was 5-120µg/L, so ideal for this work. In addition the following biomarkers 
were used in the specific studies detailed below. 
 
Biomarkers for the Pilot study 
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 Osteocalcin (Kit insert - Roche; N-MID Osteocalcin; 12149133 122 V11 2008-03), a bone 
turnover marker rather than specific bone formation or bone resorption marker was 
measured by automated immunoassay in 20µl serum; the measurable range was 0.5-
300µg/L. Both intact osteocalcin (amino acids 1-49) and the large N-MID fragment 
(amino acids 1-43) occur in blood. Intact osteocalcin is unstable due to protease cleavage 
between amino acids 43 and 44. This assay measured the resulting N-MID fraction, the 
most stable fraction (Rosenquist et al. 1995) using two monoclonal antibodies specifically 
directed against the epitopes on the MID region (amino acids 20-42) and the N-terminal 
region (amino acids 1-19).  
 OPG (Kit insert - IDS; OPG; FS-01PL V6 2008-10) a marker of osteoclastogenesis was 
measured in 50µl serum using a manual IDS ELISA. OPG is a basic glycoprotein 
comprising of 401 amino acid residues arranged into 7 structural domains. It is found as 
either a 60kDa monomer or a 120kDa dimer linked by disulphide bonds. This assay 
measured both the monomeric and dimeric forms of OPG using a sandwich principle. The 
measurable range was.14-30pmol/L.  
 Soluble RANKL (Kit insert - IDS; ampli sRANKL; FS-04PL V3 2008-10) was measured 
in 100µl serum using a similar manual IDS ELISA. This assay measured free RANKL in 
sera using a sandwich principle, as the concentration of sRANKL is usually quite low in 
normal samples the manufacturer added an additional enhancement system to increase the 
sensitivity. The measurable range was quoted as 0.02-2.0pmol/L. However this assay was 
problematic as many of the patient samples were below the sensitivity of the assay. The 
capture antibody was OPG and therefore the assay was only capable of detecting 
sRANKL not already complexed with OPG in serum and it was felt that any circulating 
OPG autoantibodies would interfere with this method so it was abandoned. 
 
The reproducibility of the automated assays was established using up to 12 replicates of 3 
levels of generic QC material (PreciControl Bone and PreciControl Varia); run in the same 
batch (intra-assay) and in different batches (inter-assay) to check precision and drift (Table 3). 
Additionally, thirty-eight spare patient samples (23 females between 27-91yrs, 15 males 
between 35-82yrs) from general practice that had ‘normal’ biochemistry results were used to 
verify the manufacturer stated reference ranges (Table 4) and to investigate age-related 
changes in these biomarkers (Figure 8). Similarly, for the manual immunoassay kits; up to 8 
replicates of QC1 supplied in the kits were included at the beginning, middle and end of the 
plate in the same batch and in different batches to check precision and drift (Table 3) and 63 
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patient samples (46 females between 30-91yrs, 17 males between 35-82yrs) to verify the 
stated reference ranges and age-related changes (Figure 8).  
 
The intra-assay coefficient of variation (CV) was less than 3.7% for the automated assays and 
less than 11% for the manual ELISA’s. As expected the inter-assay CV’s were higher 
reflecting the use of different lot numbers of reagents and calibrations but were deemed 
acceptable for the study. 
 
The mean values for each biomarker were generally consistent with those reported in the kit 
inserts by the manufacturer. Notably, the reference ranges for βCTX and PINP in pre-
menopausal women agreed with values quoted in the literature for identical methods (Glover 
et al. 2008, Eastell et al. 2012). However, reference ranges for the other BTMs have yet to be 
established. There was a trend in OPG results with age this was expected (Kudlacek et al. 
2003).  
 
In contrast to the use of reference ranges Bieglmayer and Kudlacek (Bieglmayer and 
Kudlacek 2009) have suggested combining a marker of formation and resorption to gain a 
direct insight into the changes in the balance of bone turnover in relation to a reference value. 
Individual marker concentrations can be expressed as multiples of the median (MoM), defined 
as  
MoM    =     Individual marker result 
               Median of the reference population 
 
The MoM was calculated using the median bone marker values from 72 self-reported healthy 
volunteers analysed as part of the βCTX, PINP comparison study but for this purpose only the 
E411 results were used (Wheater et al. 2013). The ratio of MoM formation (MoMF) and MoM 
resorption (MoMR) (MoMF/ MoMR) was plotted for each patient to signify bone turnover; a 
value of 1 indicated equilibrium.  The results from 53 RA patients also included in the 
comparison study (Wheater et al. 2013) were plotted to illustrate the use of this graph (Figure 
9). This model was applied to the results of the pilot and prospective studies, before and after 
RTX treatment.  
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Table 3 Biomarker precision data for the pilot study 
 
Intra-assay    Inter-assay  
 
QC1 QC2 QC3 QC1 QC2 QC3 
PINP (µg/L)          
n 12 12 12 3 3 3 
Mean 75.8 409.2 825.7 75.2 403.6 781.8 
SD 1.4 8.2 28.6 0.7 4.9 38.5 
CV 1.9 2.0 3.5 0.9 1.2 4.9 
Target mean 81.5 433 820 81.5 433 820 
Osteocalcin (µg/L)        
n 12 11 11 3 3 3 
Mean 17.7 94.6 194.2 18.6 91.4 184.0 
SD 0.5 1.9 3.8 1.8 2.8 9.5 
CV 2.7 2.0 2.0 9.7 3.1 5.2 
Target mean 19.4 101 198 19.4 101 198 
βCTX (ng/L) 
n 3 2 3    
Mean 304 720 2869    
SD 11 10 65    
CV 3.7 1.4 2.2    
Target mean 330 780 2820    
OPG(pmol/L)          
n 8 - - 6 - - 
Mean 1.8 - - 2.1 - - 
SD 0.2 - - 0.4 - - 
CV 11 - - 21.5 - - 
Target mean 2.2 - - 2.9 - - 
sRANKL (pmol/L)        
n 7 - - 5 - - 
Mean 0.65 - - 0.57 - - 
SD 0.06 - - 0.07 - - 
CV 9.5 - - 12.7 - - 
Target mean 0.51 - - 0.48 - - 
 
The reproducibility of the automated immunoassays was established using up to 12 replicates of 3 levels of 
generic QC material; run in the same batch (intra-assay) and in different batches (inter-assay) to check precision 
and drift. Similarly up to 8 replicates of QC1 included in the kits were used for the manual ELISA’s. The mean, 
SD and CV were calculated for each assay.  
βCTX: beta-isomerised carboxy terminal telopeptide of type I collagen; PINP: procollagen type 1 amino-
terminal propeptide; sRANKL: soluble receptor activator of nuclear factor kB ligand; OPG: osteoprotegerin. 
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Table 4 Manufacturer defined biomarker reference ranges 
  
PINP 
(µg/L) 
 
Median 
Value 
 
 
Osteocalcin 
(µg/L) 
 
Median 
value 
 
BALP 
(µg/L) 
 
Median 
value 
 
βCTX 
(ng/L) 
 
Mean 
value 
 
TRAP5b 
(U/L) 
  
Mean 
value 
 
OPG 
(pmol/L) 
 
Median 
value 
 
sRANKL 
(pmol/L) 
 
Median 
value 
 
SCL 
(pmol/L) 
 
 Median 
value 
 
DKK-1 
(pmol/L) 
 
 Median 
value 
Pre-
menopausal 
Female  
27.8 23.0 10.2 299 2.6 1.8 0.37 24.1 36.0 
Post-
menopausal 
Female  
37.1 27.0 10.4 556 3.2 1.8 0.37 24.1 36.0 
Male  
<50yrs 
 
- 25.0 10.6 300 3.1 1.8 0.46 24.1 36.0 
Male 
 >50yrs 
 
- 24.0 10.6 394 3.3 1.8 0.46 24.1 36.0 
 
The reference ranges included in this Table were taken from the relevant manufacturer kit inserts. 
βCTX: beta-isomerised carboxy terminal telopeptide of type I collagen; BALP: bone specific alkaline 
phosphatase; DKK-1: dickkopf- related protein 1; PINP: procollagen type 1 amino-terminal propeptide; SCL: 
sclerostin; sRANKL: soluble receptor activator of nuclear factor kB ligand; OPG: osteoprotegerin; TRAP5b: 
tartrate resistant acid phosphatase isoform 5b. 
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Figure 8 The effect of age on individual biomarkers for the pilot study 
Thirty-eight patient samples (23 females 27-91yrs, 15 males 35-82yrs) from general practice that had ‘normal’ 
biochemistry results were used to investigate age-related changes in PINP and osteocalcin. Similarly, 63 patient 
samples (46 females 30-91yrs, 17 males 35-82yrs) were used to investigate age-related changes in OPG and 
sRANKL.  
PINP: procollagen type 1 amino-terminal propeptide; sRANKL: soluble receptor activator of nuclear factor kB 
ligand; OPG: osteoprotegerin. 
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Figure 9 Ratio of the multiples of the median for a marker of bone formation and bone 
resorption to signify bone turnover in patients with rheumatoid arthritis  
A marker of bone formation (PINP) and a marker of bone resorption (βCTX) are expressed as multiples of the 
median MoMF and MoMR
 
respectively and their ratio plotted for individual patients (MoMF/ MoMR). MoM is 
calculated as ‘individual marker result/ median of the reference population’. Fifty-three RA patient results from a 
previous study (Wheater et al. 2013) were used in this plot. 
βCTX: beta-isomerised carboxy terminal telopeptide of type I collagen; PINP: procollagen type 1 amino-
terminal propeptide; MoM: multiple of the median. 
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Biomarkers for the Prospective study 
Prior to the prospective study analysis, a second automated immunoassay system; IDS iSYS 
(IDS Ltd, Boldon, Tyne and Wear, NE35 9PD, UK ) in addition to an upgraded Roche 
Elecsys 2010 renamed E411 became available within Pathology and so both systems were 
evaluated for βCTX and PINP. The Roche assay parameters remained the same however, the 
following were specific to the iSYS methods; βCTX Kit insert - IDS; iSYS βCTX; IS-
3000PLV3 2011-11) was measured in 45 µl serum, the measurable range being 33-6000ng/L; 
PINP (Kit insert - IDS; iSYS PINP; IS-4000PL V2 2009-12) was measured in 20µl serum, the 
measurable range was 2-230µg/L. Both βCTX assays were specific for cross-linked 
isomerised type I collagen fragments, independent of the nature of the crosslink (e.g. pyrrole, 
pyridinolines). Assay specificity was guaranteed through the use of two monoclonal (capture) 
antibodies each recognising the Glu-Lys-Ala-His-βAsp-Gly-Gly-Arg peptide (Crosslaps 
antigen). Additionally, PINP is released as a trimeric structure but is rapidly broken down to a 
monomeric form by thermal degradation (Brandt 1999). The iSYS detects the trimeric ‘intact’ 
molecule and the E411 measures both fractions i.e. a total PINP assay. The Roche E411 2-site 
immunometric assays combine conventional antigen-antibody reactions on the surface of 
streptavidin coated paramagnetic microparticles, with electrochemical stimulation involving a 
ruthenium label on the surface of an electrode. The luminescence generated is directly 
proportional to the amount of analyte. The iSYS methods work on the same principle, 
however, streptavidin coated microparticles are captured using a magnet and then trigger 
reagents are added. The resultant light, emitted by an acridinium label, is proportional to the 
analyte concentration. There was disparity between the methods; there was a progressive 
deviation with increasing concentration between βCTX assays and the spread of values 
around the mean increased with increasing PINP concentration (Wheater et al. 2013). For 
comparison between studies it was decided to continue using the Roche assays for the 
prospective study but to use plasma rather than serum for these two assays, in addition to the 
following biomarkers. 
 BALP is a glycoprotein found on the surface of osteoblasts, it reflects the metabolic 
activity of osteoblasts, therefore bone formation. BALP (Kit insert - IDS; iSYS BALP; IS-
2800 V1 2011-03) was quantified in 50µl serum by chemiluminescence on the IDS iSYS 
analyser. The reportable range of this assay was 1-75µg/L.  
 TRAP-5b (Kit insert - IDS; TRAP5b; SB-TR201APL V3 2007-03) was measured in 
100µl serum by a manual IDS ELISA. This method specifically measured TRAP isoform 
5b activity freshly liberated from osteoclasts and so is a marker of bone resorption. The 
measurable range of this assay was 0.5-10.0U/L.  
Chapter 2                                                                                                  Materials and Methods 
49 
 
 DKK-1 levels (Kit insert - Biomedica; DKK-1; BI-20413 rev.no.130823) were measured 
in 20µl serum using a manual Biomedica ELISA. DKK-1 is a secreted protein that acts as 
a soluble inhibitor of the Wnt signaling pathway and is an osteocyte marker. The 
reportable range was 1.7-160pmol/L.  
 SCL was quantified in 20µl serum using a manual Biomedica ELISA (Kit insert - 
Biomedica; SCL; BI-20492 rev.no.131015). SCL, a secreted glycoprotein, is mainly 
produced in osteocytes. SCL acts by binding to the Wnt co-receptor low-density 
lipoprotein receptor-related protein 5 (LRP5) thus preventing the binding of Wnt 
molecules. The measurable range was 7.5-240pmol/L.  
 Wide range wrCRP (Kit insert - Siemens; WR-CRP; 10494060_EN 2011-01) often 
termed high sensitivity CRP (hsCRP) was quantified in serum by a latex-enhanced 
immunoturbidimetric assay on the Siemens Advia 2400 analyser (Siemens Healthcare 
Diagnostics, Camberley, Surrey, GU16 8QD, UK). The assay was based on the principle 
that CRP concentration was a function of the intensity of the scattered light caused by the 
agglutination of latex particles coated with anti-CRP in the presence of CRP-forming 
aggregates. The turbidity was measured at 571nm. The reportable range was 0.03-156 
mg/L. 
 25OHD (Kit insert - IDS; iSYS 25OHD; IS-2700PL V6 2012-07) was quantified in 10µl 
of serum. Samples were subjected to a pre-treatment step to denature the vitamin D 
binding protein, the treated samples were then neutralised in assay buffer before analysis 
by chemiluminescence on the IDS iSYS analyser. The reportable range of the assay is 5-
140µg/L.  
 Intact PTH (Kit insert - Roche; PTH; 11972103 122 V19 2010-02) was quantified in 50µl 
EDTA plasma by electrochemiluminescent immunoassay on the Roche E411 analyser. 
This assay works on a sandwich principle; in which a biotinylated monoclonal antibody 
reacts with the N-terminal fragment (amino acids 1-37) and a monoclonal antibody 
labelled with a ruthenium complex reacts with the C-terminal fragment (amino acids 38-
84). The measurable range of this assay was 1.2-5000ng/L. 
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Table 5 Biomarker precision data for the prospective study 
 Intra-assay Inter-assay 
  Low High QC1 QC2 
PINP (µg/L)         
n 10 10 7 7 
Mean 20.5 805.6 29.3 170.3 
SD 0.5 25.1 1.2 5.6 
CV 2.6 3.1 4.1 3.3 
Target mean - - 27.0 181.0 
BALP (µg/L)         
n 10 10 2 2 
Mean 11.6 22.5 4.8 49.1 
SD 0.3 0.5 0.4 0.8 
CV 2.4 2.2 7.4 1.6 
Target mean - - 5.3 49.8 
βCTX(ng/L)         
n   3 5 
Mean - - 280 759 
SD - - 3.6 17 
CV - - 1.3 2.3 
Target mean - - 270 700 
TRAP5b (U/L)         
n   7 7 
Mean - - 1.7 5.6 
SD - - 0.1 0.2 
CV - - 4.3 3.4 
Target mean - - 1.9 6.0 
SCL (pmol/L)         
n 8  6  
Mean 80.8 - 89.1 - 
SD 2.9 - 8.3 - 
CV 3.6 - 9.3 - 
Target mean 89.0 - 89.0 - 
DKK-1 (pmol/L)         
n 8  6  
Mean 23.3 - 27.3 - 
SD 1.3 - 4.3 - 
CV 5.4 - 15.8 - 
Target mean 27.8 - 27.8 - 
 
The reproducibility of the automated immunoassays was established using up to 10 replicates of 2 levels of 
generic QC material; run in the same batch (intra-assay) and in different batches (inter-assay) to check precision 
and drift. Similarly up to 8 replicates of QC material supplied in the kits were used for the manual ELISA’s. The 
mean, SD and CV were calculated for each assay. βCTX: beta-isomerised carboxy terminal telopeptide of type I 
collagen; BALP: bone specific alkaline phosphatase; DKK-1: dickkopf- related protein 1; PINP: procollagen 
type 1 amino-terminal propeptide; SCL: sclerostin; TRAP5b: tartrate resistant acid phosphatase isoform 5b. 
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The reproducibility of the automated assays was established using up to 10 replicates of 2 
levels of generic QC material (PreciControl Bone and PreciControl Varia); run in the same 
batch (intra-assay) and in different batches (inter-assay) to check precision and drift (Table 5). 
Additionally, nineteen self-reported healthy volunteer samples (11 females 22-61yrs, 8 males 
24-53yrs) were used to verify the manufacturer stated reference ranges (Table 4) and to 
investigate age-related changes in these biomarkers (Figure 10). The blood samples were non-
fasting and collected between 9:00 – 10:00, they were centrifuged within one hour of 
venepuncture and the serum/ plasma was immediately stored at -80ºC until analysis. 
Similarly, for the manual immunoassay kits; up to 8 replicates of QC1 supplied in the kits 
were included at the beginning, middle and end of the plate in the same batch and in different 
batches to check precision and drift (Table 4) and the healthy volunteer bloods were used to 
verify the stated references ranges and age-related changes (Figure 10).  
 
The intra-assay coefficient of variation (CV) was less than 3.1% for the automated assays and 
less than 5.4% for the manual ELISA’s. As expected the inter-assay CV’s were higher 
reflecting the use of different lot numbers of reagents and calibrations but were deemed 
acceptable for the study. 
 
The mean values for each biomarker were generally consistent with those reported in the kit 
inserts by the manufacturer; there was an upward trend in results with age. The reference 
ranges for βCTX, BALP, PINP in pre-menopausal women agreed with values quoted in the 
literature for identical methods (Glover et al. 2008, Eastell et al. 2012).  
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Figure 10 The effect of age on individual biomarkers for the prospective study 
Nineteen self-reported healthy volunteer samples (11 females 22-61yrs, 8 males 24-53yrs) were used to 
investigate age-related changes in these biomarkers  
βCTX: beta-isomerised carboxy terminal telopeptide of type I collagen; BALP: bone specific alkaline 
phosphatase; DKK-1: dickkopf- related protein 1; PINP: procollagen type 1 amino-terminal propeptide; SCL: 
sclerostin; TRAP5b: tartrate resistant acid phosphatase isoform 5b. 
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2.2.2 In vitro experiments 
Unless otherwise stated all the cell culture reagents were prepared under sterile conditions and 
working reagents were stored at 4
◦
C. 
 Heat inactivated FCS for 60mins at 56◦C, aliquot and freeze at -20◦C until use. 
 HBSS + 1% FCS - Add 5ml heat inactivated FCS to 500ml HBSS buffer. 
 HBSS + 0.4% EDTA - Add 2ml EDTA to 500ml HBSS buffer (store between 20-25◦C) 
 αMEM complete - Add 10ml heat-inactivated FCS (10%) + 1ml Glutamax (1%) + 1ml 
pen/ strep (1%) to 88ml αMEM 
 
Peripheral blood mononuclear cell isolation 
Whole blood was collected into EDTA tubes and kept at room temperature (20
◦
 to 25
◦
C); 
samples were always processed within 8hrs. Blood was diluted 1:1 with HBSS+EDTA buffer 
at room temperature in a 50ml falcon tube. 15ml lymphoprep was added to a second falcon 
tube and 15-20ml of this diluted blood was slowly layered onto the lymphoprep using a 
pipette, the tube was then centrifuged at room temperature, 890g for 30mins using the slow 
acceleration-no brake setting. The PBMC’s (the cloudy layer at the interface) were carefully 
transferred to a new 50ml falcon tube and topped up to 50ml with ice cold HBSS + FCS, 
mixed gently and centrifuged at 600g, 4
◦
C for 7mins using the no-brake setting. All but a few 
millimetres of the supernatent was immediately poured off and the cells were resuspended and 
topped up to 50ml with ice cold HBSS+FCS, then centrifuged at 250g, 4
◦
C for 7mins using 
the no brake setting. The supernatent was again poured off and the cells resuspended and 
mixed as before. The tube was kept at 4
◦
C while the number of PBMC's were counted.  
20µl of supernatant was added to a solution of 40µl trypan blue and 40µl 3% acetic acid (i.e. 
1 in 5 dilution) and mixed well. 10µl of this mixture was loaded onto an ‘improved neubauer’ 
haemocytometer, once the appropriate coverslip was fixed firmly in place to form 'Newton's 
rings'. The number of viable PBMC's in the 4 outside corner counting grids was recorded. A 
note was made if large numbers of platelets or cellular debris was present. The number of 
PBMC’s per ml was calculated using a standard formula 
(http://www.hpacultures.org.uk/technical/ccp/cellcounting.aspx) 
 
PBMCs /ml = (Average of the 4 grids) × 10,000 × 5 
 
Fluorescence Activated Cell Sorting  
All FACS analysis was carried out by qualified Biomedical Scientists in the Haematology 
laboratory JCUH, to determine the percentages and absolute counts of mature human 
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monocytes (CD14/64), B lymphocytes (CD19) and T lymphocytes (CD3) in the cell 
suspension at baseline.  
Two separate TruCOUNT tubes were prepared:  
 Tube 1 containing 2.5µl CD45 + 5.0µl CD14/64 + 5.0µl CD3,  labelled T cell  
 Tube 2 containing 2.5µl CD45 + 5.0µl CD14/64 + 5.0µl CD19, labelled B cell  
The reagents were added onto the side of the tube just above the stainless steel retainer 
without touching the pellet, followed by 200µl of cell suspension to each tube. The tubes were 
capped, mixed gently and incubated for 15mins in the dark at room temperature (20
◦
 to 25
◦
C). 
The tubes were then thoroughly mixed/ vortexed before analysis on the BD FACSCalibur 
flow cytometer. Data was acquired and analysed using Cell Quest Pro software and the 
absolute numbers of monocytes, B cells and T cells calculated manually as per the 
manufacturer’s instructions: 
 
No. of events in region containing cell × No. of beads per test* 
No. of events in bead region               Test volume (i.e. 212.5µl)  
 
 
*
 This value was taken from the TruCOUNT absolute count tube foil pouch label and varied 
from lot to lot.      
                                                         
Osteoclast culture 
Glass coverslips (13mm diameter) and/or bone slices were sterilised in 70% ethanol for 24hrs, 
then soaked in αMEM complete for 60mins prior to use. One coverslip or bone slice was 
placed using forceps into the bottom of each labelled well, of a 24-well plate and left to dry 
for a minimum of 30mins before use. Where possible each sample was used in 3 separate 
replicates of the same experiment to estimate the technical reproducibility. 
Mononuclear cells were isolated from fresh peripheral blood (following the PBMC isolation 
procedure) and the number of PBMC's /ml was recorded. 50ml of the cell suspension was 
centrifuged at 400g, 4
˚
C for 7mins. The supernatent was poured off and the cell pellet was 
washed and resuspended in 20ml αMEM, then centrifuged at 400g, 4˚C for 7mins. This time 
the cells were resuspended in x ml αMEM complete (where x= no. of PBMC's /ml calculated 
above) giving a final concentration of 1 ×106 PBMC's /ml. 500µl of this cell suspension was 
sent for FACS analysis (following the FACS analysis procedure) and 500µl was layered onto 
each coverslip or bone slice as appropriate. The plate was incubated in 5% CO2 at 37
◦
C for up 
to 21 days. The cells were inspected under the microscope every 2-3 days prior to refreshing 
the upper 250µl of medium. After 14-21 days, or when there was evidence of osteoclast 
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formation, the coverslips were stained using the TRAP protocol, the bone slices were stained 
using the toluidine blue protocol and βCTX was measured, using the Elecsys 2010 assay, in 
the remaining medium of wells containing the bone slices. 
 
Osteoclast characterisation 
Osteoclasts were characterised by previously established characteristics namely 
multinuclearity, TRAP expression, actin ring formation that is a prerequisite of cell resorptive 
activity, also toluidine blue staining of resorption pits and βCTX release by cells cultured on 
bone slices. 
 
Tartrate Resistant Acid Phosphatase stain  
Primary osteoclasts or pre-osteoclasts cultured on glass cover slips were identified 
morphologically and histochemically using a modified TRAP testing kit from Sigma. Prior to 
use all reagents were brought to room temperature.  
 The citrate/acetone fixative was prepared i.e. 2ml citrate concentrate + 18ml deionised 
water, mixed thoroughly then 30ml acetone was added.  
 A sealed bottle containing 44ml deionised water was pre-heated in a water bath to reach 
37˚C.  
 The following reagents were then added to the pre-warmed water in this order and kept at 
37˚C until use: 
 
 
 
 
 
 
 
At the end of the culture period the remaining medium was removed and 1ml of PBS was 
added to each well. One coverslip at a time was removed with forceps and held in a beaker 
containing the citrate/acetone fixative for 30secs at room temperature, then rinsed carefully in 
beaker containing deionised water and left on a clean paper towel for at least 15mins to air 
dry. Once completely dry each coverslip was placed into a single well of a pre-labelled 6 well 
plate containing 3ml of pre-warmed stain, covered and incubated for 60mins at 37˚C in the 
dark. The remaining stain was then aspirated off and the coverslips were rinsed ×2 with 1ml 
deionised water and once with normal tap water. Finally the water was aspirated off and 1ml 
Acetate solution 2.0ml Mix gently 
Naphthol AS-BI Phosphoric 
Acid 
2.0ml Mix gently 
Tartrate solution 2.0ml Mix gently 
Fast Garnet GBC salt 1  Stir for 30-60secs then rapidly 
filter through a Whatman no. 54 
paper  
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acid haematoxylin solution was added to the wells to stain for 5mins. The stain was aspirated 
off and the coverslips were washed ×3 with 1ml deionised water and placed on a clean paper 
towel to air dry. The coverslips were mounted on labelled glass slides and evaluated 
microscopically. The number of TRAP
+
 multinuclear (i.e. >3 nuclei) cells in 9 separate fields 
were counted and the area and circumference of 3 cells per field was recorded. 
 
Tartrate resistant acid phosphatase positive cell counting procedure 
TRAP
+
 cell counting was carried out by a single independent member of staff. A coverslip 
was chosen if it had; minimum cell clumping, an even distribution of cells and a good uptake 
of stain, this was to ensure that the count was as accurate as possible. 
An Olympus CKX41 microscope with an attached Infinity2 camera was used for the TRAP
+
 
cell count, initially using ×100 magnification. The right hand side eyepiece was adapted for 
measurement purposes by the addition of a fixed, circular glass graticule with a 10×10 
measuring grid etched onto its surface. This grid was used to partition a section of the 
viewfield for counting. All slides were orientated so that the slide label was on the left hand 
side and all TRAP
+
 cells present in the 10×10 grid were counted in 9 locations on the 
coverslip (Figure 11).  At each location an image was produced and stored using the Infinity 
Capture software for later analysis. 
Osteoclasts, for the purposes of this procedure, were defined as TRAP
+
 cells that displayed 
evidence of a ruffled border and multiple (i.e. >3) nuclei. In each area the 10×10 grid was 
orientated, where possible, into the centre of each counting area so that there was a cell in the 
top left portion of the grid, cells were only counted if the area containing the nuclei was 
wholly within the grid. Counts were recorded for each area of the coverslip and the mean cell 
per area was then calculated for each coverslip.   
During the counting an image was generated using the Infinity Capture software for each of 
the 9 counting locations, 3 osteoclasts were selected from each image. Cell selection was 
based primarily on the presence of a ruffled border and >3 nuclei but was also based on the 
ability to see the entire perimeter clearly for accuracy of measurement.  In addition for each 
image 3 cells of differing size (i.e. small, medium and large) were selected to give an accurate 
overall representation. Using the Infinity Analyse software, a line was drawn around the 
selected cell (Figure 12) and the software automatically calculated the cell area (S) and 
circumference (P). The cell diameter (d) was calculated using an online calculator 
(http://www.onlineconversion.com/circlesolve.htm) from these measurements using circle 
theory. The calculation was also manually checked for accuracy i.e.  
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𝐃𝐢𝐚𝐦𝐞𝐭𝐞𝐫 = 𝟐 × √𝐚𝐫𝐞𝐚/𝛑 
Circumference = πd   
(π = 3.142) 
 
The Infinity Analyse software was initially calibrated in microns (µm) using the grid of a 
neubauer counting chamber and all measurements were performed in full screen mode.   
 
Actin ring formation 
Actin ring formation is a prerequisite for osteoclast bone resorption. Osteoclasts seeded on 
glass form podosomes, which are small cylinders of actin surrounded by vinculin. There are 
three different podosome structures dependant on the stage of osteoclast differentiation; 
namely clusters, rings and finally belts depicting mature osteoclasts (Saltel et al. 2004). The 
Invitrogen Life Technologies protocol using Alexa Fluor
®
 488 Phalloidin was optimised. All 
procedures were carried out inside a fume cupboard and gloves were worn at all times. The 
reagents were prepared as follows:  
 The phalloidin vial was dissolved in 1.5ml methanol to yield a final concentration of 
200units/ml, equivalent to approx. 6.6µM, aliquoted into 100µl amounts and stored at -
20°C until use. A 5µl stock solution was then added to 200µl PBS for each coverslip 
/bone slice to be stained. 
 1ml of 16% methanol-free formaldehyde was mixed with 3ml deionised water to give a 
4% working solution.  
 1ml of 1% Triton X-100 was mixed with 9ml PBS to give a 0.1% working solution.  
 20ml of PBS was warmed to room temperature prior to use.  
 
At the end of the culture period the remaining medium was aspirated off and the coverslips 
and /or bone slices were washed ×3 with 1ml pre-warmed PBS per well. The PBS was 
removed and 1ml of 4% formaldehyde was added for 10mins to each well, covering the 
coverslips /bone slices completely. The wells were then washed ×3 with 1ml PBS. The PBS 
was removed and 1ml of 0.1% Triton X-100 was added to each well for 5mins. The wells 
were again washed ×3 with 1ml PBS. The PBS was removed and 1ml of the diluted staining 
solution was added to each well for 20mins at room temperature. The plate was covered to 
avoid evaporation. The stain was removed and the wells were washed ×3 with 1ml PBS. The 
coverslips/ bone slices were then air-dried and mounted on labelled glass slides and evaluated 
using a fluorescent microscope. 
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                                                                                                                              Slide 
 
 
 
 
 
 
 
                                                                                                           Coverslip 
 
 
                                                                      
 
 
 
Measuring grid 
 
Figure 11 Diagrammatic representation of the microscope slide showing orientation and 
counting areas, labelled 1-9 respectively 
The right hand side eyepiece of an Olympus CKX41 microscope was adapted for measurement purposes by the 
addition of a fixed, circular glass graticule with a 10×10 measuring grid etched onto its surface. The measuring 
grid was used to partition a section of the viewfield for counting. All slides were orientated so that the slide label 
was on the left hand side and all TRAP
+
 cells present in the 10×10 grid were counted in the 9 locations shown 
on the coverslip. 
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Figure 12 Infinity analyse software showing the cell area and circumference 
measurement for 3 TRAP
+
 osteoclast-like cells 
An image was generated using the Infinity Capture software for each of the 9 counting locations on the glass 
coverslip and 3 TRAP
+
 cells with > 3 nuclei were selected from each image. Using the Infinity Analyse 
software, a line was drawn around the selected cell and the software then automatically calculated the cell area 
(S) and cell circumference (P). 
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Toluidine Blue stain for bone slices 
The toluidine blue staining reagents were freshly prepared as follows:  
 100mg toluidine blue was added to 100mg di-sodium tetraborate in100ml deionised water.  
 A 5% sodium hypochlorite solution was made from 1ml concentrate + 15.5ml deionised 
water. 
At the end of the culture period 250µl of medium from each well containing a circular bovine 
cortical bone slice of 0.4mm thickness and 6mm diameter, was pipetted into a labelled 
75x12mm plastic tubes for βCTx analysis. The bone slices were then washed in 1ml of PBS, 
soaked in 1ml 5% sodium hypochlorite for 5mins, followed by three washes with 1ml 
deionised water. The water was removed and 300µl 0.1% toluidine blue staining solution was 
added to each well for 5mins. The bone slice was then removed using forceps and dropped 
into a labelled beaker containing 300ml deionised water, the water was poured off and fresh 
water added ×2 until it remained clear. The bone slices were removed and placed on a clean 
paper towel to air dry before mounting on labelled glass slides to evaluate microscopically. 
 
Beta-isomerised Carboxy terminal Telopeptide of type I collagen analysis 
The osteoclast activity was assessed by measuring βCTX in the medium of wells containing 
bone slices at the end of the culture period. 250µl of cell medium was analysed using the 
βCTX assay on the Elecsys 2010, described previously in section 2.3.1. 
 
B cell depletion 
B cell depletion was carried out using MACS separation prior to osteoclast culture, unless 
otherwise stated in a limited number of experiments.  
 
Using Magnetic-Activated Cell Sorting  
Cells were always kept cold and pre-cooled solutions were used to prevent capping of 
antibodies on the cell surface and non-specific cell labelling. The following reagents were 
prepared prior to use: 
 MACS working buffer - 1ml BSA stock solution + 20ml autoMACS rinsing solution, the 
buffer was then kept cold at 4-8˚C  
Mononuclear cells were isolated from fresh peripheral blood (refer to the PBMC isolation 
protocol) and the cell number was determined. 50ml of cell suspension was centrifuged at 
300g at 4
˚
C for 10mins and then the supernatent was completely removed. The cell pellet was 
resuspended in 80µl (per 10
7
 cells) of cold MACS buffer and 20µl (per 10
7
 total cells) of 
CD20 microbeads were added, mixed well and then incubated for 15mins at 4-8˚C. The cells 
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were washed with 1-2ml MACS buffer (per 10
7
 cells) and then centrifuged at 300g at 4
˚
C for 
10mins. While the suspension was spinning the column was prepared as follows: 
 A LD column was placed in the magnetic field of a midiMACS separator, making sure the 
wings face forwards. 
 The column was rinsed with 2ml MACS buffer to waste until the liquid was completely 
removed.  
The supernatant was completely removed and resuspended in 500µl MACS buffer (up to 1.25 
×108 cells). This solution was added to the column and unlabelled (CD20 –) cells were 
collected into a labelled 15ml falcon tube placed underneath the column. The column was 
washed ×2 with 1ml MACS buffer, this was also collected into the falcon tube, and each time 
the liquid was allowed to pass completely through the column before more buffer was added.  
The column was removed from the separator and placed over another labelled 15ml falcon 
tube. 1-2ml MACS buffer was added to the column and the CD20
+
 magnetically labelled cells 
were immediately flushed out into the falcon tube by firmly applying the plunger supplied 
with the column.  
Both tubes were centrifuged at 300g at 4
˚
C for 10mins and the supernatents were pipetted off 
completely. Each tube was resuspended in 20ml αMEM medium and the number of CD20- 
and CD20
+
 cells in each respective tube was counted as follows: 
20µl of supernatant was added to a solution of 40µl trypan blue and 40µl 3% acetic acid (i.e. 
1 in 5 dilution) and mixed well. 10µl of this mixture was loaded onto an ‘improved neubauer’ 
haemocytometer, once the appropriate coverslip was fixed firmly in place to form 'Newton's 
rings'. The number of viable CD20
-
 or CD20
+
 cells in the 4 outside corner counting grids was 
calculated using a standard formula 
(http://www.hpacultures.org.uk/technical/ccp/cellcounting.aspx) 
 
CD20
-
 or CD20
+
 cells /ml = (Average of the 4 grids) × 10,000 × 5 
 
The tubes were then centrifuged at 300g at 4
˚
C for 10mins. The supernatant was again 
discarded and the cells were resuspend in x ml αMEM complete medium (where x= no. of 
CD20
-
 or CD20
+
 cells/ml) giving a final concentration of 1 ×106 cells/ml. 500µl of each 
fraction was sent for FACS analysis to determine the percentage and absolute numbers of 
monocytes, T cells and B cells.  
 
Using rituximab 
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RTX is a chimeric monoclonal antibody that binds specifically to CD20 and is an approved 
therapeutic B cell depleting agent. CD20 is expressed on the surface of B lineage cells from 
the pre–B cell stage and throughout B cell maturation, but is lost at the final transformation to 
plasma cells (Cartron et al. 2004). RTX was therefore particularly useful in both in vitro and 
in vivo B cell depletion studies. 
The RTX working solutions were prepared from serial dilutions of the stock RTX solution 
(10mg/ml) in αMEM complete medium immediately prior to use: 
 100µg/ml; 50µl of stock + 4950µl αMEM complete 
 10µg/ml; 500µl of 100µg/ml + 4500µl αMEM complete 
 1µg/ml: 500µl of 10µg/ml + 4500µl αMEM complete 
 0.1µg/ml: 500µl of 1µg/ml + 4500µl αMEM complete 
 
Mononuclear cells were isolated from fresh peripheral blood (following the PBMC isolation 
procedure) and the number of PBMC's /ml was recorded. 50ml of the cell suspension was 
centrifuged at 400g, 4
˚
C for 7mins. The supernatent was poured off and the cell pellet was 
washed and resuspended in 20ml αMEM, then centrifuged at 400g, 4˚C for 7mins. This time 
the cells were resuspended in x ml αMEM complete (where x= no. of PBMC's /ml calculated) 
giving a final concentration of 1 ×106 PBMC's /ml. 500µl of this cell suspension was sent for 
FACS analysis (following the FACS analysis procedure) and 4× 2ml fractions were removed 
to labelled tubes and centrifuged at 400g, 4
˚
C for 7mins. The supernatents were pipetted off 
completely and the cell pelletes were reconstituted in concentrations of rituximab in αMEM 
complete medium as follows: 
 2ml suspension reconstituted in 2ml 100µg/ml RTX in medium 
 2ml suspension reconstituted in 2ml 10µg/ml RTX in medium 
 2ml suspension reconstituted in 2ml 1µg/ml RTX in medium 
 2ml suspension reconstituted in 2ml 0.1µg/ml RTX in medium 
 
Giving a final concentration of 1×106 cells/ml. 500µl of each fraction was sent for FACS 
analysis to determine the percentage and absolute numbers of monocytes, T cells and B cells.  
 
2.3 Subjects 
The main characteristics and time-lines of the sub studies are summarised in table 6.
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Table 6 Main characteristics of all the sub studies 
Study Number of 
participants 
and site 
 
Gender and 
menopausal 
status 
Disease state Samples and analysis Time-lines 
The effects of B cell 
depletion on bone 
turnover in patients 
with rheumatoid 
arthritis - the pilot 
study 
 
46   
2 Dutch centres 
32 Female 
  -  13 pre 
  -  19 post 
14 Male 
Severe, refractory 
RA, pre and 6 
months post RTX 
Serum samples at baseline and 6 months post 
RTX to measure BTMs, inflammatory markers 
and DAS28 
 
Recruitment Mar 
2005 - Sep 2006 
6 - 24 month follow-
up ‘Last patient last 
visit’ May 2008’ 
Analysed Feb – Jun 
2009 
 
The effects of B cell 
depletion on bone 
turnover in patients 
with rheumatoid 
arthritis - the 
prospective study 
 
45 
10 UK centres 
36 Female 
  - 7 pre 
  - 29 post  
  9 Male 
Severe, refractory 
RA, pre and up to 
12 months post 
RTX 
 
Serum/plasma samples at baseline and 3, 6, 9, 
12 months post RTX to measure BTMs, 
inflammatory markers and DAS28 
BMD measured at baseline and 12 months post 
RTX 
 
Recruitment Aug 
2011 - Sep 2012  
12 month follow-up 
‘Last patient last 
visit’ Sept 2013’ 
Analysed Sep – Dec 
2013 
 
The effect of in vitro 
B cell depletion 
12 
1 UK centre 
 6 Female 
 6 Male 
Self-reported 
healthy volunteers 
with no previous or 
current history of 
autoimmune or 
bone disease 
 
PBMCs isolated from EDTA blood, 
unfractionated and CD20 depleted fractions  
cultured to compare the numbers of TRAP
+
 
cells generated  
Recruitment Nov 
2012 - Apr 2014 
Analysed Nov 2012 – 
Apr 2014 
The effects of ex vivo 
B cell depletion 
5 
1 UK centre 
 4 Female 
  - 4 post 
 1 Male 
Severe, refractory 
RA, pre and up to 
12 months post 
RTX 
 
PBMCs isolated from EDTA blood at baseline 
and 3, 6, 12 months post RTX and cultured to 
determine the numbers of TRAP
+
 cells 
generated at each time point 
 
Recruitment Aug 
2011 - Sep 2012  
12 month follow-up 
‘Last patient last 
visit’ Sep 2013’ 
Analysed Apr 2012 – 
Aug 2013 
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2.3.1 Pilot study 
Serum samples had previously been collected from 46 adult patients who participated in a 
Dutch, two-centre, open-label clinical trial to investigate the clinical and immunologic effects 
of treatment with RTX in severe refractory RA (Teng et al. 2009). All patients were older 
than 18yrs of age, had a clinical diagnosis of RA according to the American College of 
Rheumatology (ACR) criteria and had failed treatments with a combination(s) of DMARD's 
and/or TNF blocking agents. RTX was administered as a 1000mg intravenous infusion on 
days 1 and 15 in conjunction with intravenous methylprednisolone 100mg. TNF blocking 
agents were discontinued during a washout period of 8 weeks, whereas DMARD’s (MTX 2.5-
30mg/week; prednisolone 2.5-20mg/day) were continued (Teng et al. 2009). Serum samples 
were available at baseline (prior to treatment) and 6 months after the RTX infusion. Blood 
samples were collected between 10:00 -16:00hrs and were non-fasting, all samples were 
stored at -80ºC until analysis. Written informed consent was obtained from all patients and the 
study was approved by the Ethics Committees of Leiden and Utrecht University Medical 
Centres in the Netherlands and the Research and Development department at The James Cook 
University Hospital (Reference no. 2008006) (Wheater et al. 2011). 
 
2.3.2 Prospective study 
This was a multicentre, open-label, single treatment arm, prospective clinical trial on a cohort 
of 45 adult patients with severe RA who started RTX after failure of other DMARDs, 
including at least one anti-TNF-α. This study did not have a control group; the optimal design 
would have been a double-blind randomized comparison with placebo. However, as RTX is 
an approved treatment for refractory RA and is already known to reduce disease activity 
(Teng et al. 2007), such a control arm would have had to be matched for disease activity and 
it would have been unethical to have an untreated arm with that level of active disease. The 
trial was approved by the North East - Newcastle & North Tyneside 1 Research Ethics 
Committee (REC reference no. 10/H0906/57), the Medicines and Healthcare Products 
Regulatory Agency (MHRA) (Reference no. 21464/0205/001-0001) and the Research and 
Development department at The James Cook University Hospital (Reference no. 2010161). 
This work was funded by a grant from Roche Products Limited (Welwyn Garden City, UK). 
Recruitment took place in ten UK centres: South Tees Hospitals NHS Foundation Trust; 
Newcastle Hospitals NHS Foundation Trust; City Hospitals Sunderland NHS Foundation 
Trust; The Mid Yorkshire Hospitals NHS Trust; Northumbria Healthcare NHS Foundation 
Trust; County Durham and Darlington NHS Foundation Trust; Gateshead Health NHS 
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Foundation Trust; North Tees and Hartlepool Hospitals NHS Foundation Trust; South 
Warwickshire NHS Foundation Trust; and Mid Staffordshire NHS Foundation Trust.  
Written informed consent was obtained from all patients in compliance with the Declaration 
of Helsinki. Patients fulfilled the ACR classification criteria 1987 for the diagnosis of RA and 
the UK National Institute for Health and Care Excellence (NICE) eligibility criteria for 
treatment with RTX i.e. patients had severe active disease and had an inadequate response to, 
or were intolerant of, other DMARDs including at least one anti-TNF-α. Patients were 
excluded if they were younger than 18yrs old, had previously received any B cell depleting 
agent or had been treated for osteoporosis with bisphosphonates, calcitonin, strontium 
ranelate, denosumab or teriparatide within the last 3 months. Calcium, vitamin D, 
corticosteroids, non-biological DMARDs and treatment for concomitant medical conditions 
were all continued throughout the study at the discretion of the treating physician. RTX was 
administered following recommended protocol as a 1000mg intravenous infusion on days 1 
and 15 in conjunction with intravenous methylprednisolone 100mg. Patients who responded 
to the first RTX course received a second course at 6 months unless they attained a state of 
low disease activity, in accordance with clinical practice. Patients were assessed at baseline 
prior to RTX treatment and then every 3 months over a 12 month follow up period. 25OHD 
was measured once at the baseline visit, patients were recruited from August 2011 until 
September 2012 and were spread out evenly throughout the year.  Fasting morning blood 
samples were taken every 3 months into serum separator (SST) and 
ethylenediaminetetraacetic acid (EDTA) tubes. Serum and plasma were separated within 
60mins and immediately stored at -80˚C until analysis. Additionally, in a sub group of 
patients from Middlesbrough and Newcastle an extra 10ml EDTA blood was collected for in 
vitro osteoclastogenesis at baseline, 3, 6 and 12 months and processed within 8hrs. 
 
2.3.3 Osteoclast work 
Blood samples (20mls i.e. 5× EDTA blood tubes) were collected by normal venepuncture, by 
a trained phlebotomist, from self-reported healthy volunteers with no current or previous 
history of autoimmune or bone disease. The samples were non-fasting and were collected 
between 9:00 – 10:00. The blood was used to isolate mononuclear cell's following the PBMC 
isolation procedure (Section 2.2.2) prior to the osteoclast experiments. Volunteers were given 
an information sheet explaining the study and full written consent to participate was 
documented. All samples were fully anonymised and identified only by a sample number. The 
volunteer had no further involvement and individual results were not traceable in any way. 
The study was approved by the North East - Tyne and Wear South Ethics Committee (REC 
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reference number 11/NE/0317) and the Research and Development department at The James 
Cook University Hospital (Reference no. 2011083). 
2.4 Statistical analysis 
Some statistical tests should only be used on data which are ‘normally’ distributed i.e. follow 
a Gaussian distribution and are referred to as parametric tests. While non-parametric or 
‘distribution-free’ tests can be used with any data however distributed and including outliers. 
Non-parametric tests are based on fewer assumptions; hence they are generally less powerful 
than their parametric counterparts. Power being the probability that you will correctly reject 
the null hypothesis when it is false therefore there is an increased chance of making a Type II 
error with non-parametric tests and they are less likely to detect an effect or association when 
one really exists (Bowers et al. 2006). In the case of extremely small sample size, where it is 
difficult to ascertain the distribution of the data then non-parametric tests are more suitable. In 
this thesis; if the sample could not be transformed to be normal and the sample size was not 
sufficient (approximately 30 or more) that a parametric test could be used on a marginally 
non-normal sample then a non-parametric test was used. To assess the distributional shape 
and to evaluate if the data collected throughout this thesis were normally distributed, 
histograms were plotted and their shape visibly assessed. In addition analytical methods such 
as; ‘sktest’ based on skewness and kurtosis; and ‘swilk’ the Shapiro-Wilk tests for normality 
of data were used. Each is essentially a goodness of fit test, the null hypothesis for each test is 
H0: data follow a normal distribution versus H1: data do not follow a normal distribution. 
Therefore if the test was statistically significant (e.g. p<0.05) then data do not follow a normal 
distribution and a non-parametric test was warranted. The complete set of normality tests for 
variables used throughout this thesis are included in Appendix B and the results are 
summarised below or in their respective results section. P values ≤0.05 were considered 
statistically significant. Statistical analyses were performed using STATA 11 and 12 
(StataCorp LP, Texas, USA). 
 
2.4.1 Pilot study 
The histograms and tests for normality of data (Appendix B) showed that baseline, 6 month 
and percent change in βCTX, PINP, osteocalcin, OPG, CRP and ESR and percent change in 
DAS28 were not normally distributed and so were expressed as medians. However, the 
absolute change in these variables was normally distributed and so they were expressed as 
means. Baseline, 6 month and absolute change in DAS28 were normally distributed and so 
were also expressed as means. Similar results were found for these variables for the 
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bisphosphonate sub-group analysis. A paired t-test was used to compare change from baseline 
to 6 months (normally distributed). Spearman’s rank correlation coefficient was used to 
correlate the percentage change from baseline (non-normal distribution) in individual marker.  
 
2.4.2 Prospective study 
The determination of sample size was based on the primary endpoint, change in LS BMD 12 
months after the first RTX course. Assuming the true change in LS BMD was ≥0.01g/cm2 and 
that the DXA scan was reproducible with a SD of 0.02g/cm
2
; the study would have 80% 
power to detect a statistically significant difference (at the 5% significance level) if 33 
patients were included in the final analysis based on a one sample t-test. To allow for a 20% 
dropout 42 patients should be recruited. The histograms and tests for normality of data 
(Appendix B) showed generally the BMD data was normally distributed and so they were 
expressed as means; however, T- and Z- scores were not normally distributed and were 
expressed as medians. Baseline, 12 month and percent change in βCTX, TRAP5b, PINP, 
BALP, SCL, DKK-1, CRP and ESR and percent change in DAS28 were not normally 
distributed and so were expressed as medians. However, the absolute change in these 
variables was normally distributed and so they were expressed as means. Baseline, 12 month 
and absolute change in DAS28 were normally distributed and so were also expressed as 
means. Similar results were found for all variables for the vitamin D sub-group analysis. The 
primary endpoint; change in LS BMD and secondary endpoints; change in mean total femur, 
mean neck of femur and mean forearm BMD, change in BTMs and change in inflammatory 
markers and DAS28, between baseline and 12 months were investigated using a one sample t-
test. The median percentage change from baseline across 4 visits (3, 6, 9 and 12 months) was 
calculated for BTM’s, inflammatory markers and disease activity. Spearman’s rank 
correlation coefficient (Rs) was used to correlate percentage change in inflammatory markers 
with percentage change in BMD site or BTMs. The change over 12 months for each vitamin 
D category was compared using a Student’s t-test or Mann-Whitney test. Missing BMD or 
biomarker measurements were not imputed at any time point so using a completer analysis 
approach.   
 
2.4.3 Osteoclast work 
The histograms and tests for normality of data are included in Appendix B, however the 
sample sizes for the osteoclast cultures were small (in vitro n=12 and ex vivo n=5) and so non-
parametric tests were used. Results were expressed as medians and interquartile range. 
Wilcoxon signed-rank test was used to determine if there was a statistically significant 
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difference between unfractionated and CD20 depleted PBMC fractions. Spearman’s rank 
correlation coefficient Rs was used to correlate the initial number of cells and number of 
TRAP
+ 
cells generated. The Kruskal-Wallis test was used to determine if there was a 
statistically significant difference between visits and the nptrend statistic in Stata 11 was used 
to determine if there was a statistically significant trend in the results from baseline to 12 
months for the RA patient data set. Multiple regression analysis was used to investigate which 
factors predicted osteoclast formation in unfractionated and CD20 depleted blood. Automated 
stepwise selection was used to create the models and the distribution of the residuals was 
verified graphically and with the Shapiro-Wilk W test for normal data (Appendix C).
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Chapter 3. The effects of B cell depletion on bone turnover in patients with 
rheumatoid arthritis - the pilot study 
 
3.1 Introduction 
Progress has been made towards a greater understanding of the cross-regulation between the 
immune system and bone. A number of the same family members of cell surface receptors, 
cytokines and signalling pathways serve a critical role in both systems (Datta et al. 2008) and 
this is facilitated by their proximity in the bone marrow. The role of the immune system, 
specifically activated T cells, in inflammatory bone resorption and osteoclastogenesis is well 
established (Schett 2006, Li et al. 2007), but the role of B cells in osteoclast formation 
remains controversial. B cells can produce pro-osteoclastogenic cytokines including RANKL 
(Choi et al. 2001, Manabe et al. 2001) and under pathologic conditions such as RA this 
process is markedly enhanced by pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and 
IL-17 (Schett 2006). B cells also produce cytokines that inhibit osteoclast differentiation from 
the progenitor cells, such as OPG and TGF-β (Li et al. 2007, Neale Weitzmann et al. 2000). 
The biological implications of these interactions are now being realised and targeted for 
therapeutic interventions. RA is the most prevalent inflammatory joint disease in which B 
cells play an important role. Controlled trials have shown that RTX, an antibody directed 
against CD20, depletes B cells and is an effective biological therapy for RA (Teng et al. 
2007). Consequently RA subjects treated with RTX provide an ideal model for examining the 
effects of B cell depletion on bone turnover. It could be hypothesized that prolonged B cell 
depletion in patients with RA would affect bone turnover through modulation of 
osteoclastogenesis. However, some of these effects may be indirect through attenuation of 
systemic inflammation, while others may be direct as a result of the absence of B cells during 
osteoclast formation.  
The availability of detailed clinical data and serial samples of blood from RA patients, before 
and after treatment with RTX, who participated in a prior clinical study carried out in The 
Netherlands (Teng et al. 2009) provided a unique opportunity to examine the role of B cells in 
inflammatory bone resorption and the results of this pilot study are described in the following 
Chapter. 
 
3.2 Materials and methods 
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3.2.1 Patient cohort 
The present pilot study involved 46 patients who participated in a prior Dutch, two-centre, 
open-label clinical trial to investigate the clinical and immunologic effects of treatment with 
RTX in severe refractory RA (Teng et al. 2009). All patients had failed treatment with a 
combination of DMARDs and/or TNF blocking agents, the clinical protocol is described in 
Chapter 2 section 2.3.1. Clinical efficacy had been previously assessed in The Netherlands 
using DAS28 and all routine laboratory results were available on a database. Menopausal 
status was confirmed using oestradiol and follicle-stimulating hormone (FSH) results. All 
patients were depleted of peripheral B cells following treatment with RTX (B-cell lineage 
marker CD19 analysed by quantitative flow cytometry), (Teng et al. 2009). Blood samples 
were taken between 1000 and 1600hrs and were non-fasting; all sera were stored at −80°C 
until biomarker analysis.  
 
3.2.1 Biomarker measurements 
Total PINP, osteocalcin and βCTX were quantified in serum by ECLIA on the Elecsys 2010 
analyser. Both the free and complexed OPG-sRANKL concentration was measured in serum 
by manual ELISA. Individual assay details are described in Chapter 2 section 2.3.1. 
 
3.2.2 Statistical analysis 
Details of the statistical analysis are described in Chapter 2 section 2.4.1. 
 
3.3 Results 
 
3.3.1 Demographic and clinical characteristics 
Twenty-six patients (20 females and 6 males) from Leiden and 20 patients (12 females and 8 
males) from Utrecht were included in the study. Samples were collected from all patients at 
baseline and 6 months. Additional blood samples were available at 3, 12, 18 and 24 months 
from the Leiden cohort; 26 samples were available at 3 months, 2 female patients were 
withdrawn from the study before their 6 month RTX infusion and at 24 months a further 5 
females and 3 males were withdrawn before completing all 3 infusions due to serious adverse 
events. Only a limited number of samples were collected at the 18 month visit (Figure 13). 
The baseline characteristics of the 46 RA patients are provided in Table 7. Briefly, their mean 
age was 54.6yrs and disease duration 15.2yrs, 41 (89%) of patients were positive for IgM-RF 
and 38 (83%) were positive for ACPA-IgG. The baseline characteristics of patients from 
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Leiden and Utrecht were compared; there was a significant difference in smoking status and 
baseline βCTX and OPG, but no significant difference in any other parameters per site (Table 
7). Utrecht patients had significantly lower βCTX levels however; fifty percent of these 
patients were already taking bisphosphonates which would explain the lower values. The 
effects of anti-osteoporotic medication were examined in Table 9. Additionally, Utrecht 
patients had significantly lower OPG levels but a greater percentage of these patients were 
current or former smokers and smoking has been reported to suppress OPG production 
(Lappin et al. 2007). 
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Figure 13 Flowchart showing the pilot study numbers at each time point 
Patients from two Dutch centres; 26 from Leiden and 20 from Utrecht, were recruited into this pilot study. At 6 
months samples were available from 26 Leiden patients and 19 Utrecht patients. Additional samples were 
collected from the Leiden patients at 3 (n=26), 12 (n=24), 18 (n=7) and 24 months (n=16). 
 
  
BASELINE (n=46) 
26 Leiden Patients     +     20 Utrecht Patients  
 (20F (12Post +8Pre): 6M)         (12F (7Post +5Pre): 8M) 
3 MONTHS (n=26) 
26 Leiden Patients  
 (20F (12Post +8Pre): 6M) 
6 MONTHS (n=45) 
 26 Leiden Patients    + 19 Utrecht Patients 
 (20F (12Post +8Pre): 6M)      (12F (7Post +5Pre): 7M)  
12 MONTHS (n=24) 
24 Leiden Patients 
 (18F (10Post +8Pre): 6M) 
18 MONTHS (n=7)  
7 Leiden Patients  
(4F (2Post + 1Pre): 3M) 
24 MONTHS (n=16) 
16 Leiden Patients 
 (13F (9Post + 4Pre): 3M) 
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Table 7 Baseline characteristics of the forty-six rheumatoid arthritis patients 
 
Baseline characteristic  
No. (%) 
All patients 
(n=46) 
Leiden patients 
(n=26) 
Utrecht patients 
(n=20) 
P value 
(Difference 
by site) 
Age mean (sd), yrs 
Gender 
54.6 (12.0) 53.2 (12.4) 56.5 (11.6) 0.353 
 
- Male 
- Female 
- Pre-menopausal 
- Post-menopausal 
14 (30) 
32 (70) 
13 (41) 
19 (59) 
6 (23) 
20 (77) 
8 (40) 
12(60) 
8 (40) 
12 (60) 
5 (42) 
7 (58) 
0.216 
 
0.487 
Smoking status  
- Current 
- Former 
- Never 
 
12 (26) 
17 (37) 
17 (37) 
 
5 (19) 
7 (27) 
14 (54) 
 
7 (35) 
10 (50) 
3 (15) 
 
0.035 
Concomitant medication 
- Methotrexate 
 
32 (70) 
 
21 (81) 
 
11 (55) 
 
0.060 
- Prednisolone 
- Bisphosphonate 
Disease duration, mean (sd), yrs 
28 (61) 
17 (37) 
15.2 (11.8) 
14 (54) 
7 (27) 
15.9 (13.2) 
14 (70) 
10 (50) 
14.4 (10.0) 
0.266 
0.109 
0.691 
RF positive 41 (89) 22 (85) 19 (95) 0.262 
ACPA positive 
eGFR mean (sd), mls/min/1.73m
2
 
38 (83) 
88 (23) 
21 (81) 
89 (20) 
17 (85) 
87 (28) 
0.707 
0.869 
HAQ mean (sd) 
DAS28-CRP median (IQR) 
1.60 (0.64) 
5.62 (5.00-6.64) 
1.66 (0.71) 
5.62 (4.85-6.64) 
1.53 (0.55) 
5.66 (5.00-6.68) 
0.517 
0.673 
ESR median (IQR), mm/hr 42 (22-66) 44 (22-66) 39 (18-63) 0.732 
CRP median (IQR), mg/L 21.0 (8.0-57.0) 26.0 (15.0-84.0) 16.5 (8.0-44.5) 0.299 
TSH median (IQR), mU/L 1.26 (0.69-2.10) 1.62 (0.80-2.24) 0.89 (0.62-1.8) 0.178 
LH median (IQR), U/L – females 25.8 (2.0-41.4) 32.9 (4.2-41.4) 21.9 (1.7-37.2) 0.641 
FSH median (IQR), U/L – females  47.0 (4.0-61.4) 51.0 (5.2-66.2) 46.5 (2.7-59.2) 0.824 
Testosterone median (IQR), nmol/L – 
males  
9.7 (8.3-15.0) 9.0 (8.2-9.7) 13.0 (8.5-20.0) 0.175 
βCTX median (IQR), ng/L 224 (114-415) 368 (165-455) 137 (76-252) 0.003 
PINP median (IQR), µg/L 35.5 (22.7-46.7) 39.9 (24.8-57.1) 33.4 (18.5-42.3) 0.138 
Osteocalcin median (IQR), µg/L 15.2 (9.6-21.4) 16.8 (9.7-30.8) 12.6 (9.6-19.6) 0.150 
OPG median (IQR), pmol/L 3.2 (2.2-4.4) 3.9 (2.6-5.5) 2.6 (1.8-3.2) 0.004 
 
 
Continuous data are presented as means and standard deviation or medians and interquartile range depending on 
the distribution of the data set; groups were compared using the student’s t-test or Mann-Whitney test when 
appropriate. Categorical variables are displayed as absolute frequencies and percentages; groups were compared 
using Fisher’s exact test. ACPA: Anti-cyclic Citrullinated Peptide Antibody; βCTX: β-isomerised carboxy 
terminal telopeptide of type I collagen; CRP: C-Reactive Protein; DAS28: Disease Activity Score using 28 
tender and swollen joints; eGFR: estimated Glomerular Filtration Rate; ESR: Erythrocyte Sedimentation Rate; 
FSH: Follicle Stimulating Hormone; HAQ: Health Assessment Questionnaire; LH: Luteinising Hormone; OPG: 
osteoprotegerin; PINP: procollagen type 1 amino-terminal propeptide; RF: Rheumatoid Factor;  TSH: Thyroid 
Stimulating Hormone. 
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3.3.2 Changes in biomarker levels 
Changes in median biomarker concentrations from baseline i.e. before the RTX treatment, to 
6 months after the infusion are shown in Table 8. There was a significant reduction in βCTX 
at 6 months (-97ng/L; 95% CI -147, -47; p<0.001; a reduction of 37%). These results were 
mirrored by a significant reduction in CRP (-15mg/L; 95% CI -24, -6.8; p<0.001; a reduction 
of 43%), ESR (-17mm/hr; 95% CI -25, -9; p<0.001; a reduction of 33%) and DAS28 score (-
0.94; 95% CI -1.35, -0.52; p<0.001; a reduction of 14%). There was a significant increase in 
PINP over 6 months (9.7μg/L; 95% CI 3.0, 16.4; p=0.006; an increase of 13%) but no 
significant change in osteocalcin or OPG levels (Wheater et al. 2011). Additionally, a marker 
of formation (PINP) and a marker of resorption (βCTX) were expressed as multiples of the 
median MoMF and MoMR respectively (described in Chapter 2 section 2.2.1), (Bieglmayer 
and Kudlacek 2009) and their ratios (MoMF/ MoMR) plotted before and 6 months after RTX 
to show the effect of treatment on bone turnover (Figure 14).  At baseline 24 (53%) patients 
had a bone turnover ratio <1 (i.e. resorption predominated); whereas 6 months post RTX there 
were only 5 (11%) such patients, the majority had a ratio of ≥ 1 (i.e. formation predominated). 
 
3.3.3 Time course of change in bone turnover 
Additional serial samples were available from a subset of patients (n=26) at 3, 12 and 24 
months. There was a wide variance in the changes in biomarker levels, but generally median 
βCTX levels decreased up until 6 months then gradually returned to baseline values and there 
was a small increase in bone formation markers; PINP, osteocalcin (Figure 15).   
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Table 8 Change in biomarker concentration for the forty-six rheumatoid arthritis 
patients 
 Baseline 6 Month Difference 
( ±95% CI) 
p value 
 
% change 
( ±95% CI) 
Bone Formation      
PINP (µg/L) 35.5 44.4  9.7 (3.0, 16.4) 0.006 13 (-3, 38) 
Osteocalcin (µg/L) 15.2 18.7 2.2 (-0.5, 4.9) 0.113 12 (-5, 31) 
Bone Resorption 
βCTX (ng/L) 
 
224 
 
161 
 
-97 (-147, -47) 
 
<0.001 
 
-37 (-47, -5) 
Osteocyte marker 
OPG (pmol/L) 
 
3.2 
 
2.9 
 
-0.4 (-0.9, 0.1) 
 
0.090 
 
-14 (-32, 10) 
Inflammatory markers 
CRP (mg/L) 
ESR (mm/hr) 
 
21 
42 
 
14 
24 
 
-15 (-24, -6.8) 
-17 (-25, -9) 
 
<0.001 
<0.001 
 
-43 (-55, -5) 
-33 (-46, -15) 
Disease activity 
DAS28 score 
 
5.71 
 
4.78 
 
-0.94 (-1.35, -0.52) 
 
<0.001 
 
-14 (-21, -8) 
 
βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; CRP: C-Reactive Protein; DAS28: Disease 
Activity Score using 28 tender and swollen joints; ESR: Erythrocyte Sedimentation Rate; OPG: osteoprotegerin; 
PINP: procollagen type 1 amino-terminal propeptide.  Baseline, 6 months and percent change data for PINP, 
osteocalcin, βCTX, OPG, CRP, ESR and percent change for DAS28 were not normally distributed therefore 
results were expressed as medians. Baseline and 6 months DAS28 and all absolute change results were normally 
distributed and were expressed as means. P values were recorded between baseline and 6 months for all 
parameters using paired t-tests; p values ≤0.05 were considered significant. 
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Figure 14 Ratio of bone marker multiples of the median depicting bone turnover in 
forty-six rheumatoid arthritis patients’ pre and 6 months post rituximab 
Blood samples from 72 healthy volunteers (33 males aged 19 to 62yrs and 39 females aged 20 to 64yrs) were 
analysed on the Elecsys 2010 for βCTX and PINP to calculate the median of the reference population. Multiples 
of the median (MoM) were defined as ‘individual marker result/ median of the reference population’ 
(Bieglmayer and Kudlacek 2009). Individual βCTX and PINP results from this pilot study looking at 46 patients 
with refractory RA analysed pre and post RTX, were expressed as ratios of  their multiples of the median 
(MoMF/ MoMR).  
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Bone Formation 
 
Bone Resorption      Cytokine
 
 
Figure 15 Change in individual bone markers over the course of the study 
Serial biomarker results in a subset of RA patients from the pilot study: n= 26 (6M, 8 pre-, 12 post-menopausal 
F) at 0, 3 and 6 months; n=24 (6M, 8 pre-, 10 post-menopausal F) at 12 months; n=7 (3M, 2 pre-, 2 post-
menopausal F) at 18 months; n=16 (3M, 4 pre-, 9 post-menopausal F) at 24 months. 
           Indicates the median values. 
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3.3.4 The effect of gender and menopausal status 
As menopausal status is known to markedly affect bone turnover rate and to investigate the 
wide variance in biomarker results the data was plotted (Figure 16) by gender and menopausal 
status separately (14 males, 13 pre-menopausal and 19 post-menopausal females). There was 
a significant decrease in βCTX in males (p=0.016) and a borderline significant decrease in 
postmenopausal females (p=0.05), the latter also showed a significant increase in PINP 
(p=0.024) from baseline to 6 months. Premenopausal females had the lowest baseline results 
overall and least change at 6 months for all bone markers (Wheater et al. 2011). However, the 
numbers in each group are small and so the gender specific differences should be interpreted 
with caution. 
 
3.3.5 The effect of concomitant medication 
Seventeen patients (4 males; 5 pre- and 8 post-menopausal females) were taking 
bisphosphonates and prednisolone, a further 11 patients (4 males; 3 pre- and 4 post-
menopausal females) were on prednisolone alone and the remaining 18 (6 males; 5 pre- and 7 
post-menopausal females) were on neither medication. No patients were on hormone 
replacement therapy. Results are included in Table 9, there was a significant reduction in 
βCTX (mean change -129ng/L 95% CI,-191, -67; p<0.001; a -37% decrease) and OPG (mean 
change −0.7pmol/L 95% CI-1.3, -0.0; p=0.048; a 16% decrease) at 6 months for patients not 
taking a bisphosphonates, but no significant change in patients on bisphosphonates. 
Conversely, there was a significant increase in PINP (mean change 14.3µg/L 95% CI, 3.3, 
25.2; p=0.014; a 42% increase) and osteocalcin (mean change 5.6µg/L 95% CI, 1.0, 10.3; 
p=0.021; a 31% increase) in patients on bisphosphonate, but no significant change on those 
not taking bisphosphonate (Wheater et al. 2011). Patients on bisphosphonate had increased 
bone formation at 6 months but no significant change in bone resorption; whereas patients not 
on bisphosphonate had decreased bone resorption at 6 months but no significant change in 
bone formation. There was however a significant improvement in the bone turnover ratio 6 
months post RTX in bisphosphonate naïve patients (mean change 0.5, 95% CI, 0.2, 0.8; 
p<0.001), but no significant change in this ratio in patients taking bisphosphonate. 
 
3.3.6 Correlations between inflammatory activity and bone turnover 
Only the patients not on bisphosphonate or prednisolone (n=18) were included in the 
correlation analysis to examine the effect of RTX on the change in biomarker levels (Table 
10). Significant correlations were observed between βCTX and DAS28 (Rs=0.570, p=0.014) 
and borderline significant between βCTX and CRP (Rs=0.485, p=0.057), (Wheater et al. 
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2011). The significant correlations between the bone turnover markers and between the 
inflammatory markers were as expected. 
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Bone Formation 
  
Bone Resorption     Cytokine 
  
Inflammatory markers 
  
Disease activity 
 
Figure 16 The effects of gender and menopausal status on median biomarker levels  
Blood samples were taken at baseline before RTX and at 6 months after the infusion in a total of 46 patients with 
RA.  Patients were split by gender and menopausal status (14 males, 13 pre-menopausal and 19 post-menopausal 
females). Results were expressed as medians. 
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Table 9 Effect of bisphosphonate treatment on change in biomarker concentration for 
forty-six rheumatoid arthritis patients from baseline to six months 
 Baseline     6 
Month  
Difference 
( ±95% CI) 
p value % change  
( ±95% CI) 
Bone Formation 
PINP (µg/L) 
All Patients (n=46) 
- Bisphosphonate (n=17) 
- No Bisphosphonate (n=29) 
 
 
35.5 
19.8 
44.9 
 
 
44.4 
29.4 
45.6 
 
 
 9.7 (3.0, 16.4) 
14.3 (3.3, 25.2) 
7.2 (-1.7, 16.1) 
 
 
0.006 
0.014 
0.108 
 
 
13 (-3, 39) 
42 (-3, 99) 
8 (-10, 33) 
Osteocalcin (µg/L) 
All Patients (n=46) 
- Bisphosphonate (n=17) 
- No Bisphosphonate (n=29) 
 
15.2 
9.4 
20.1 
 
18.7 
11.6 
20.7 
 
 2.2 (-0.5, 4.9) 
5.6 (1.0, 10.3) 
0.3 (-3.1, 3.7) 
 
0.113 
0.021 
0.850 
 
12 (-6, 33) 
31 (-7, 127) 
6 (-16, 21) 
Bone Resorption 
βCTX (ng/L) 
All Patients (n=46) 
- Bisphosphonate (n=17) 
- No Bisphosphonate (n=29) 
 
 
224 
154 
328 
 
 
161 
82 
186 
 
 
 -97 (-147, -47) 
-40 (-127, 47) 
-128 (-191, -67) 
 
 
<0.001 
 0.346 
<0.001 
 
 
-37 (-49, -6) 
-36 (-71, 39) 
-37 (-45, -6) 
Cytokine 
OPG (pmol/L) 
All Patients (n=46)) 
- Bisphosphonate (n=17) 
- No Bisphosphonate (n=29) 
 
 
3.2 
2.9 
3.4 
 
 
2.9 
2.9 
2.7 
 
 
 -0.4 (-0.9, 0.1) 
0.0 (-0.7, 0.7) 
-0.7 (-1.3, -0.0) 
 
 
0.090 
0.925 
0.048 
 
 
-14 (-33, 12.5) 
3 (-22, 27) 
-16 (-37, 10) 
 
βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; PINP: procollagen type 1 amino-terminal 
propeptide; OPG: osteoprotegerin.  Baseline, 6 months and percent change data for PINP, osteocalcin, βCTX 
and OPG were not normally distributed therefore results were expressed as medians. All absolute change results 
were normally distributed and were expressed as means. P values were recorded between baseline and 6 months 
for all parameters using paired t-tests; p values ≤0.05 were considered significant. 
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Table 10 Correlations between the percentage change from baseline of biomarker values 
for patients not on bisphosphonates or prednisolone (n=18) 
 
 PINP Osteocalcin OPG CRP ESR DAS28 
 
 
βCTX 
 
0.425 
 
0.567
*
 
 
-0.020 
 
0.485 
 
0.212 
 
0.570
*
 
PINP  0.715
***
 0.057 -0.090 -0.020 0.422 
Osteocalcin   0.016 -0.004 -0.034 0.348 
OPG 
CRP 
ESR 
   0.074 -0.150 
0.677
**
 
0.135 
0.596
*
 
0.628
**
 
 
βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; PINP: procollagen type 1 amino-terminal 
propeptide; OPG: osteoprotegerin; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; DAS28: 
Disease Activity Score using 28 tender and swollen joints. The percent change data was not normally distributed 
therefore Spearman’s rank correlation Rs was used. 
 *
 p<0.05; 
**
 p<0.01; 
***
 p<0.001. 
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3.4 Discussion 
The aim of this study was to investigate the effects of B cell depletion with RTX on bone 
turnover in patients with severe RA. There was a significant suppression of bone resorption 
depicted by βCTX, along with an increase in PINP a marker of bone formation albeit subjects 
being treated with a range of therapies, including corticosteroids, which are known to increase 
bone turnover and bone loss. Glucocorticoids have strong anti-inflammatory effects but their 
use in RA has been reported to increase the risk of osteoporosis by inducing apoptosis of 
osteoblasts and osteocytes leading to an uncoupling between bone formation (suppressed) and 
bone resorption (unchanged or relatively increased), (Lems 2007). This effect can be 
counteracted by the use of bisphosphonates that induce osteoclast apoptosis (Breuil 2006). 
Over half of the patients in this study had been on prednisolone alone or in combination with 
a bisphosphonate for at least six months prior to the start of the study. Bisphosphonates are 
synthetic analogs of pyrophosphate; they avidly bind to the hydroxyapatite component of the 
bone matrix and so suppress osteoclast-mediated bone resorption (Goldring and Gravallese 
2004). There are two distinct types of bisphosphonates based on the presence or absence of an 
amino group on the carbon side chain. The amino bisphosphonates; alendronate, risedronate 
and zolendronate, were commonly used in this pilot study; they inhibit osteoclast recruitment, 
differentiation, formation of the ruffled border and acid production and induce osteoclast 
apoptosis (Deal 2005). Typically, bisphosphonates decrease bone resorption rapidly within 
one to three months and because of the coupling of bone formation and resorption, this 
inhibition of resorption results in a decrease in formation by six to twelve months (Deal 2005, 
Brown et al. 2009). There was a significant suppression of bone resorption six months after 
RTX in this pilot study; however the extent of this decrease was masked by the number of 
patients already on bisphosphonate; these patients already had suppressed bone resorption at 
baseline and therefore a non-significant decrease at six months. Interestingly, this group of 
bisphosphonate treated patients still had a significant increase in bone formation six months 
after RTX despite the suppressed resorption. 
Additionally, there was a significant correlation between the reduction in bone resorption and 
disease activity in a subset of patients, not on bisphosphonates or prednisolone indicating that 
the anti-resorptive action and anti-inflammatory therapeutic response may be related.  The 
suppression of bone resorption was possibly due to a combination of factors namely; 
diminished osteoclast activity resulting from decreased B-cell mediated osteoclastogenesis; 
decreased systemic inflammatory cytokines; or increased physical activity following RTX 
treatment (Wheater et al. 2011). The magnitude of difference in the bone markers was 
difficult to determine because of the heterogeneity of the patients examined in this study with 
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respect to age, gender and menopausal status. In young adults bone formation and resorption 
are in balance and reach peak bone mass during the third decade of life, but with ageing there 
is a net loss of bone (Datta et al. 2008). Additionally, menopausal status is known to markedly 
affect the rate of bone turnover (Garneo et al. 2000) and so the results were re-assessed by 
gender and pre- or post-menopause. However, as the numbers per group were small any such 
differences were interpreted with caution. In general pre-menopausal females had the lowest 
baseline results overall and showed the least improvement post RTX therapy. Post- 
menopausal females had higher levels of bone markers at baseline, possibly because bone loss 
is more rapid post menopause (Garneo et al. 2000). Likewise, the male cohort were older 
(median age 60.9; range 50.6 – 81.5yrs) and had higher baseline values and an apparent 
reduction in bone resorption over six months, although the small numbers impacted on the 
confidence limits and further studies are needed to confirm these observations (Wheater et al. 
2011).  
Although, several studies have reported that RTX inhibits the progression of structural joint 
damage in RA (Keystone 2009, Boumans 2012), few studies have reported the effects of a B 
cell depleting therapy on biochemical markers of bone turnover. These results do however, 
confirm and extend recent findings with RTX in 13 patients with active RA. The authors 
reported a significant decrease in bone resorption after 15 months, but no significant change 
in markers of bone formation (Hein et al. 2010). A review of comparable studies using TNF 
blocking agents (Barnabe and Hanley 2008), mainly infliximab on markers of bone turnover, 
show variable results, the majority reporting a similar positive effect on bone six months post 
therapy. 
 
3.5 Conclusion 
In conclusion, the results of this pilot study indicated that depletion of B cells with RTX in 
this RA cohort ameliorated bone turnover, as reflected by the changes in βCTX and PINP six 
months after treatment. Significant correlations between the percentage decrease from 
baseline in βCTX and DAS28 suggested that the improvement in disease activity accounted in 
part for the reduction in bone resorption. However, there were a number of limitations to be 
addressed in further work. The comparatively small number of subjects impacted on the 
confidence intervals for the median change from baseline and the study was not powered to 
adjust for confounders. Additionally, this analysis was not a predefined aim of the original 
RTX study so thirty-seven percent of patients were already on bisphosphonates, this may have 
masked the effects of RTX. Furthermore, the blood samples were not all fasted, early morning 
samples as recommended for markers of bone turnover (Wheater et al. 2013). A further study 
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is needed over a longer follow-up period and after subsequent treatments to confirm these 
associations, adjust for potential confounders and investigate whether the observed changes in 
biochemical markers of bone turnover translate into changes in bone mass. 
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Chapter 4. The effects of B cell depletion on bone turnover in patients with 
rheumatoid arthritis - the prospective study 
 
4.1 Introduction 
The results of the pilot study indicated that there was a significant suppresion of bone 
resorption in twenty-nine bisphosphonate naïve patients with severe refractory RA, after a 
single treatment course of RTX. However, it was evident that the true effect of B cell 
depletion was masked by including seventeen patients already treated with bisphosphonate in 
the total cohort. Additionally, the blood samples were not all taken under identical conditions. 
Bone turnover shows a circadian rhythm, this is most apparent in serum βCTX; levels are 
highest between 01:30 and 04:30 and may be more than twice that at the nadir between 11:00 
and 15:00 (Wichers et al. 1999). Blood samples in the pilot study were all taken between 
10:00 and 16:00, the finding that RTX caused the ‘trough’ levels of βCTX to drop was 
therefore of significance. The disparity in levels can be diminished with fasting and is 
influenced by variations in serum insulin (Bjarnason et al. 2002). Bone markers are 
significantly lower in the fed state and dependant on the clearance rate of individual markers 
or food composition (Clowes et al. 2002). Consequently the timing of the sample collection 
and fasting status should be tightly controlled in subsequent studies.  
Data describing the effect of in vivo B cell depletion on general bone loss in patients with RA 
are still limited. Therefore, a prospective observational study was designed to investigate bone 
density and biomarkers of bone turnover in RA patients treated with RTX over a 12 month 
period. The aim of this study was to confirm and extend the results of the pilot study and to 
address the apparent limitations mentioned above, in a different cohort of patients. It was 
postulated that the presumed bone-protective effects of RTX on bone density and bone 
turnover are due either to a direct effect of B cell depletion on osteoclastogenesis, or a 
reduction in disease activity, or alternatively to both of these effects.  
 
4.2 Materials and methods 
This was a multicentre, open-label, single treatment arm, prospective clinical trial on a cohort 
of adult patients with severe RA who started RTX after failure of other DMARDs, including 
at least one anti-TNF-α. The primary outcome measure was change in lumbar spine BMD. 
The secondary outcomes were: change in mean total femur, mean neck of femur and mean 
forearm BMD, change in bone turnover markers, change in inflammatory markers and change 
in DAS28. Parameters were assessed between baseline and 12 months.  
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4.2.1 Patient cohort 
All patients were older than 18 years of age and had an established diagnosis of RA according 
to the American College of Rheumatology (ACR)-criteria and were eligible for treatment with 
RTX, according to the UK National Institute for Health and Care Excellence (NICE) 
eligibility criteria. Patients were excluded if they had previously received any B cell depleting 
agent, or had been treated for osteoporosis with bisphosphonates, calcitonin, strontium 
ranelate, denosumab or teriparatide. However, calcium, vitamin D, corticosteroids, non-
biological DMARDs and treatment for concomitant medical conditions were all continued 
throughout the study at the discretion of the treating physician. Patients were recruited from 
10 UK centres (Figure 17). The clinical protocol is described in Chapter 2 section 2.3.2.  
 
4.2.2 Clinical and laboratory assessments 
Patients were assessed at baseline prior to the first RTX treatment and then every 3 months 
over a 12 month follow up period. Clinical assessment of disease activity was undertaken 
using the 28-joint disease activity score and wrCRP (DAS28-CRP). Routine laboratory 
investigations were performed locally at baseline and every three months. Fresh whole blood 
samples were analyzed using a flow cytometer (FACS Canto II) to determine the numbers of 
CD19
+
 B cells in a subset of patients as per the study protocol at baseline and 3-monthly 
visits.  
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Figure 17 Location of the ten UK centres recruiting into the prospective study 
Patients were recruited from ten UK Rheumatology centres: South Tees Hospitals n=13; Newcastle Hospitals 
n=9; City Hospitals Sunderland n=4; Northumbria Healthcare n=3; County Durham and Darlington n=3; North 
Tees and Hartlepool n=2; Gateshead Health n=3; South Warwickshire n=2; Mid Yorkshire n=4; Mid 
Staffordshire n=2. 
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2.  Newcastle Hospitals NHS Foundation Trust 
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4.2.3 Bone mineral density measurements 
BMD was measured at baseline and 12 month by dual-energy X-ray absorptiometry (DXA). 
Measurements were taken at the lumbar spine (mean L2-L4), also right and left femoral neck, 
total femur and ultra-distal radius (RUD) forearm; however results were reported as the mean 
of both sides. Two different DXA machines were used across the 10 centres; 7 centres used 
GE Lunar Prodigy (Lunar, Madison, Wisconsin, USA) and 3 centres used Hologic Discovery 
(Hologic, Waltham, Massachusetts, USA). However, in all cases the same machine was used 
at baseline and follow-up measurement for each patient. The inter-assay coefficient of 
variation (CV), measured using a local spine phantom, for the different centres were all less 
than 1.8%.  
 
4.2.4 Biomarker measurements 
Fasting morning blood samples were taken every 3 months into SST and EDTA tubes. Serum 
and plasma were separated within 60mins and immediately stored at -80˚C until analysis. All 
measurements were performed as per manufacturer’s instructions and in a centralized 
laboratory to reduce analytical variation. Total PINP, βCTX and PTH were quantified in 
plasma by automated ECLIA on the Elecsys 411 analyser. BALP and 25OHD were quantified 
in serum by chemiluminescence on the iSYS analyser and TRAP5b was measured in serum 
by a manual ELISA.  SCL and DKK-1 were measured in serum using a manual ELISA. 
Method details are included in Chapter 2 section 2.2.1. 
 
4.2.5 Statistical analysis 
Details of the statistical analysis are described in Chapter 2 section 2.4.2. 
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4.3 Results 
A total of 45 patients met the eligibility criteria and were enrolled into the study (Figure 18). 
One patient was subsequently diagnosed with chronic lymphocytic leukaemia (CLL) and 
excluded; therefore 44 patients received the first RTX infusion. A total of 36 patients 
completed the 12 month follow up period and were included in the analysis; 32 of these 
patients received a second course of RTX as per protocol and four patients did not (two 
patients had low disease activity (DAS28<3.2); one patient had undetectable B cells and one 
patient refused the second course). 
 
4.3.1 Demographic and clinical characteristics 
There was no significant difference in any baseline characteristic (Table 11) between patients 
who completed the study (n=36) compared to the total number of patients recruited (n=45), or 
between patients who completed the study (n=36) compared to non-completers (n=9). 
Therefore the following analysis included only the 36 patients who completed 12 month 
follow-up. Seven of these patients were male and 29 were female; 23 females were post-
menopausal. Briefly, their mean age was 58.6 ±12.1yrs and the mean disease duration was 
10.4 ±7.0yrs, 33% of patients were current smokers (n=12) consisting of one pre-menopausal, 
nine post-menopausal and two male patients. Eighty-three percent (n=30) of patients were 
positive for IgM-RF and 76% (n=25) were ACPA positive. Thirty-nine percent (n=14) of the 
patients had vitamin D deficiency defined as 25OHD levels below 25nmol/L, only one of 
these patients was on a calcium and vitamin D supplement at baseline, a further four patients 
started on supplements during the course of the study. The numbers of CD19
+
 B cells were 
determined in a subset of 16 patients at each visit; all had values less than 0.01 ×109/L at 3 
months and four patients had rapid reconstitution of their B cells at 6 months, while the others 
had long-term depletion.  
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Figure 18 Consort flow diagram for the prospective study 
Forty-seven patients were screened; 2 patients did not meet the eligibility criteria and so 45 were enrolled onto 
the study. One patient was subsequently diagnosed with chronic lymphocytic leukaemia therefore only 44 
patients received the first course of RTX. A further 8 patients did not complete the study and a total of 36 
patients were included in the final analysis; of these only 32 received the second RTX course. 
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nd
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          1 Previous B cell depletion 
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Table 11 Baseline characteristics of the prospective study patients 
Characteristics  
No. (%) 
All patients 
(n=45) 
Completed 
study (n=36) 
Did not complete 
study (n=9) 
Age mean (sd), yrs 
Gender 
59.3 (12.2) 58.6 (12.1) 62.3 (12.5) 
- Male 
- Female 
- Pre-menopausal 
- Post-menopausal 
9 (20) 
36 (80) 
7 (19) 
29 (81) 
7 (19) 
29 (81) 
6 (21) 
23 (79) 
2 (22) 
7 (78) 
1 (14) 
6 (86) 
Ethnicity  
- White 
- Asian 
 
43 (96) 
2 (4) 
 
34 (94) 
2 (6) 
 
9 (100) 
0 
Smoking status  
- Current 
- Former 
- Never 
 
15 (33) 
14 (31) 
16 (36) 
 
12 (33) 
11 (31) 
13 (36) 
 
3 (33) 
3 (33) 
3 (33) 
Concomitant medication 
- Hydroxycloroquine 
- Leflunomide 
- Methotrexate 
- Sulfasalazine 
 
2 (4) 
5 (11) 
25 (56) 
5 (11) 
 
1 (3) 
3 (8) 
21 (58) 
5 (14) 
 
1 (11) 
2 (22) 
4 (44) 
0 
- Prednisolone 14 (31) 11 (31) 3 (33) 
- Calcium/ Vitamin D 5 (11) 4 (11) 1 (11) 
BMI mean (sd), kg/m
2
 
Disease duration mean (sd), yrs 
29.6 (7.5) 
10.9 (7.8) 
29.4 (8.0) 
10.4 (7.0) 
30.5 (5.5) 
12.9 (10.9) 
RF positive 37 (82) 30 (83) 7 (78) 
ACPA positive 32 (76) 25 (76) 7 (78) 
DAS28-CRP mean (sd) 5.72 (1.32) 5.62 (1.33) 6.10 (1.24) 
HAQ mean (sd) 1.94 (0.47) 1.92 (0.43) 2.02 (0.63) 
ESR median (IQR), mm/hr 33 (12, 45) 32 (11, 43) 55 (26, 69) 
hs-CRP median (IQR), mg/L 12.6 (2.9, 38.1) 11.7 (2.8, 38.8) 29.3 (4.1, 34.0) 
eGFR mean (sd), mls/min/1.73m
2
 84 (25) 85 (25) 80 (26) 
PTH median (IQR), ng/L 32.1 (27.3, 49.0) 30.2 (26.4, 48.6) 42.4 (28.3, 50.0) 
25OHD median (IQR), nmol/L 31.2 (18.3, 64.4) 36.1 (20.6, 74.1) 18.3 (14.0, 34.8) 
TSH median (IQR), mU/L 1.43 (1.03, 2.23) 1.45 (1.07, 2.51) 1.40 (0.67, 1.82) 
LH median (IQR), U/L – females 30.0 (18.0, 38.0) 30.0 (16.4, 39.8) 27.0 (25.8, 29.3) 
FSH median (IQR), U/L – females  59.6 (24.1, 83.7) 59.6 (13.3, 89.8) 60.9 (36.1, 78.0) 
Testosterone median (IQR), nmol/L – males  13.4 (10.7, 15.5) 13.4 (9.8, 15.6) 13.5 (11.5, 15.4) 
SHBG median (IQR), nmol/L - males 56.5 (21.8, 63.0) 49.7 (21.8, 63.0) 56.5 (56.5, 56.5) 
βCTX median (IQR), ng/L 
PINP median (IQR), µg/L 
BALP median (IQR), µg/L 
TRAP5b median (IQR), U/L 
DKK-1 median (IQR), pmol/L 
SCL median (IQR), pmol/L 
Lumbar Spine L2-L4  
- BMD mean (sd), g/cm3 
- T score median (IQR) 
- Z score median (IQR) 
436(269, 555) 
41.9 (30.9, 52.4) 
17.9 (14.1, 22.2) 
3.1 (2.6, 3.7) 
52.8 (37.9, 68.6) 
54.5 (43.8, 63.0) 
 
1.168 (0.23) 
-0.4 (-1.1, 0.6) 
0.5 (-0.6, 1.7) 
423 (257, 511) 
39.8 (29.6, 46.9) 
17.2 (13.7, 20.7) 
3.0 (2.5, 4.0) 
47.9 (34.9, 67.7) 
53.4 (42.0, 63.8) 
 
1.171 (0.25) 
-0.4 (-1.3, 0.8) 
0.4 (-0.6, 1.7) 
578 (336, 627) 
53.9 (41.7, 65.1) 
25.2 (18.5, 27.7) 
3.4 (2.9, 3.7) 
55.9 (52.8, 74.1) 
55.8 (47.7, 60.0) 
 
1.158 (0.17) 
-0.4 (-0.8, -0.2) 
0.8 (0.2, 0.9) 
Mean neck of femur  
- BMD mean (sd), g/cm3 
- T score median (IQR) 
- Z score median (IQR) 
 
0.875 (0.15) 
-0.8 (-1.4, -0.3) 
0.2 (-0.7, 0.8) 
 
0.884 (0.14) 
-0.7 (-1.3, -0.2) 
0.3 (-0.5, 0.8) 
 
0.840 (0.20) 
-1.3 (-2.7, -0.5) 
-0.4 (-1.6, 0.3) 
Mean total femur  
- BMD mean (sd), g/cm3 
- T score median (IQR) 
- Z score median (IQR) 
 
0.935 (0.16) 
-0.6 (-1.7, 0.1) 
0.1 (-0.6, 0.8) 
 
0.944 (0.15) 
-0.5 (-1.2, 0.2) 
0.3 (-0.5, 0.9) 
 
0.901 (0.21) 
-0.7 (-2.3, -0.5) 
-0.6 (-1.2, 0.4) 
Mean radius UD  
- BMD mean (sd), g/cm3 
- T score median (IQR) 
- Z score median (IQR) 
 
0.376 (0.1) 
-1.1 (-2.4, 0.2) 
-0.6 (-1.4, 1.3) 
 
0.381 (0.10) 
-1.1 (-2.4, 0.2) 
-0.6 (-1.3, 0.8) 
 
0.354 (0.07) 
-1.4 (-2.9, 0.6) 
-0.4 (-2.3, 1.6) 
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Continuous data were presented as means and standard deviation or medians and interquartile range depending 
on the distribution of the data set; groups were compared using the student’s t-test or Mann-Whitney test when 
appropriate. Categorical variables were displayed as absolute frequencies and percentages, groups were 
compared using Fisher’s exact test. Neck of femur, total femur and radius UD results were reported as the mean 
of both sides. There was no significant difference in any baseline characteristic for those patients who completed 
the study (n=36) compared to the total number of patients recruited (n=45) or for those patients who completed 
the study (n=36) compared to non-completers (n=9).  
25OHD: 25Hydroxy vitamin D; ACPA: Anti-cyclic Citrullinated Peptide Antibody; BALP: bone specific 
alkaline phosphatase; βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; BMI: Body Mass 
Index; CRP: C-Reactive Protein; DAS28: Disease Activity Score using 28 tender and swollen joints; DKK-1: 
dickkopf-related protein 1; eGFR: estimated Glomerular Filtration Rate; ESR: Erythrocyte Sedimentation Rate; 
FSH: Follicle Stimulating Hormone; HAQ: Health Assessment Questionnaire; LH: Luteinising Hormone; PINP: 
procollagen type 1 amino-terminal propeptide; PTH: Parathyroid Hormone; RA: Rheumatoid Arthritis; RF: 
Rheumatoid Factor;  SCL: sclerostin; SHBG: Sex Hormone Binding Globulin; SJC: Swollen Joint Count; TJC: 
Tender Joint Count; TRAP5b: tartrate resistant acid phosphatase isoform 5b; TSH: Thyroid Stimulating 
Hormone.  
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4.3.2 Changes in bone mineral density 
There was a significant decrease in mean neck of femur BMD (mean difference -0.017g/cm
2
, 
95% CI -0.030, -0.004 a decrease of -2.0%; p=0.011) and mean total femur BMD (mean 
difference -0.016g/cm
2
, 95% CI -0.025, -0.007 a decrease of -1.7%; p=0.001) after 12 months 
but no significant change in lumbar spine or ultra-distal forearm BMD (Table 12). Patients 
were excluded if they had been treated with anti-osteoporotic medication either during or 
prior to this study and this has had an impact on the T- and Z-scores which were a lot higher 
than expected for this RA population. Left and right side femoral neck and total femur were 
analysed separately and comparable decreases were found; femoral neck (left mean difference  
-0.020g/cm
2
, 95% CI -0.039, -0.002 p=0.031 and right mean difference -0.012g/cm
2
, 95% CI 
-0.025, 0.000 p=0.059) and total femur (left mean difference -0.015g/cm
2
, 95% CI -0.026, -
0.005 p=0.005 and right mean difference -0.017g/cm
2
, 95% CI -0.027, -0.007 p=0.001). There 
was no significant difference between each side for either BMD site (femoral neck p=0.336 
and total femur p=0.690). Despite the general reduction in BMD at all sites, a small 
percentage of patients did have an increase in BMD after 12 months; 13 (36%) patients (3 
males, 4 pre- and 6 post-menopausal females) had an increase (mean change 0.037 ±0.06 
g/cm
2
;
 
2.9 ±3.9%)
 
in LSBMD; 12 (34%) patients (2 males, 4 pre- and 6 post-menopausal 
females) had an increase (mean change 0.016 ±0.01 g/cm
2
;
 
1.8 ±1.1%)
 
in MNBMD; 8 (23%) 
patients (1 male, 2 pre- and 5 post-menopausal females) had an increase (mean change 0.015 
±0.01 g/cm
2
;
 
1.7 ±1.4%)
 
in MTBMD; and 10 (31%) patients (3 males, 3 pre- and 4 post-
menopausal females) had an increase (mean change 0.031 ±0.04 g/cm
2
;
 
7.0 ±8.3%)
 
in 
MRUDBMD at 12 months. Although, these positive changes in BMD were not uniformly 
seen at every site in these patients. 
As menopausal status noticeably affected bone turnover in the pilot study, this data was also 
examined by gender and menopausal status (Table 12). However, as the study was not 
powered for sub-group analysis these results were interpreted with caution. Seventy nine 
percent of the women (n=23) were post-menopausal, there was a significant decrease in mean 
neck of femur (mean difference -0.018g/cm
2
, 95% CI -0.036, -0.000 a decrease of -2.1%; 
p=0.049) and mean total femur BMD (mean difference -0.020g/cm
2
, 95% CI -0.033, -0.008 a 
decrease of -2.1%; p=0.003) in these women.  
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Table 12 Change in bone mineral density from baseline to 12 months 
 BMD (g/cm
2) - Mean (SD) T score - Median (IQR) Z score - Median (IQR) 
 Baseline 12 month Diff (95% CI) p value Baseline 12 month Diff (95% CI) p value Baseline 12 month Diff (95% CI) p value 
Lumbar spine (L2-4) 
All patient (n=36) 
 
1.171 
(0.245) 
1.161 
(0.250) 
-0.010                  
(-0.029, 0.009) 
0.302 
 
-0.40                    
(-1.2,1.00) 
-0.20            
(-1.2,0.50) 
-0.10                       
(-0.30, 0.00) 
0.075 
 
0.50              
(-0.60,1.70) 
0.30               
(-0.70,1.70) 
0.00              
(-0.30, 0.10) 
0.198 
 
  Males (n=7) 1.252 
(0.188) 
1.251 
(0.263) 
-0.001                  
(-0.100, 0.098) 
0.984 
0.20              
(-0.40,1.50) 
-0.20             
(-0.30,1.2) 
-0.30            
(-0.77, 1.33) 
0.499 
0.70              
(0.20,1.00) 
0.40              
(-0.20,0.60) 
-0.30            
(-0.79, 1.71) 
0.399 
  Pre-menopausal (n=6) 1.223 
(0.271) 
1.219 
(0.261) 
-0.004                  
(-0.041, 0.033) 
0.790 
 
-0.45            
(-0.7,1.7) 
-0.35            
(-1.10,1.90) 
0.05              
(-0.39, 0.20) 
0.833 
-0.30             
(-1.80,1.70) 
-0.05             
(-2.20,1.90) 
0.15              
(-0.39, 0.29) 
0.917 
  Post-menopausal (n=23) 1.132 
(0.255) 
1.118 
(0.244) 
-0.014                  
(-0.031, 0.003) 
0.103 
-0.45            
(-1.3,0.6) 
-0.60            
(-1.30,0.40) 
-0.10            
(-0.31, 0.00) 
0.077 
0.60              
(-0.60,1.80) 
0.55              
(-0.70,1.70) 
0.00              
(-0.31, 0.10) 
0.311 
Mean neck femur 
All patient (n=35) 
 
0.884 
(0.140) 
0.867 
(0.143) 
-0.017              
(-0.030, -0.004) 
0.011 
-0.70            
(-1.30,-0.20) 
-0.75             
(-1.50,-0.50) 
-0.15            
(-0.30, 0.02) 
0.007 
0.30              
(-0.50,0.70) 
0.20              
(-0.60,0.80) 
-0.10             
(-0.20, 0.00) 
0.043 
  Males (n=7) 
 
0.920 
(0.134) 
0.894 
(0.154) 
-0.026              
(-0.058, 0.006) 
0.091 
-1.30             
(-1.60,-0.30) 
-1.50            
(-1.90,-0.60) 
-0.20            
(-0.57, 0.17) 
0.149 
0.05              
(-0.50,0.70) 
-0.30            
(-0.70,0.80) 
-0.20             
(-0.58, 0.10) 
0.116 
  Pre-menopausal (n=6) 
 
0.917 
(0.111) 
0.913 
(0.093) 
-0.004              
(-0.039, 0.031) 
0.780 
-0.55            
(-0.80,-0.20) 
-0.70            
(-0.80,-0.10) 
-0.05            
(-0.49, 0.28) 
0.463 
-0.45            
(-1.00,-0.10) 
-0.35            
(-1.00,0.00) 
0.05              
(-0.38, 0.38) 
0.751 
  Post-menopausal (n=22) 
 
0.863 
(0.150) 
0.845 
(0.152) 
-0.018              
(-0.036, -0.000) 
0.049 
-0.70            
(-1.40,-0.20) 
-0.80            
(-1.50,-0.50) 
-0.10            
(-0.30, 0.01) 
0.021 
0.50              
(0.20,0.80) 
0.30               
(-0.20,1.00) 
-0.10            
(-0.20, 0.00) 
0.078 
Mean total femur 
All patient (n=35) 
 
0.944 
(0.153) 
0.928 
(0.150) 
-0.016              
(-0.025, -0.007) 
0.001 
-0.45             
(-1.20,0.20) 
-0.60            
(-1.30,0.20) 
-0.10            
(-0.20, 0.00) 
0.002 
0.20              
(-0.50,0.90) 
0.00              
(-0.60,0.80) 
-0.10            
(-0.20, 0.00) 
0.005 
  Males (n=7) 
 
0.954 
(0.171) 
0.945 
(0.164) 
-0.010              
(-0.032, 0.013) 
0.333 
-1.00            
(-1.70,-0.40) 
-0.90            
(-2.00,-0.50) 
-0.10            
(-0.27, 0.21) 
0.344 
0.00              
(-0.70,0.40) 
0.00              
(-0.80,0.50) 
-0.15             
(-0.20, 0.37) 
0.463 
  Pre-menopausal (n=6) 
 
1.021 
(0.126) 
1.012 
(0.137) 
-0.009              
(-0.031, 0.014) 
0.367 
0.15               
(-0.70, 0.60) 
0.00              
(-0.70,0.30) 
-0.10            
(-0.30, 0.18) 
0.281 
-0.40            
(-0.50,0.40) 
-0.40            
(-0.70,0.40) 
-0.05            
(-0.19, 0.28) 
0.916 
  Post-menopausal (n=22) 
 
0.920 
(0.154) 
0.900 
(0.145) 
-0.020              
(-0.033, -0.008) 
0.003 
-0.40             
(-1.60,0.10) 
-0.60            
(-1.70,0.20) 
-0.10            
(-0.25, 0.05) 
0.004 
0.60              
(-0.40,1.00) 
0.00              
(-0.50,0.90) 
-0.20            
(-0.25, 0.00) 
0.004 
Mean UD Radius 
All patient (n=32) 
 
0.382 
(0.104) 
0.380 
(0.114) 
-0.002              
(-0.013, 0.010) 
0.787 
-1.10 
 (-2.3, 0.40) 
-1.40            
(-2.38, 0.63) 
-0.10            
(-0.33, 0.05) 
0.167 
-0.50            
(-1.20, 0.90) 
-0.65             
(-1.20, 1.05) 
-0.05             
(-0.29, 0.09) 
0.416 
  Males (n=7) 
 
0.444 
(0.111) 
0.456 
(0.135) 
0.012                
(-0.042, 0.066) 
0.597 
0.20              
(-2.60, 2.00) 
1.80              
(-3.75, 2.15) 
-0.10            
(-0.88, 2.34) 
1.000 
1.33              
(-1.10, 2.40) 
2.13              
(-1.20, 3.35) 
0.03              
(-1.07, 2.89) 
0.753 
  Pre-menopausal (n=6) 
 
0.389 
(0.066) 
0.393 
(0.084) 
0.004               
(-0.021, 0.030) 
0.679 
-0.30             
(-1.70, 0.60) 
-0.33            
(-1.80, 0.70) 
0.00               
(-0.49, 0.35) 
0.753 
-0.30            
(-1.70, 0.90) 
-0.33            
(-1.80, 1.00) 
0.00              
(-0.49, 0.39) 
0.753 
  Post-menopausal (n=19) 
 
0.357 
(0.105) 
0.348 
(0.105) 
-0.009              
(-0.018, 0.001) 
0.070 
-1.70                
(-2.60, -0.70) 
-1.65            
(-2.40, -0.70) 
-0.10            
(-0.51, 0.00) 
0.067 
-0.60            
(-1.20, 0.30) 
-0.95            
(-1.10, 0.60) 
-0.05            
(-0.49, 0.04) 
0.190 
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Bone mineral density (BMD) was measured in lumbar spine (n=36) mean L2-L4. Also neck of femur (n=35), total femur (n=35) and ultra-distal radius (n=31), the results 
were reported as mean of both sides. All measured at time 0 before the 1st RTX infusion and after 12 months in patients who completed the study. Results were expressed as 
mean and standard deviation at baseline and 12 months and mean percentage change form baseline, the mean change from baseline was calculated by paired t-test. T and Z 
scores for each site were not normally distributed so results were expressed as medians and interquartile range, the median change from baseline was calculated using 
Wilcoxon signed rank test. Results were also stratified by gender and menopausal status. 
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4.3.3 Changes in biomarker levels 
Changes in median biomarker concentration from baseline i.e. before the start of the RTX 
treatment, to the 12 month visit are shown in Table 13. Additionally, as the markers were 
measured every 3 months, the median percentage change from baseline across all 4 visits was 
calculated to estimate the average change over 12 months. There was a significant increase in 
bone formation over 12 months; PINP (mean change 11.2µg/L; 95% CI -0.4, 22.8; p=0.05; 
30% increase) and BALP (mean change 3.4µg/L; 95% CI 1.1, 5.8; p=0.006; 13% increase). 
These results were mirrored by a significant reduction in inflammation; CRP (mean change -
12.4mg/L; 95% CI -21.1, -3.7; p=0.007; 21% decrease), ESR (mean change -15mm/hr; 95% 
CI -24, -5; p=0.003; 20% decrease) and disease activity DAS28-CRP (mean change-1.14; 
95% CI -1.70, -0.58; p<0.001; 19% decrease) following treatment with RTX. There was no 
significant change in bone resorption or osteocyte markers. Additionally, the data was 
reviewed by gender and menopausal status; there was no significant difference in BTMs 
between men and pre-menopausal women and so they were combined. Post-menopausal 
women (n=23) had higher bone resorption at 12 months, but no difference in bone formation 
or osteocyte markers compared to the males and pre-menopausal women (n=13).  
There was a wide variance in the changes in biomarker levels, but generally there was a 
gradual increase in bone formation markers (PINP, BALP) in a similar pattern to the pilot 
cohort. However, median βCTX levels decreased to 3 months then gradually returned to 
baseline values (Figure 19). There was a gradual decrease in median inflammatory markers 
and disease activity levels (Figure 20). 
Furthermore, a marker of formation (PINP) and a marker of resorption (βCTX) were 
expressed as multiples of the median MoMF and MoMR respectively (described in Chapter 2 
section 2.2.1), (Bieglmayer and Kudlacek 2009) and their ratios (MoMF/ MoMR) plotted at 
baseline and then every 3 months until the 12 month follow-up visit, to show the effect of 
treatment on bone turnover (Figure 21). At baseline 25 (83%) patients had a bone turnover 
ratio <1 (i.e. resorption predominated); at 3 months 21 (70%); at 6 months 23 (77%); at 9 
months 24 (80%) and at 12 months 23 (77%) such patients still had ratios <1. However, 17 
(57%) patients (7 patients had ratios >1 but 10 patients still had ratios <1) had a small 
increase in their bone turnover ratio from baseline to 12 months, indicating some albeit 
minimal improvement in bone turnover. 
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4.3.4 Correlations between inflammatory activity and bone density or bone turnover 
There was a significant positive correlation between median percentage change in ESR and 
percentage change in mean neck of femur BMD (Rs=0.384; p=0.030) also between median 
percentage change in CRP and percentage change in mean neck of femur BMD (Rs=0.349; 
p=0.040). Additionally, there was a significant positive correlation between median 
percentage change in CRP and median percentage change in DKK-1 (Rs=0.409; p=0.013) and 
between median percentage change in DAS28 and median percentage change in DKK-1 
(Rs=0.373; p=0.025).  
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Table 13 Change in biomarkers from baseline to twelve months 
 Baseline 
 
12 Month 
 
Difference 
(95% CI) 
p 
value 
 
Median % change 
over 12 month 
( 95% CI) 
βCTX (ng/L)      
All patient (n=34) 417 (245, 509) 384 (279, 518) 4 (-72, 80) 0.916 -8 (-23, 15) 
Males + Pre-menopausal (n=12) 267 (177, 428) 275 (199, 318) -33 (-154, 88) 0.562 -6 (-36, 83) 
Post-menopausal (n=22) 489 (372, 512) 455 (371, 651) 24 (-78, 127) 0.630 -8 (-23, 27) 
TRAP5b (U/L)      
All patient (n=34) 3.0 (2.5, 4.0) 2.9 (2.7, 3.8) 0.0 (-0.2, 0.3) 0.835 0 (-7, 8) 
Males + Pre-menopausal (n=12) 2.6 (1.9, 3.7) 2.7 (2.2, 3.3) 0.0 (-0.4, 0.4) 1.000 -0 (-10.6, 22.1) 
Post-menopausal (n=22) 3.2 (2.6, 4.1) 3.2 (2.8, 3.9) 0.0 (-0.3, 0.3) 0.804 3.5 (-7.4, 8.0) 
PINP (µg/L)      
All patient (n=34) 39.8 (30.9, 46.4) 48.8 (37.8, 70.0) 11.2 (-0.4, 22.8) 0.05 30 (3, 50) 
Males + Pre-menopausal (n=12) 35.2 (25.9, 45.1) 46.8 (35.4, 62.3) 15.8 (-1.9, 33.4) 0.076 11.4 (-11.8, 97.6) 
Post-menopausal (n=22) 42.0 (31.8, 46.4) 53.6 (41.9, 71.5) 8.7 (-7.4, 24.8) 0.273 32.2 (2.6, 88.1) 
BALP (µg/L)      
All patient (n=34) 17.2 (14.1, 20.6) 19.3 (15.6, 26.2) 3.4 (1.1, 5.8) 0.006 13 (4, 19) 
Males + Pre-menopausal (n=12) 15.5 (13.1, 17.8) 17.6 (13.5, 19.9) 3.1 (0.3, 5.9) 0.035 10.8 (-5.1, 17.7) 
Post-menopausal(n=22) 18.5 (15.9, 23.2) 22.7 (17.2, 27.5) 3.6 (0.1, 7.0) 0.044 14.0 (0.7, 32.3) 
SCL (pmol/L)      
All patient (n=34) 53.4 (40.5, 64.4) 55.7 (46.5, 67.6) 4.4 (-0.9, 9.7) 0.100 0.1 (-3, 8) 
Males + Pre-menopausal (n=12) 62.6 (44.5, 73.3) 64.5 (51.2, 73.6) 4.6 (-4.7, 13.9) 0.300 -1.1 (-17.1, 15.6) 
Post-menopausal (n=22) 52.5 (38.7, 61.1) 54.3 (46.0, 62.5) 4.3 (-2.7, 11.2) 0.217 1.3 (-3.8, 11.7) 
DKK-1 (pmol/L)      
All patient (n=34) 47.9 (35.6, 68.6) 51.5 (32.9, 72.8) 2.6 (-4.7, 9.9) 0.479 -2 (-10, 14) 
Males + Pre-menopausal (n=12) 44.7 (34.6, 52.2) 44.7 (30.9, 57.6) 1.0 (-7.6, 9.6) 0.803 -13.9 (-23.7, 44.7) 
Post-menopausal (n=22) 53.2 (37.9, 77.6) 60.8 (39.8, 90.1) 3.4 (-7.3, 14.2) 0.515 -0.6 (-6.6, 23.8) 
CRP (mg/L) 
All patient (n=36) 11.7 (2.8, 38.8) 6.4 (2.5, 14.1) -12.4 (-21.1, -3.7) 0.007 -21 (-49, 75) 
Males + Pre-menopausal (n=13) 14.1 (6.3, 38.1) 4.2 (2.4, 13.0) -16.0 (-36.4, 4.4) 0.113 -42 (-72, 377) 
Post-menopausal (n=23) 7.2 (2.1,  46.7) 7.0 (2.6, 14.7) -10.4 (-19.3, -1.5) 0.024 -10 (-47, 87) 
ESR (mm/hr) 
All patient (n=32) 32 (11, 43) 17 (9, 33) -15 (-24, -5) 0.003 -20 (-50, 25) 
Males + Pre-menopausal (n=11) 39 (28, 62) 13 (6, 33) -25 (-48, -2) 0.038 -40 (-64, 52) 
Post-menopausal (n=21) 30 (10, 39) 19 (11, 27) -9 (-17, -1) 0.032 -6 (-42, 52) 
DAS28 score 
All patient (n=36) 5.62 (1.33) 4.47 (1.44) -1.14 (-1.70, -0.58) <0.001 19 (-27, -14) 
Males + Pre-menopausal (n=13) 5.67 (1.13) 4.48 (1.33) -1.19 (-2.26, -0.12) 0.032 -27 (-39, -8) 
Post-menopausal (n=23) 5.59 (1.46) 4.48 (1.53) -1.12 (-1.82, -0.42) 0.003 -17 (-23, -12) 
 
Biomarkers were measured at baseline before the RTX infusion and then at 3, 6, 9 and 12 months in all patients who 
completed the study. Baseline, 12 months and percent change biomarker data were not normally distributed and were 
expressed as median and IQR, the median percentage change from baseline across all 4 visits was calculated. Baseline and 12 
months DAS28 and all absolute change results were normally distributed and were expressed as means. P values were 
recorded between baseline and 12 months for all parameters using paired t-tests; p values ≤0.05 were considered significant. 
Results were also stratified by post-menopausal females and combined males plus pre-menopausal females. BALP: bone 
specific alkaline phosphatase; βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; DKK-1: dickkopf-related 
protein 1; ESR: erythrocyte sedimentation rate; DAS28: disease activity score using 28 tender and swollen joints; CRP: high 
sensitivity -C reactive protein; PINP: procollagen type 1 amino-terminal propeptide; SCL: sclerostin; TRAP5b: tartrate 
resistant acid phosphatase isoform 5b.  
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Bone Formation 
  
Bone Resorption 
  
Osteocyte markers 
  
Figure 19 Change in individual bone markers over the course of the study 
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Inflammatory markers 
 
Disease activity 
 
Figure 20 Change in individual inflammatory markers over the course of the study 
Individual patient results for markers of bone resorption, bone formation, osteocytes, inflammation and disease 
activity were plotted at baseline before the RTX infusion and then at 3, 6, 9 and 12 months in all patients who 
completed the study.  
BALP: bone specific alkaline phosphatase; βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; 
DKK-1: dickkopf-related protein 1; ESR: erythrocyte sedimentation rate; DAS28: disease activity score using 28 
tender and swollen joints; CRP: high sensitivity -C reactive protein; PINP: procollagen type 1 amino-terminal 
propeptide; SCL: sclerostin; TRAP5b: tartrate resistant acid phosphatase isoform 5b. 
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Figure 21 Ratio of bone marker multiples of the median depicting bone turnover in thirty rheumatoid arthritis patients pre and 3, 6, 9 and 12 
months post rituximab  
Blood samples from 72 healthy volunteers (33 males aged 19 to 62yrs and 39 females aged 20 to 64yrs) were analysed on the Elecsys 2010, for βCTX and PINP to calculate the 
median of the reference population. Multiples of the median (MoM) were defined as ‘individual marker result/ median of the reference population’ (Bieglmayer and Kudlacek 2009). 
Individual βCTX and PINP results from this prospective study looking at 30 patients with refractory RA analysed pre and post RTX, were expressed as ratios of their multiples of the 
median (MoMF/ MoMR) at each visit.
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4.3.5 The effects of vitamin D 
Fourteen (39%) patients (2 males; 2 pre- and 10 post-menopausal females) in this cohort had 
25OHD levels below 25nmol/L. There was no significant difference (p=0.274) in median 
25OHD between males (69nmol/L), pre- (36nmol/L) or post-menopausal females (30nmol/L) 
at baseline. However, there was a significant difference (p=0.001) in median PTH levels 
(males 19.8; pre- 39.6 and post-menopausal females 33.0ng/L). Total 25OHD was measured 
due to its effects on disease activity and its critical role in the maintenance of bone health, 
25OHD levels could affect the primary and secondary endpoints and so results were stratified 
by 25OHD concentration; group 1 (n=14) included levels below 25nmol/L; group 2 (n=22) 
equal to or greater than 25nmol/L. 
The differences between vitamin D group for BMD, BTM and inflammatory biomarkers are 
included in Table 14. Additionally, there was no significant difference in age, PTH, eGFR, 
weight, height or BMI at baseline, or HAQ, VAS, tender and swollen joint count at baseline 
and 12 months between these vitamin D groups. 
 
Bone Mineral Density 
Vitamin D deficient patients had significantly lower LS BMD at baseline (Group 1: mean 
1.048, 95% CI 0.940, 1.156g/cm
2
; Group 2: mean 1.249, 95% CI 1.138, 1.360g/cm
2
; p= 
0.014), but no significant difference in baseline BMD at the femoral neck (p=0.272), total 
femur (p=0.174) or forearm (p=0.074). However, vitamin D deficient patients had a 
significantly greater loss (p=0.016) of mean neck of femur BMD from baseline to 12 months 
(mean change -0.036, 95% CI -0.064, -0.007g/cm
2
 p=0.017, a decrease of -4.1%) compared to 
patients with 25OHD ≥25 nmol/L (mean change -0.005, 95% CI -0.014, 0.005g/cm2 p=0.314, 
a decrease of -0.6%). Additionally they had a significantly greater loss (p=0.015) of mean 
total femur BMD from baseline to 12 months, (25OHD <25nmol/L: mean change -0.029, 
95% CI -0.047, -0.010g/cm
2
 p=0.005 a decrease of -3.0%; compared to 25OHD ≥25nmol/L: -
0.008, 95% CI -0.016, 0.000g/cm
2
 p=0.063, a decrease of -0.8%). There was no significant 
difference in the bone lost at the LS (p=0.496) or UD forearm (p=0.318) between the two 
categories (Table 14).  
 
Inflammation and disease activity 
There was no significant difference in CRP, ESR or DAS28 score between vitamin D groups 
over 12 months. 
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Bone turnover markers 
There was a significant difference (p=0.002) between 25OHD groups in TRAP5b (Group 1: 
mean change 0.4, 95% CI 0.1, 0.8U/L, p=0.011, 12.3% increase; Group 2: mean change -0.3, 
95% CI -0.5, 0.0U/L, p=0.041, a -8.6% decrease) from baseline to 12 months. A similar 
disparity was found in βCTX at several time points; specifically from baseline to 6 months 
(p=0.006); (Group 1: mean change 129, 95% CI 3, 256ng/L, 27% increase; Group 2: mean 
change-67, 95% CI-135, 1ng/L, a -20% decrease), but there was no significant difference 
between baseline and 12 months (p=0.115). Additionally, there was no significant difference 
between vitamin D groups for bone formation or osteocyte markers (Table 14). 
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Table 14 Change in bone mineral density and biomarkers by vitamin D category from baseline to 12 months 
 
 
 
Results were stratified by 25OHD status; Group 1 levels up to 24.9 nmol/L; Group 2 levels greater than or equal to 25 nmol/L. Bone mineral density, expressed as mean and 
standard deviation, was measured in the lumbar spine (mean L2-L4), femoral neck, total femur and UD radius (reported as the mean of both sides), at baseline before the first 
RTX infusion and after 12 months in all patients who completed the study (n=36). A second RTX cycle was given at 6 months if clinically indicated (n=32). Blood samples 
taken at baseline and at 12 months were analysed for the following biomarkers: BALP: bone specific alkaline phosphatase; βCTX: β-isomerised carboxy terminal telopeptide 
 Group 1: 25OHD (<25 nmol/L) 
n=14 
Group 2: 25OHD (≥25 nmol/L) 
n=22 
Between  
group 
p value  
(%change) 
 
Baseline 12 month 
Difference 
(95% CI) 
% change  
p value 
Difference 
Baseline 12 month 
Difference 
(95% CI) 
% change  
p value 
Difference 
Lumbar spine  
(g/cm
2
) 
1.048   
(0.187) 
1.052   
(0.245) 
0.004              
(-0.040, 0.048) 
-0.2         
(6.1) 
0.845 
1.249      
(0.250) 
1.230 
(0.232) 
- 0.019            
(-0.036, -0.002) 
-1.3         
(2.8) 
0.031 0.496 
Mean neck of femur 
(g/cm
2
) 
0.851   
(0.160) 
0.816   
(0.153) 
-0.036             
(-0.064, -0.007) 
-4.1         
(5.6) 
0.017 
0.905    
(0.124) 
0.900 
(0.129) 
-0.005             
(-0.014, 0.005) 
-0.6         
(2.4) 
0.314 0.016 
Mean total femur 
(g/cm
2
) 
0.901   
(0.163) 
0.872   
(0.148) 
-0.029             
(-0.047, -0.010) 
-3.0         
(3.2) 
0.005 
0.973    
(0.143) 
0.965 
(0.142) 
-0.008             
(-0.016, 0.000) 
-0.8         
(1.8) 
0.063 0.015 
Mean UD radius 
(g/cm
2
) 
 
0.344  
(0.072) 
0.336 
(0.079) 
-0.008  
(-0.021, 0.006) 
-2.4  
(5.7) 
0.231 
0.411  
(0.116) 
0.414 
(0.128) 
0.003  
(-0.016, 0.022) 
0.3  
(9.0) 
0.763 0.373 
βCTX (ng/L) 304           
(244,491) 
410         
(274,626) 
95 
(-44, 234) 
18.5              
(-14,169) 
0.166 
446          
(375,555) 
384       
(287,476) 
-60                   
(-143, 24) 
-5.0              
(-31,12.5) 
0.151 0.115 
TRAP5b (U/L) 
 
2.6           
(2.1,3.5) 
3.0           
(2.8,4.0) 
0.4              
(0.1, 0.8) 
12.3              
(9.0,31.5) 
0.011 
3.1            
(2.8,4.1) 
2.9        
(2.6,3.5) 
-0.3                  
(-0.5, 0.0) 
-8.6              
(-18.0,5.1)) 
0.041 0.002 
PINP (µg/L) 
 
38.3        
(33.4,46.4) 
47.2   
(37.8,70.0) 
14.6 
 (0.2, 28.9) 
25.9              
(0.0,79.0) 
0.047 
39.8        
(27.5,47.3) 
55.8    
(38.6,70.8) 
8.9 (-9.2, 26.9) 
12.7              
(-23.8,99.2) 
0.317 0.713 
BALP (µg/L) 
 
19.2         
(15.9,22.2) 
27.4       
(17.2,32.3) 
6.5  
(2.0, 11.0) 
23.1              
(1.7,81.5) 
0.009 
16.0        
(13.2,19.7) 
18.2    
(15.3,22.7) 
1.2 
(-1.1, 3.6) 
15.3              
(4.1,25.2) 
0.280 0.310 
SCL (pmol/L) 51.8       
(40.5,57.4) 
56.7          
(50.3,74.6) 
7.9                  
(-2.8, 18.7) 
15.6              
(-10.9,34.4) 
0.135 
53.5        
(45.5,64.4) 
54.5     
(45.6,65.3) 
1.9                   
(-3.7, 7.5) 
3.8                
(-9.2,14.7) 
0.487 0.421 
DKK-1 (pmol/L) 53.2       
(37.9,82.6) 
59.8    
(41.6,76.3) 
2.1  
(-9.2, 13.5) 
14.8              
(-14.8,28.9) 
0.693 
46.4        
(33.2,64.2) 
49.2       
(32.0,66.1) 
2.9 
(-7.5, 13.3) 
2.0                
(-25.1,35.4) 
0.569 1.000 
CRP (mg/L) 17.3         
(6.7,46.7) 
11.0         
(2.6,15.4) 
-14.9 
 (-27.1, -2.7) 
-61                   
(-74.7,9.2) 
0.020 
7.6            
(1.9,28.6) 
5.6         
(2.2,9.8) 
-10.8 
 (-23.5, 1.9) 
-18                
(-67.1,69.0) 
0.091 0.364 
ESR (mm/hr) 31.0                
(28.0,41.0) 
21.5              
(10.0,33.0) 
-21  
(-41, -2) 
-46.3            
(-77.4,17.9) 
0.037 
31.5          
(9.0,41.5) 
13.0             
(7.0,33.0) 
-10  
(-19, -1) 
-5.4               
(-66.7,11.1) 
0.034 0.443 
DAS28 score 5.58  
(1.61) 
4.66  
(1.53) 
-0.92  
(-1.81, -0.03 
-18.7            
(-24.2,-3.2) 
0.043 
5.65  
(1.17) 
4.36  
(1.41) 
-1.28  
(-2.05, -0.51) 
-18.9             
(-38.1,-1.00) 
0.002 0.770 
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of type I collagen; DKK-1: dickkopf-related protein 1; ESR: erythrocyte sedimentation rate; DAS28: disease activity score using 28 tender and swollen joints ; CRP: high 
sensitivity -C reactive protein; PINP: procollagen type 1 amino-terminal propeptide; SCL: sclerostin; TRAP5b: tartrate resistant acid phosphatase isoform 5b.  
Baseline, 12 months and percent change data for βCTX, TRAP5b, PINP, BALP, SCL, DKK-1, CRP and ESR were not normally distributed therefore results were expressed 
as medians and interquartile ranges. Baseline and 12 months DAS28 and all absolute change results were normally distributed and were expressed as means. P values were 
recorded between baseline and 12 months within each group using paired t-tests; p values ≤0.05 were considered significant.The difference in percentage change from 
baseline to 12 months for each vitamin D group was compared using a two-sample t-test (for BMD) or Mann-Whitney test (biomarkers).  
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4.4 Discussion 
The aim of this study was to investigate the effects of B cell depletion with RTX on bone 
density and bone turnover in patients with severe, refractory RA, to confirm and extend the 
results of the pilot study discussed in the previous Chapter. There was a significant decrease 
in BMD at the femoral neck (-2%) and total femur (-1.7%) after 12 months, but no significant 
change in BMD at the lumbar spine or ultra-distal forearm.  
There was a significant increase in bone formation in both PINP and BALP biomarkers over 
12 months, but no significant change in bone resorption or osteocyte markers. Nevertheless, 
there was a significant reduction in inflammatory markers and disease activity following 
treatment with RTX, indicating that the drug was effective in reducing the inflammation of 
RA in this patient cohort.  
Post-menopausal females also had a significant decrease in mean neck (-2.1%) and mean total 
femur BMD (-2.1%) after 12 months. Additionally,  post-menopausal women had the highest 
levels of bone turnover, specifically βCTX, at baseline and throughout the 12 months, 
consistent with the results of the pilot study and reflecting the fact that bone loss is more rapid 
post-menopause (Garnero et al. 2000). Thirty-nine percent of patients in this study (29% 
males; 33% pre- and 43% post-menopausal females) were classed as vitamin D deficient i.e. 
25OHD below 25nmol/L and these patients had significantly lower lumbar spine BMD at 
baseline compared to patients with 25OHD above 25nmol/L. Furthermore, they had a 
significantly greater fall in mean femoral neck and total femur BMD after 12 months. 
Moreover, vitamin D deficient patients had an increase in bone resorption, measured by 
TRAP5b, whereas patients with higher vitamin D levels had a reduction in TRAP5b. These 
results are in keeping with a recent Chinese study which reported that serum 25OHD levels in 
130 RA patients (95 women and 35 men), were lower in those with osteopenia and 
osteoporosis than in those with normal BMD (Hong et al. 2014). Vitamin D influences bone 
quality and is important in maintaining bone density, it has been reported that higher serum 
25OHD levels may prevent the occurrence of osteoporosis at the femoral neck, but not at the 
lumbar spine L2–4 (Yoshimura et al. 2015). However, the precise definition of the vitamin D 
sufficiency range remains to be established and the methodology and definition of vitamin D 
deficiency varies widely between studies, many quoting a cut-off value as high as 50nmol/L. 
While post-menopausal women had the lowest 25OHD concentration in our cohort, there was 
no significant difference in median levels between males, pre- or post-menopausal women, so 
vitamin D deficiency may not explain why the post-menopausal women lost BMD more than 
pre-menopausal women or men. 
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This is the first longitudinal study investigating the effects of RTX on BMD and bone 
turnover markers. The effects of TNF inhibitors on bone have typically shown that anti-TNF 
therapy has a beneficial effect on BMD and BTMs (Barnabe and Hanley 2008). However, 
results vary by study with regard to the magnitude of the observed change and the time points 
of the DXA scanning, also on the number and gender of patients included and the 
concomitant use of prednisolone and/or anti-osteoporotic drugs.
 
A study investigating the 
effect of RTX on13 patients with active RA reported a significant decrease in bone resorption 
after 15 months, but no significant change in markers of bone formation (Hein et al. 2010). 
Results of the pilot study (Chapter 4) confirmed and extended these results, there was a 
statistically significant decrease in βCTX mirrored by a reduction in disease activity and a 
small but statistically significant increase in PINP, in a cohort of 46 RA patients 6 months 
after a single treatment course of RTX (Wheater et al. 2011), though  no BMD data was 
available and vitamin D levels were not measured. Patients in that cohort had lower bone 
resorption at baseline compared to patients in this prospective study. However, thirty-seven 
percent of those patients were taking bisphosphonates and bisphosphonates induce osteoclast 
apoptosis (Breuil 2006), none of the patients in the current cohort were treated for 
osteoporosis with bisphosphonates, calcitonin, strontium ranelate, denosumab or teriparatide 
prior to/ or during the study. The present cohort also contained a higher percentage of 
postmenopausal females (79% compared to 58% in the pilot) and notably a higher percentage 
of these women were current smokers (39% compared to 18% in the pilot), above the national 
average quoted as 19% in 2013 (Office for National Statistics 2013).
 
Smoking may adversely 
influence the severity of RA (Saag et al. 1997) and RA patients who smoke have a higher 
need for DMARDs and are reportedly more likely to show a poor response to biologics 
treatment such as TNF inhibitors (Mattey et al. 2009). Tobacco also increases bone resorption 
and affects bone mass by alterations in sex hormone metabolism, but also importantly by 
alterations on the vitamin D-PTH axis (Supervia et al. 2006).  
There are still limitations that have not been addressed in this study; the numbers of 
participants remained relatively small, this limited the power to detect smaller changes in 
variables such as bone turnover that may have been significant and although all the patients 
had high disease activity and fulfilled the criteria for treatment with RTX the group was 
heterogeneous, consisting of men, pre and postmenopausal women and different age groups. 
Additionally, this study was designed as a single treatment arm trial with no control group, 
whereas, the optimal design would have been a double-blind randomized comparison with 
placebo. However, as RTX is an approved treatment for refractory RA and is already known 
Chapter 4                                                                                                           Prospective study                                                                                                                                                        
                                   
110 
 
to reduce disease activity (Teng et al. 2007), such a control arm would have had to be 
matched for disease activity and it would have been unethical to have an untreated arm with 
that level of active disease. Patients with active RA would have been expected to have 
continued bone loss and abnormal bone turnover until the disease activity had been 
adequately suppressed (Marotte et al. 2007). It is therefore possible that the RTX could have 
slowed the bone loss that was occurring, but this study would be unable to detect this without 
a control arm. The duration of the study was also short at only 12 months and it is possible 
that; a longer evaluation and follow-up of patients after subsequent treatment courses may 
have shown improvements in BMD and bone turnover. Larger, long-term studies of more 
clearly defined patient groups are warranted; additionally vitamin D deficiency should be 
corrected first. 
 
4.5 Conclusion 
The present study revealed that in a cohort of RA patients treated with RTX, BMD fell at the 
hip sites in postmenopausal women, but was maintained at the lumbar spine and UD radius 
forearm. The results suggest that treatment with RTX may have slowed down the expected 
bone loss in these patients and this could be mediated by reduced disease activity or by the 
reduction of B cells influencing bone cell activity. However, this was hard to quantify without 
a control group. Men and premenopausal women did not lose BMD and also had lower bone 
resorption indicating they had lower bone cell activity. Thirty-nine percent of patients had 
vitamin D deficiency (<25nmol/L), they had significant falls in hip BMD and evidence of 
higher bone turnover in comparison to patients with vitamin D levels ≥25nmol/L. These data 
demonstrate that vitamin D deficiency is common in RA patients and contributes to a 
decrease in BMD. There was an increase in bone formation with RTX as measured with 
markers of bone turnover, but this did not correspond to an improvement in BMD suggesting 
a more complex interaction with bone. In conclusion RTX may have had effects on BMD, but 
this seemed to be influenced by gender, menopausal status, changes in disease activity and 
vitamin D status and could be confounded by the requirement for prednisolone. A larger study 
powered to take into account all these factors is required and this will necessitate that vitamin 
D insufficiency or deficiency be corrected from the start.
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Chapter 5. In vitro osteoclastogenesis 
 
5.1 Introduction 
Inflammation and bone resorption are often linked, this is apparent in the joint destruction 
seen in diseases such as RA where the bone compartment in closest proximity to the inflamed 
joint suffers the most severe damage (Schett 2006). B cells have a role in both the 
pathogenesis of  RA and the regulation of bone cell activity. A complex relationship exists 
between B cells and osteoclasts, although the exact nature of this association is still evolving. 
Osteoclasts are the bone cells solely responsible for breaking down and resorbing the bone 
matrix, they are end-differentiated multinucleated cells of the myeloid lineage originating 
from HSC’s (Figure 1) and their differentiation pathway is common to that of macrophages 
and dendritic cells (Väänänen 2000). B cells on the other hand are responsible for the 
generation and production of immunoglobulins and together with T cells encompass the 
adaptive immune system (Horowitz et al. 2010). B cells, like osteoclasts, differentiate from 
HSC’s (Figure 1) but from the lymphoid progenitor cells.  
Historically murine studies used co-cultures of bone marrow, spleen and stromal cells to yield 
multinuclear osteoclast-like cells from the fusion of mononuclear precursors (Takahashi et al. 
1988); it was thought that close contact between these cells was essential for 
osteoclastogenesis (Fujikawa et al. 1996). The majority of these systems relied on endogenous 
stimulators of osteoclastogenesis such as 1, 25(OH)2D3 and PTH via their action on 
osteoblastic cells. However, it is now recognised that osteoclast formation and activation is 
critically dependent on two membrane-bound proteins produced by the osteoblasts and 
stromal cells; M-CSF and RANKL (Datta et al. 2008), that are both essential and sufficient to 
provide the necessary signals enabling promyeloid precursor cells to differentiate into mature 
osteoclasts (Figure 7). Moreover, one murine monocytic cell line, RAW 264.7, has been 
widely used; it only requires stimulation with RANKL to form fully-differentiated osteoclasts 
as RAW cells already express M-CSF (Collin-Osgdoby et al. 2003). 
M-CSF, acting through its receptor c-Fms, stimulates the proliferation and prevents the 
apoptosis of early osteoclast precursors and RANKL targets specialized osteoclast 
differentiation specifically in the bone marrow milieu (Datta et al. 2008). RANKL binds and 
activates its cellular receptor RANK thereby inducing a signalling cascade leading to the 
differentiation and fusion of osteoclast precursor cells. Multi-nucleation of osteoclasts being 
essential as mono-nucleated macrophages cannot resorb bone efficiently; the multi-nucleated 
osteoclasts are formed from this fusion of RANK with mononuclear precursors after contact 
with RANKL (Yavropoulou and Yovos 2008). The effects of RANKL can be 
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counterbalanced by OPG, a soluble decoy receptor which binds and neutralises RANKL, thus 
inhibiting osteoclastogenesis and inducing osteoclast apoptosis (Blair and Zaidi 2006). The 
production of RANKL and OPG by osteoblasts is influenced by hormones (PTH, oestrogen, 
glucocorticoids); growth factors (BMP, IGF1, TGFβ) and cytokines (TNF-α, IL-1, IL-6, IL-
17) and the balance between RANKL and OPG can therefore determine the degree of 
osteoclastic bone resorption (Geusens 2012). Mature B cells also have the capacity to both 
inhibit and stimulate osteoclastogenesis by virtue of their ability to secrete these cytokines. B 
cells produce pro-osteoclastogenic cytokines including RANKL (Choi et al. 2001, Manabe et 
al. 2001) and under pathologic conditions such as RA this process is markedly enhanced by 
pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and IL-17 (Schett 2006). B cells also 
produce cytokines that inhibit osteoclast differentiation from the progenitor cells, such as 
OPG and TGF-β (Li et al. 2007, Neale Weitzmann et al. 2000). Additionally, some studies 
have described early developmental stage B-lymphoid lineage cells that have the potential to 
differentiate into osteoclasts when stimulated with M-CSF and RANKL in vitro (Manabe et 
al. 2001), so it is not surprising that the role of B cells in osteoclastogenesis remains 
controversial. 
Recently, techniques have been described that involve the generation of osteoclasts from 
human precursor cells, using either fresh bone marrow or peripheral blood. These in vitro 
osteoclastogenesis protocols rely on the isolation of PBMCs to serve as precursors and 
although this can sometimes be more challenging the results are easier to translate clinically. 
The protocols described in Table 15 are perhaps typical of this approach (D’Amelio et al. 
2004, Nose et al. 2009, Vandooren et al. 2009, Durand et al. 2011), each has certain 
advantages and disadvantages but the efficiency of osteoclastogenesis in vitro is variable. 
Several systems describe osteoclast formation without additional M-CSF and RANKL i.e. 
spontaneous osteoclastogenesis. Whilst there is no direct evidence that spontaneous 
osteoclastogenesis occurs in vivo, Vandooren (Vandooren et al. 2009) proposes that it is a 
potential system to represent osteoclast formation in a variety of conditions associated with 
bone destruction and loss such as in RA. Furthermore, D’Amelio (D’Amelio et al. 2004) 
suggests that the essential triggers may already be present in peripheral blood, so the addition 
of exogenous cytokines could mask endogenous differences in their production making it 
difficult to distinguish patients from healthy controls. There are wide methodological 
differences in these culture systems including; the number of mononuclear cells plated; 
composition of the medium, timeframe plus defining osteoclastogenic characteristics (Table 
15). Therefore the protocol described and used in this section had to be optimised to take 
these variables into account. A standard TRAP stain was most frequently described in these 
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studies to identify osteoclast-like cells attached to glass cover slips and defining 
morphological characteristics commonly included; the presence of multiple nuclei (i.e. >3) 
and a basal ruffled border. Additionally, evidence of osteoclast maturation and activity was 
assessed using various stains on bone or dentine slices to identify evidence of resorption 
lacunae.  
The aim of this Chapter was therefore to evaluate a protocol for use in the research laboratory 
at Middlesbrough; to create a robust and reproducible method for osteoclast formation and 
characterisation from peripheral blood in vitro, representative of in vivo conditions without 
the addition of endogenous substances. To use this culture system to investigate the potential 
role of B cells on osteoclastogenesis; using healthy volunteer blood depleted of B cells in 
vitro, plus blood from RA patients following in vivo B cell depletion. 
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Table 15 Osteoclast culture techniques described in recent literature 
Reference D’Amelio et al. 
2004 
Nose et al.                  
2009 
Vandooren et al.  
2009 
Durand et al.          
2011 
PBMC 
isolation 
Ficoll-Paque Ficoll-Paque Plus Ficoll-Paque Ficoll density gradient 
No. of cells 
plated 
2× 105 unfractionated 
PBMCs/well in 96-well 
plates or 1× 106 PBMCs on 
dentin slices 
 
5× 104 unfractionated 
cells/well on an ST2 cell 
layer in 24-well plates with 
coverslips or                       
96-well plates on 6mm 
dentine slices 
7× 105 unfractionated 
PBMCs/well in 16-well                           
plates with coverslips or 
96-well plates on dentine                    
discs 
1.5× 106 unfractionated 
cells/cm2 in 24-well plates 
with 12mm coverslips or 
48-well plates with bone 
slices 
Medium α-MEM 
10% FBS                                       
100 IU/ml Penicillin 
100µg/ml Streptomycin 
± 10-8 M 1,25(OH)2D3 
± 30ng/ml RANKL                       
± 25ng/ml M-CSF 
α-MEM                                      
10% FBS                                       
50U/ml Penicillin 
50µg/ml Streptomycin                  
ST2 cell preparation                       
± 10-8 M 1,25(OH)2D3                    
± 10-7 M dexamethasone                 
± 25ng/ml RANKL                       
± 50ng/ml M-CSF 
 
300µl RPMI 1640 
complete 
± 40ng/ml RANKL                           
± 10ng/ml M-CSF 
 
α-MEM                                   
10% FBS                                 
1% Penicillin-
Streptomycin 
50ng/ml RANKL                    
10ng/ml M-CSF 
 
Culture 
conditions 
10 days                         
@37˚C; 5%CO2 
21 days for resorption 
14 days                         
@37˚C; 5%CO2                          
21 days for resorption 
14 days 
@37˚C; 5%CO2                  
21 days for resorption 
21 days 
@37˚C; 5%CO2 
Medium 
change 
3 days 3/4 day 3 day 3/4 day 
Flow 
cytometry 
Not done Frequency of OC 
precursors determined 
using a limiting dilution 
assay and quantification by 
flow cytometry 
Not done Quantification of OC 
precursors by flow 
cytometry 
Histochem 
Stain 
Sigma TRAP 
Vitronectin receptor 
TRAP Sigma TRAP Sigma TRAP 
Calcitonin receptor 
Count TRAP+ and VNR+ 
cells/well with  >3 nuclei 
TRAP+ cells/well  with  
>3 nuclei 
TRAP+ cells TRAP+ cells/well                  
with >3 nuclei 
RT-PCR Not done RT-PCR for human TRAP 
(ACP6), human CD51/αν 
integrin (ITGAV), human 
β-actin (ACTB) genes 
Not done RT-PCR for Cathepsin K 
and β-actin 
Resorption 
assay 
Dentine slices stained with 
0.5% Toluidine blue 
Dentine slices stained with 
Coomassie brilliant blue 
R250 
Dentin resorption assay 
(IDS) stained with 
Toluidine blue 
Bone slices stained with 
0.2% Toluidine blue and 
resorption area quantified 
Other 
identification 
Supernatant level of TNF-
α and RANKL 
Cell viability 
N/A N/A Osteoclast apoptosis 
Caspase activity 
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5.2 Osteoclastogenesis protocol 
PBMC’s, isolated by a standard Ficoll density-gradient centrifugation procedure, were used 
immediately and without further enhancement to optimise an in vitro osteoclast culture 
system for use in future work in this Chapter. Specifically; the need for exogenous cytokines, 
PBMC plating density, length of the culture period and osteoclast characterisation was 
evaluated in this section.  
 
5.2.1 Methods 
PBMC’s were isolated from the fresh peripheral blood (described in Chapter 2 section 2.2.2) 
of self-reported healthy volunteers (Chapter 2 section 2.3.3). Thereafter, unfractionated cells 
were cultured in αMEM complete medium supplemented with recombinant human M-CSF 
(30ng/ml) and RANKL (25ng/ml), (Chapter 2 section 2.1.2) with the aim of establishing an 
osteoclast culture system. However, in order to investigate spontaneous osteoclastogenesis in 
vitro, further experiments were carried out without the addition of these two cytokines.  
To determine the optimum number of mononuclear cell’s for the osteoclast culture (Chapter 2 
section 2.2.2), varying numbers of PBMC’s; 250,000, 500,000, 750,000 and 1,000,000 were 
re-suspended in 500µl αMEM complete medium and layered onto glass coverslips in a 
labelled 24 well plate. The plate was incubated at 37
◦
C in a humidified atmosphere 5% CO2 
for up to 21 days. The medium was refreshed every 2-3 days by replacement of the upper 
250µl. Osteoclasts have a limited lifespan and eventually die via apoptosis, therefore to 
determine the optimal time period for the culture, one set of coverslips was stained using the 
TRAP protocol described in Chapter 2 section 2.2.2 on day 1, day 7 day 14 and day 21. 
Additionally bone slices were stained with toluidine blue (Chapter 2 section 2.2.2) to identify 
any resorption lacunae on day 14 and day 21. All experimental conditions were assayed in 
triplicate. 
Primary osteoclasts were characterised by size, morphology, TRAP and actin staining on 
glass coverslips and toluidine blue staining on bone slices (Chapter 2 section 2.2.2 for 
individual osteoclast characterisation methods). Additionally, functional evidence of 
osteoclast differentiation was determined by measuring the βCTX concentration in the cell 
supernatant harvested from cells cultured on bone slices for 14 and 21 days. The supernatant 
was collected three days after the final medium change at the end of the culture period on 
bone slices. Collagen fragments were quantified using the Roche serum βCTX assay (Chapter 
2 section 2.2.1). A control sample consisting of culture medium from a well containing a bone 
slice but with no added cells was also assayed and the result was subtracted from the values 
obtained for samples plus cells. Any minus values were adjusted to zero. The within batch 
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precision of the assay was assessed by measuring βCTX levels in the cell supernatant from 5 
separate wells containing control samples after the final medium change at the end of the 
culture period. The mean βCTX control value was also compared to that obtained from a 
similar well from the same plate but with added cells. The between batch precision was 
calculated retrospectively from control results taken from 10 separate plates over several 
months.  
 
5.2.2 Results 
Numerous multi-nucleated osteoclast-like cells developed from the fresh PBMC’s, following 
14 days culture in αMEM complete medium supplemented with and without M-CSF plus 
RANKL (Figure 22), the appropriate medium being replenished every 2-3 days. However, the 
resulting TRAP
+
 cells, from the medium supplemented with cytokines, were more defined, 
larger and contained more nuclei/cell.  
RPMI 1650 medium was also tested but αMEM complete was found to be the best for 
supporting optimal growth of osteoclasts. In order to identify the optimum PBMC plating 
density for spontaneous osteoclastogenesis varying concentrations of mononuclear cells were 
cultured and the number and quality of the resulting TRAP
+
 cells determined. Optimal growth 
of osteoclast-like cells was obtained at a concentration of 1×106 cells/ml i.e. 500,000 cells 
plated in 500µl medium (Figure 23). Increasing the plating density did not further increase the 
osteoclast yield and at 1,000,000 cells in 500µl medium the cells appeared to be overcrowded.  
TRAP
+
 cells first appeared at day 7 and their number had increased at day 14, however there 
was some evidence of cell fragmentation on glass coverslips by day 21 (Figure 24). In order 
to verify the osteoclast-like cells on glass coverslips the Sigma TRAP staining protocol was 
optimised (Chapter 2 section 2.2.2) and osteoclasts were identified by TRAP staining, 
morphology (i.e. cell size and presence of a ruffled border) and greater than 3 nuclei (Figure 
25), commonly accepted methods of osteoclast identification. In future experiments the 
number of TRAP
+
 cells was also counted (Chapter 2 section 2.2.2), plus the cell diameter and 
circumference was recorded. Additionally, the Invitrogen Life Technologies protocol using 
Alexa Fluor
®
 488 Phalloidin was optimised (see 2.2.2) and there was evidence of actin ring 
formation on the glass coverslips (Figure 26).  
Toluidine blue staining of the bone slice identified areas of resorption after 14 and 21 days 
(Figure 27). Additionally during bone metabolism, type I collagen is degraded and small 
fragments of C-terminal telopeptides are released, there was evidence of increased 
osteoclastic activity on the bone slice as the levels of βCTX in the cell supernatant were also 
increased. The within batch CV (2.2%) of the βCTX assay after 14 days was calculated from 
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the mean (88.3ng/L) and SD (2.0ng/L) in 5 separate control wells of cell supernatant from the 
same plate. In comparison the supernatant βCTX concentration in this plate was 113.4ng/L in 
the well containing 500,000 cells. The between batch CV (8.7%) of the βCTX assay was 
calculated retrospectively from the mean (100.9ng/L) and SD (8.8ng/L) in 10 separate control 
wells containing cell supernatant made up from different batches of αMEM complete medium 
over several months. 
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A. With the addition of M-CSF (30ng/ml) and RANKL (25ng/ml) 
 
B. Spontaneous osteoclastogenesis 
Figure 22 Comparison with and without the addition of cytokines (×200) 
TRAP stained osteoclast-like cells generated from 500,000 unfractionated, healthy volunteer PBMC’s 
in 500µl αMEM complete medium containing; A: αMEM complete supplemented with M-CSF 
(30ng/ml) and RANKL (25ng/ml); B: αMEM complete with no added cytokines, after 14 days culture 
at 37
◦
C in 5% CO2, the upper 250µl medium was replenished every 2-3 days. The cells were stained 
using an optimised Sigma TRAP kit. (×200 magnification). 
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      A. 250,000 PBMC's/well 
      B. 500,000 PBMC's/well 
      C. 750,000 PBMC's/well 
    D. 1,000,000 PBMC's/well 
Figure 23 Evaluation of PBMC plating density (×200) showing typical patterns 
of TRAP
+
 cell formation at each concentration 
TRAP stained osteoclast-like cells generated from varying numbers of unfractionated, healthy 
volunteer PBMC’s in 500µl αMEM complete medium. A: 250,000; B: 500,000; C: 750,000; D: 
1,000,000 PBMC’s/well after 14 days culture at 37◦C in 5% CO2, the upper 250µl medium was 
replenished every 2-3 days. The cells were stained using an optimised Sigma TRAP kit. (×200 
magnification). 
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      A. Day 1  
    B. Day 7  
     C. Day 14 
    D. Day 21 
Figure 24 Evaluation of the time of culture period (×200) showing typical 
patterns of TRAP
+
 cell formation at each day 
TRAP stained osteoclast-like cells generated from 500,000 unfractionated, healthy volunteer PBMC’s 
in 500µl αMEM complete medium with no additional cytokines after; A: 1 day; B: 7 days; C: 14 days; 
D: 21 days, culture at 37
◦
C in 5% CO2, the upper 250µl medium was replenished every 2-3 days. The 
cells were stained using an optimised Sigma TRAP kit. (×200 magnification). 
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Figure 25 Representative TRAP
+
 multinucleated cells on a glass coverslip 
Osteoclasts-like cells on glass coverslips demonstrating TRAP staining. The cells were generated from 500,000 
unfractionated, healthy volunteer PBMC’s in 500µl αMEM complete medium with no additional cytokines after 
14 days culture at 37
◦
C in 5% CO2, the upper 250µl medium was replenished every 2-3 days. The cells were 
stained using an optimised Sigma TRAP kit. (×200 magnification). 
 
 
 
Figure 26 Representative actin ring formation on a glass coverslip 
Osteoclasts-like cells on glass coverslips demonstrating actin ring formation. The cells were generated from 
500,000 unfractionated, healthy volunteer PBMC’s in 500µl αMEM complete medium with no additional 
cytokines after 14 days culture at 37
◦
C in 5% CO2, the upper 250µl medium was replenished every 2-3 days. The 
cells were stained with Alexa Fluor® 488 Phalloidin, using an optimised Invitrogen Life Technologies staining 
protocol. (×200 magnification). 
Cell nuclei 
Ruffled border 
TRAP
+
 cells 
Actin ring formation 
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Figure 27 Representative resorption pits on a bone slice, visualised by toluidine blue 
staining  
The cells were generated from 500,000 unfractionated, healthy volunteer PBMC’s in 500µl αMEM complete 
medium with no additional cytokines seeded on bone slices after 14 days culture at 37
◦
C in 5% CO2, the upper 
250µl medium was replenished every 2-3 days. The bone slices were stained with 0.1% toluidine blue following 
an optimised protocol. (×200 magnification). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Resorption pits 
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5.2.3 Discussion 
Osteoclast-like cells were generated from peripheral blood using an optimised culture system. 
It appeared that exogenous cytokines were not essential to the process and spontaneous 
osteoclastogenesis was observed with unfractionated PBMC’s from healthy volunteers. 
Comparable to the results reported in similar culture systems (D’Amelio et al. 2004, 
Vandooren et al. 2009). Unfractionated cells were used, allowing the co-culture of monocytes 
and lymphocytes; additionally the initial medium was not changed for at least 48hrs to mimic 
in vivo conditions as closely as possible. It is likely that there was sufficient endogenous 
cytokine present in the peripheral blood to stimulate osteoclastogenesis. Although the 
resulting TRAP
+
 cells, from the medium supplemented with M-CSF and RANKL, were more 
defined, larger and appeared to contain more nuclei. The addition of exogenous cytokines can 
mask any differences in the amounts of these components in the blood thus making it difficult 
to distinguish patients from healthy controls (D’Amelio et al. 2004) in future experiments.  
PBMC plating density did not essentially affect the maximal number of osteoclasts formed. 
1×106 PBMC’s/ml was taken as a workable concentration and guaranteed enough cells for all 
experimental conditions. Furthermore, osteoclasts have a limited lifespan and eventually die 
via apoptosis if the culture period is too long (Akchurin et al. 2008). Optimal numbers of 
osteoclast-like cells formed at 14 days on glass cover-slips and measurable resorptive activity 
was also achieved after 14 days on bone slices, this was consistent with similar 
osteoclastogenesis protocols (D’Amelio et al. 2004, Nose et al. 2009, Vandooren et al. 2009, 
Durand et al. 2011). Osteoclasts were identified as multinucleated (more than 3 nuclei) cells 
that stained positive for TRAP. Actin ring formation is also a prerequisite for osteoclast bone 
resorption. Osteoclasts seeded on glass form podosomes, which are small cylinders of actin 
surrounded by vinculin. There are three different podosome structures dependant on the stage 
of osteoclast differentiation; namely clusters, rings and belts depicting mature osteoclasts 
(Saltel et al. 2004). After 14 days the osteoclast cells were found to be fully functional; this 
was confirmed by their ability to form actin rings on glass coverslips, resorption pits on bone 
slices and by increased βCTX levels in the cell supernatant. However, the Roche crosslaps 
assay has not been verified for use in cell supernatants. The assay was found to have 
acceptable precision during the evaluation but there was a lack of sensitivity in subsequent 
experiments and it was deemed to be semi-quantitative at best. 
 
In conclusion the results demonstrate that using this culture system the multinucleated cells 
formed from human PBMCs exhibit several characteristics of osteoclasts. Moreover, optimum 
conditions for detection of a high number of osteoclast-like cells were observed after 14 days 
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of culture on glass coverslips or bone slices, using 500,000 PBMC’s in 500µl αMEM 
complete medium. 
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5.3 The effect of in vitro B cell depletion 
The aim of this section was to investigate the potential role of B cells on osteoclastogenesis 
specifically using healthy volunteer PBMC’s depleted of B cells in vitro. B cell depletion in 
vitro can be achieved via; MACS separation with CD20 microbeads; or by using RTX, an 
approved therapeutic B cell depleting agent that binds to CD20. In each case the antibody 
recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33–35kDa 
(Cartron et al. 2004) that is expressed on the surface of B lineage cells from the pre–B cell 
stage and throughout B cell maturation, but is lost at the final transformation to plasma cells 
(Figure 1).  
The MACS method allows the cells to be separated by incubating with magnetic 
nanoparticles coated with antibodies against CD20. The cells expressing CD20 i.e.CD20
+
 
cells, attach to the magnetic nanoparticles and if this cell solution is then transferred to a 
column placed in a strong magnetic field, the CD20
+
 cells remain on the column, while CD20
-
 
cells flow straight through. Using either technique in vitro results in rapid B cell depletion, 
however in vivo B cell depletion with RTX is much slower. The mechanisms by which RTX 
actually works in vivo still need to be elucidated. A large body of evidence shows that 
therapeutically RTX induces cell death by different pathways (Cartron et al. 2004); CD20
-   
induced apoptosis; complement dependent cytotoxicity; antibody dependent cell-mediated 
cytotoxicity; and selective targeting and depletion of B cell subsets. It is also likely that the 
different mechanisms work together, the importance of each one being dependent on the 
target cell (Clark and Ledbetter 2005).  
Additionally, the effect of monocytes on RTX action is uncertain. Pederson et al. report that 
monocytes compromise RTX treatment in vivo in cases such as haematological malignancies 
with increased numbers of B cells. In vitro results in healthy volunteers suggest a monocyte-
mediated ‘shaving’ reaction, leading to complete loss of anti-CD20 antibodies from the 
surface of B cells (Pederson et al. 2011). Therefore the effect of in vitro RTX on 
unfractionated and CD14
+
 purified PBMC’s was also explored. 
 
5.3.1 Methods 
PBMC’s were isolated from the fresh peripheral blood (described in Chapter 2 section 2.2.2) 
of self-reported healthy volunteers (Chapter 2 section 2.3.3) in this section. Thereafter, 
500,000 unfractionated cells were compared to either 500,000 cells subjected to CD20 
depletion or CD14 purification in different experiments described below. All cells were 
suspended in 500µl αMEM complete medium and were layered onto glass coverslips in a 
labelled 24 well plate, all experimental conditions were assayed in duplicate. The initial 
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number of monocytes, B cells and T cells was determined in 500µl of this cell suspension by 
FACS analysis (Chapter 2 section 2.2.2). The plate was incubated at 37
◦
C in a humidified 
atmosphere 5% CO2 for 14 days. The medium was refreshed every 2-3 days by replacement 
of the upper 250µl. The coverslips were stained using the TRAP protocol described in 
Chapter 2 section 2.2.2 on day 14.  
 
Unfractionated vs CD20 depleted PBMC’s using magnetic activated cell sorting  
PBMC’s were isolated from the fresh peripheral blood of 12 self-reported healthy volunteers 
(Chapter 2 section 2.3.3) and cultured as described above to compare unfractionated to CD20 
depleted fractions. B cell depletion was carried out using CD20 microbeads and MACS 
separation (Miltenyi Biotec) prior to osteoclast culture (described in Chapter 2 section 2.2.2) 
and the initial numbers of monocytes, B cells and T cells in each fraction was determined by 
FACS. The number, cell circumference and diameter of the resulting TRAP
+
 cells generated 
after 14 days was also recorded for each fraction. 
 
Comparison of CD20 depleted PBMC’s using MACS or in vitro rituximab 
PBMC’s were isolated from the fresh peripheral blood of  3 self-reported healthy volunteers 
(Chapter 2 section 2.2.2) and cultured as described above to compare unfractionated to CD20 
depleted fractions. However in this instance, B cell depletion was accomplished 
simultaneously from the same unfractionated PBMC’s, via MACS separation with CD20 
microbeads or via the addition of RTX at varying concentrations between 0.1 – 100µg/ml 
(described in Chapter 2 section 2.2.2) prior to osteoclast culture. Additionally a set of 
unfractionated PBMC’s were cultured and RTX at varying concentrations between 0.1 – 
100µg/ml was added at the end of the culture (day 14) for comparison. The initial numbers of 
monocytes, B cells and T cells in each fraction was determined by FACS after 3, 12 and 
24hrs. The number, cell circumference and diameter of the resulting TRAP
+
 cells generated 
after 14 days was also recorded for each fraction. 
 
Effect of in vitro rituximab on unfractionated and CD14
+
 purified PBMC’s  
PBMC’s were isolated from the fresh peripheral blood of 2 self-reported healthy volunteers 
(Chapter 2 section 2.2.2) and cultured as described above to compare unfractionated to CD14 
purified fractions with and without CD20 depletion. B cell depletion was accomplished via 
the addition of either 1.0 or 10µg/ml RTX added simultaneously on day 1 to unfractionated 
PBMCs and to MACS purified CD14
+
 monocytes. The initial numbers of monocytes, B cells 
and T cells in each fraction was determined by FACS after 3 and 24hrs. The number, cell 
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circumference and diameter of the resulting TRAP
+
 cells generated after 14 days was also 
recorded for each fraction. 
 
Statistical analysis 
Details of the statistical analysis are described in Chapter 2 section 2.4.3 
 
5.3.2 Results 
Unfractionated vs CD20 depleted PBMC’s using magnetic activated cell sorting  
To investigate whether in vitro B cell depletion affects osteoclastogenesis in healthy 
volunteers unfractionated PBMC’s and MACS CD20 depleted PBMC’s were cultured, the 
generation of TRAP
+
 osteoclast-like cells and evidence of bone resorption was recorded after 
14 days, the results are included in Table 16. The group consisted of 12 self-reported healthy 
volunteers; 6 females (median age 41yrs, IQR 31.5-49.0) and 6 males (median age 35.5yrs; 
IQR 31.3-46.5), with no history of bone or autoimmune disease. There was a significant 
difference in the initial number of B cells, between unfractionated and CD20 depleted PBMC 
fractions as expected (median difference 16650, 95% CI 9101, 31251; p=0.002). But there 
was no significant difference between the initial number of T cells (median difference 7867, 
95% CI -49809, 77228; p=0.875) or monocytes (median difference -8396, 95% CI -42743, 
20963; p=0.158) between these fractions. Moreover, there was a significant difference in the 
absolute numbers of TRAP
+ 
cells generated (median difference -31, 95% CI -61,-2.9; 
p=0.023) i.e. there was a greater number of TRAP
+
 cells generated from the CD20 depleted 
compared to the unfractionated PBMC’s, yet if these results were analysed by gender the 
difference was only significant in the male volunteers. However, when the TRAP
+
 cell 
numbers were adjusted to account for any differences in initial monocyte number, there was 
no significant difference (median difference -0.01, 95% CI  -0.08, 0.06; p=0.530) in the cell 
numbers between these PBMC fractions. There was also no significant difference in TRAP
+
 
cell circumference (p=0.530) or cell diameter (p=0.454) or the βCTX concentration in the 
final cell supernatant (p=0.969). 
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Table 16 Unfractionated and CD20 depleted cultures in twelve healthy volunteers 
 Unfractionated 
Cells  
Median (IQR) 
 
 
 
CD20 Depleted 
Cells 
Median (IQR) 
Median Difference 
(95%CI) 
p value 
Initial no. Monocytes 
 All samples (n=12) 
 
49227 
(41696,65712) 
72472 
(33641,100783) 
-8396                         
(-42743,20963) 
0.158 
   Female (n=6) 
 
56221 
(41530,66665) 
72472 
(33710,84782) 
-6760               
  (-40197,31116) 
0.753 
   Male (n=6) 
 
46507 
(41861,53311) 
79811 
(33571,109500) 
-23328                 
  (-85016,28769) 
0.116 
Initial no. B cells 
     All samples (n=12) 
 
17476 
(10541,32009) 
1013  
 (431,2549) 
16650 
 (9101,31251) 
0.002 
   Female (n=6) 
 
19482 
(11668,29213) 
1083   
 (565,1522) 
16566  
(6908,33429) 
0.028 
   Male (n=6) 
 
17476 
(9414,35250) 
868    
 (413,3575) 
16650  
(2424,33897) 
0.028 
Initial no. T cells 
 All samples (n=12) 
 
146028 
(107045,227305) 
139242 
(59800,207437) 
7867                    
   (-49809,77228) 
0.875 
   Female (n=6) 
 
143464 
(68000,227758) 
109266 
(41733,196879) 
13832                 
   (-37657,102506) 
0.345 
   Male (n=6) 
 
146028 
(112665,226851) 
169316 
(95812,214061) 
-8909                   
  (-225391,88228) 
0.600 
Absolute no. TRAP+ cells 
 All samples (n=12) 60 (42,76) 86 (48,121) 
 
-31 (-61,-2.9) 
 
0.023 
 
    Female (n=6) 54 (31,76) 
 
80 (40,87) 
 
-19 (-61,28) 
 
0.345 
 
    Male (n=6) 67 (54,75) 109 (56,139) -39 (-81,-3) 0.028 
 
Monocyte corrected TRAP+ cells 
     All samples (n=12) 
 
0.12 (0.07,0.16) 0.14 (0.08,0.20) -0.01 (-0.08,0.06) 0.530 
   Female (n=6) 
 
0.08 (0.07,0.15) 0.12 (0.06,0.23) -0.02 (-0.20,0.09) 0.463 
   Male (n=6) 
 
0.15 (0.10,0.17) 0.15 (0.09,0.20) -0.01 (-0.08,0.11) 0.917 
TRAP+ cell circumference 
 All samples (n=12) 
 
329 (293,342) 310 (293,329) 7 (-16,28) 0.530 
   Female (n=6) 
 
317 (279,332) 310 (295,332) -7 (-28,7) 0.291 
   Male (n=6) 
 
334 (320,345) 311 (291,325) 25 (-33,117) 0.249 
TRAP+ cell diameter 
 All samples (n=12) 
 
86 (75,89) 81 (75,86) 2 (-4,9) 0.454 
   Female (n=6) 
 
83 (70,89) 81 (75,86) -1 (-9,5) 0.673 
   Male (n=6) 
 
87 (83,88) 81 (74,85) 6 (-7,31) 0.139 
Final βCTX concentration 
     All samples (n=12) 
 
2.2 (0.7,6.5) 0.7 (0,13) 0.2 (-5.1,2.4) 0.969 
   Female (n=6) 
 
1.8 (1.3,18.3) 0.7 (0,23.8) 0.2 (-9.9,1.8) 0.833 
   Male (n=6) 
 
3.4 (0,6.5) 0.8 (0,2.2) 1.3 (-19.9,4.3) 0.673 
 
The data were not normally distributed and so results were expressed as medians and interquartile range. 
Wilcoxon signed-rank test was used to determine if there was a statistically significant difference between 
unfractionated and CD20 depleted PBMC fractions. P values ≤0.05 were considered statistically significant. 
Chapter 5                                                                                             In vitro osteoclastogenesis 
129 
 
Collectively examining the unfractionated and CD20 depleted fractions, there was no 
significant correlation between; the initial number of monocytes and the absolute number of 
TRAP
+
 cells generated (Rs= 0.312; p= 0.137), (Figure 28); or the initial numbers of B cells 
and the number of TRAP
+
 cells generated corrected for the number of monocytes (Rs= -
0.086; p=0.689), (Figure 29); or the initial numbers of T cells and the number of TRAP
+
 cells 
generated corrected for the number of monocytes (Rs= -0.345; p=0.098), (Figure 30). 
However, when assessing the unfractionated and CD20 depleted fractions separately; there 
was a significant positive correlation (Rs= 0.671; p= 0.017) between the initial number of 
monocytes and the absolute numbers of TRAP
+
 cells generated and a significant negative 
correlation between the initial number of T cells and the TRAP
+
 cells generated corrected for 
the number of monocytes (Rs= -0.627; p= 0.029), in CD20 depleted PBMC’s. Yet, no 
significant correlations were found between these parameters and the unfractionated PBMC’s, 
(Figures 28 – 30). 
 
  
Chapter 5                                                                                             In vitro osteoclastogenesis 
130 
 
 
 
 
Figure 28 The effect of the initial number of monocytes on TRAP
+
 cells generated from 
twelve healthy volunteer peripheral blood mononuclear cells 
TRAP
+
 cells were generated from 500,000 unfractionated PBMC’s or MACS CD20 depleted PBMC’s, in 500µl 
αMEM complete medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl 
medium was replenished every 2-3 days. The absolute number of TRAP
+
 cells generated was plotted against the 
initial number of monocytes for A: all fractions and B: for unfractionated and CD20 depleted PBMC’s. The line 
of best fit/ trendline and equation were generated using Microsoft Excel 2010. Spearman’s rank correlation 
coefficient Rs was used to correlate these parameters. 
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Figure 29 The effect of the initial number of B cells on TRAP
+
 cells generated from 
twelve healthy volunteer peripheral blood mononuclear cells 
TRAP
+
 cells were generated from 500,000 unfractionated PBMC’s or MACS CD20 depleted PBMC’s, in 500µl 
αMEM complete medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl 
medium was replenished every 2-3 days. The absolute number of TRAP
+
 cells generated was corrected for the 
number of monocytes in the initial cell suspension and plotted against the initial number of B cells for A: all 
fractions and B: for unfractionated and CD20 depleted PBMC’s. The line of best fit/ trendline and equation were 
generated using Microsoft Excel 2010. Spearman’s rank correlation coefficient Rs was used to correlate these 
parameters. 
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Figure 30 The effect of the initial number of T cells on TRAP
+
 cells generated from 
twelve healthy volunteer peripheral blood mononuclear cells 
TRAP
+
 cells were generated from 500,000 unfractionated PBMC’s or MACS CD20 depleted PBMC’s, in 500µl 
αMEM complete medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl 
medium was replenished every 2-3 days. The absolute number of TRAP
+
 cells generated was corrected for the 
number of monocytes in the initial cell suspension and plotted against the initial number of T cells for A: all 
fractions and B: for unfractionated and CD20 depleted PBMC’s. The line of best fit/ trendline and equation were 
generated using Microsoft Excel 2010. Spearman’s rank correlation coefficient Rs was used to correlate these 
parameters. 
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Comparison of CD20 depleted PBMC’s using MACS or in vitro rituximab 
B cell depletion was accomplished simultaneously, from the same unfractionated PBMC’s, 
via MACS separation with CD20 microbeads or via the addition of RTX at varying 
concentrations. Although there were insufficient samples to perform statistical analysis, there 
was as expected reduced numbers of B cells in the MACS and RTX (at RTX concentrations 
between 0.1-100µg/ml added on day 1) CD20 depleted PBMC fractions compared to 
unfractionated PBMC’s. Moreover, as previously demonstrated, there were greater numbers 
of TRAP
+ 
cells generated and TRAP
+
 cell numbers corrected for the initial numbers of 
monocytes, from the CD20 depleted compared to the unfractionated PBMC’s (Table 17). 
Varying concentrations of RTX (0.1-100µg/ml) were also added at the end of the culture (day 
14) but generated a similar number of TRAP
+
 cells compared to unfractionated PBMC’s. The 
timing of the FACS analysis was also varied between 3, 12 and 24hrs. The effect of this delay 
in analysis was minimal on the results of the unfractionated and MACS CD20 depleted 
PBMC’s. However, after 24hrs there was a vast reduction in the initial numbers of 
monocytes, B cells and T cells counted by FACS in all the tubes containing RTX regardless 
of the RTX concentration, but this did not seem to affect the eventual numbers of TRAP
+
 cells 
generated after 14 days. 
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Table 17 Comparison of CD20 depleted mononuclear cells using either magnetic-activated cell sorting or in vitro rituximab 
Sample  Initial no. 
Monocytes 
Initial no. 
B cells 
Initial no. 
T cells 
Absolute no. 
TRAP
+ 
cells 
Mean (SD) 
Monocyte corrected 
TRAP
+
 cells 
TRAP
+
 cell 
circumference 
Mean (SD) 
TRAP
+
 cell 
diameter 
Mean (SD) 
Sample 1 (Female) FACS done after  3hrs 
Unfractionated (UF) 20,451 24,512 112,436 61 (20) 0.298 310 (58) 80 (15) 
MACS CD20
-  
cells 25,129 996 75,432 140 (40) 0.557 291 (66) 77 (18) 
MACS CD20
+
 cells 40,794 66,662 67,668     
UF + RTX [0.1µg/ml] added Day 1  16,469 16,756 112,650 160 (32) 0.972 351 (88) 93 (23) 
UF + RTX [1.0µg/ml] added Day 1 16,227 14,345 101,789 142 (28) 0.875 326 (72) 86 (19) 
UF + RTX [10µg/ml] added Day 1  18,424 14,002 101,163 141 (34) 0.765 333 (118) 88 (30) 
UF + RTX [100µg/ml] added Day 1 17,920 14,514 105,150 139 (43) 0.776 304 (81) 82 (22) 
UF + RTX [0.1µg/ml] added Day 14  20,451 24,512 112,436 63 (26) 0.308 339 (96) 89 (26) 
UF + RTX [1.0µg/ml] added Day 14  20,451 24,512 112,436 49 (19) 0.240 318 (73) 84 (21) 
UF + RTX [10µg/ml] added Day 14  20,451 24,512 112,436 43 (17) 0.210 335 (126) 87 (29) 
UF + RTX [100µg/ml] added Day 14  20,451 24,512 112,436 50 (25) 0.244 309 (111) 83 (27) 
Sample 2 (Female) FACS done after 12hrs 
Unfractionated  124,327 27,031 227,758 31 (11) 0.025 346 (83) 89 (22) 
MACS CD20
- 
cells 92,373 5,266 265,879 84 (27) 0.091 359 (100) 93 (100) 
MACS CD20
+
 cells 90,597 103,818 87,143     
UF + RTX [1.0µg/ml] added Day 1 69,981 14,775 218,540 26 (13) 0.037 353 (162) 87 (39) 
Sample 3 (Male) FACS done after 24hrs 
Unfractionated  32,625 20,880 129,195 54 (21) 0.166 345 (86) 88 (20) 
MACS CD20
-
 cells 33,571 366 95,812 56 (26) 0.167 325 (91) 85 (25) 
MACS CD20
+ 
cells 22,053 47,279 36,440     
UF + RTX [0.1µg/ml] added Day 1  2,610 1,305 6,525 89 (38) 3.410 368 (80) 94 (20) 
UF + RTX [1.0µg/ml] added Day 1 2,610 1,305 6,525 85 (40) 3.257 335 (119) 89 (31) 
UF + RTX [10µg/ml] added Day 1  2,610 1,305 6,525 70 (23) 2.682 338 (74) 89 (19) 
 
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated  and MACS or varying concentrations of RTX-CD20 depleted PBMC’s, all in 500µl αMEM 
complete medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was replenished every 2-3 days. The absolute number of TRAP
+
 
cells generated was corrected for the number of monocytes in the initial cell suspension. The TRAP
+
 cell circumference and cell diameter was also recorded. The initial 
numbers of monocytes, B cells and T cells was determined by FACS.                                                                                                                                                               
FACS: Fluorescence Activated Cell Sorting MACS: Magnetic-Activated Cell Sorting; RTX: rituximab; UF unfractionated peripheral blood mononuclear cells 
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Effect of in vitro rituximab on unfractionated and CD14
+
 purified PBMC’s  
B cell depletion was accomplished via the addition of RTX added simultaneously on day 1 to 
unfractionated PBMCs and to MACS purified CD14
+
 monocytes and the results are included 
in Table 18. Although there were insufficient samples to perform statistical analysis, the 
initial monocyte numbers were increased following MACS CD14
+ 
purification and these 
purified monocyte fractions generated the highest absolute numbers of TRAP
+ 
cells that had 
the largest cell circumference and diameter. However, even though the CD14
- 
fractions 
generated the lowest numbers of TRAP
+
 cells, when they were corrected for the initial 
numbers of monocytes they actually generated the highest percentage of TRAP
+ 
cells overall, 
possibly due to the higher numbers of B and T cells in these fractions. Sample 2 was 
consistent with previous findings i.e. there were greater numbers of TRAP
+ 
cells generated 
from the RTX CD20 depleted fractions, this being true for both the unfractionated and CD14
+ 
fractions. However, the converse was true for sample 1. Additionally, there was a vast 
reduction in the initial numbers of monocytes, B cells and T cells in the unfractionated PBMC 
tube containing RTX when the FACS analysis was delayed for 24 hrs and unfortunately the 
FACS analysis did not work and so there are no initial monocyte, B and T cell counts for all 
the tubes containing CD14
+
 cells plus RTX.  
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Table 18 Effect of in vitro rituximab on unfractionated and CD14
+
 purified peripheral blood mononuclear cells 
Sample Initial no. 
Monocytes 
Initial no. 
B cells 
Initial no. 
T cells 
Absolute no. 
TRAP
+ 
cells 
Mean (SD) 
Monocyte corrected 
TRAP
+
 cells 
TRAP
+
 cell 
circumference 
Mean (SD) 
TRAP
+ 
cell 
diameter 
Mean (SD) 
Sample 1 (Male) FACS done after 3hrs 
 
Unfractionated (UF) 
 
48,478 21,216 251,970 82 (47) 0.169 318 (65) 84 (17) 
UF + RTX [10µg/ml] added Day 1 
 
47,295 18,465 223,955 63 (18) 0.133 351 (90) 93 (25) 
CD14
+
 cells 
 
139,863 2,593 12,737 74 (22) 0.053 425 (125) 107 (29) 
CD14
+
 cells + RTX [10µg/ml] added Day 1    11 (8)  360 (115) 92 (29) 
CD14
-
 cells 
 
1,808 26,217 319,777 26 (10) 1.438 320 (74) 84 (20) 
Sample 2 (Female) FACS done after 24hrs 
 
Unfractionated (UF) 
 
45,508 20,753 163,147 48 (19) 0.105 350 (159) 91 (33) 
UF + RTX [1.0µg/ml] added Day 1 
 
6,088 1,371 8,840 65 (27) 1.068 366 (66) 99 (19) 
CD14
+
 cells 
 
100,548 1,629 19,518 106 (31) 0.105 377 (188) 96 (27) 
CD14
+
 cells + RTX [1.0µg/ml] added Day 1    141 (19)  339 (93) 93 (25) 
CD14
- 
cells 
 
1,108 21,890 121,489 18 (7) 1.625 318 (79) 85 (21) 
 
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated  or MACS CD14 purified PBMC’s, with or without the addition of RTX, also CD14 depleted 
PBMC’s, all in 500µl αMEM complete medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was replenished every 2-3 days. 
The absolute number of TRAP
+
 cells generated was corrected for the number of monocytes in the initial cell suspension. The TRAP
+
 cell circumference and cell diameter was 
also recorded. The initial numbers of monocytes, B cells and T cells was determined by FACS. 
FACS: Fluorescence Activated Cell Sorting MACS: Magnetic-Activated Cell Sorting; PBMC: Peripheral Blood Mononuclear Cells; RTX: rituximab; UF unfractionated 
peripheral blood mononuclear cells.
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5.3.3 Discussion 
The aim of this section was to investigate in vitro B cell depletion on osteoclastogenesis in 
PBMC’s isolated from the blood of self-reported healthy volunteers. There was a significant 
difference in the initial number of B cells, between unfractionated and MACS CD20 depleted 
PBMC fractions as expected. But there was no significant difference between the initial 
number of T cells or monocytes between these fractions. Additionally, there was a greater 
number of TRAP
+
 cells generated from the CD20 depleted compared to unfractionated 
PBMC’s and specifically in male volunteers. However, when the TRAP+ cell numbers were 
adjusted to account for any differences in initial monocyte number, there was no significant 
difference between these PBMC fractions. Moreover, solely in the CD20 depleted fraction as 
the initial number of monocytes increased more TRAP
+
 cells were generated and as the initial 
number of T cells decreased TRAP
+
 cells adjusted for the initial number of monocytes 
increased. CD14
+
 monocytes are known to be osteoclast precursor cells (Costa-Rodrigues et 
al. 2011, Vandooren et al. 2009) and so with the appropriate stimulus the increased generation 
of TRAP
+
 cells with higher numbers of monocytes was predictable. Osteoclast differentiation 
is known to be critically controlled by RANKL activating its receptor RANK and thereby 
inducing a signalling cascade leading to the differentiation and fusion of osteoclast precursor 
cells (Datta et al. 2008). The catabolic effects of RANKL can be counterbalanced by OPG, a 
soluble decoy receptor which binds and neutralises RANKL, thus inhibiting 
osteoclastogenesis and inducing osteoclast apoptosis (Blair and Zaidi 2006). A study in mice 
by Li et al. reported that B lineage cells were responsible for up to 64% of total bone marrow 
OPG, 45% of which being derived from mature B cells (Li et al. 2007). Thus by depleting 
CD20 B cells in vitro, OPG may also be supressed and the RANKL/OPG ratio increased in 
favour of RANKL activated osteoclastogenesis, generating more TRAP
+
 osteoclast-like cells. 
A further study by Weitzmann et al. using human peripheral blood stem cells, also 
demonstrated that in vitro B cells inhibit osteoclastogenesis, via their ability to secrete TGF-β 
and that TGF-β inhibits osteoclast formation through its ability to induce OPG in B cells 
following CD40 activation (Weitzmann et al. 2000). 
The conditions available in the laboratory vary significantly from the clinical environment, 
therefore to represent therapeutic B cell depletion as closely as possible; RTX was used in 
vitro in an attempt to mirror in vivo effects and the working concentration of RTX and timing 
of the FACS analysis was evaluated. However, although the results were comparable to CD20 
depletion by MACS separation, RTX was less efficient in depleting B cells. RTX has been 
shown to induce apoptosis, complement-mediated lysis and antibody-dependent cellular 
cytotoxicity in vitro to deplete B cells and the different outcomes may be dependent on the B 
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cell stage amongst other factors (Cartron et al. 2004). Additionally the number of B cells was 
determined by FACS using CD19 antibodies and this may be inaccurate. A study of the 
addition of RTX to healthy donor PBMC’s in vitro, reported a complement independent loss 
of CD19 without causing B cell death. CD19 was transferred from B cells to monocytes and 
neutrophils during shaving of the RTX-CD20 complex in an Fc dependent manner, the 
authors therefore suggest that using CD19
+
 cell counts may be compromised by this effect 
(Jones et al. 2012). Additionally the effect of adding RTX to purified monocytes was 
inconsistent and the FACS analysis was unreliable. Monocytes reportedly compromise the 
effects of RTX via a monocyte-mediated ‘shaving’ reaction, leading to complete loss of anti-
CD20 antibodies from the surface of B cells (Pederson et al. 2011).  More samples are needed 
to confirm the effects of adding RTX to purified CD14
+
 cells in this osteoclast culture. 
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5.4 The effects of ex vivo B cell depletion 
RA is a chronic systemic inflammatory joint disease, in which B cells play an important role 
(Edwards and Cambridge 2001). RTX, a chimeric monoclonal antibody directed against the B 
cell-specific membrane protein CD20, is a successful biologic approved in the UK for 
treatment of patients with severe refractory RA who have had an inadequate response to, or 
are intolerant of, other DMARDs including at least one anti-TNF-α. (NICE technology 
appraisal guidance - TA195, August 2010). Clinical trials have shown that RTX effectively 
depletes B cells in peripheral blood (Nakou et al. 2009, Teng et al. 2007). Therefore, the RA 
subjects treated with RTX, in the prospective clinical trial described in Chapter 4, were 
deemed an ideal ex vivo model for determining the role of B cells in osteoclastogenesis. 
 
5.4.1 Methods 
Peripheral blood was collected from 5 adult patients enrolled in the prospective clinical trial, 
comprising RA patients who started RTX after failure of other DMARDs, previously 
described in Chapter 4. All patients had severe active disease and had an inadequate response 
to, or were intolerant of; other DMARDs including at least one anti-TNF-α. RTX was 
administered following recommended protocol and patients who responded to the first RTX 
course received a second course at 6 months unless they attained a state of low disease 
activity, in accordance with clinical practice. Patients were assessed at baseline prior to RTX 
treatment and then every 3 months over a 12 month follow up period and blood samples were 
collected at each visit. 
To investigate the effect of ex vivo B cell depletion on osteoclastogenesis, PBMC’s were 
isolated from 10ml EDTA blood within 6hrs by density-gradient centrifugation (Chapter 2 
section 2.2.2). The total number of PBMC’s was counted and 500,000 cells, suspended in 
αMEM complete medium without the addition of exogenous cytokines, were cultured on 
glass coverslips and bone slices in 24 well plates in 5% CO2 at 37
◦
C for 14 days, the medium 
being replaced every 2-3 days, following the procedures described in Chapter 2 section 2.2.2. 
Additionally, as PBMC’s are heterogeneous consisting of subsets of many cells, the number 
of monocytes, B cells and T cells in the initial cell suspension was determined by FACS 
analysis (Chapter 2 section 2.2.2). At the end of the culture period the coverslips were stained 
for TRAP activity, the number of TRAP
+ 
cells was counted and the mean cell diameter and 
circumference calculated. The bone slices were stained with toluidine blue to identify 
resorption pits and the final medium was analysed for βCTX (All methods are described in 
Chapter 2 section 2.2.2).   
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Statistical analysis 
Details of the statistical analysis are described in Chapter 2 section 2.4.3 
 
5.4.2 Results 
Five patients with severe, refractory RA were included, all patients received the first RTX 
infusion but only 4 patients received the second RTX course and completed the study, one 
patient dropped out before the 6 month visit. The baseline characteristics are included in 
Table 19. Briefly the group consisted of 4 post-menopausal females (aged 55-79yrs) and 1 
male (aged 47yrs); all 5 patients were RF and ACPA positive. No patient was on 
prednisolone, however 2 patients received MTX and 1 patient was on a calcium/vitamin D 
supplement throughout the study period.  All patients had normal bone biochemistry; 
corrected calcium (CCa), phosphate (PO4) and total alkaline phosphatase (ALP), but all 
females had low serum 25OHD, 2 of which also had increased PTH levels, at baseline. The 
clinical, BMD and bone marker data per patient, per visit is shown in Table 20, this data was 
collected as part of the prospective clinical trial described in Chapter 4. The change in disease 
activity, inflammation and bone turnover was variable and the majority of patients seemed to 
have a slight decrease in BMD over 12 months. 
Chapter 5                                                                                                                                                                               In vitro osteoclastogenesis 
141 
 
Table 19 Baseline trial data for five rheumatoid arthritis patients 
 
ID 
Age  
(yrs) 
Gender 
RA 
duration 
(yrs) 
Menopause 
Smoke 
Status 
BMI 
(kg/m2) 
MTX 
(mg/wk) 
Steroid 
(mg/day) 
Ca/Vit D 
(tab/day) 
2nd 
RTX 
course 
at 6 
months 
Study 
complete 
ACPA RF 
 CCa 
(mmol/L) 
PO4 
(mmol/L) 
ALP 
(U/L) 
25OHD 
(nmol/L) 
PTH 
(ng/L) 
0206 55.4 Female 4 Yes Never  31.5 No No 2 Yes Yes POS POS 2.16 1.07 86 26.5 83.9 
0207 79.8 Female 27 Yes Former  25.1 No No No No No POS POS 2.23 1.07 91 14.0 73.6 
0208 61.6 Female 11 Yes Never  22.4 No No No Yes Yes POS POS 2.19 1.12 57 17.5 29.2 
0209 66.2 Female 17 Yes Current  25.0 20 No No Yes Yes POS POS 2.25 1.06 103 18.8 37.7 
0210 47.0 Male 2 N/A Former  33.3 25 No No Yes Yes POS POS 2.20 0.94 75 58.0 27.3 
 
25OHD: 25 Hydroxy Cholecalciferol; ALP: Total Alkaline Phosphatase; ACPA: Anti-cyclic Citrullinated Peptide Antibody; BMI: Body Mass Index; Ca/VitD: 
Calcium/Vitamin D supplement; CCa: Corrected calcium; MTX: Methotrexate; PTH: Parathyroid Hormone; PO4: Phosphate; RA: Rheumatoid Arthritis; RF: Rheumatoid 
Factor; RTX:  Rituximab. 
Reference ranges: 
ALP 30-120U/L; CCa 2.1-2.6mmol/L; PO4 0.8-1.5mmol/L; PTH 12-72ng/L; 25OHD <25nmol/L =deficient, 25-50nmol/L =insufficient, 50-75nmol/L =adequate, >75nmol/L 
=optimum.  
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Table 20 Bone marker and bone mineral density results at each visit for five rheumatoid arthritis patients 
ID Visit 
(month) 
HAQ ESR 
(mm/hr) 
CRP 
(mg/L) 
TJC SJC VAS 
(mm) 
DAS28 eGFR 
(ml/min/1.73m2) 
CD19 
(x109/L) 
PINP 
(µg/L) 
BALP 
(µg/L) 
βCTX 
(ng/L) 
TRAP5b 
(U/L) 
SCL 
(pmol/L) 
DKK1 
(pmol/L) 
LS BMD 
(g/cm3) 
MN BMD 
(g/cm3) 
MT BMD 
(g/cm3) 
0206 0 2.125 37 9.0 16 9 43 5.47 90 0.420 37.8 16.8 504 2.9 31.5 77.6 1.562 1.061 1.092 
 
3 2.500 37 8.1 18 3 54 5.36 94 0.001 56.5 16.1 247 2.8 43.3 81.0 
   
 
6 2.750 20 5.4 19 6 64 5.63 95 0.370 49.4 19.9 257 3.0 41.8 70.0 
   
 
9 2.625 
 
8.2 20 3 44 5.35 97 0.674 44.8 21.8 218 3.3 52.5 65.7 
   
 
12 2.750 35 9.8 20 11 55 5.99 80 
 
47.1 22.2 339 3.5 52.9 74.3 1.561 1.093 1.074 
0207 0 2.500 55 30.9 10 4 52 5.27 80 0.387 52.4 21.2 498 3.5 47.7 65.9 1.122 0.576 0.661 
 
3 1.625 
 
30.6 1 0 4 2.82 87 0 57.5 15.9 461 3.1 33.2 52.6 
   
0208 0 1.375 9 0.9 6 4 31 3.33 83 0.384 20.7 11.7 318 2.5 37.6 119.4 1.103 0.965 1.006 
 
3 1.375 10 2.5 6 8 70 4.51 86 0 36.7 
 
339 2.1 35.9 83.8 
   
 
6 1.500 10 2.9 6 10 72 4.64 102 0.001 25.4 13.8 269 2.6 30.2 127.8 
   
 
9 1.750 10 3.8 14 9 72 5.41 86 0 29.8 14.3 166 2.7 32.2 236.9 
   
 
12 1.625 27 10.3 15 13 65 5.92 93 
 
20.7 11.9 274 2.8 33.0 150.8 1.116 0.916 0.929 
0209 0 1.500 29 7.2 22 15 77 6.51 54 0.039 62.6 28.8 269 3.6 55.3 45.4 0.949 0.928 0.940 
 
3 1.375 10 4.2 5 4 33 3.82 98 0.001 47.3 28.1 470 2.4 64.2 57.4 
   
 
6 1.375 17 22.3 16 11 67 6.2 78 0.002 51.0 33.7 504 2.8 57.1 45.0 
   
 
9 1.625 5 2.2 12 2 20 3.96 72 0 51.5 27.5 665 2.7 79.9 24.7 
   
 
12 1.625 2 2.6 9 13 41 4.63 74 0 41.9 30.1 745 3.9 76.7 58.5 0.941 0.922 0.906 
0210 0 2.125 2 0.4 26 11 87 5.97 97 0.370 24.2 15.3 181 2.7 45.5 48.3 1.439 1.153 1.268 
 
3 2.125 8 0.5 28 24 81 6.44 102 0 40.2 15.9 236 3.0 50.3 45.6 
   
 
6 1.875 12 6.2 24 10 89 6.54 101 0.008 29.2 17.5 97 2.8 51.7 54.3 
   
 
9 2.375 20 29.1 27 23 76 7.51 94 
 
26.1 16.3 216 2.8 57.6 59.5 
   
 
12 2.500 2 0.3 22 21 76 5.94 87 0.001 16.8 18.1 164 2.2 52.5 67.3 1.409 1.171 1.239 
 
βCTX: β-isomerised carboxy terminal telopeptide of type I collagen; BALP: Bone Specific Alkaline Phosphatase; BMD: Bone Mineral Density; CRP: C-Reactive Protein; 
CD19: Cluster of Differentiation19; DAS28: Disease Activity Score in 28 joints; DKK-1: Dickkopf-related protein 1; ESR: Erythrocyte Sedimentation Rate; eGFR: estimated 
Glomerular Filtration Rate; HAQ: Health Assessment Questionnaire; LS: Lumbar Spine mean L2-L4; MN: Mean of left and right side neck of femur; MT: Mean of left and 
right side total femur; PINP: Procollagen type 1 amino-terminal propeptide; SCL: Sclerostin; SJC: Swollen Joint Count; TRAP5b: Tartrate Resistant Acid Phosphatase 
isoform 5b; TJC: Tender Joint Count; VAS: Visual Analogue Scale. 
Reference ranges: 
All: CRP <5mg/L; eGFR >60ml/min/1.73m
2
. 
Postmenopausal females: BALP 3.8-22.6µg/L; βCTX 104-1008ng/L; PINP 16.3-73.9µg/L; TRAP5b 1.5-4.9U/L. 
Females: DKK-1 12.4-72.2pmol/L; ESR 5-15mm/hr; SCL 21.6-68.1pmol/L. 
Males: BALP 3.7-20.9µg/L; βCTX 0-854ng/L; DKK-1 15.5-80.8pmol/L; ESR 2-10mm/hr; PINP 15.1-58.6µg/L; SCL 26.4-68.0pmol/L; TRAP5b 1.9-4.8U/L.  
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To investigate whether B cell depletion with RTX affects osteoclastogenesis in this subgroup 
of patients, PBMC’s were cultured, without the addition of exogenous cytokines, at each visit 
and the generation of TRAP
+
 osteoclast-like cells and evidence of bone resorption was 
recorded after 14 days. A typical pattern of change in the number and appearance of TRAP
+
 
osteoclast-like cells per visit is presented in Figure 31 and results are included in Table 21. 
There was a significant decrease (p=0.046) in the initial number of B cells in the PBMC 
fraction analysed by FACS, from baseline to 12 months, as expected following RTX therapy 
in these patients. There was no significant difference in the number of T cells (p=0.230) or 
monocytes (p=0.064), however there was a significant upward trend in the number of 
monocytes (p=0.014) from baseline to 12 months but there was a significant negative 
correlation (Rs = -0.638; p=0.014) between the initial number of monocytes and the number 
of TRAP
+
 cells generated (Figure 32). Moreover, there was a significant decrease (p=0.012) 
in the absolute numbers of TRAP
+ 
cells generated over 12 months. TRAP
+
 cell numbers were 
also adjusted to account for any differences in initial monocyte number and there was still a 
significant decrease (p=0.010) over 12 months, individual patient results are illustrated in 
Figure 33. There was no significant difference in TRAP
+
 cell circumference (p=0.104) or cell 
diameter (p=0.068) or the βCTX concentration in the final cell supernatant (p=0.501). 
There was a significant positive correlation (Rs = 0.583; p=0.029) between the initial number 
of B cells and the number of TRAP
+
 cells generated corrected for the number of monocytes. 
As the number of B cells decreased the number of TRAP
+
 cells generated decreased (Figure 
34). Conversely, there was a borderline significant negative correlation (Rs = -0.533; 
p=0.050) between the initial number of T cells and the number of TRAP
+
 cells generated 
corrected for the number of monocytes. As the number of T cells decreased the number of 
TRAP
+
 cells generated increased (Figure 35). 
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 A Baseline 
 B 3 months 
 C 6 months 
 D 12 months 
Figure 31 An example of a patient culture at baseline, 3, 6 and 12 months  
TRAP stained osteoclast-like cells generated from 500,000 unfractionated PBMC’s in 500µl αMEM complete 
medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was 
replenished every 2-3 days. The cells were stained using an optimised Sigma TRAP kit. (×200 magnification). 
Blood was collected at; A: Baseline, prior to RTX infusion; B: after 3 months; C: after 6 months; D: after 12 
months treatment.
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Table 21 Median cell counts at baseline and at 3, 6 and 12 month post-rituximab from four rheumatoid arthritis patient cultures 
 Baseline 
median (IQR) 
 
 
 
 
3 month  
median (IQR) 
 
6 month 
median (IQR) 
 
12 month 
median (IQR) 
 
p value  
difference by visit  
p value  
trend by visit 
Initial no. 
monocytes 
 
31607 
(27838,35169) 
50573 
(31507,68923) 
 
 
66761 
(47572,85012) 
76537 
(38901,87097) 
0.064 0.014 
Initial no.               
B cells 
 
15457 
(10575,20857) 
352 
(182,525) 
433 
(96,1276) 
197 
(194,685) 
0.046 0.047 
Initial no.               
T cells 
 
71725 
(23750,143603) 
124725 
(79709,194930) 
121741 
(25337,294781) 
191818 
(139331,348075) 
0.230 0.053 
Absolute no. 
TRAP
+
 cells 
 
 
137 
(132,145) 
90 
(74,97) 
34 
(27,34) 
21 
(12,79) 
0.012 0.003 
Monocyte corrected 
TRAP
+
 cells 
0.44 
(0.38,0.51) 
0.19 
(0.13,0.25) 
0.04 
(0.04,0.07) 
0.05 
(0.01,0.10) 
0.010 0.003 
TRAP
+
 cell 
circumference 
 
361 
(344,391) 
348 
(308,375) 
330 
(289,335) 
299 
(251,322) 
0.104 0.014 
TRAP
+
 cell 
diameter 
 
90 
(85,99) 
89 
(79,98) 
81 
(72,83) 
77 
(60,82) 
0.068 0.012 
Final βCTX 
concentration 
 
5.4 
(1.0,9.8) 
7.2 
(4.2,14.1) 
3.3 
(3.1,6.5) 
2.0 
(1.3,4.9) 
0.501 0.279 
 
The data were not normally distributed and so results were expressed as medians and interquartile range. The Kruskal-Wallis test was used to determine if there was a statistically 
significant difference between visits and the nptrend statistic in Stata 11 was used to determine if there was a statistically significant trend in the results from baseline to 12 months. P 
values ≤0.05 were considered statistically significant. 
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Figure 32 The effect of the initial number of monocytes on TRAP
+ 
cells generated from 
four rheumatoid arthritis patient cultures 
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated PBMC’s in 500µl αMEM complete 
medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was 
replenished every 2-3 days. The absolute number of TRAP
+
 cells generated each visit was plotted against the 
initial number of monocytes for A: All samples and B: Baseline and following CD20 depletion. The line of best 
fit/ trendline and equation were generated using Microsoft Excel 2010. Spearman’s rank correlation coefficient 
Rs was used to correlate these parameters. 
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Figure 33 TRAP
+
 cells generated from five rheumatoid arthritis patient cultures before 
and 3, 6, 12 months post rituximab  
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated PBMC’s in 500µl αMEM complete 
medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was 
replenished every 2-3 days. The absolute number of TRAP
+
 cells generated each visit was corrected for the 
number of monocytes in the initial cell suspension. The dotted line represents the median values.
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Figure 34 The effect of the initial number of B cells on TRAP
+
 cells generated from four 
rheumatoid arthritis patient cultures 
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated PBMC’s in 500µl αMEM complete 
medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was 
replenished every 2-3 days. The absolute number of TRAP
+
 cells generated each visit was corrected for the 
number of monocytes in the initial cell suspension and plotted against the initial number of B cells for  A: All 
samples and B: Baseline and following CD20 depletion. The line of best fit/trendline and equation were 
generated using Microsoft Excel 2010. Spearman’s rank correlation coefficient Rs was used to correlate these 
parameters. 
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Figure 35 The effect of the initial numbers of T cells on TRAP
+
 cells generated from four 
rheumatoid arthritis patient cultures 
TRAP
+
 osteoclast-like cells were generated from 500,000 unfractionated PBMC’s in 500µl αMEM complete 
medium with no added cytokines, after 14 days culture in 5% CO2 at 37
◦
C, the upper 250µl medium was 
replenished every 2-3 days. The absolute number of TRAP
+
 cells generated each visit was corrected for the 
number of monocytes in the initial cell suspension and plotted against the initial number of T cells for  A: All 
samples and B: Baseline and following CD20 depletion. The line of best fit/trendline and equation were 
generated using Microsoft Excel 2010. Spearman’s rank correlation coefficient was used to correlate these 
parameters. 
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5.4.3 Multiple regression analysis to explore factors affecting osteoclastogenesis 
There were not enough samples to carry out multiple regression analysis on the healthy 
volunteer and RA patient samples separately so the data were combined to explore predictors 
of osteoclastogenesis in two multiple regression models (Stepwise analysis for each model 
included in Appendix C). 
 
Model 1: the model investigated the effect of the following variables; initial numbers of 
monocytes, B cells, T cells, age and gender, on the outcome i.e. TRAP
+
 cells generated from 
unfractionated PBMCs from healthy volunteers and baseline RA patient samples. 
  
In this model it was found that in unfractionated cells, B cells were borderline significant 
predictors of osteoclastogenesis (p=0.045) but this effect was predominantly dependent on the 
subject i.e. healthy volunteer or RA patient (p<0.001). 
 
Model 2: the model investigated the effect of the following variables; initial numbers of 
monocytes, B cells, T cells, age and gender, on the outcome i.e. TRAP
+
 cells generated from 
in vitro CD20 depleted PBMCs in healthy volunteers and RA patient samples 12 months after 
RTX.  
 
In this model it was found that when cells are CD20 depleted, monocytes significantly 
increase osteoclastogenesis (p=0.002) and to a lesser extent T cells suppress 
osteoclastogenesis (p=0.016). 
 
In summary these results indicate that in CD20 depleted cells, monocytes increase and T cells 
suppress osteoclastogenesis. However, at baseline i.e. in the presence of CD20 cells these 
effects are not significant and it is the disease state itself that has the most significant effect on 
osteoclastogenesis. 
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5.4.4 Discussion 
The aim of this section was to investigate B cell depletion with RTX, ex vivo, on 
osteoclastogenesis in PBMC’s isolated from the blood of patients with refractory RA. There 
was a significant decrease in B cells in the PBMC fraction following RTX therapy, this was 
verified by the CD19 results in peripheral blood and confirmed B cell depletion as expected in 
these patients consistent with the results of other clinical trials using RTX (Nakou et al. 2009, 
Teng et al. 2007). There was, however, no significant difference in the number of T cells or 
monocytes in the PBMC fraction from baseline to 12 months, although as the B cells 
decreased there was an apparent increase in the percentage of monocytes in the fraction 
counted by FACS. Since CD14
+
 monocytes are known to be osteoclast precursor cells (Costa-
Rodrigues et al. 2011, Vandooren et al. 2009), with the appropriate stimulus an increase in the 
resulting number of TRAP
+
 cells might have been expected. Yet, there was a significant 
decrease in both the absolute numbers of TRAP
+ 
cells and TRAP
+
 cells adjusted to account 
for any differences in initial monocyte number, from baseline to 12 months in these patients. 
Additionally, there was a significant positive correlation between the initial number of B cells 
and the number of TRAP
+
 cells generated corrected for the number of monocytes. As the 
number of B cells decreased the number of TRAP
+
 cells generated also decreased. 
Conversely, there was a borderline significant negative correlation between the initial number 
of T cells and the number of TRAP
+
 cells generated corrected for the number of monocytes. 
As the number of T cells decreased the number of TRAP
+
 cells generated increased.  
The differentiation and activation of osteoclasts requires the binding of RANKL to its 
receptor RANK on osteoclast precursors (Lacey et al. 1998). Activated B cells, involved in 
the development of inflammatory arthritis, are known to express RANKL as well as other 
cytokines that are involved in bone resorption (Horowitz et al. 2010, Yeo 2011), switched 
memory B cells (CD27
+
IgD
-
) having the highest propensity (Meednu et al. 2015). These 
results suggest that depletion of RANKL-expressing B cells may contribute to the inhibition 
of bone erosion by RTX. However, there are several limitations to this work; the extent to 
which in vitro osteoclastogenesis reflects the in vivo situation in the inflamed joint remains in 
question and as this was a small patient sample, these results would have to be replicated in a 
much larger group. Although, several studies have reported that the B cell-targeted therapy, 
RTX, inhibits the progression of structural joint damage in RA (Keystone 2009, Boumans 
2012).  
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5.5 Conclusion 
The initial aim of this Chapter was to create a robust and reproducible protocol for osteoclast 
formation and characterisation from peripheral blood in vitro, without the addition of 
endogenous substances. Subsequently to use this culture system to investigate the potential 
role of B cells on osteoclastogenesis; using healthy volunteer blood depleted of B cells in 
vitro, plus blood from RA patients following in vivo B cell depletion.  
Predictably, there was a significant difference in the initial number of B cells; between 
unfractionated and CD20 depleted PBMC fractions in the healthy volunteers, also between 
baseline and following RTX therapy in the RA patients; but no significant difference between 
the initial number of T cells or monocytes in either group. Interestingly, significantly greater 
numbers of TRAP
+
 cells were generated from in vitro CD20 depleted compared to 
unfractionated PBMCs in healthy volunteer blood, however this was not significant after 
adjustment for initial monocyte number. Moreover, as the initial number of monocytes 
increased more TRAP
+
 cells were generated and as the initial number of T cells decreased 
TRAP
+
 cells adjusted for the initial number of monocytes increased, specifically in the CD20 
depleted fraction. Whereas, in RA patients following ex vivo CD20 depletion with RTX, there 
were significantly reduced numbers of TRAP
+ 
cells generated and this number remained 
significant even after adjustment for the initial number of monocytes, when compared to 
baseline. Furthermore, as the initial number of monocytes decreased more TRAP
+
 cells were 
generated and as the initial number of T cells decreased TRAP
+
 cells adjusted for the initial 
number of monocytes increased. Although the trendline for all samples and CD20 depleted 
samples were comparable there were too few samples to correlate the fractions separately. 
Additionally, in vitro osteoclastogenesis was significantly higher in the baseline RA samples 
compared to unfractionated PBMC’s from healthy controls. These results were consistent 
with the IODA study; in vitro osteoclastogenesis varied among healthy individuals and the 
authors hypothesized that increased osteoclastogenesis was a potential marker for the 
presence of RA, also osteoclasts from RA patients showed lower apoptotic rates and there was 
no difference in bone resorptive activity between RA patients and controls. (Durand et al. 
2011). In summary the multiple linear regression results indicate that in CD20 depleted cells, 
monocytes increase and T cells suppress osteoclastogenesis. However, at baseline i.e. in the 
presence of CD20 cells these effects are not significant and it is the disease state itself that has 
the most significant effect on osteoclastogenesis.
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Chapter 6. Discussion 
 
6.1 Discussion 
The aim of this project was to address the role of human B cells in bone turnover. Given the 
impact of B-cells in the pathogenesis of RA and apparent importance in regulating bone cell 
activity it was postulated that prolonged B cell depletion in patients with RA may have a 
beneficial effect on the bone loss that would otherwise be expected in active disease. It was 
proposed to initially explore the effects of in vivo B cell depletion on serum BTMs before and 
after RTX treatment in a cohort of patients with severe RA. Subsequently to confirm and 
extend these findings in a second cohort of RA patients; to additionally measure the change in 
bone density and to explore factors that may influence the outcome such as change in disease 
activity and vitamin D status. Finally to evaluate and create a robust, reproducible protocol for 
osteoclast formation and characterisation from peripheral blood in vitro, representative of in 
vivo conditions without the addition of endogenous substances and to use this culture system 
to investigate the potential role of B cells on osteoclastogenesis; using healthy volunteer 
blood depleted of B cells in vitro, plus blood from RA patients following B cell depletion ex 
vivo. 
Preliminary results from the pilot study indicated that there was a significant suppression in 
bone resorption accompanied to a lesser degree by an increase in bone formation in RA 
patients six months after B cell depletion. The fact that there was a significant correlation 
between the change from baseline in βCTX and DAS28 in this cohort indicated that the anti-
resorptive action and anti-inflammatory therapeutic response were related. This was expected 
as decreased bone resorption is likely to be due to a combination of diminished osteoclast 
activity, which results from decreased B-cell mediated osteoclastogenesis, decreased systemic 
inflammatory cytokines and increased physical activity following RTX treatment. However, 
this significant reduction in bone resorption was not replicated in a second group of RA 
patients treated with RTX over twelve months. Although there was a significant increase in 
bone formation, BMD fell at the femur sites but was maintained at the lumbar spine and 
forearm. Nevertheless, there was still a significant reduction in inflammatory markers and 
disease activity following B cell depletion with RTX, indicating that the drug was effective in 
reducing the inflammation of RA in this patient cohort. There were several differences 
between the two cohorts to explain these results. Patients in the pilot study had lower bone 
resorption at baseline and 37% of these patients were taking bisphosphonates which are 
known to induce osteoclast apoptosis (Lems 2007); none of the patients in the prospective 
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study were treated for osteoporosis with bisphosphonates, calcitonin, strontium ranelate, 
denosumab or teriparatide prior to/ or during the study. However, there was a higher 
percentage of post-menopausal women in the prospective cohort; 79% compared to 58% and 
the loss of BMD at the femur sites was more pronounced in these women. Oestrogen decline 
post-menopause induces accelerated bone loss (Garnero et al. 2000) and although oestrogen 
withdrawal is associated with a significant expansion in the mature B cell population, the role 
of these cells as mediators of the bone loss remains unclear.  
Ageing is also a risk factor; the development of an inflammatory environment during ageing 
can also lead to increased bone resorption and loss of BMD (Li at al. 2014). Furthermore, a 
higher percentage of the post-menopausal women were current smokers (39% compared to 
18% in the pilot study).
 
Smoking may adversely influence the severity of RA (Saag et al. 
1997) and RA patients who smoke have a higher need for DMARDs and are reportedly more 
likely to show a poor response to biologics treatment such as TNF inhibitors (Mattey et al. 
2009). Tobacco also increases bone resorption and affects bone mass by alterations in sex 
hormone metabolism, but also importantly by alterations on the vitamin D-PTH axis 
(Supervia et al. 2006). The prospective study results were confounded by a high prevalence of 
vitamin D deficiency and these patients had a significant decrease in femur BMD and 
evidence of higher bone turnover i.e. an increase in serum TRAP5b compared to decreased 
levels over 12 months in patients with ‘normal’ 25OHD. Vitamin D influences bone quality 
and is important for maintaining bone density, research indicates that higher vitamin D levels 
may prevent the occurrence of osteoporosis at the femoral neck, but not at the lumbar spine 
L2–4 (Yoshimura et al. 2015). Although post-menopausal women had the lowest median 
25OHD concentration in this cohort, there was no significant difference in median levels 
between males, pre- or post-menopausal women, so vitamin D deficiency may not explain 
why the post-menopausal women lost BMD more than pre-menopausal women or men. 
Additionally, as there were no control groups it was difficult to establish whether depletion of 
B cells had in fact slowed down the expected bone loss in the prospective cohort. The 
relatively short duration of follow-up and small number of participants limited the power of 
the study and the reduction in inflammation and disease activity could increase mobility and 
possibly reduce the need of drugs such as glucocorticoid which may then improve bone 
health. 
Results of the in vitro osteoclastogenesis indicated that significantly greater numbers of 
TRAP
+
 cells were generated from in vitro CD20 depleted when compared to unfractionated 
PBMCs in healthy volunteer blood. Moreover, as the initial number of monocytes increased 
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more TRAP
+
 cells were generated and as the initial number of T cells decreased TRAP
+
 cells 
adjusted for the initial number of monocytes increased, specifically after B cell depletion. In 
contrast, there were significantly reduced numbers of TRAP
+ 
cells generated in PBMCs from 
RA patients following ex vivo CD20 depletion with RTX compared to baseline. Furthermore, 
as the initial number of monocytes decreased more TRAP
+
 cells were generated and as the 
initial number of T cells decreased TRAP
+
 cells adjusted for the initial number of monocytes 
increased. Additionally, in vitro osteoclastogenesis was significantly higher in the baseline 
RA samples compared to unfractionated PBMC’s from healthy controls. In summary multiple 
regression analysis indicated that in CD20 depleted cells, monocytes increase and T cells 
suppress osteoclastogenesis. However, at baseline i.e. in the presence of CD20 cells these 
effects are not significant and it is the disease state itself that has the most significant effect on 
osteoclastogenesis. These results were consistent with the IODA study; the authors 
hypothesized that increased osteoclastogenesis was a potential marker for the presence of RA 
(Durand et al. 2011). CD14
+
 monocytes are known to be osteoclast precursor cells (Costa-
Rodrigues et al. 2011, Vandooren et al. 2009) and so with the appropriate stimulus the 
increased generation of TRAP
+
 cells with higher numbers of monocytes was predictable in 
healthy volunteers. B cells are an important source of OPG (Li et al. 2007), thus by depleting 
CD20 B cells in vitro, OPG may also be supressed and the RANKL/OPG ratio increased in 
favour of RANKL activated osteoclastogenesis, generating more TRAP
+
 osteoclast-like cells. 
This is consistent with the fact that B-cell KO mice were observed to be osteoporotic and 
deficient in OPG, suggesting that the production of OPG by B cells outweighs the production 
of RANKL under basal conditions (Li et al. 2007). RANKL is required for osteoclastogenesis 
and plays a key role in mediating bone erosion. It is now known that B cells also contribute to 
RANKL production in the inflamed rheumatoid joint (Yeo et al. 2011) and in particular 
switched memory B cells have the greatest propensity to produce RANKL (Meednu et al. 
2015). Meednu et al. also hypothesise that the role of B cells in bone erosion is developmental 
and stage-dependent; they confirmed that stimulated B cells promote in vitro 
osteoclastogenesis from monocytes in a RANKL dependent manner (Meednu et al. 2015). 
Recently a subset of B cells, expressing FcRL4, has been identified in the rheumatoid 
synovium that are capable of producing RANKL and TNF-α and these pathogenic B cells are 
reportedly not found in healthy individuals (Yeo et al. 2015). FcRL4
+
 B cells also express 
high levels of CD20 and are therefore significantly reduced with RTX (Yeo et al. 2015).  
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6.2 Conclusion 
Preliminary results indicated that there was a significant suppression in bone resorption 
accompanied to a lesser degree by an increase in bone formation in RA patients six months 
after RTX, possibly due to a direct effect on osteoclasts and osteoblasts, respectively, or at 
least partially explained by the decreased inflammation and disease activity. However, the 
significant reduction in bone resorption was not replicated in a second cohort of RA patients 
treated with RTX over twelve months. Nevertheless there was a significant reduction in 
inflammatory markers and disease activity following B cell depletion, indicating that the drug 
was effective in reducing the inflammation of RA. Additionally, despite a significant increase 
in bone formation, BMD fell at the femur sites in postmenopausal women, but was 
maintained at the lumbar spine and forearm. Men and premenopausal women did not lose 
BMD and also had lower bone resorption indicating they had lower bone cell activity. But the 
results were confounded by a high prevalence of vitamin D deficiency and these patients had 
significant falls in femur BMD and evidence of higher bone turnover. Furthermore, as there 
were no control groups it was difficult to establish whether depletion of B cells had in fact 
slowed down the expected bone loss in these patients. Results of in vitro osteoclastogenesis 
indicated that in healthy subjects B cell depletion tended to increase osteoclast formation, 
suggesting that the production of OPG by B cells outweighed the production of RANKL 
under basal conditions. In contrast, in pro-inflammatory states, where B cells are activated 
e.g. RA, B cells produce cytokines like RANKL that stimulate osteoclastogenesis resulting in 
an increased production of osteoclasts. In summary when B cells are depleted, monocytes 
increase and T cells suppress osteoclastogenesis. However, in the presence of B cells these 
effects are not significant and it is the disease state itself that has the most significant effect on 
osteoclastogenesis. 
 
6.3 Future perspective 
On reflection there are many things that could have been improved; although BMD was 
measured and the pre-analytical blood collection was standardised in the prospective cohort 
any improvement in bone turnover was hard to establish. This study was designed as a single 
treatment arm trial with no control group, whereas, the optimal design would have been a 
double-blind randomized comparison with placebo. However, as RTX is an approved 
treatment for refractory RA and is already known to reduce disease activity, such a control 
arm would have had to be matched for disease activity and it would have been unethical to 
have an untreated arm with that level of active disease. A possible follow-on study could 
Chapter 6                                                                                                                     Discussion 
                                                                                                                                                                                    
157 
 
include RA patients naive to biologic treatment; to compare the change in bone density and 
bone turnover between B cell depletion and TNF-α inhibition, over 24 months in post-
menopausal women with optimal vitamin D status. Additionally, the in vitro osteoclastic 
potential of this new cohort of patients should be investigated and FACS performed to 
identify subsets of pathogenic B cells specific to inflammatory bone erosion.
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Appendix A. Generic Materials 
 
General reagents 
 Glacial Acetic acid (99.8-100.5%); product code 27225 (2.5L), Acetone (≥99.5%); 
product code SIGM650501 (1L), Ethyl Alcohol -pure (≥99.5%); product code 459844 
(2.5L), Ethylene Diamine Tetraacetic Acid - disodium salt solution (EDTA); product 
code E7889 (100ml; 0.5M in H2O), Fetal Calf Serum (FCS); product code F7524 
(100ml), Hank's Balanced Salt Solution (HBSS); product code H9394 (500ml), 
Methyl Alcohol -pure (≥99.8%); product code 32213(2.5L), Penicillin/ Streptomycin 
(pen/strep); product code P0781 (100ml; with 10,000units penicillin and 10mg 
streptomycin per ml in 0.9% saline), were purchased from LabShop
®
 (Hartlepool, 
Cleveland, TS25 2DL, UK), a UK distributor for Sigma-Aldrich Company Ltd. 
(Gillingham, SP8 4XT, UK). 
 Sterile Phosphate Buffered Saline (PBS); product code 10010-015 (500ml) and Triton 
X-100; product code HFH-10 (10ml; 1% solution) were purchased from Invitrogen 
Life Technologies (Paisley PA4 9RF, UK).  
 Di-Sodium tetraborate; product code 102674E (500g), was purchased from VWR 
International - UK Ltd (Lutterworth, Leicestershire, LE17 4XN, UK).  
 Sodium Hypochlorite solution; product code 129905 (0.82mol/L), was purchased from 
Siemens Healthcare Diagnostics (Camberley, Surrey, GU16 8QD, UK). 
 Formaldehyde 16% (methanol-free solution); product code 28908 (10ml), was 
purchased from Fischer Scientific UK Ltd. (Loughborough, Leicestershire, LE11 
5RG, UK).  
General consumables 
 Coverslips for counting chamber; product code HAE2130, coverslips for microscope 
slides (22×26mm, 22×32mm, 22×50mm); product codes MIC3200, MIC3202, 
MIC3206, Eppendorf tubes (1.5ml); product code E0030108051, Eppendorf  sterile 
pipette tips (0.1-20µl, 2-200µl, 50-1000µl); product codes EPPE0030075005, 
EPPE0030075021, EPPE0030075064, Eppendorf pipette tips (0.1-20µl, 2-200µl, 50-
1000µl); product codes E0030000838, E0030000870, E0030000919, microscope 
slides (76×26mm); product code MIC2152, multichannel pipette reservoirs; product 
code PIP5704,  Pasteur pipettes (0.5, 1.0, 3.0ml); product codes PIP4216, PIP4236, 
PIP4210, sterile 15ml and 50ml BD falcon tubes; product codes 352096, 352098,  
sterile 75×12mm polypropylene tubes (5ml); product code TIS5402, sterile 
  
 
serological pipettes (5, 10 and 25ml); product codes SLS4010, SLS4020, SLS4030 
and Whatman No.54 filter paper; product code FIL2272, were purchased from 
LabShop
®
 (Hartlepool, Cleveland, TS25 2DL, UK). 
General equipment 
 Advia 2400; automated clinical chemistry analyser (Siemens Healthcare Diagnostics, 
Camberley, Surrey, GU16 8QD, UK). 
 Elecsys 2010 analyser and updated version E411; automated electrochemiluminescent 
immunoassay (ECLIA) systems (Roche Diagnostics Ltd. Burgess Hill, West Sussex, 
RH15 9RY, UK).  
 iSYS analyser; a fully-automated system based on chemiluminescence and absorbency 
technology (IDS Ltd, Boldon, Tyne and Wear, NE35 9PD, UK). 
 Eppendorf Mixmate; a microplate mixer; product code E535300030, supplied by 
Scientific Laboratory Supplies Ltd. (Hessle, East Riding of Yorkshire, HU13 0AE, 
UK). 
 Microplate reader LT-4000 with Manta software for data analysis and management 
and Strip Washer LT-3000 (Labtech International Ltd. Uckfield, East Sussex, TN22 
1QQ, UK).   
 FACSCalibur™ Flow Cytometer- 4 Colour: (BD BioSciences, Oxford, OX4 4DQ 
UK). 
 MiniMACS and MidiMACS separators (Miltenyi Biotec, Bisley, Surrey GU24 9DR, 
UK). 
 Olympus CKX41 inverted microscope with a fixed Infinity2 camera and Lumenera 
Infinity image software, supplied by J.B Microscopes Ltd. (Rothbury, 
Northumberland, NE65 7YG, UK). 
 Sanyo CO2 incubator at 5% CO2 and 37
◦
C; product code MCO-18AIC (Panasonic 
Biomedical Sales Europe BV, Loughborough, Leicestershire, LE11 1QJ, UK). 
 Esco Airstream class 2 biological safety cabinet AC2-4E1, Forceps; product code 
INS4356, Grant water bath; product code BAT3060, Improved neubauer 
haemocytometer; product code HAE2118, Rota-filler 5000 pipette filler; product code 
PIP7595, Tally Counter; product code COU2000 and Techne NOICE; product code 
FNOICE, were supplied by Scientific Laboratory Supplies Ltd. (Hessle, East Riding 
of Yorkshire, HU13 0AE, UK). 
 Eppendorf 8 channel pipette (10-100µl); product code E114000131. (30-300µl); 
product code E3114000158. (0.5-10µl); product code E3111000122. Eppendorf 
  
 
pipette (10-100µl); product code E3111000149 and (100-1000µl); product code 
E3111000165, were supplied by Scientific Laboratory Supplies Ltd. (Hessle, East 
Riding of Yorkshire, HU13 0AE, UK). All annually calibrated by Pipette Doctor 
(Sartorius Ltd, Epsom, Surry, KT19 9QQ, UK). 
 Biocold upright lab refrigerator; product code BIO280FRS, lab freezer -20ºC; product 
code BIO245FZS, Brunswick Scientific freezer -80ºC; product code FRE6010, filter 
funnel (100mm diameter); product code FUN1060, glass beakers (50 and 100ml); 
product codes BEA1004 and BEA1006, measuring cylinders (100ml, 500ml); product 
codes CYL2006, CYL2010, Select vortex mixer; product code SLS5100, Sigma 
refrigerated centrifuge (2-16PK); product code 10160 and timer; product code 
TIM0280, were supplied by Scientific Laboratory Supplies Ltd. (Hessle, East Riding 
of Yorkshire, HU13 0AE, UK). 
 ELGA deionised water system and Purelab UHQ (Veolia, High Wycombe, 
Buckinghamshire, HP11 1JU, UK). 
  
 
 
  
  
 
Appendix B. Tests for normality of data 
Pilot Study 
βCTX 
- All 
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ctxperchange       45    0.69897     13.036     5.442    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxperchange
ctxperchange       45      0.0000         0.0000        35.33         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxperchange
   ctxchange       45    0.95446      1.972     1.439    0.07504
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxchange
   ctxchange       45      0.0566         0.6348         4.05         0.1322
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxchange
       ctx6m       45    0.90476      4.124     3.003    0.00134
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx6m
       ctx6m       45      0.0021         0.0571        10.69         0.0048
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx6m
       boctx       46    0.87306      5.592     3.653    0.00013
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx
       boctx       46      0.0003         0.0069        15.82         0.0004
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx
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  bctxchange       16    0.75909      4.881     3.149    0.00082
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctxchange if bisphos ==1
  bctxchange       16      0.0017         0.0153        11.92         0.0026
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctxchange if bisphos ==1
     bctx60m       16    0.95974      0.816    -0.404    0.65707
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx60m if bisphos ==1
     bctx60m       16      0.2523         0.5257         1.95         0.3777
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx60m if bisphos ==1
      bctx6m       16    0.82085      3.630     2.561    0.00522
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx6m if bisphos ==1
      bctx6m       16      0.0572         0.8417         3.98         0.1364
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx6m if bisphos ==1
      bctx0m       17    0.87116      2.722     1.997    0.02292
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx0m if bisphos ==1
      bctx0m       17      0.2284         0.2196         3.42         0.1806
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx0m if bisphos ==1
. 
  bctxchange       29    0.89000      3.409     2.531    0.00569
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctxchange if bisphos ==0
  bctxchange       29      0.0023         0.0150        11.93         0.0026
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctxchange if bisphos ==0
     bctx60m       29    0.92571      2.302     1.721    0.04264
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx60m if bisphos ==0
     bctx60m       29      0.0500         0.7492         4.14         0.1261
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx60m if bisphos ==0
      bctx6m       29    0.85619      4.457     3.084    0.00102
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx6m if bisphos ==0
      bctx6m       29      0.0013         0.0236        12.12         0.0023
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx6m if bisphos ==0
      bctx0m       29    0.88114      3.684     2.691    0.00357
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx0m if bisphos ==0
      bctx0m       29      0.0048         0.0474         9.75         0.0076
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx0m if bisphos ==0
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  p1npchange       16    0.90982      1.827     1.197    0.11560
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1npchange if bisphos ==1
  p1npchange       16      0.0427         0.2251         5.38         0.0680
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1npchange if bisphos ==1
     p1np60m       16    0.87485      2.536     1.848    0.03229
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np60m if bisphos ==1
     p1np60m       16      0.1492         0.5353         2.85         0.2406
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np60m if bisphos ==1
      p1np6m       16    0.86834      2.668     1.949    0.02565
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np6m if bisphos ==1
      p1np6m       16      0.2955         0.1247         3.83         0.1473
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np6m if bisphos ==1
      p1np0m       17    0.90626      1.980     1.362    0.08653
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np0m if bisphos ==1
      p1np0m       17      0.3318         0.1683         3.28         0.1938
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np0m if bisphos ==1
. 
  p1npchange       29    0.72795      8.432     4.399    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1npchange if bisphos ==0
  p1npchange       29      0.0000         0.0001        25.74         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1npchange if bisphos ==0
     p1np60m       29    0.91002      2.789     2.116    0.01717
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np60m if bisphos ==0
     p1np60m       29      0.0129         0.0260         9.25         0.0098
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np60m if bisphos ==0
      p1np6m       29    0.80544      6.030     3.707    0.00010
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np6m if bisphos ==0
      p1np6m       29      0.0003         0.0042        16.00         0.0003
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np6m if bisphos ==0
      p1np0m       29    0.96228      1.169     0.323    0.37352
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk p1np0m if bisphos ==0
      p1np0m       29      0.3785         0.2855         2.09         0.3525
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest p1np0m if bisphos ==0
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osteocperc~e       45    0.63713     15.714     5.838    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteocperchange
osteocperc~e       45      0.0000         0.0000        41.83         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteocperchange
osteocchange       45    0.94227      2.500     1.942    0.02609
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteocchange
osteocchange       45      0.0597         0.1704         5.26         0.0722
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteocchange
    osteoc6m       45    0.92736      3.145     2.429    0.00758
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc6m
    osteoc6m       45      0.0030         0.0163        11.74         0.0028
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc6m
    boosteoc       46    0.89328      4.701     3.285    0.00051
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boosteoc
    boosteoc       46      0.0014         0.0641        11.11         0.0039
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boosteoc
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osteocchange       16    0.87617      2.509     1.827    0.03384
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteocchange if bisphos ==1
osteocchange       16      0.1171         0.7400         2.97         0.2264
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteocchange if bisphos ==1
   osteoc60m       16    0.79200      4.214     2.857    0.00214
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc60m if bisphos ==1
   osteoc60m       16      0.0091         0.1481         7.60         0.0224
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc60m if bisphos ==1
    osteoc6m       16    0.84608      3.119     2.259    0.01194
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc6m if bisphos ==1
    osteoc6m       16      0.0247         0.2821         5.80         0.0549
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc6m if bisphos ==1
    osteoc0m       17    0.93632      1.345     0.592    0.27707
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc0m if bisphos ==1
    osteoc0m       17      0.6362         0.2743         1.59         0.4518
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc0m if bisphos ==1
. 
osteocchange       29    0.45372     16.931     5.838    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteocchange if bisphos ==0
osteocchange       29      0.0000         0.0000        41.17         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteocchange if bisphos ==0
   osteoc60m       29    0.96297      1.148     0.284    0.38807
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc60m if bisphos ==0
   osteoc60m       29      0.2845         0.4404         1.89         0.3888
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc60m if bisphos ==0
    osteoc6m       29    0.84289      4.869     3.266    0.00055
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc6m if bisphos ==0
    osteoc6m       29      0.0003         0.0018        17.05         0.0002
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc6m if bisphos ==0
    osteoc0m       29    0.91034      2.779     2.109    0.01748
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk osteoc0m if bisphos ==0
    osteoc0m       29      0.0164         0.1860         6.75         0.0342
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest osteoc0m if bisphos ==0
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opgperchange       45    0.95375      2.003     1.472    0.07050
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opgperchange
opgperchange       45      0.0493         0.6822         4.18         0.1234
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opgperchange
   opgchange       45    0.97237      1.197     0.380    0.35183
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opgchange
   opgchange       45      0.7335         0.1660         2.15         0.3405
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opgchange
       opg6m       45    0.89003      4.762     3.308    0.00047
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg6m
       opg6m       45      0.0001         0.0004        20.33         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg6m
       boopg       46    0.93138      3.023     2.347    0.00945
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boopg
       boopg       46      0.0041         0.0724         9.61         0.0082
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boopg
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   opgchange       16    0.88231      2.385     1.726    0.04217
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opgchange if bisphos ==1
   opgchange       16      0.0139         0.0339         8.67         0.0131
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opgchange if bisphos ==1
      opg60m       16    0.96434      0.723    -0.646    0.74071
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg60m if bisphos ==1
      opg60m       16      0.4887         0.2502         2.05         0.3583
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg60m if bisphos ==1
       opg6m       16    0.80690      3.913     2.710    0.00337
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg6m if bisphos ==1
       opg6m       16      0.0013         0.0039        13.64         0.0011
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg6m if bisphos ==1
       opg0m       17    0.85224      3.122     2.270    0.01160
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg0m if bisphos ==1
       opg0m       17      0.0066         0.0459         9.21         0.0100
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg0m if bisphos ==1
. 
   opgchange       29    0.92333      2.376     1.786    0.03707
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opgchange if bisphos ==0
   opgchange       29      0.1900         0.1915         3.73         0.1547
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opgchange if bisphos ==0
      opg60m       29    0.98789      0.375    -2.023    0.97844
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg60m if bisphos ==0
      opg60m       29      0.7617         0.0849         3.37         0.1856
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg60m if bisphos ==0
       opg6m       29    0.97981      0.626    -0.967    0.83326
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg6m if bisphos ==0
       opg6m       29      0.6945         0.2952         1.34         0.5110
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg6m if bisphos ==0
       opg0m       29    0.96126      1.201     0.377    0.35304
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk opg0m if bisphos ==0
       opg0m       29      0.2688         0.8450         1.36         0.5078
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest opg0m if bisphos ==0
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crpperchange       40    0.78260      8.593     4.527    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpperchange
crpperchange       40      0.0001         0.0091        16.75         0.0002
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpperchange
   crpchange       40    0.93852      2.430     1.869    0.03084
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpchange
   crpchange       40      0.0234         0.1816         6.36         0.0416
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpchange
       crp6m       43    0.86768      5.531     3.615    0.00015
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp6m
       crp6m       43      0.0302         0.2586         5.67         0.0588
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp6m
       bocrp       43    0.84063      6.661     4.008    0.00003
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp
       bocrp       43      0.0066         0.9128         6.70         0.0351
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp
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   crpchange       15    0.69088      5.994     3.542    0.00020
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpchange if bisphos ==1
   crpchange       15      0.0004         0.0021        15.64         0.0004
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpchange if bisphos ==1
      crp60m       15    0.95440      0.884    -0.243    0.59614
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp60m if bisphos ==1
      crp60m       15      0.3808         0.9369         0.84         0.6574
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp60m if bisphos ==1
       crp6m       16    0.88298      2.371     1.715    0.04320
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp6m if bisphos ==1
       crp6m       16      0.3634         0.0779         4.19         0.1229
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp6m if bisphos ==1
       crp0m       16    0.84350      3.171     2.292    0.01095
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp0m if bisphos ==1
       crp0m       16      0.2513         0.1368         3.89         0.1430
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp0m if bisphos ==1
. 
   crpchange       25    0.82241      4.935     3.263    0.00055
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpchange if bisphos ==0
   crpchange       25      0.0037         0.0946         9.27         0.0097
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpchange if bisphos ==0
      crp60m       25    0.93414      1.830     1.235    0.10833
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp60m if bisphos ==0
      crp60m       25      0.3406         0.7085         1.13         0.5689
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp60m if bisphos ==0
       crp6m       27    0.86372      4.006     2.851    0.00218
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp6m if bisphos ==0
       crp6m       27      0.0457         0.6576         4.34         0.1144
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp6m if bisphos ==0
       crp0m       27    0.83313      4.906     3.267    0.00054
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp0m if bisphos ==0
       crp0m       27      0.0123         0.4583         6.26         0.0438
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp0m if bisphos ==0
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esrperchange       44    0.77525      9.564     4.779    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrperchange
esrperchange       44      0.0000         0.0000        29.66         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrperchange
    esrchage       44    0.92996      2.980     2.311    0.01041
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrchage
    esrchage       44      0.0084         0.1712         7.74         0.0209
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrchage
       esr6m       45    0.86568      5.816     3.731    0.00010
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr6m
       esr6m       45      0.0040         0.5597         7.60         0.0223
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr6m
       boesr       45    0.91057      3.872     2.869    0.00206
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr
       boesr       45      0.0451         0.4120         4.69         0.0957
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr
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   esrchange       16    0.83302      3.383     2.421    0.00774
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrchange if bisphos ==1
   esrchange       16      0.0030         0.0120        11.50         0.0032
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrchange if bisphos ==1
      esr60m       16    0.95721      0.867    -0.284    0.61161
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr60m if bisphos ==1
      esr60m       16      0.1703         0.3146         3.37         0.1859
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr60m if bisphos ==1
       esr6m       16    0.87463      2.540     1.852    0.03204
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr6m if bisphos ==1
       esr6m       16      0.0993         0.8536         3.20         0.2024
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr6m if bisphos ==1
       esr0m       17    0.85703      3.020     2.204    0.01375
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr0m if bisphos ==1
       esr0m       17      0.0903         0.7336         3.46         0.1776
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr0m if bisphos ==1
. 
   esrchange       28    0.78250      6.568     3.875    0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrchange if bisphos ==0
   esrchange       28      0.0000         0.0003        21.29         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrchange if bisphos ==0
      esr60m       28    0.89180      3.267     2.438    0.00739
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr60m if bisphos ==0
      esr60m       28      0.0102         0.1421         7.62         0.0221
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr60m if bisphos ==0
       esr6m       29    0.84629      4.764     3.221    0.00064
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr6m if bisphos ==0
       esr6m       29      0.0123         0.5735         6.10         0.0473
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr6m if bisphos ==0
       esr0m       28    0.91907      2.444     1.840    0.03289
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr0m if bisphos ==0
       esr0m       28      0.1175         0.6323         2.95         0.2291
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr0m if bisphos ==0
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das28perch~e       44    0.92752      3.084     2.384    0.00857
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28perchange
das28perch~e       44      0.0330         0.0098         9.42         0.0090
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28perchange
 das28change       44    0.96265      1.589     0.980    0.16344
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28change
 das28change       44      0.0684         0.0430         6.73         0.0346
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28change
     das286m       45    0.98416      0.686    -0.799    0.78794
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das286m
     das286m       45      0.8802         0.8921         0.04         0.9797
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das286m
     bodas28       45    0.95539      1.932     1.395    0.08145
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28
     bodas28       45      0.0935         0.7054         3.15         0.2072
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28
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 das28change       15    0.95637      0.846    -0.331    0.62956
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28change if bisphos ==1
 das28change       15      0.2350         0.1303         4.02         0.1337
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28change if bisphos ==1
    das2860m       15    0.96240      0.729    -0.625    0.73408
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2860m if bisphos ==1
    das2860m       15      0.2609         0.2995         2.72         0.2570
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2860m if bisphos ==1
     das286m       16    0.92040      1.613     0.949    0.17123
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das286m if bisphos ==1
     das286m       16      0.3547         0.3666         1.90         0.3872
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das286m if bisphos ==1
     das280m       16    0.93522      1.312     0.540    0.29456
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das280m if bisphos ==1
     das280m       16      0.1937         0.6868         2.11         0.3476
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das280m if bisphos ==1
. 
 das28change       29    0.89989      3.103     2.336    0.00974
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28change if bisphos ==0
 das28change       29      0.0172         0.0025        11.71         0.0029
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28change if bisphos ==0
    das2860m       29    0.96932      0.951    -0.104    0.54133
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2860m if bisphos ==0
    das2860m       29      0.8177         0.1338         2.52         0.2842
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2860m if bisphos ==0
     das286m       29    0.96582      1.059     0.119    0.45267
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das286m if bisphos ==0
     das286m       29      0.3249         0.5759         1.38         0.5020
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das286m if bisphos ==0
     das280m       29    0.95890      1.274     0.499    0.30873
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das280m if bisphos ==0
     das280m       29      0.1595         0.4926         2.68         0.2615
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das280m if bisphos ==0
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  changlsbmd       36    0.82720      6.301     3.849    0.00006
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changlsbmd
  changlsbmd       36      0.0001         0.0001        21.30         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changlsbmd
    lsbmd12m       36    0.93321      2.435     1.861    0.03135
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m
    lsbmd12m       36      0.0269         0.2036         6.05         0.0484
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m
     bolsbmd       36    0.94493      2.008     1.458    0.07244
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd
     bolsbmd       36      0.0158         0.0802         7.75         0.0207
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd
     lsbmdpr       36    0.90344      3.521     2.632    0.00424
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  lsbmdpr
     lsbmdpr       36      0.0108         0.0027        12.23         0.0022
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest  lsbmdpr
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     lsbmdpr        6    0.82021      2.227     1.349    0.08863
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdpr if menopausal ==0
     lsbmdpr        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdpr if menopausal ==0
 changelsbmd        6    0.80502      2.415     1.513    0.06518
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changelsbmd if menopausal ==0
 changelsbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changelsbmd if menopausal ==0
    lsbmd12m        6    0.84061      1.974     1.117    0.13190
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m if menopausal ==0
    lsbmd12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m if menopausal ==0
     bolsbmd        6    0.84945      1.864     1.012    0.15580
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd if menopausal ==0
     bolsbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd if menopausal ==0
  
 
 
     lsbmdpr       23    0.96745      0.851    -0.327    0.62826
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdpr if menopausal ==1
     lsbmdpr       23      0.6643         0.2108         1.94         0.3795
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdpr if menopausal ==1
 changelsbmd       23    0.93795      1.623     0.985    0.16239
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changelsbmd if menopausal ==1
 changelsbmd       23      0.5905         0.4477         0.93         0.6287
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changelsbmd if menopausal ==1
    lsbmd12m       23    0.90820      2.401     1.781    0.03743
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m if menopausal ==1
    lsbmd12m       23      0.0237         0.0423         7.92         0.0191
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m if menopausal ==1
     bolsbmd       23    0.89874      2.649     1.981    0.02381
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd if menopausal ==1
     bolsbmd       23      0.0080         0.0175        10.19         0.0061
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd if menopausal ==1
  
 
 
  
     lsbmdpr        7    0.87377      1.658     0.841    0.20019
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdpr if menopausal ==2
     lsbmdpr        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdpr if menopausal ==2
 changelsbmd        7    0.79159      2.737     1.828    0.03379
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changelsbmd if menopausal ==2
 changelsbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changelsbmd if menopausal ==2
    lsbmd12m        7    0.94816      0.681    -0.562    0.71293
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m if menopausal ==2
    lsbmd12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m if menopausal ==2
     bolsbmd        7    0.97833      0.285    -1.655    0.95105
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd if menopausal ==2
     bolsbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd if menopausal ==2
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     lsbmdpr       22    0.96373      0.919    -0.171    0.56805
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdpr if vitdcat ==2
     lsbmdpr       22      0.3035         0.6847         1.34         0.5125
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdpr if vitdcat ==2
 lsbmdchange       22    0.92537      1.891     1.292    0.09826
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdchange if vitdcat ==2
 lsbmdchange       22      0.1419         0.8173         2.47         0.2909
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdchange if vitdcat ==2
    lsbmd12m       22    0.92819      1.819     1.213    0.11250
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m if vitdcat ==2
    lsbmd12m       22      0.0476         0.1696         5.54         0.0626
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m if vitdcat ==2
     bolsbmd       22    0.94076      1.501     0.823    0.20518
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd if vitdcat ==2
     bolsbmd       22      0.0432         0.1268         5.97         0.0505
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd if vitdcat ==2
. 
     lsbmdpr       14    0.90423      1.772     1.127    0.12990
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdpr if vitdcat ==1
     lsbmdpr       14      0.1095         0.0877         5.30         0.0707
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdpr if vitdcat ==1
 lsbmdchange       14    0.81682      3.390     2.403    0.00812
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmdchange if vitdcat ==1
 lsbmdchange       14      0.0042         0.0073        11.55         0.0031
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmdchange if vitdcat ==1
    lsbmd12m       14    0.87166      2.375     1.703    0.04428
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsbmd12m if vitdcat ==1
    lsbmd12m       14      0.0127         0.0240         9.07         0.0107
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsbmd12m if vitdcat ==1
     bolsbmd       14    0.94973      0.930    -0.142    0.55651
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsbmd if vitdcat ==1
     bolsbmd       14      0.1510         0.1908         4.09         0.1296
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsbmd if vitdcat ==1
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  lstschange       35    0.84083      5.681     3.626    0.00014
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lstschange
  lstschange       35      0.8283         0.0004        10.37         0.0056
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lstschange
     lsts12m       35    0.90871      3.258     2.466    0.00684
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsts12m
     lsts12m       35      0.0071         0.0927         8.58         0.0137
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsts12m
      bolsts       36    0.91575      3.072     2.347    0.00947
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsts
      bolsts       36      0.0038         0.0316        10.59         0.0050
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsts
  
 
- By gender and menopausal status 
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  lstschange        6    0.85856      1.752     0.899    0.18428
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lstschange if menopause ==0
  lstschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lstschange if menopause ==0
     lsts12m        6    0.90565      1.168     0.232    0.40843
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsts12m if menopause ==0
     lsts12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsts12m if menopause ==0
      bolsts        6    0.90216      1.212     0.288    0.38685
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsts if menopause ==0
      bolsts        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsts if menopause ==0
  lstschange       22    0.79978      5.072     3.293    0.00050
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lstschange if menopause ==1
  lstschange       22      0.0003         0.0008        17.60         0.0002
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lstschange if menopause ==1
     lsts12m       22    0.87536      3.158     2.331    0.00986
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsts12m if menopause ==1
     lsts12m       22      0.0040         0.0128        11.35         0.0034
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsts12m if menopause ==1
      bolsts       23    0.87087      3.377     2.475    0.00666
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsts if menopause ==1
      bolsts       23      0.0021         0.0081        12.60         0.0018
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsts if menopause ==1
  
 
 
 
  
  lstschange        7    0.79493      2.693     1.793    0.03649
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lstschange if menopause ==2
  lstschange        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lstschange if menopause ==2
     lsts12m        7    0.89113      1.430     0.581    0.28062
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lsts12m if menopause ==2
     lsts12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lsts12m if menopause ==2
      bolsts        7    0.97439      0.336    -1.462    0.92814
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolsts if menopause ==2
      bolsts        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolsts if menopause ==2
  
 
LS z score 
- All 
 
 
 
0
.1
.2
.3
D
e
n
s
it
y
-2 0 2 4 6 8
bolszs
0
.0
5
.1
.1
5
.2
.2
5
D
e
n
s
it
y
-2 0 2 4 6 8
lszs12m
0
.2
.4
.6
.8
1
D
e
n
s
it
y
-1 0 1 2
lszschange
  
 
 
  
  lszschange       34    0.84887      5.277     3.466    0.00026
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszschange
  lszschange       34      0.0003         0.0004        19.05         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszschange
     lszs12m       34    0.93688      2.204     1.647    0.04979
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszs12m
     lszs12m       34      0.0194         0.1519         6.77         0.0338
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszs12m
      bolszs       35    0.92779      2.577     1.976    0.02406
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolszs
      bolszs       35      0.0074         0.0564         9.09         0.0106
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolszs
  
 
- By gender and menopausal status 
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  lszschange        6    0.83840      2.001     1.143    0.12644
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszschange if menopause ==0
  lszschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszschange if menopause ==0
     lszs12m        6    0.93853      0.761    -0.378    0.64740
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszs12m if menopause ==0
     lszs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszs12m if menopause ==0
      bolszs        6    0.93437      0.813    -0.290    0.61422
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolszs if menopause ==0
      bolszs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolszs if menopause ==0
  lszschange       22    0.94819      1.313     0.551    0.29067
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszschange if menopause ==1
  lszschange       22      0.8667         0.8242         0.08         0.9620
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszschange if menopause ==1
     lszs12m       22    0.90668      2.364     1.745    0.04052
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszs12m if menopause ==1
     lszs12m       22      0.0111         0.0380         8.92         0.0116
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszs12m if menopause ==1
      bolszs       23    0.88208      3.084     2.290    0.01100
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolszs if menopause ==1
      bolszs       23      0.0038         0.0188        11.00         0.0041
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolszs if menopause ==1
  
 
  
  lszschange        6    0.77091      2.837     1.857    0.03167
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszschange if menopause ==2
  lszschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszschange if menopause ==2
     lszs12m        6    0.88426      1.433     0.556    0.28918
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk lszs12m if menopause ==2
     lszs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest lszs12m if menopause ==2
      bolszs        6    0.90615      1.162     0.223    0.41157
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bolszs if menopause ==2
      bolszs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bolszs if menopause ==2
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  changmnbmd       35    0.87251      4.551     3.163    0.00078
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changmnbmd
  changmnbmd       35      0.0008         0.0102        13.78         0.0010
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changmnbmd
    mnbmd12m       35    0.93644      2.269     1.710    0.04362
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m
    mnbmd12m       35      0.1270         0.4143         3.24         0.1974
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m
     bomnbmd       35    0.95849      1.482     0.821    0.20591
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd
     bomnbmd       35      0.1505         0.4884         2.75         0.2526
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd
     mnbmdpr       35    0.87864      4.331     3.060    0.00111
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  mnbmdpr
     mnbmdpr       35      0.0011         0.0145        13.02         0.0015
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest  mnbmdpr
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      mnbmdpr        6    0.93594      0.793    -0.323    0.62670
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdpr if menopausal ==0
     mnbmdpr        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdpr if menopausal ==0
 changemnbmd        6    0.92131      0.974    -0.037    0.51487
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemnbmd if menopausal ==0
 changemnbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemnbmd if menopausal ==0
    mnbmd12m        6    0.95474      0.560    -0.767    0.77846
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m if menopausal ==0
    mnbmd12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m if menopausal ==0
     bomnbmd        6    0.96973      0.375    -1.230    0.89061
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd if menopausal ==0
     bomnbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd if menopausal ==0
  
 
      mnbmdpr       22    0.80990      4.816     3.187    0.00072
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdpr if menopausal ==1
     mnbmdpr       22      0.0012         0.0114        12.86         0.0016
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdpr if menopausal ==1
 changemnbmd       22    0.80009      5.064     3.289    0.00050
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemnbmd if menopausal ==1
 changemnbmd       22      0.0008         0.0069        13.85         0.0010
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemnbmd if menopausal ==1
    mnbmd12m       22    0.89335      2.702     2.015    0.02194
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m if menopausal ==1
    mnbmd12m       22      0.0944         0.9955         3.15         0.2071
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m if menopausal ==1
     bomnbmd       22    0.94821      1.312     0.551    0.29089
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd if menopausal ==1
     bomnbmd       22      0.1685         0.9455         2.11         0.3476
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd if menopausal ==1
  
 
 
  
     mnbmdpr        7    0.95184      0.633    -0.663    0.74644
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdpr if menopausal ==2
     mnbmdpr        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdpr if menopausal ==2
 changemnbmd        7    0.92151      1.031     0.047    0.48123
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemnbmd if menopausal ==2
 changemnbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemnbmd if menopausal ==2
    mnbmd12m        7    0.95638      0.573    -0.797    0.78717
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m if menopausal ==2
    mnbmd12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m if menopausal ==2
     bomnbmd        7    0.94015      0.786    -0.359    0.64004
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd if menopausal ==2
     bomnbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd if menopausal ==2
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     mnbmdpr       21    0.95971      0.987    -0.026    0.51021
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdpr if vitdcat ==2
     mnbmdpr       21      0.9521         0.1128         2.84         0.2420
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdpr if vitdcat ==2
 mnbmdchange       21    0.94678      1.304     0.537    0.29570
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdchange if vitdcat ==2
 mnbmdchange       21      0.7448         0.0775         3.62         0.1640
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdchange if vitdcat ==2
    mnbmd12m       21    0.98209      0.439    -1.665    0.95200
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m if vitdcat ==2
    mnbmd12m       21      0.8358         0.4440         0.66         0.7172
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m if vitdcat ==2
     bomnbmd       21    0.98336      0.408    -1.814    0.96513
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd if vitdcat ==2
     bomnbmd       21      0.8663         0.6660         0.21         0.8982
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd if vitdcat ==2
. 
     mnbmdpr       14    0.93741      1.158     0.289    0.38618
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdpr if vitdcat ==1
     mnbmdpr       14      0.1633         0.6811         2.46         0.2930
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdpr if vitdcat ==1
 mnbmdchange       14    0.93559      1.192     0.346    0.36469
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmdchange if vitdcat ==1
 mnbmdchange       14      0.1409         0.6155         2.83         0.2425
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmdchange if vitdcat ==1
    mnbmd12m       14    0.80644      3.582     2.512    0.00600
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnbmd12m if vitdcat ==1
    mnbmd12m       14      0.0984         0.5762         3.53         0.1708
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnbmd12m if vitdcat ==1
     bomnbmd       14    0.91531      1.567     0.885    0.18818
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnbmd if vitdcat ==1
     bomnbmd       14      0.2060         0.9371         1.84         0.3990
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnbmd if vitdcat ==1
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  mntschange       34    0.93899      2.130     1.576    0.05752
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mntschange
  mntschange       34      0.0269         0.1125         6.70         0.0350
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mntschange
     mnts12m       34    0.98189      0.632    -0.955    0.83034
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnts12m
     mnts12m       34      0.6027         0.7935         0.34         0.8439
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnts12m
      bomnts       35    0.98409      0.568    -1.181    0.88121
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnts
      bomnts       35      0.7847         0.5250         0.49         0.7816
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnts
  
 
- By gender and menopausal status 
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  mntschange        6    0.92809      0.891    -0.165    0.56544
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mntschange if menopause ==0
  mntschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mntschange if menopause ==0
     mnts12m        6    0.97743      0.280    -1.539    0.93810
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnts12m if menopause ==0
     mnts12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnts12m if menopause ==0
      bomnts        6    0.85998      1.734     0.881    0.18908
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnts if menopause ==0
      bomnts        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnts if menopause ==0
  mntschange       21    0.90991      2.208     1.601    0.05470
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mntschange if menopause ==1
  mntschange       21      0.0467         0.1382         5.79         0.0554
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mntschange if menopause ==1
     mnts12m       21    0.94917      1.246     0.444    0.32852
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnts12m if menopause ==1
     mnts12m       21      0.2413         0.7533         1.63         0.4436
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnts12m if menopause ==1
      bomnts       22    0.98409      0.403    -1.843    0.96731
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnts if menopause ==1
      bomnts       22      0.4688         0.5103         1.03         0.5961
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnts if menopause ==1
  
 
 
 
  
  mntschange        7    0.94657      0.702    -0.520    0.69843
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mntschange if menopause ==2
  mntschange        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mntschange if menopause ==2
     mnts12m        7    0.86786      1.736     0.924    0.17779
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnts12m if menopause ==2
     mnts12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnts12m if menopause ==2
      bomnts        7    0.89300      1.405     0.551    0.29070
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnts if menopause ==2
      bomnts        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnts if menopause ==2
  
 
MN z score 
- All 
 
 
 
 
0
.2
.4
.6
D
e
n
s
it
y
-2 -1 0 1 2
bomnzs
0
.1
.2
.3
.4
.5
D
e
n
s
it
y
-2 -1 0 1 2
mnzs12m
0
.5
1
1
.5
2
D
e
n
s
it
y
-1.5 -1 -.5 0 .5
mnzschange
  
 
 
  
  mnzschange       33    0.92175      2.671     2.044    0.02049
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzschange
  mnzschange       33      0.0135         0.0291         9.10         0.0106
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzschange
     mnzs12m       33    0.97598      0.820    -0.412    0.65994
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzs12m
     mnzs12m       33      0.5488         0.2514         1.80         0.4064
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzs12m
      bomnzs       34    0.98142      0.649    -0.902    0.81640
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnzs
      bomnzs       34      0.5425         0.4045         1.13         0.5685
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnzs
  
 
- By gender and menopausal status 
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  mnzschange        6    0.98901      0.136    -2.215    0.98661
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzschange if menopause ==0
  mnzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzschange if menopause ==0
     mnzs12m        6    0.90259      1.206     0.281    0.38945
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzs12m if menopause ==0
     mnzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzs12m if menopause ==0
      bomnzs        6    0.85865      1.751     0.898    0.18459
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnzs if menopause ==0
      bomnzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnzs if menopause ==0
  mnzschange       21    0.86060      3.416     2.483    0.00651
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzschange if menopause ==1
  mnzschange       21      0.0201         0.0406         8.14         0.0171
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzschange if menopause ==1
     mnzs12m       21    0.92374      1.869     1.264    0.10310
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzs12m if menopause ==1
     mnzs12m       21      0.1122         0.8973         2.86         0.2390
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzs12m if menopause ==1
      bomnzs       22    0.92913      1.795     1.187    0.11770
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnzs if menopause ==1
      bomnzs       22      0.0837         0.5772         3.67         0.1596
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnzs if menopause ==1
  
 
  
  mnzschange        6    0.91741      1.023     0.033    0.48689
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzschange if menopause ==2
  mnzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzschange if menopause ==2
     mnzs12m        6    0.86736      1.643     0.786    0.21590
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mnzs12m if menopause ==2
     mnzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mnzs12m if menopause ==2
      bomnzs        6    0.96019      0.493    -0.920    0.82123
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomnzs if menopause ==2
      bomnzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomnzs if menopause ==2
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  changmtbmd       35    0.96779      1.150     0.291    0.38553
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changmtbmd
  changmtbmd       35      0.1478         0.2759         3.56         0.1685
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changmtbmd
    mtbmd12m       35    0.96245      1.340     0.611    0.27048
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m
    mtbmd12m       35      0.9476         0.5136         0.44         0.8018
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m
     bomtbmd       35    0.97506      0.890    -0.243    0.59601
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd
     bomtbmd       35      0.6838         0.7554         0.26         0.8768
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd
     mtbmdpr       35    0.97811      0.781    -0.515    0.69670
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  mtbmdpr
     mtbmdpr       35      0.4731         0.5129         0.99         0.6083
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest  mtbmdpr
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     mtbmdpr        6    0.96969      0.375    -1.228    0.89034
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdpr if menopausal ==0
     mtbmdpr        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdpr if menopausal ==0
 changemtbmd        6    0.95839      0.515    -0.868    0.80728
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemtbmd if menopausal ==0
 changemtbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemtbmd if menopausal ==0
    mtbmd12m        6    0.79451      2.545     1.622    0.05242
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m if menopausal ==0
    mtbmd12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m if menopausal ==0
     bomtbmd        6    0.86239      1.704     0.851    0.19751
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd if menopausal ==0
     bomtbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd if menopausal ==0
  
 
 
     mtbmdpr       22    0.96754      0.822    -0.396    0.65411
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdpr if menopausal ==1
     mtbmdpr       22      0.4040         0.9903         0.74         0.6908
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdpr if menopausal ==1
 changemtbmd       22    0.93905      1.544     0.881    0.18916
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemtbmd if menopausal ==1
 changemtbmd       22      0.1105         0.5845         3.20         0.2014
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemtbmd if menopausal ==1
    mtbmd12m       22    0.94908      1.290     0.516    0.30281
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m if menopausal ==1
    mtbmd12m       22      0.3127         0.5691         1.47         0.4787
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m if menopausal ==1
     bomtbmd       22    0.94649      1.356     0.617    0.26865
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd if menopausal ==1
     bomtbmd       22      0.2922         0.5021         1.72         0.4230
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd if menopausal ==1
  
 
 
  
     mtbmdpr        7    0.92010      1.049     0.075    0.47017
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdpr if menopausal ==2
     mtbmdpr        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdpr if menopausal ==2
 changemtbmd        7    0.92780      0.948    -0.081    0.53237
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemtbmd if menopausal ==2
 changemtbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemtbmd if menopausal ==2
    mtbmd12m        7    0.96313      0.484    -1.016    0.84510
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m if menopausal ==2
    mtbmd12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m if menopausal ==2
     bomtbmd        7    0.94712      0.695    -0.534    0.70340
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd if menopausal ==2
     bomtbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd if menopausal ==2
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     mtbmdpr       21    0.96881      0.764    -0.544    0.70662
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdpr if vitdcat ==2
     mtbmdpr       21      0.9112         0.2604         1.40         0.4956
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdpr if vitdcat ==2
 mtbmdchange       21    0.95344      1.141     0.266    0.39496
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdchange if vitdcat ==2
 mtbmdchange       21      0.4204         0.1985         2.59         0.2743
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdchange if vitdcat ==2
    mtbmd12m       21    0.95286      1.155     0.292    0.38525
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m if vitdcat ==2
    mtbmd12m       21      0.3666         0.4949         1.41         0.4950
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m if vitdcat ==2
     bomtbmd       21    0.95173      1.183     0.339    0.36717
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd if vitdcat ==2
     bomtbmd       21      0.5697         0.5455         0.73         0.6935
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd if vitdcat ==2
. 
     mtbmdpr       14    0.95895      0.760    -0.541    0.70577
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdpr if vitdcat ==1
     mtbmdpr       14      0.3193         0.5064         1.63         0.4430
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdpr if vitdcat ==1
 mtbmdchange       14    0.97525      0.458    -1.537    0.93788
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmdchange if vitdcat ==1
 mtbmdchange       14      0.7995         0.5381         0.46         0.7956
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmdchange if vitdcat ==1
    mtbmd12m       14    0.89887      1.872     1.234    0.10862
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtbmd12m if vitdcat ==1
    mtbmd12m       14      0.3134         0.2947         2.46         0.2925
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtbmd12m if vitdcat ==1
     bomtbmd       14    0.94460      1.025     0.049    0.48037
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtbmd if vitdcat ==1
     bomtbmd       14      0.4216         0.4225         1.45         0.4832
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtbmd if vitdcat ==1
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  mttschange       34    0.95125      1.702     1.108    0.13388
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mttschange
  mttschange       34      0.0978         0.1575         4.74         0.0935
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mttschange
     mtts12m       34    0.97758      0.783    -0.510    0.69506
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtts12m
     mtts12m       34      0.5100         0.8056         0.51         0.7748
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtts12m
      bomtts       35    0.98495      0.537    -1.297    0.90272
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtts
      bomtts       35      0.8512         0.6675         0.22         0.8960
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtts
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  mttschange        6    0.87155      1.591     0.731    0.23246
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mttschange if menopause ==0
  mttschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mttschange if menopause ==0
     mtts12m        6    0.85444      1.803     0.951    0.17089
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtts12m if menopause ==0
     mtts12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtts12m if menopause ==0
      bomtts        6    0.87653      1.529     0.664    0.25350
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtts if menopause ==0
      bomtts        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtts if menopause ==0
  mttschange       21    0.92068      1.944     1.344    0.08953
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mttschange if menopause ==1
  mttschange       21      0.0683         0.3201         4.45         0.1081
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mttschange if menopause ==1
     mtts12m       21    0.96425      0.876    -0.268    0.60553
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtts12m if menopause ==1
     mtts12m       21      0.7106         0.3405         1.14         0.5662
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtts12m if menopause ==1
      bomtts       22    0.95619      1.110     0.211    0.41631
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtts if menopause ==1
      bomtts       22      0.5981         0.4241         0.99         0.6102
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtts if menopause ==1
  
 
  
  mttschange        7    0.93201      0.893    -0.172    0.56816
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mttschange if menopause ==2
  mttschange        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mttschange if menopause ==2
     mtts12m        7    0.90787      1.210     0.302    0.38133
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtts12m if menopause ==2
     mtts12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtts12m if menopause ==2
      bomtts        7    0.88986      1.447     0.601    0.27395
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtts if menopause ==2
      bomtts        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtts if menopause ==2
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  mtzschange       33    0.96891      1.061     0.124    0.45069
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzschange
  mtzschange       33      0.7615         0.3921         0.87         0.6479
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzschange
     mtzs12m       33    0.95471      1.546     0.906    0.18234
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzs12m
     mtzs12m       33      0.0446         0.1213         5.99         0.0499
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzs12m
      bomtzs       34    0.98359      0.573    -1.161    0.87709
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtzs
      bomtzs       34      0.3425         0.5238         1.39         0.4981
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtzs
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  mtzschange        6    0.93341      0.825    -0.271    0.60671
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzschange if menopause ==0
  mtzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzschange if menopause ==0
     mtzs12m        6    0.71258      3.560     2.393    0.00837
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzs12m if menopause ==0
     mtzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzs12m if menopause ==0
      bomtzs        6    0.71138      3.574     2.403    0.00813
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtzs if menopause ==0
      bomtzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtzs if menopause ==0
  mtzschange       21    0.95893      1.006     0.013    0.49488
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzschange if menopause ==1
  mtzschange       21      0.4400         0.8023         0.70         0.7051
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzschange if menopause ==1
     mtzs12m       21    0.98589      0.346    -2.146    0.98408
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzs12m if menopause ==1
     mtzs12m       21      0.9817         0.9189         0.01         0.9946
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzs12m if menopause ==1
      bomtzs       22    0.97248      0.697    -0.732    0.76779
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtzs if menopause ==1
      bomtzs       22      0.3033         0.9484         1.15         0.5614
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtzs if menopause ==1
  
 
 
  
  mtzschange        6    0.78160      2.705     1.752    0.03989
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzschange if menopause ==2
  mtzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzschange if menopause ==2
     mtzs12m        6    0.93999      0.743    -0.410    0.65912
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mtzs12m if menopause ==2
     mtzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mtzs12m if menopause ==2
      bomtzs        6    0.95665      0.537    -0.819    0.79357
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomtzs if menopause ==2
      bomtzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomtzs if menopause ==2
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changmrudbmd       32    0.83496      5.505     3.541    0.00020
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changmrudbmd
changmrudbmd       32      0.0001         0.0003        19.98         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changmrudbmd
  mrudbmd12m       33    0.87973      4.106     2.938    0.00165
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m
  mrudbmd12m       33      0.0091         0.3311         6.94         0.0312
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m
   bomrudbmd       33    0.89630      3.540     2.629    0.00428
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd
   bomrudbmd       33      0.0044         0.0721         9.42         0.0090
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd
   mrudbmdpr       32    0.85884      4.709     3.217    0.00065
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  mrudbmdpr
   mrudbmdpr       32      0.0003         0.0005        18.57         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest  mrudbmdpr
  
 
- By gender and menopausal status 
 
 
 
 
0
2
4
6
8
0
2
4
6
8
.2 .4 .6 .8
.2 .4 .6 .8
male post
preD
e
n
s
it
y
bomrudbmd
Graphs by menopause
0
5
1
0
1
5
0
5
1
0
1
5
.2 .4 .6 .8
.2 .4 .6 .8
male post
preD
e
n
s
it
y
mrudbmd12m
Graphs by menopause
0
1
0
2
0
3
0
0
1
0
2
0
3
0
-.05 0 .05 .1 .15
-.05 0 .05 .1 .15
male post
preD
e
n
s
it
y
changemrudbmd
Graphs by menopause
0
.0
5
.1
0
.0
5
.1
-20 0 20 40
-20 0 20 40
male post
preD
e
n
s
it
y
mrudbmdpr
Graphs by menopause
  
 
 
   mrudbmdpr        6    0.96303      0.458    -1.006    0.84278
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdpr if menopausal ==0
   mrudbmdpr        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdpr if menopausal ==0
changemrud~d        6    0.94421      0.691    -0.505    0.69325
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemrudbmd if menopausal ==0
changemrud~d        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemrudbmd if menopausal ==0
  mrudbmd12m        6    0.85162      1.838     0.985    0.16222
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m if menopausal ==0
  mrudbmd12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m if menopausal ==0
   bomrudbmd        6    0.92470      0.933    -0.100    0.53982
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd if menopausal ==0
   bomrudbmd        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd if menopausal ==0
  
 
 
   mrudbmdpr       19    0.94945      1.154     0.288    0.38678
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdpr if menopausal ==1
   mrudbmdpr       19      0.4313         0.6112         0.95         0.6218
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdpr if menopausal ==1
changemrud~d       19    0.94880      1.169     0.313    0.37701
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemrudbmd if menopausal ==1
changemrud~d       19      0.6089         0.2345         1.88         0.3916
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemrudbmd if menopausal ==1
  mrudbmd12m       20    0.79622      4.823     3.171    0.00076
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m if menopausal ==1
  mrudbmd12m       20      0.0005         0.0027        15.31         0.0005
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m if menopausal ==1
   bomrudbmd       20    0.81036      4.489     3.026    0.00124
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd if menopausal ==1
   bomrudbmd       20      0.0007         0.0034        14.76         0.0006
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd if menopausal ==1
  
 
 
  
   mrudbmdpr        7    0.89319      1.403     0.548    0.29173
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdpr if menopausal ==2
   mrudbmdpr        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdpr if menopausal ==2
changemrud~d        7    0.89147      1.425     0.576    0.28242
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk changemrudbmd if menopausal ==2
changemrud~d        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest changemrudbmd if menopausal ==2
  mrudbmd12m        7    0.89259      1.411     0.558    0.28846
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m if menopausal ==2
  mrudbmd12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m if menopausal ==2
   bomrudbmd        7    0.97548      0.322    -1.513    0.93486
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd if menopausal ==2
   bomrudbmd        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd if menopausal ==2
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   mrudbmdpr       18    0.80876      4.204     2.874    0.00203
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdpr if vitdcat ==2
   mrudbmdpr       18      0.0009         0.0032        14.41         0.0007
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdpr if vitdcat ==2
mrudbmdcha~e       18    0.80818      4.217     2.880    0.00199
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdchange if vitdcat ==2
mrudbmdcha~e       18      0.0008         0.0025        14.76         0.0006
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdchange if vitdcat ==2
  mrudbmd12m       19    0.89877      2.311     1.683    0.04623
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m if vitdcat ==2
  mrudbmd12m       19      0.1134         0.9235         2.86         0.2391
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m if vitdcat ==2
   bomrudbmd       19    0.89326      2.437     1.789    0.03680
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd if vitdcat ==2
   bomrudbmd       19      0.0362         0.3358         5.19         0.0747
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd if vitdcat ==2
. 
   mrudbmdpr       14    0.97013      0.553    -1.167    0.87844
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdpr if vitdcat ==1
   mrudbmdpr       14      0.3587         0.2855         2.30         0.3169
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdpr if vitdcat ==1
mrudbmdcha~e       14    0.95379      0.855    -0.308    0.62086
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmdchange if vitdcat ==1
mrudbmdcha~e       14      0.5499         0.1361         3.03         0.2199
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmdchange if vitdcat ==1
  mrudbmd12m       14    0.87238      2.362     1.692    0.04532
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudbmd12m if vitdcat ==1
  mrudbmd12m       14      0.0233         0.0628         7.37         0.0251
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudbmd12m if vitdcat ==1
   bomrudbmd       14    0.94984      0.928    -0.146    0.55818
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudbmd if vitdcat ==1
   bomrudbmd       14      0.2347         0.5800         1.97         0.3726
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudbmd if vitdcat ==1
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mrudtschange       31    0.78485      7.008     4.034    0.00003
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudtschange
mrudtschange       31      0.0000         0.0000        25.18         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudtschange
   mrudts12m       32    0.87765      4.081     2.920    0.00175
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudts12m
   mrudts12m       32      0.0009         0.0071        14.01         0.0009
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudts12m
    bomrudts       33    0.84953      5.137     3.404    0.00033
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudts
    bomrudts       33      0.0001         0.0011        18.49         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudts
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mrudtschange        6    0.91543      1.047     0.068    0.47305
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudtschange if menopause ==0
mrudtschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudtschange if menopause ==0
   mrudts12m        6    0.95373      0.573    -0.740    0.77038
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudts12m if menopause ==0
   mrudts12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudts12m if menopause ==0
    bomrudts        6    0.94914      0.630    -0.623    0.73328
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudts if menopause ==0
    bomrudts        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudts if menopause ==0
mrudtschange       18    0.96372      0.797    -0.453    0.67471
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudtschange if menopause ==1
mrudtschange       18      0.9741         0.9537         0.00         0.9978
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudtschange if menopause ==1
   mrudts12m       19    0.67920      7.324     3.999    0.00003
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudts12m if menopause ==1
   mrudts12m       19      0.0000         0.0001        22.54         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudts12m if menopause ==1
    bomrudts       20    0.70650      6.947     3.906    0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudts if menopause ==1
    bomrudts       20      0.0000         0.0002        21.70         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudts if menopause ==1
  
 
 
  
mrudtschange        7    0.84065      2.093     1.277    0.10076
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudtschange if menopause ==2
mrudtschange        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudtschange if menopause ==2
   mrudts12m        7    0.83095      2.220     1.394    0.08169
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudts12m if menopause ==2
   mrudts12m        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudts12m if menopause ==2
    bomrudts        7    0.92513      0.983    -0.026    0.51028
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudts if menopause ==2
    bomrudts        7          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudts if menopause ==2
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mrudzschange       30    0.78967      6.685     3.929    0.00004
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzschange
mrudzschange       30      0.0000         0.0001        24.46         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzschange
   mrudzs12m       31    0.83916      5.239     3.431    0.00030
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzs12m
   mrudzs12m       31      0.0001         0.0007        19.00         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzs12m
    bomrudzs       32    0.77488      7.509     4.186    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudzs
    bomrudzs       32      0.0000         0.0001        25.61         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudzs
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mrudzschange        6    0.91855      1.009     0.013    0.49497
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzschange if menopause ==0
mrudzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzschange if menopause ==0
   mrudzs12m        6    0.94637      0.664    -0.556    0.71078
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzs12m if menopause ==0
   mrudzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzs12m if menopause ==0
    bomrudzs        6    0.93912      0.754    -0.391    0.65209
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudzs if menopause ==0
    bomrudzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudzs if menopause ==0
mrudzschange       18    0.95209      1.053     0.104    0.45874
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzschange if menopause ==1
mrudzschange       18      0.8406         0.8461         0.08         0.9617
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzschange if menopause ==1
   mrudzs12m       19    0.59993      9.133     4.443    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzs12m if menopause ==1
   mrudzs12m       19      0.0000         0.0000        25.55         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzs12m if menopause ==1
    bomrudzs       20    0.61890      9.021     4.433    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudzs if menopause ==1
    bomrudzs       20      0.0000         0.0000        25.67         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudzs if menopause ==1
  
 
  
mrudzschange        6    0.89409      1.312     0.412    0.34018
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzschange if menopause ==2
mrudzschange        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzschange if menopause ==2
   mrudzs12m        6    0.86660      1.652     0.796    0.21299
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk mrudzs12m if menopause ==2
   mrudzs12m        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest mrudzs12m if menopause ==2
    bomrudzs        6    0.89160      1.342     0.449    0.32666
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bomrudzs if menopause ==2
    bomrudzs        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bomrudzs if menopause ==2
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ctxmeancha~e       30    0.83240      5.327     3.459    0.00027
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxmeanchange
ctxmeancha~e       30      0.0055         0.3040         7.63         0.0221
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxmeanchange
    ctxpr12m       30    0.82071      5.699     3.598    0.00016
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxpr12m
    ctxpr12m       30      0.0066         0.4575         7.05         0.0295
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxpr12m
     ctxc12m       30    0.97998      0.636    -0.935    0.82515
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxc12m
     ctxc12m       30      0.5805         0.7713         0.40         0.8192
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxc12m
      ctx12m       34    0.91746      2.882     2.206    0.01370
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx12m
      ctx12m       34      0.0075         0.0797         8.67         0.0131
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx12m
       boctx       36    0.89407      3.863     2.826    0.00236
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx
       boctx       36      0.0026         0.0082        12.61         0.0018
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx
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 ctxmeancha~e       10    0.83212      2.587     1.806    0.03549
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxmeanchange if menopausal ==0
ctxmeancha~e       10      0.0551         0.3796         4.56         0.1024
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxmeanchange if menopausal ==0
    ctxpr12m       10    0.82243      2.737     1.925    0.02711
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxpr12m if menopausal ==0
    ctxpr12m       10      0.1115         0.9874         3.07         0.2155
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxpr12m if menopausal ==0
     ctxc12m       10    0.96847      0.486    -1.157    0.87633
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxc12m if menopausal ==0
     ctxc12m       10      0.9618         0.6590         0.20         0.9062
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxc12m if menopausal ==0
      ctx12m       12    0.95598      0.735    -0.599    0.72534
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx12m if menopausal ==0
      ctx12m       12      0.2647         0.4590         2.09         0.3517
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx12m if menopausal ==0
       boctx       13    0.94699      0.934    -0.135    0.55352
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx if menopausal ==0
       boctx       13      0.5816         0.3276         1.43         0.4898
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx if menopausal ==0
  
 
 
  
ctxmeancha~e       20    0.84265      3.725     2.650    0.00402
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxmeanchange if menopausal ==1
ctxmeancha~e       20      0.0121         0.2193         6.92         0.0314
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxmeanchange if menopausal ==1
    ctxpr12m       20    0.80583      4.596     3.074    0.00106
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxpr12m if menopausal ==1
    ctxpr12m       20      0.0116         0.2988         6.68         0.0354
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxpr12m if menopausal ==1
     ctxc12m       20    0.96645      0.794    -0.465    0.67896
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxc12m if menopausal ==1
     ctxc12m       20      0.6559         0.8972         0.22         0.8980
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxc12m if menopausal ==1
      ctx12m       22    0.93224      1.717     1.096    0.13663
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx12m if menopausal ==1
      ctx12m       22      0.0423         0.1727         5.66         0.0589
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx12m if menopausal ==1
       boctx       23    0.80825      5.016     3.279    0.00052
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx if menopausal ==1
       boctx       23      0.0011         0.0077        13.40         0.0012
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx if menopausal ==1
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    ctxpr12m       12    0.87360      2.112     1.457    0.07261
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxpr12m if vitdcat ==1
    ctxpr12m       12      0.7165         0.0354         4.65         0.0978
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxpr12m if vitdcat ==1
     ctxc12m       12    0.91550      1.412     0.672    0.25082
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxc12m if vitdcat ==1
     ctxc12m       12      0.9070         0.0708         3.73         0.1548
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxc12m if vitdcat ==1
      ctx12m       14    0.92876      1.318     0.544    0.29314
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx12m if vitdcat ==1
      ctx12m       14      0.6794         0.1487         2.63         0.2681
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx12m if vitdcat ==1
       boctx       14    0.95211      0.886    -0.237    0.59384
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx if vitdcat ==1
       boctx       14      0.9697         0.7319         0.12         0.9423
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx if vitdcat ==1
  
 
  
    ctxpr12m       18    0.86049      3.067     2.243    0.01245
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxpr12m if vitdcat ==2
    ctxpr12m       18      0.0046         0.0111        11.20         0.0037
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxpr12m if vitdcat ==2
     ctxc12m       18    0.96981      0.664    -0.821    0.79412
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxc12m if vitdcat ==2
     ctxc12m       18      0.4166         0.6884         0.89         0.6417
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxc12m if vitdcat ==2
      ctx12m       20    0.85394      3.457     2.500    0.00621
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctx12m if vitdcat ==2
      ctx12m       20      0.0035         0.0204        10.92         0.0043
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctx12m if vitdcat ==2
       boctx       22    0.85939      3.562     2.576    0.00500
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boctx if vitdcat ==2
       boctx       22      0.0107         0.0333         9.10         0.0105
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boctx if vitdcat ==2
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trapmeanch~e       29    0.94046      1.845     1.264    0.10312
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapmeanchange
trapmeanch~e       29      0.1060         0.5625         3.24         0.1978
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapmeanchange
   trappr12m       29    0.91718      2.567     1.945    0.02588
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trappr12m
   trappr12m       29      0.0071         0.0215        10.18         0.0062
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trappr12m
    trapc12m       29    0.98651      0.418    -1.800    0.96404
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapc12m
    trapc12m       29      0.6143         0.6668         0.45         0.7976
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapc12m
     trap12m       34    0.98591      0.492    -1.478    0.93036
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trap12m
     trap12m       34      0.9499         0.5316         0.40         0.8171
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trap12m
      botrap       36    0.97743      0.823    -0.407    0.65803
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk botrap
      botrap       36      0.7475         0.3184         1.16         0.5592
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest botrap
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 trapmeanch~e        9    0.93230      0.995    -0.009    0.50359
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapmeanchange if menopausal ==0
trapmeanch~e        9      0.2146         0.6038         2.15         0.3417
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapmeanchange if menopausal ==0
   trappr12m        9    0.93021      1.025     0.042    0.48335
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trappr12m if menopausal ==0
   trappr12m        9      0.4335         0.4379         1.38         0.5007
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trappr12m if menopausal ==0
    trapc12m        9    0.93222      0.996    -0.007    0.50279
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapc12m if menopausal ==0
    trapc12m        9      0.9421         0.7015         0.15         0.9267
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapc12m if menopausal ==0
     trap12m       12    0.94421      0.932    -0.137    0.55452
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trap12m if menopausal ==0
     trap12m       12      0.5791         0.5901         0.63         0.7288
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trap12m if menopausal ==0
      botrap       13    0.94582      0.954    -0.092    0.53650
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk botrap if menopausal ==0
      botrap       13      0.5679         0.2707         1.77         0.4135
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest botrap if menopausal ==0
  
 
 
  
trapmeanch~e       20    0.93424      1.557     0.892    0.18626
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapmeanchange if menopausal ==1
trapmeanch~e       20      0.1790         0.3771         2.93         0.2311
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapmeanchange if menopausal ==1
   trappr12m       20    0.86749      3.137     2.304    0.01062
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trappr12m if menopausal ==1
   trappr12m       20      0.0039         0.0060        12.14         0.0023
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trappr12m if menopausal ==1
    trapc12m       20    0.96961      0.719    -0.664    0.74651
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapc12m if menopausal ==1
    trapc12m       20      0.5289         0.3759         1.30         0.5233
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapc12m if menopausal ==1
     trap12m       22    0.96729      0.829    -0.381    0.64843
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trap12m if menopausal ==1
     trap12m       22      0.7996         0.8145         0.12         0.9420
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trap12m if menopausal ==1
      botrap       23    0.96980      0.790    -0.479    0.68414
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk botrap if menopausal ==1
      botrap       23      0.4122         0.7114         0.86         0.6489
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest botrap if menopausal ==1
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   trappr12m       12    0.86397      2.273     1.600    0.05483
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trappr12m if vitdcat ==1
   trappr12m       12      0.0282         0.0605         7.13         0.0283
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trappr12m if vitdcat ==1
    trapc12m       12    0.94469      0.924    -0.154    0.56115
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapc12m if vitdcat ==1
    trapc12m       12      0.5020         0.2011         2.46         0.2929
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapc12m if vitdcat ==1
     trap12m       14    0.92034      1.474     0.764    0.22240
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trap12m if vitdcat ==1
     trap12m       14      0.7268         0.0845         3.58         0.1673
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trap12m if vitdcat ==1
      botrap       14    0.95053      0.916    -0.174    0.56898
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk botrap if vitdcat ==1
      botrap       14      0.3201         0.9727         1.10         0.5782
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest botrap if vitdcat ==1
  
 
  
   trappr12m       17    0.96248      0.793    -0.463    0.67841
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trappr12m if vitdcat ==2
   trappr12m       17      0.2861         0.9405         1.27         0.5312
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trappr12m if vitdcat ==2
    trapc12m       17    0.96426      0.755    -0.561    0.71244
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapc12m if vitdcat ==2
    trapc12m       17      0.3772         0.7539         0.96         0.6201
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapc12m if vitdcat ==2
     trap12m       20    0.98009      0.471    -1.516    0.93522
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trap12m if vitdcat ==2
     trap12m       20      0.9126         0.9418         0.02         0.9914
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trap12m if vitdcat ==2
      botrap       22    0.92299      1.951     1.355    0.08770
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk botrap if vitdcat ==2
      botrap       22      0.2232         0.8725         1.66         0.4353
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest botrap if vitdcat ==2
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pinpmeanch~e       30    0.73171      8.528     4.432    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpmeanchange
pinpmeanch~e       30      0.0000         0.0002        23.52         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpmeanchange
   pinppr12m       30    0.83141      5.359     3.471    0.00026
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinppr12m
   pinppr12m       30      0.0041         0.1933         8.45         0.0146
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinppr12m
    pinpc12m       30    0.93596      2.036     1.470    0.07081
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpc12m
    pinpc12m       30      0.1176         0.2019         4.24         0.1199
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpc12m
     pinp12m       34    0.92111      2.755     2.111    0.01737
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinp12m
     pinp12m       34      0.0240         0.4607         5.41         0.0668
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinp12m
      bopinp       36    0.58280     15.213     5.692    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bopinp
      bopinp       36      0.0000         0.0000        36.57         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bopinp
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pinpmeanch~e       10    0.81887      2.791     1.968    0.02456
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpmeanchange if menopausal ==0
pinpmeanch~e       10      0.0503         0.4042         4.61         0.0998
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpmeanchange if menopausal ==0
   pinppr12m       10    0.83524      2.539     1.766    0.03869
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinppr12m if menopausal ==0
   pinppr12m       10      0.1918         0.6961         2.20         0.3334
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinppr12m if menopausal ==0
    pinpc12m       10    0.82375      2.716     1.909    0.02813
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpc12m if menopausal ==0
    pinpc12m       10      0.0278         0.0666         6.94         0.0312
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpc12m if menopausal ==0
     pinp12m       12    0.86295      2.290     1.614    0.05323
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinp12m if menopausal ==0
     pinp12m       12      0.0115         0.0195         9.27         0.0097
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinp12m if menopausal ==0
      bopinp       13    0.96516      0.614    -0.957    0.83068
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bopinp if menopausal ==0
      bopinp       13      0.3415         0.4703         1.63         0.4431
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bopinp if menopausal ==0
  
 
 
  
pinpmeanch~e       20    0.71890      6.654     3.819    0.00007
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpmeanchange if menopausal ==1
pinpmeanch~e       20      0.0001         0.0010        18.19         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpmeanchange if menopausal ==1
   pinppr12m       20    0.81195      4.451     3.009    0.00131
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinppr12m if menopausal ==1
   pinppr12m       20      0.0022         0.0232        11.33         0.0035
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinppr12m if menopausal ==1
    pinpc12m       20    0.95714      1.014     0.029    0.48849
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpc12m if menopausal ==1
    pinpc12m       20      0.4384         0.3280         1.73         0.4210
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpc12m if menopausal ==1
     pinp12m       22    0.94326      1.437     0.736    0.23097
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinp12m if menopausal ==1
     pinp12m       22      0.1508         0.9631         2.30         0.3161
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinp12m if menopausal ==1
      bopinp       23    0.57850     11.025     4.881    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bopinp if menopausal ==1
      bopinp       23      0.0000         0.0001        24.58         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bopinp if menopausal ==1
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   pinppr12m       12    0.81579      3.078     2.190    0.01424
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinppr12m if vitdcat ==1
   pinppr12m       12      0.0361         0.3802         5.07         0.0793
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinppr12m if vitdcat ==1
    pinpc12m       12    0.92735      1.214     0.378    0.35286
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpc12m if vitdcat ==1
    pinpc12m       12      0.0892         0.1850         4.71         0.0947
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpc12m if vitdcat ==1
     pinp12m       14    0.91100      1.647     0.982    0.16293
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinp12m if vitdcat ==1
     pinp12m       14      0.0686         0.3528         4.38         0.1117
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinp12m if vitdcat ==1
      bopinp       14    0.97006      0.554    -1.162    0.87740
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bopinp if vitdcat ==1
      bopinp       14      0.6651         0.7566         0.28         0.8678
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bopinp if vitdcat ==1
  
 
  
   pinppr12m       18    0.82603      3.824     2.685    0.00363
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinppr12m if vitdcat ==2
   pinppr12m       18      0.0109         0.1248         7.60         0.0224
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinppr12m if vitdcat ==2
    pinpc12m       18    0.92607      1.625     0.972    0.16558
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinpc12m if vitdcat ==2
    pinpc12m       18      0.2553         0.2482         3.01         0.2220
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinpc12m if vitdcat ==2
     pinp12m       20    0.92885      1.684     1.051    0.14673
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk pinp12m if vitdcat ==2
     pinp12m       20      0.0903         0.5717         3.59         0.1657
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest pinp12m if vitdcat ==2
      bopinp       22    0.57007     10.892     4.842    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bopinp if vitdcat ==2
      bopinp       22      0.0000         0.0002        23.26         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bopinp if vitdcat ==2
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bapmeancha~e       28    0.95174      1.457     0.775    0.21906
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapmeanchange
bapmeancha~e       28      0.0821         0.2294         4.54         0.1031
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapmeanchange
    bappr12m       28    0.93201      2.053     1.481    0.06931
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bappr12m
    bappr12m       28      0.0412         0.1890         5.60         0.0609
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bappr12m
     bapc12m       28    0.91472      2.575     1.947    0.02574
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapc12m
     bapc12m       28      0.3192         0.0854         4.15         0.1256
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapc12m
      bap12m       34    0.93746      2.184     1.627    0.05184
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bap12m
      bap12m       34      0.0744         0.8943         3.48         0.1755
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bap12m
       bobap       36    0.93330      2.432     1.859    0.03154
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bobap
       bobap       36      0.0065         0.0345         9.82         0.0074
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bobap
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bapmeancha~e        9    0.87095      1.896     1.146    0.12586
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapmeanchange if menopausal ==0
bapmeancha~e        9      0.2262         0.7729         1.81         0.4047
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapmeanchange if menopausal ==0
    bappr12m        9    0.94686      0.781    -0.401    0.65563
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bappr12m if menopausal ==0
    bappr12m        9      0.7125         0.9930         0.14         0.9343
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bappr12m if menopausal ==0
     bapc12m        9    0.88261      1.725     0.965    0.16726
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapc12m if menopausal ==0
     bapc12m        9      0.0754         0.0696         5.80         0.0551
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapc12m if menopausal ==0
      bap12m       12    0.87285      2.124     1.468    0.07104
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bap12m if menopausal ==0
      bap12m       12      0.0239         0.0780         7.05         0.0294
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bap12m if menopausal ==0
       bobap       13    0.98096      0.335    -2.140    0.98384
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bobap if menopausal ==0
       bobap       13      0.8207         0.9656         0.05         0.9737
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bobap if menopausal ==0
  
 
 
  
bapmeancha~e       19    0.95783      0.963    -0.076    0.53039
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapmeanchange if menopausal ==1
bapmeancha~e       19      0.3159         0.8421         1.14         0.5646
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapmeanchange if menopausal ==1
    bappr12m       19    0.95188      1.099     0.189    0.42508
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bappr12m if menopausal ==1
    bappr12m       19      0.2002         0.9482         1.84         0.3985
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bappr12m if menopausal ==1
     bapc12m       19    0.96210      0.865    -0.291    0.61440
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapc12m if menopausal ==1
     bapc12m       19      0.6947         0.5381         0.56         0.7562
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapc12m if menopausal ==1
      bap12m       22    0.96015      1.010     0.019    0.49235
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bap12m if menopausal ==1
      bap12m       22      0.3164         0.7203         1.23         0.5400
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bap12m if menopausal ==1
       bobap       23    0.93494      1.702     1.081    0.13979
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bobap if menopausal ==1
       bobap       23      0.0417         0.1447         5.87         0.0531
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bobap if menopausal ==1
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    bappr12m       11    0.89729      1.663     0.949    0.17126
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bappr12m if vitdcat ==1
    bappr12m       11      0.3522         0.3593         1.99         0.3690
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bappr12m if vitdcat ==1
     bapc12m       11    0.85351      2.372     1.670    0.04741
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapc12m if vitdcat ==1
     bapc12m       11      0.2774         0.2329         3.13         0.2088
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapc12m if vitdcat ==1
      bap12m       14    0.94571      1.005     0.009    0.49634
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bap12m if vitdcat ==1
      bap12m       14      0.8459         0.1404         2.58         0.2757
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bap12m if vitdcat ==1
       bobap       14    0.98474      0.282    -2.490    0.99360
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bobap if vitdcat ==1
       bobap       14      0.8033         0.9056         0.08         0.9627
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bobap if vitdcat ==1
  
 
     bappr12m       17    0.93661      1.339     0.582    0.28019
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bappr12m if vitdcat ==2
    bappr12m       17      0.2715         0.9459         1.35         0.5098
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bappr12m if vitdcat ==2
     bapc12m       17    0.87097      2.726     2.000    0.02277
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bapc12m if vitdcat ==2
     bapc12m       17      0.0092         0.0277         9.39         0.0092
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bapc12m if vitdcat ==2
      bap12m       20    0.95129      1.153     0.287    0.38707
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bap12m if vitdcat ==2
      bap12m       20      0.5494         0.1197         3.16         0.2063
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bap12m if vitdcat ==2
       bobap       22    0.82998      4.307     2.961    0.00153
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bobap if vitdcat ==2
       bobap       22      0.0007         0.0044        14.48         0.0007
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bobap if vitdcat ==2
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dkk1meanch~e       29    0.86450      4.199     2.961    0.00153
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1meanchange
dkk1meanch~e       29      0.0029         0.0460        10.39         0.0055
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1meanchange
   dkk1pr12m       29    0.90395      2.977     2.251    0.01219
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1pr12m
   dkk1pr12m       29      0.0072         0.0554         9.08         0.0107
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1pr12m
    dkk1c12m       29    0.97838      0.670    -0.826    0.79550
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1c12m
    dkk1c12m       29      0.9777         0.4539         0.58         0.7464
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1c12m
     dkk112m       34    0.93082      2.416     1.838    0.03305
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk112m
     dkk112m       34      0.0107         0.0579         8.59         0.0136
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk112m
      bodkk1       36    0.92298      2.809     2.159    0.01541
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodkk1
      bodkk1       36      0.0166         0.3311         6.18         0.0455
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodkk1
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dkk1meanch~e        9    0.78491      3.160     2.205    0.01372
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1meanchange if menopausal ==0
dkk1meanch~e        9      0.0684         0.6214         3.93         0.1399
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1meanchange if menopausal ==0
   dkk1pr12m        9    0.87944      1.771     1.016    0.15490
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1pr12m if menopausal ==0
   dkk1pr12m        9      0.0430         0.1186         5.84         0.0538
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1pr12m if menopausal ==0
    dkk1c12m        9    0.90307      1.424     0.612    0.27033
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1c12m if menopausal ==0
    dkk1c12m        9      0.1171         0.4634         3.53         0.1714
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1c12m if menopausal ==0
     dkk112m       12    0.92829      1.198     0.352    0.36234
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk112m if menopausal ==0
     dkk112m       12      0.7884         0.1686         2.31         0.3153
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk112m if menopausal ==0
      bodkk1       13    0.98519      0.261    -2.632    0.99576
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodkk1 if menopausal ==0
      bodkk1       13      0.8876         0.9291         0.03         0.9861
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodkk1 if menopausal ==0
  
 
 
  
dkk1meanch~e       20    0.85141      3.517     2.535    0.00563
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1meanchange if menopausal ==1
dkk1meanch~e       20      0.0047         0.0250        10.35         0.0057
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1meanchange if menopausal ==1
   dkk1pr12m       20    0.90230      2.313     1.690    0.04556
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1pr12m if menopausal ==1
   dkk1pr12m       20      0.0234         0.0840         7.14         0.0281
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1pr12m if menopausal ==1
    dkk1c12m       20    0.98311      0.400    -1.847    0.96764
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1c12m if menopausal ==1
    dkk1c12m       20      0.7587         0.7403         0.20         0.9029
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1c12m if menopausal ==1
     dkk112m       22    0.95434      1.157     0.295    0.38396
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk112m if menopausal ==1
     dkk112m       22      0.1237         0.2714         3.89         0.1431
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk112m if menopausal ==1
      bodkk1       23    0.94188      1.520     0.852    0.19721
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodkk1 if menopausal ==1
      bodkk1       23      0.2097         0.7637         1.83         0.3996
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodkk1 if menopausal ==1
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   dkk1pr12m       12    0.93154      1.144     0.262    0.39671
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1pr12m if vitdcat ==1
   dkk1pr12m       12      0.6425         0.2377         1.86         0.3940
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1pr12m if vitdcat ==1
    dkk1c12m       12    0.97470      0.423    -1.678    0.95330
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1c12m if vitdcat ==1
    dkk1c12m       12      0.6248         0.8735         0.26         0.8761
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1c12m if vitdcat ==1
     dkk112m       14    0.92408      1.405     0.670    0.25159
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk112m if vitdcat ==1
     dkk112m       14      0.0607         0.1510         5.37         0.0682
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk112m if vitdcat ==1
      bodkk1       14    0.90342      1.787     1.143    0.12646
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodkk1 if vitdcat ==1
      bodkk1       14      0.2103         0.6616         2.03         0.3631
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodkk1 if vitdcat ==1
  
 
  
   dkk1pr12m       17    0.88229      2.487     1.817    0.03464
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1pr12m if vitdcat ==2
   dkk1pr12m       17      0.0359         0.3085         5.28         0.0715
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1pr12m if vitdcat ==2
    dkk1c12m       17    0.96175      0.808    -0.425    0.66464
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk1c12m if vitdcat ==2
    dkk1c12m       17      0.8220         0.2985         1.25         0.5350
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk1c12m if vitdcat ==2
     dkk112m       20    0.95035      1.175     0.325    0.37249
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk dkk112m if vitdcat ==2
     dkk112m       20      0.3183         0.6087         1.38         0.5005
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest dkk112m if vitdcat ==2
      bodkk1       22    0.94642      1.357     0.620    0.26771
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodkk1 if vitdcat ==2
      bodkk1       22      0.4136         0.2525         2.20         0.3326
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodkk1 if vitdcat ==2
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sclmeancha~e       28    0.86399      4.107     2.909    0.00182
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclmeanchange
sclmeancha~e       28      0.0009         0.0033        14.86         0.0006
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclmeanchange
    sclpr12m       28    0.84212      4.768     3.216    0.00065
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclpr12m
    sclpr12m       28      0.0003         0.0020        16.72         0.0002
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclpr12m
     sclc12m       28    0.98087      0.578    -1.130    0.87074
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclc12m
     sclc12m       28      0.3965         0.3347         1.79         0.4082
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclc12m
      scl12m       34    0.97414      0.903    -0.213    0.58420
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk scl12m
      scl12m       34      0.3036         0.8427         1.16         0.5587
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest scl12m
       boscl       36    0.97769      0.814    -0.431    0.66690
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boscl
       boscl       36      0.4359         0.7464         0.74         0.6898
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boscl
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sclmeancha~e        9    0.96538      0.509    -1.048    0.85260
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclmeanchange if menopausal ==0
sclmeancha~e        9      0.5123         0.8861         0.45         0.7996
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclmeanchange if menopausal ==0
    sclpr12m        9    0.97939      0.303    -1.763    0.96106
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclpr12m if menopausal ==0
    sclpr12m        9      0.8235         0.7606         0.14         0.9312
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclpr12m if menopausal ==0
     sclc12m        9    0.92729      1.068     0.111    0.45596
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclc12m if menopausal ==0
     sclc12m        9      0.4996         0.5632         0.85         0.6528
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclc12m if menopausal ==0
      scl12m       12    0.91789      1.372     0.616    0.26892
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk scl12m if menopausal ==0
      scl12m       12      0.5443         0.3357         1.47         0.4788
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest scl12m if menopausal ==0
       boscl       13    0.97790      0.389    -1.848    0.96770
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boscl if menopausal ==0
       boscl       13      0.8730         0.5349         0.42         0.8112
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boscl if menopausal ==0
  
 
 
  
sclmeancha~e       19    0.83744      3.711     2.634    0.00422
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclmeanchange if menopausal ==1
sclmeancha~e       19      0.0033         0.0101        11.73         0.0028
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclmeanchange if menopausal ==1
    sclpr12m       19    0.86171      3.157     2.309    0.01047
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclpr12m if menopausal ==1
    sclpr12m       19      0.0038         0.0181        10.91         0.0043
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclpr12m if menopausal ==1
     sclc12m       19    0.98628      0.313    -2.331    0.99014
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclc12m if menopausal ==1
     sclc12m       19      0.5968         0.5237         0.73         0.6935
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclc12m if menopausal ==1
      scl12m       22    0.97744      0.572    -1.134    0.87166
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk scl12m if menopausal ==1
      scl12m       22      0.8386         0.5955         0.32         0.8507
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest scl12m if menopausal ==1
       boscl       23    0.96759      0.848    -0.336    0.63156
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boscl if menopausal ==1
       boscl       23      0.9721         0.4573         0.58         0.7484
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boscl if menopausal ==1
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    sclpr12m       11    0.94770      0.847    -0.292    0.61473
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclpr12m if vitdcat ==1
    sclpr12m       11      0.8124         0.2298         1.73         0.4204
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclpr12m if vitdcat ==1
     sclc12m       11    0.96938      0.496    -1.176    0.88020
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclc12m if vitdcat ==1
     sclc12m       11      0.6538         0.8569         0.23         0.8898
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclc12m if vitdcat ==1
      scl12m       14    0.97216      0.515    -1.305    0.90412
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk scl12m if vitdcat ==1
      scl12m       14      0.7150         0.8814         0.16         0.9251
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest scl12m if vitdcat ==1
       boscl       14    0.95527      0.828    -0.372    0.64508
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boscl if vitdcat ==1
       boscl       14      0.3857         0.8857         0.84         0.6574
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boscl if vitdcat ==1
  
 
  
    sclpr12m       17    0.75949      5.081     3.242    0.00059
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclpr12m if vitdcat ==2
    sclpr12m       17      0.0007         0.0046        14.22         0.0008
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclpr12m if vitdcat ==2
     sclc12m       17    0.92282      1.630     0.975    0.16483
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk sclc12m if vitdcat ==2
     sclc12m       17      0.0576         0.0976         5.91         0.0520
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest sclc12m if vitdcat ==2
      scl12m       20    0.96483      0.832    -0.369    0.64411
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk scl12m if vitdcat ==2
      scl12m       20      0.2602         0.6655         1.61         0.4468
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest scl12m if vitdcat ==2
       boscl       22    0.97436      0.650    -0.875    0.80910
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boscl if vitdcat ==2
       boscl       22      0.6814         0.8850         0.19         0.9096
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boscl if vitdcat ==2
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crpmeancha~e       30    0.47901     16.560     5.804    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpmeanchange
crpmeancha~e       30      0.0000         0.0000        38.75         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpmeanchange
    crppr12m       30    0.54401     14.494     5.528    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crppr12m
    crppr12m       30      0.0000         0.0000        36.34         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crppr12m
     crpc12m       30    0.83265      5.319     3.456    0.00027
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpc12m
     crpc12m       30      0.0003         0.0036        15.92         0.0003
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpc12m
      crp12m       36    0.71408     10.426     4.902    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp12m
      crp12m       36      0.0000         0.0001        26.08         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp12m
       bocrp       36    0.80123      7.248     4.142    0.00002
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp
       bocrp       36      0.0006         0.0266        13.01         0.0015
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp
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crpmeancha~e       10    0.54210      7.057     4.236    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpmeanchange if menopausal ==0
crpmeancha~e       10      0.0003         0.0011        15.73         0.0004
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpmeanchange if menopausal ==0
    crppr12m       10    0.77142      3.523     2.483    0.00651
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crppr12m if menopausal ==0
    crppr12m       10      0.0191         0.1186         6.77         0.0339
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crppr12m if menopausal ==0
     crpc12m       10    0.76660      3.597     2.531    0.00569
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpc12m if menopausal ==0
     crpc12m       10      0.0031         0.0058        11.60         0.0030
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpc12m if menopausal ==0
      crp12m       13    0.66383      5.921     3.484    0.00025
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp12m if menopausal ==0
      crp12m       13      0.0004         0.0021        15.21         0.0005
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp12m if menopausal ==0
       bocrp       13    0.79126      3.677     2.551    0.00538
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp if menopausal ==0
       bocrp       13      0.0039         0.0166        10.67         0.0048
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp if menopausal ==0
  
 
 
  
crpmeancha~e       20    0.76021      5.676     3.499    0.00023
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpmeanchange if menopausal ==1
crpmeancha~e       20      0.0055         0.1637         8.15         0.0170
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpmeanchange if menopausal ==1
    crppr12m       20    0.50908     11.620     4.943    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crppr12m if menopausal ==1
    crppr12m       20      0.0000         0.0000        28.78         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crppr12m if menopausal ==1
     crpc12m       20    0.85556      3.419     2.478    0.00661
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpc12m if menopausal ==1
     crpc12m       20      0.0462         0.9233         4.21         0.1220
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpc12m if menopausal ==1
      crp12m       23    0.80822      5.016     3.279    0.00052
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp12m if menopausal ==1
      crp12m       23      0.0005         0.0030        15.49         0.0004
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp12m if menopausal ==1
       bocrp       23    0.77723      5.827     3.584    0.00017
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp if menopausal ==1
       bocrp       23      0.0245         0.9613         5.00         0.0821
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp if menopausal ==1
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    crppr12m       12    0.47860      8.712     4.218    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crppr12m if vitdcat ==1
    crppr12m       12      0.0000         0.0002        19.91         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crppr12m if vitdcat ==1
     crpc12m       12    0.90528      1.583     0.895    0.18553
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpc12m if vitdcat ==1
     crpc12m       12      0.2397         0.6158         1.89         0.3881
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpc12m if vitdcat ==1
      crp12m       14    0.89638      1.918     1.282    0.09994
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp12m if vitdcat ==1
      crp12m       14      0.1860         0.5993         2.35         0.3090
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp12m if vitdcat ==1
       bocrp       14    0.88856      2.062     1.425    0.07706
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp if vitdcat ==1
       bocrp       14      0.2525         0.3590         2.50         0.2861
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp if vitdcat ==1
  
 
  
    crppr12m       18    0.86483      2.971     2.180    0.01464
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crppr12m if vitdcat ==2
    crppr12m       18      0.0176         0.1754         6.68         0.0354
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crppr12m if vitdcat ==2
     crpc12m       18    0.74530      5.599     3.448    0.00028
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crpc12m if vitdcat ==2
     crpc12m       18      0.0003         0.0012        16.89         0.0002
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crpc12m if vitdcat ==2
      crp12m       22    0.65551      8.727     4.393    0.00001
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk crp12m if vitdcat ==2
      crp12m       22      0.0001         0.0012        18.89         0.0001
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest crp12m if vitdcat ==2
       bocrp       22    0.73292      6.766     3.877    0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bocrp if vitdcat ==2
       bocrp       22      0.0010         0.0190        12.55         0.0019
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bocrp if vitdcat ==2
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esrmeancha~e       25    0.66685      9.257     4.549    0.00000
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrmeanchange
esrmeancha~e       25      0.0000         0.0000        27.83         0.0000
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrmeanchange
    esrpr12m       25    0.87611      3.443     2.527    0.00575
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrpr12m
    esrpr12m       25      0.0035         0.0150        11.38         0.0034
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrpr12m
     esrc12m       25    0.81836      5.047     3.309    0.00047
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrc12m
     esrc12m       25      0.0003         0.0027        16.08         0.0003
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrc12m
      esr12m       35    0.92415      2.707     2.079    0.01881
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr12m
      esr12m       35      0.1670         0.1534         4.13         0.1269
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr12m
       boesr       33    0.85760      4.861     3.289    0.00050
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr
       boesr       33      0.0006         0.0039        15.32         0.0005
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr
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esrmeancha~e       10    0.63686      5.596     3.611    0.00015
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrmeanchange if menopausal ==0
esrmeancha~e       10      0.0005         0.0017        14.61         0.0007
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrmeanchange if menopausal ==0
    esrpr12m       10    0.90035      1.536     0.769    0.22105
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrpr12m if menopausal ==0
    esrpr12m       10      0.4428         0.2893         2.01         0.3657
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrpr12m if menopausal ==0
     esrc12m       10    0.84386      2.406     1.654    0.04907
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrc12m if menopausal ==0
     esrc12m       10      0.0330         0.1485         5.97         0.0505
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrc12m if menopausal ==0
      esr12m       12    0.85098      2.490     1.777    0.03775
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr12m if menopausal ==0
      esr12m       12      0.3155         0.1394         3.67         0.1600
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr12m if menopausal ==0
       boesr       12    0.87354      2.113     1.458    0.07247
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr if menopausal ==0
       boesr       12      0.0333         0.0698         6.81         0.0333
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr if menopausal ==0
  
 
 
  
esrmeancha~e       15    0.93680      1.225     0.402    0.34379
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrmeanchange if menopausal ==1
esrmeancha~e       15      0.6199         0.1093         3.29         0.1930
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrmeanchange if menopausal ==1
    esrpr12m       15    0.88217      2.285     1.634    0.05112
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrpr12m if menopausal ==1
    esrpr12m       15      0.0168         0.0518         7.97         0.0186
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrpr12m if menopausal ==1
     esrc12m       15    0.96034      0.769    -0.520    0.69836
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrc12m if menopausal ==1
     esrc12m       15      0.2695         0.6737         1.58         0.4546
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrc12m if menopausal ==1
      esr12m       23    0.94705      1.385     0.662    0.25395
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr12m if menopausal ==1
      esr12m       23      0.2130         0.7195         1.85         0.3961
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr12m if menopausal ==1
       boesr       21    0.88261      2.877     2.136    0.01633
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr if menopausal ==1
       boesr       21      0.0278         0.0753         7.07         0.0292
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr if menopausal ==1
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    esrpr12m        9    0.82729      2.537     1.732    0.04163
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrpr12m if vitdcat ==1
    esrpr12m        9      0.0213         0.0589         7.23         0.0269
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrpr12m if vitdcat ==1
     esrc12m        9    0.83739      2.389     1.607    0.05401
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrc12m if vitdcat ==1
     esrc12m        9      0.0171         0.0376         7.88         0.0195
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrc12m if vitdcat ==1
      esr12m       14    0.95480      0.836    -0.352    0.63744
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr12m if vitdcat ==1
      esr12m       14      0.4028         0.9108         0.77         0.6812
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr12m if vitdcat ==1
       boesr       13    0.81552      3.249     2.309    0.01048
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr if vitdcat ==1
       boesr       13      0.0085         0.0370         9.00         0.0111
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr if vitdcat ==1
  
 
  
    esrpr12m       16    0.95042      1.004     0.009    0.49645
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrpr12m if vitdcat ==2
    esrpr12m       16      0.3500         0.9620         0.96         0.6202
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrpr12m if vitdcat ==2
     esrc12m       16    0.85971      2.842     2.075    0.01899
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esrc12m if vitdcat ==2
     esrc12m       16      0.0078         0.0257         9.62         0.0082
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esrc12m if vitdcat ==2
      esr12m       21    0.88770      2.752     2.047    0.02035
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk esr12m if vitdcat ==2
      esr12m       21      0.2072         0.1187         4.23         0.1204
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest esr12m if vitdcat ==2
       boesr       20    0.92783      1.708     1.079    0.14026
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk boesr if vitdcat ==2
       boesr       20      0.3267         0.7539         1.16         0.5607
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest boesr if vitdcat ==2
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das28meanc~e       33    0.93243      2.307     1.739    0.04106
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28meanchange
das28meanc~e       33      0.0385         0.0949         6.45         0.0397
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28meanchange
  das28pr12m       33    0.94203      1.979     1.420    0.07784
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28pr12m
  das28pr12m       33      0.1323         0.0769         5.23         0.0731
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28pr12m
   das28c12m       33    0.97627      0.810    -0.438    0.66920
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28c12m
   das28c12m       33      0.3720         0.5723         1.19         0.5526
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28c12m
    das2812m       36    0.92791      2.629     2.021    0.02164
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2812m
    das2812m       36      0.1302         0.3531         3.41         0.1816
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2812m
     bodas28       36    0.98072      0.703    -0.737    0.76945
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28
     bodas28       36      0.2656         0.9371         1.32         0.5163
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28
  
 
- By gender and menopausal status 
 
 
 
0
.2
.4
.6
2 4 6 8 2 4 6 8
male + pre post
D
e
n
s
it
y
bodas28
Graphs by menopause
0
.2
.4
.6
0 2 4 6 0 2 4 6
male + pre post
D
e
n
s
it
y
das2812m
Graphs by menopause
0
.2
.4
.6
-6 -4 -2 0 2 -6 -4 -2 0 2
male + pre post
D
e
n
s
it
y
das28C12m
Graphs by menopause
0
.0
1
.0
2
.0
3
-100 -50 0 50 100 -100 -50 0 50 100
male + pre post
D
e
n
s
it
y
das28PR12m
Graphs by menopause
0
.0
1
.0
2
.0
3
.0
4
-100 -50 0 50 -100 -50 0 50
male + pre post
D
e
n
s
it
y
das28meanchange
Graphs by menopause
  
 
 
das28meanc~e       12    0.95846      0.694    -0.712    0.76170
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28meanchange if menopausal ==0
das28meanc~e       12      0.2915         0.3147         2.50         0.2859
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28meanchange if menopausal ==0
  das28pr12m       12    0.94441      0.929    -0.144    0.55722
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28pr12m if menopausal ==0
  das28pr12m       12      0.4649         0.3980         1.42         0.4925
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28pr12m if menopausal ==0
   das28c12m       12    0.87920      2.018     1.368    0.08561
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28c12m if menopausal ==0
   das28c12m       12      0.0763         0.3814         4.19         0.1230
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28c12m if menopausal ==0
    das2812m       13    0.95371      0.815    -0.400    0.65540
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2812m if menopausal ==0
    das2812m       13      0.2580         0.9426         1.46         0.4830
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2812m if menopausal ==0
     bodas28       13    0.89243      1.895     1.252    0.10530
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28 if menopausal ==0
     bodas28       13      0.4278         0.1638         3.04         0.2190
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28 if menopausal ==0
  
 
 
  
das28meanc~e       21    0.86766      3.243     2.378    0.00869
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28meanchange if menopausal ==1
das28meanc~e       21      0.0112         0.0359         8.95         0.0114
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28meanchange if menopausal ==1
  das28pr12m       21    0.92105      1.935     1.334    0.09106
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28pr12m if menopausal ==1
  das28pr12m       21      0.0537         0.0591         6.57         0.0374
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28pr12m if menopausal ==1
   das28c12m       21    0.98465      0.376    -1.977    0.97596
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28c12m if menopausal ==1
   das28c12m       21      0.6848         0.5452         0.56         0.7575
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28c12m if menopausal ==1
    das2812m       23    0.92097      2.067     1.477    0.06987
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2812m if menopausal ==1
    das2812m       23      0.2143         0.3937         2.53         0.2824
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2812m if menopausal ==1
     bodas28       23    0.97766      0.584    -1.092    0.86263
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28 if menopausal ==1
     bodas28       23      0.3932         0.8145         0.84         0.6582
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28 if menopausal ==1
  
 
- By vitamin D category 
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  das28pr12m       13    0.90252      1.717     1.059    0.14480
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28pr12m if vitdcat ==1
  das28pr12m       13      0.1026         0.1115         5.10         0.0781
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28pr12m if vitdcat ==1
   das28c12m       13    0.96566      0.605    -0.985    0.83771
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28c12m if vitdcat ==1
   das28c12m       13      0.3978         0.4244         1.54         0.4634
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28c12m if vitdcat ==1
    das2812m       14    0.89946      1.861     1.223    0.11076
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2812m if vitdcat ==1
    das2812m       14      0.1780         0.8575         2.13         0.3445
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2812m if vitdcat ==1
     bodas28       14    0.96614      0.627    -0.920    0.82127
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28 if vitdcat ==1
     bodas28       14      0.3335         0.9057         1.05         0.5923
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28 if vitdcat ==1
  
 
  
  das28pr12m       20    0.97138      0.678    -0.785    0.78364
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28pr12m if vitdcat ==2
  das28pr12m       20      0.6584         0.8192         0.25         0.8835
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28pr12m if vitdcat ==2
   das28c12m       20    0.93820      1.463     0.767    0.22166
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das28c12m if vitdcat ==2
   das28c12m       20      0.1554         0.9887         2.27         0.3219
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das28c12m if vitdcat ==2
    das2812m       22    0.93319      1.693     1.067    0.14295
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk das2812m if vitdcat ==2
    das2812m       22      0.2538         0.6100         1.72         0.4222
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest das2812m if vitdcat ==2
     bodas28       22    0.96625      0.855    -0.317    0.62455
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bodas28 if vitdcat ==2
     bodas28       22      0.6918         0.7140         0.29         0.8644
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bodas28 if vitdcat ==2
  
 
In vitro unfractionated and CD20 depleted PBMC comparisons 
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    monodiff       12    0.93331      1.114     0.211    0.41657
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk monodiff
    monodiff       12      0.3728         0.9168         0.88         0.6445
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest monodiff
  bmonocytes       12    0.94967      0.841    -0.337    0.63211
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bmonocytes
  bmonocytes       12      0.6643         0.4327         0.88         0.6449
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bmonocytes
  umonocytes       12    0.84724      2.552     1.826    0.03394
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk umonocytes
  umonocytes       12      0.0096         0.0155         9.71         0.0078
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest umonocytes
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    monodiff        6    0.94297      0.706    -0.477    0.68319
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk monodiff if gender ==1
    monodiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest monodiff if gender ==1
  bmonocytes        6    0.88370      1.440     0.564    0.28649
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bmonocytes if gender ==1
  bmonocytes        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bmonocytes  if gender ==1
  umonocytes        6    0.90532      1.173     0.237    0.40634
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk umonocytes  if gender ==1
  umonocytes        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest umonocytes  if gender ==1
    monodiff        6    0.96969      0.375    -1.228    0.89032
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk monodiff if gender ==0
    monodiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest monodiff if gender ==0
  bmonocytes        6    0.90635      1.160     0.220    0.41285
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bmonocytes if gender ==0
  bmonocytes        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bmonocytes  if gender ==0
  umonocytes        6    0.94492      0.682    -0.522    0.69904
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk umonocytes  if gender ==0
  umonocytes        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest umonocytes  if gender ==0
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   bcelldiff       12    0.91836      1.364     0.605    0.27260
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcelldiff
   bcelldiff       12      0.7648         0.1108         3.14         0.2076
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcelldiff
     bbcells       12    0.79580      3.412     2.391    0.00840
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bbcells
     bbcells       12      0.0459         0.5659         4.48         0.1064
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bbcells
     ubcells       12    0.92370      1.275     0.473    0.31805
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ubcells
     ubcells       12      0.7923         0.0882         3.50         0.1736
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ubcells
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   bcelldiff        6    0.92236      0.962    -0.056    0.52252
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcelldiff if gender ==1
   bcelldiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcelldiff if gender ==1
     bbcells        6    0.74360      3.175     2.115    0.01723
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bbcells if gender ==1
     bbcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bbcells  if gender ==1
     ubcells        6    0.88997      1.363     0.473    0.31803
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ubcells if gender ==1
     ubcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ubcells if gender ==1
   bcelldiff        6    0.94138      0.726    -0.441    0.67034
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcelldiff if gender ==0
   bcelldiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcelldiff if gender ==0
     bbcells        6    0.77791      2.750     1.788    0.03685
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bbcells if gender ==0
     bbcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bbcells  if gender ==0
     ubcells        6    0.93448      0.811    -0.293    0.61509
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ubcells if gender ==0
     ubcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ubcells if gender ==0
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   tcelldiff       12    0.90470      1.592     0.906    0.18238
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk tcelldiff
   tcelldiff       12      0.0585         0.1424         5.45         0.0655
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest tcelldiff
     btcells       12    0.85458      2.430     1.730    0.04184
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btcells
     btcells       12      0.0156         0.0350         8.34         0.0155
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btcells
     utcells       12    0.96038      0.662    -0.804    0.78922
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utcells
     utcells       12      0.9858         0.4831         0.51         0.7750
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utcells
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   tcelldiff        6    0.88808      1.386     0.501    0.30824
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk tcelldiff if gender ==1
   tcelldiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest tcelldiff if gender ==1
     btcells        6    0.94061      0.736    -0.424    0.66412
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btcells if gender ==1
     btcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btcells if gender ==1
     utcells        6    0.95593      0.546    -0.799    0.78793
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utcells if gender ==1
     utcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utcells if gender ==1
   tcelldiff        6    0.91078      1.105     0.147    0.44157
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk tcelldiff if gender ==0
   tcelldiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest tcelldiff if gender ==0
     btcells        6    0.86100      1.721     0.868    0.19262
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btcells if gender ==0
     btcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btcells if gender ==0
     utcells        6    0.89854      1.256     0.344    0.36538
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utcells if gender ==0
     utcells        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utcells if gender ==0
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    trapdiff       12    0.97946      0.343    -2.083    0.98139
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapdiff
    trapdiff       12      0.8114         0.5036         0.52         0.7696
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapdiff
       btrap       12    0.95075      0.823    -0.380    0.64794
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrap
       btrap       12      0.2112         0.3671         2.82         0.2439
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrap
       utrap       12    0.96208      0.634    -0.889    0.81308
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrap
       utrap       12      0.5748         0.6245         0.58         0.7475
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrap
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    trapdiff        6    0.95654      0.538    -0.816    0.79271
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapdiff if gender ==1
    trapdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapdiff if gender ==1
       btrap        6    0.94872      0.635    -0.613    0.72993
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrap if gender ==1
       btrap        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrap if gender ==1
       utrap        6    0.98199      0.223    -1.763    0.96102
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrap if gender ==1
       utrap        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrap if gender ==1
    trapdiff        6    0.94880      0.634    -0.614    0.73051
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapdiff if gender ==0
    trapdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapdiff if gender ==0
       btrap        6    0.97201      0.347    -1.315    0.90568
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrap if gender ==0
       btrap        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrap if gender ==0
       utrap        6    0.93400      0.817    -0.283    0.61131
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrap if gender ==0
       utrap        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrap if gender ==0
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trapcorrdiff       12    0.96505      0.584    -1.048    0.85278
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapcorrdiff
trapcorrdiff       12      0.4866         0.8129         0.57         0.7538
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapcorrdiff
btrapcorre~d       12    0.92874      1.191     0.340    0.36699
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrapcorr
btrapcorre~d       12      0.1038         0.2459         4.25         0.1193
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrapcorr
utrapcorre~d       12    0.93693      1.054     0.102    0.45940
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrapcorr
utrapcorre~d       12      0.2006         0.5903         2.26         0.3232
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrapcorr
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trapcorrdiff        6    0.93307      0.829    -0.264    0.60403
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapcorrdiff if gender ==1
trapcorrdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapcorrdiff if gender ==1
btrapcorre~d        6    0.91351      1.071     0.101    0.45990
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrapcorr if gender ==1
btrapcorre~d        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrapcorr if gender ==1
utrapcorre~d        6    0.89137      1.345     0.453    0.32545
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrapcorr if gender ==1
utrapcorre~d        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrapcorr if gender ==1
trapcorrdiff        6    0.93307      0.829    -0.264    0.60402
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk trapcorrdiff if gender ==0
trapcorrdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest trapcorrdiff if gender ==0
btrapcorre~d        6    0.93325      0.827    -0.267    0.60539
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk btrapcorr if gender ==0
btrapcorre~d        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest btrapcorr if gender ==0
utrapcorre~d        6    0.93717      0.778    -0.349    0.63646
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk utrapcorr if gender ==0
utrapcorre~d        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest utrapcorr if gender ==0
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  circumdiff       12    0.82845      2.866     2.052    0.02010
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk circumdiff
  circumdiff       12      0.0057         0.0093        10.78         0.0046
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest circumdiff
     bcircum       12    0.95240      0.795    -0.446    0.67225
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcircum
     bcircum       12      0.7361         0.5621         0.46         0.7942
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcircum
     ucircum       12    0.85798      2.373     1.684    0.04612
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ucircum
     ucircum       12      0.0552         0.0412         6.82         0.0330
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ucircum
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  circumdiff        6    0.92006      0.990    -0.014    0.50577
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk circumdiff if gender ==1
  circumdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest circumdiff if gender ==1
     bcircum        6    0.90677      1.155     0.214    0.41546
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcircum if gender ==1
     bcircum        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcircum if gender ==1
     ucircum        6    0.93569      0.796    -0.318    0.62472
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ucircum if gender ==1
     ucircum        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ucircum if gender ==1
  circumdiff        6    0.88308      1.448     0.572    0.28351
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk circumdiff if gender ==0
  circumdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest circumdiff if gender ==0
     bcircum        6    0.96968      0.375    -1.228    0.89031
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bcircum if gender ==0
     bcircum        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bcircum if gender ==0
     ucircum        6    0.88400      1.437     0.559    0.28793
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ucircum if gender ==0
     ucircum        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ucircum if gender ==0
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    diamdiff       12    0.84457      2.597     1.859    0.03148
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk diamdiff
    diamdiff       12      0.0076         0.0122        10.19         0.0061
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest diamdiff
       bdiam       12    0.96127      0.647    -0.848    0.80178
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bdiam
       bdiam       12      0.9816         0.6872         0.16         0.9219
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bdiam
       udiam       12    0.85443      2.432     1.732    0.04165
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk udiam
       udiam       12      0.1074         0.0637         5.65         0.0593
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest udiam
  
 
- By gender 
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    diamdiff        6    0.96915      0.382    -1.209    0.88666
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk diamdiff if gender ==1
    diamdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest diamdiff if gender ==1
       bdiam        6    0.92469      0.933    -0.100    0.53980
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bdiam if gender ==1
       bdiam        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bdiam if gender ==1
       udiam        6    0.94600      0.669    -0.547    0.70779
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk udiam if gender ==1
       udiam        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest udiam if gender ==1
    diamdiff        6    0.90783      1.142     0.196    0.42225
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk diamdiff if gender ==0
    diamdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest diamdiff if gender ==0
       bdiam        6    0.98916      0.134    -2.227    0.98702
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bdiam if gender ==0
       bdiam        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bdiam if gender ==0
       udiam        6    0.86725      1.644     0.788    0.21546
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk udiam if gender ==0
       udiam        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest udiam if gender ==0
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     ctxdiff       12    0.72797      4.545     2.950    0.00159
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxdiff
     ctxdiff       12      0.0039         0.0191        10.44         0.0054
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxdiff
        bctx       12    0.64116      5.996     3.490    0.00024
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx
        bctx       12      0.0095         0.1205         7.63         0.0220
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx
        uctx       12    0.66419      5.611     3.360    0.00039
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk uctx
        uctx       12      0.0010         0.0059        13.10         0.0014
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest uctx
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     ctxdiff        6    0.81473      2.294     1.409    0.07941
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxdiff if gender ==1
     ctxdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxdiff if gender ==1
        bctx        6    0.76076      2.963     1.954    0.02534
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx if gender ==1
        bctx        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx if gender ==1
        uctx        6    0.73971      3.224     2.150    0.01577
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk uctx if gender ==1
        uctx        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest uctx if gender ==1
     ctxdiff        6    0.55393      5.524     3.667    0.00012
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk ctxdiff if gender ==0
     ctxdiff        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest ctxdiff if gender ==0
        bctx        6    0.58356      5.157     3.442    0.00029
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk bctx if gender ==0
        bctx        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest bctx if gender ==0
        uctx        6    0.99522      0.059    -2.885    0.99804
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk uctx if gender ==0
        uctx        6          .              .             .              .
                                                                             
    Variable      Obs   Pr(Skewness)   Pr(Kurtosis)  adj chi2(2)    Prob>chi2
                                                                 joint       
                    Skewness/Kurtosis tests for Normality
. sktest uctx if gender ==0
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   monocytes        3    0.90481      1.421     0.251    0.40098
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  monocytes if visit ==12
   monocytes        3    0.99979      0.003    -1.917    0.97238
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  monocytes if visit ==6
   monocytes        4    0.93036      0.803    -0.244    0.59650
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  monocytes if visit ==3
   monocytes        4    0.87298      1.465     0.497    0.30953
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  monocytes if visit ==0
  
 
Initial number of b cells 
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      bcells        3    0.75458      3.664     2.323    0.01009
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   bcells if visit ==12
      bcells        3    0.94225      0.862    -0.092    0.53649
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   bcells if visit ==6
      bcells        4    0.90165      1.134     0.153    0.43929
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   bcells if visit ==3
      bcells        4    0.85540      1.668     0.693    0.24413
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   bcells if visit ==0
  
 
Initial number of t cells 
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      tcells        3    0.92389      1.136     0.085    0.46620
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   tcells if visit ==12
      tcells        3    0.97374      0.392    -0.493    0.68916
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   tcells if visit ==6
      tcells        4    0.92990      0.808    -0.237    0.59381
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   tcells if visit ==3
      tcells        4    0.91160      1.019     0.023    0.49092
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   tcells if visit ==0
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        trap        3    0.84869      2.259     0.716    0.23693
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    trap if visit ==12
        trap        3    0.75000      3.732         .    -0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    trap if visit ==6
        trap        4    0.89950      1.159     0.180    0.42859
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    trap if visit ==3
        trap        4    0.94544      0.629    -0.490    0.68777
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    trap if visit ==0
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trapcorrec~d        3    0.99660      0.051    -1.219    0.88863
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  trapcorrected if visit ==12
trapcorrec~d        3    0.75000      3.732         .    -0.00005
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  trapcorrected if visit ==6
trapcorrec~d        4    0.90074      1.145     0.164    0.43473
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  trapcorrected if visit ==3
trapcorrec~d        4    0.96266      0.431    -0.826    0.79561
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  trapcorrected if visit ==0
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      circum        3    0.96031      0.592    -0.298    0.61697
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  circum if visit ==12
      circum        3    0.83046      2.531     0.880    0.18946
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  circum if visit ==6
      circum        4    0.91769      0.949    -0.060    0.52409
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  circum if visit ==3
      circum        4    0.95089      0.566    -0.588    0.72171
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk  circum if visit ==0
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        diam        3    0.90977      1.347     0.209    0.41732
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   diam if visit ==12
        diam        3    0.88107      1.775     0.447    0.32754
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   diam if visit ==6
        diam        4    0.95318      0.540    -0.631    0.73600
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   diam if visit ==3
        diam        4    0.89277      1.237     0.264    0.39603
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk   diam if visit ==0
  
 
βCTX concentration of supernatant 
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         ctx        3    0.88930      1.653     0.379    0.35219
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    ctx if visit ==12
         ctx        3    0.79396      3.076     1.281    0.10011
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    ctx if visit ==6
         ctx        4    0.89470      1.214     0.240    0.40523
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    ctx if visit ==3
         ctx        2          .          .         .          .
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
. swilk    ctx if visit ==0
  
 
Appendix C. Multiple regression analysis 
 
Stepwise regression model 1 – unfractionated mononuclear cells 
 
 
                                                                               
       _cons     32.15892   15.36872     2.09   0.057    -1.043189    65.36102
      bcells     .0014469   .0006527     2.22   0.045     .0000368    .0028571
     subject     83.35144   16.25066     5.13   0.000     48.24402    118.4589
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total         31538    15  2102.53333           Root MSE      =  27.706
                                                       Adj R-squared =  0.6349
    Residual    9979.09242    13  767.622493           R-squared     =  0.6836
       Model    21558.9076     2  10779.4538           Prob > F      =  0.0006
                                                       F(  2,    13) =   14.04
      Source         SS       df       MS              Number of obs =      16
p = 0.2700 >= 0.0500  removing age
p = 0.5213 >= 0.0500  removing gender
p = 0.5291 >= 0.0500  removing tcells
p = 0.8149 >= 0.0500  removing monocytes
                      begin with full model
. stepwise, pr(.0500001)pe(.05):regress trap monocytes bcells tcells subject age gender
                                                                              
       _cons     32.15892   15.36872     2.09   0.057    -1.043189    65.36102
      bcells     .0014469   .0006527     2.22   0.045     .0000368    .0028571
     subject     83.35144   16.25066     5.13   0.000     48.24402    118.4589
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total         31538    15  2102.53333           Root MSE      =  27.706
                                                       Adj R-squared =  0.6349
    Residual    9979.09242    13  767.622493           R-squared     =  0.6836
       Model    21558.9076     2  10779.4538           Prob > F      =  0.0006
                                                       F(  2,    13) =   14.04
      Source         SS       df       MS              Number of obs =      16
p = 0.0451 <  0.0500  adding   bcells
p = 0.0008 <  0.0500  adding   subject
                      begin with empty model
. stepwise, pr(.0500001)pe(.05)forward:regress trap monocytes bcells tcells subject age gender
                                                                              
       _cons     32.15892   15.36872     2.09   0.057    -1.043189    65.36102
      bcells     .0014469   .0006527     2.22   0.045     .0000368    .0028571
     subject     83.35144   16.25066     5.13   0.000     48.24402    118.4589
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total         31538    15  2102.53333           Root MSE      =  27.706
                                                       Adj R-squared =  0.6349
    Residual    9979.09242    13  767.622493           R-squared     =  0.6836
       Model    21558.9076     2  10779.4538           Prob > F      =  0.0006
                                                       F(  2,    13) =   14.04
      Source         SS       df       MS              Number of obs =      16
p = 0.2700 >= 0.0500  removing age
p = 0.5213 >= 0.0500  removing gender
p = 0.5291 >= 0.0500  removing tcells
p = 0.8149 >= 0.0500  removing monocytes
                      begin with full model
. stepwise, pr(.05):regress trap monocytes bcells tcells subject age gender
                                                                              
       _cons     32.15892   15.36872     2.09   0.057    -1.043189    65.36102
      bcells     .0014469   .0006527     2.22   0.045     .0000368    .0028571
     subject     83.35144   16.25066     5.13   0.000     48.24402    118.4589
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total         31538    15  2102.53333           Root MSE      =  27.706
                                                       Adj R-squared =  0.6349
    Residual    9979.09242    13  767.622493           R-squared     =  0.6836
       Model    21558.9076     2  10779.4538           Prob > F      =  0.0006
                                                       F(  2,    13) =   14.04
      Source         SS       df       MS              Number of obs =      16
p = 0.0451 <  0.0500  adding  bcells
p = 0.0008 <  0.0500  adding  subject
                      begin with empty model
. stepwise, pe(.05):regress trap monocytes bcells tcells subject age gender
  
 
Check validity of model i.e. residuals normally distributed 
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      resids       16    0.97172      0.573    -1.106    0.86557
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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Stepwise regression model 2 – CD20 depleted mononuclear cells 
 
 
 
 
                                                                              
       _cons     23.25103   22.57972     1.03   0.322     -25.5295    72.03156
      tcells    -.0002916   .0001057    -2.76   0.016      -.00052   -.0000633
   monocytes     .0015291   .0003967     3.85   0.002     .0006721    .0023862
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    42932.4375    15   2862.1625           Root MSE      =  39.223
                                                       Adj R-squared =  0.4625
    Residual    20000.1382    13  1538.47217           R-squared     =  0.5341
       Model    22932.2993     2  11466.1497           Prob > F      =  0.0070
                                                       F(  2,    13) =    7.45
      Source         SS       df       MS              Number of obs =      16
p = 0.0647 >= 0.0500  removing gender
p = 0.0635 >= 0.0500  removing bcells
p = 0.4101 >= 0.0500  removing age
p = 0.5554 >= 0.0500  removing subject
                      begin with full model
. stepwise, pr(.0500001) pe(.05) :regress  trap monocytes bcells tcells gender age subject
                                                                              
       _cons     23.25103   22.57972     1.03   0.322     -25.5295    72.03156
      tcells    -.0002916   .0001057    -2.76   0.016      -.00052   -.0000633
   monocytes     .0015291   .0003967     3.85   0.002     .0006721    .0023862
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    42932.4375    15   2862.1625           Root MSE      =  39.223
                                                       Adj R-squared =  0.4625
    Residual    20000.1382    13  1538.47217           R-squared     =  0.5341
       Model    22932.2993     2  11466.1497           Prob > F      =  0.0070
                                                       F(  2,    13) =    7.45
      Source         SS       df       MS              Number of obs =      16
p = 0.0163 <  0.0500  adding   tcells
p = 0.0430 <  0.0500  adding   monocytes
                      begin with empty model
. stepwise, pr(.0500001) pe(.05) forward:regress  trap monocytes bcells tcells gender age subject
                                                                              
       _cons     23.25103   22.57972     1.03   0.322     -25.5295    72.03156
      tcells    -.0002916   .0001057    -2.76   0.016      -.00052   -.0000633
   monocytes     .0015291   .0003967     3.85   0.002     .0006721    .0023862
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    42932.4375    15   2862.1625           Root MSE      =  39.223
                                                       Adj R-squared =  0.4625
    Residual    20000.1382    13  1538.47217           R-squared     =  0.5341
       Model    22932.2993     2  11466.1497           Prob > F      =  0.0070
                                                       F(  2,    13) =    7.45
      Source         SS       df       MS              Number of obs =      16
p = 0.0647 >= 0.0500  removing gender
p = 0.0635 >= 0.0500  removing bcells
p = 0.4101 >= 0.0500  removing age
p = 0.5554 >= 0.0500  removing subject
                      begin with full model
. stepwise, pr(.05):regress  trap monocytes bcells tcells gender age subject
                                                                              
       _cons     23.25103   22.57972     1.03   0.322     -25.5295    72.03156
      tcells    -.0002916   .0001057    -2.76   0.016      -.00052   -.0000633
   monocytes     .0015291   .0003967     3.85   0.002     .0006721    .0023862
                                                                              
        trap        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
       Total    42932.4375    15   2862.1625           Root MSE      =  39.223
                                                       Adj R-squared =  0.4625
    Residual    20000.1382    13  1538.47217           R-squared     =  0.5341
       Model    22932.2993     2  11466.1497           Prob > F      =  0.0070
                                                       F(  2,    13) =    7.45
      Source         SS       df       MS              Number of obs =      16
p = 0.0163 <  0.0500  adding  tcells
p = 0.0430 <  0.0500  adding  monocytes
                      begin with empty model
. stepwise, pe(.05):regress  trap monocytes bcells tcells gender age subject
  
 
Check validity of model i.e. residuals normally distributed 
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      resids       16    0.95322      0.948    -0.106    0.54232
                                                                
    Variable      Obs       W           V         z       Prob>z
                   Shapiro-Wilk W test for normal data
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